2,3,6-Trisubstituted-4-pyrimidone derivatives

ABSTRACT

A pyrimidone derivative having tau protein kinase 1 inhibitory activity which is represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof; useful for prventive and/or therapeutic treatment of diseass such as neurodegenerative diseases (e.g. Alzheimer disease); wherein Q represents CH or nitrogen atom; R represents a C 1 -C 12  alkyl group; the ring of Formula (I): represents piperazine ring or piperidine ring; each X independently represents a C 1 -C 8  alkyl group, an optionally partially hydrogenated C 6 -C 10  aryl ring, an indan ring or the like; m represents an integer of 1 to 3; each independently represents a halogen atom, a hydroxy group, a cyano group, a C 1 -C 6  alkyl group or the like; n represents an integer of 0 to 8; when X and Y or two Y groups are attached on the same carbon atom, they may combine to each other to form a C 2 -C 6  alkylene group.

TECHNICAL FIELD

The present invention relates to compounds that are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases mainly caused by abnormal activity of tau protein kinase 1, such as neurodegenerative diseases (e.g. Alzheimer disease).

BACKGROUND ART

Alzheimer disease is progressive senile dementia, in which marked cerebral cortical atrophy is observed due to degeneration of nerve cells and decrease of nerve cell number. Pathologically, numerous senile plaques and neurofibrillary tangles are observed in brain. The number of patients has been increased with the increment of aged population, and the disease arises a serious social problem. Although various theories have been proposed, a cause of the disease has not yet been elucidated. Early resolution of the cause has been desired.

It has been known that the degree of appearance of two characteristic pathological changes of Alzheimer disease well correlates to the degree of intellectual dysfunction. Therefore, researches have been conducted from early 1980's to reveal the cause of the disease through molecular level investigations of components of the two pathological changes. Senile plaques accumulate extracellularly, and β amyloid protein has been elucidated as their main component (abbreviated as “A β” hereinafter in the specification: Biochem. Biophys. Res. Commun., 120, 855 (1984); EMBO J., 4, 2757 (1985); Proc. Natl. Acad. Sci. USA, 82, 4245 (1985)). In the other pathological change, i.e., the neurofibrillary tangles, a double-helical filamentous substance called paired helical filament (abbreviated as “PHF” hereinafter in the specification) accumulate intracellularly, and tau protein, which is a kind of microtubule-associated protein specific for brain, has been revealed as its main component (Proc. Natl. Acad. Sci. USA, 85, 4506 (1988); Neuron, 1, 827 (1988)).

Furthermore, on the basis of genetic investigations, presenilins 1 and 2 were found as causative genes of familial Alzheimer disease (Nature, 375, 754 (1995); Science, 269, 973 (1995); Nature. 376, 775 (1995)), and it has been revealed that presence of mutants of presenilins 1 and 2 promotes the secretion of A β (Neuron, 17, 1005 (1996); Proc. Natl. Acad. Sci. USA, 94, 2025 (1997)). From these results, it is considered that, in Alzheimer disease, A β abnormally accumulates and agglomerates due to a certain reason, which engages with the formation of PHF to cause death of nerve cells. It is also expected that extracellular outflow of glutamic acid and activation of glutamate receptor responding to the outflow may possibly be important factors in an early process of the nerve cell death caused by ischemic cerebrovascular accidents (Sai-shin Igaku [Latest Medicine], 49, 1506 (1994)).

It has been reported that kainic acid treatment that stimulates the AMPA receptor, one of glutamate receptor, increases mRNA of the amyloid precursor protein (abbreviated as “APP” hereinafter in the specification) as a precursor of A β (Society for Neuroscience Abstracts, 17, 1445 (1991)), and also promotes metabolism of APP (The Journal of Neuroscience, 10, 2400 (1990)). Therefore, it has been strongly suggested that the accumulation of A β is involved in cellular death due to ischemic cerebrovascular disorders. Other diseases in which abnormal accumulation and agglomeration of A β are observed include, for example, Down syndrome, cerebral bleeding due to solitary cerebral amyloid angiopathy, Lewy body disease (Shin-kei Shinpo [Nerve Advance], 34, 343 (1990); Tanpaku-shitu Kaku-san Koso [Protein, Nucleic Acid, Enzyme], 41, 1476 (1996)) and the like. Furthermore, as diseases showing neurofibrillary tangles due to the PHF accumulation, examples include progressive supranuclear palsy, subacute sclerosing panencephalitic parkinsonism, postencephalitic parkinsonism, pugilistic encephalitis, Guam parkinsonism-dementia complex, Lewy body disease and the like (Tanpakushitu Kakusan Koso [Protein, Nucleic Acid, Enzyme], 36, 2 (1991); Igaku no Ayumi [Progress of Medicine], 158, 511 (1991); Tanpakushitu Kakusan Koso [Protein, Nucleic Acid, Enzyme], 41, 1476 (1996)).

The tau protein is generally composed of a group of related proteins that forms several bands at molecular weights of 48-65 kDa in SDS-polyacrylamide gel electrophoresis, and it promotes the formation of microtubules. It has been verified that tau protein incorporated in the PHF in the brain suffering from Alzheimer disease is abnormally phosphorylated compared with usual tau protein (J. Biochem., 99, 1807 (1986); Proc. Natl. Acad. Sci. USA, 83, 4913 (1986)). An enzyme catalyzing the abnormal phosphorylation has been isolated. The protein was named as tau protein kinase 1 (abbreviated as “TPK1” hereinafter in the specification), and its physicochemical properties have been elucidated (Seikagaku [Biochemistry], 64, 308 (1992); J. Biol. Chem., 267, 10897 (1992)). Moreover, cDNA of rat TPK1 was cloned from a rat cerebral cortex cDNA library based on a partial amino acid sequence of TPK1, and its nucleotide sequence was determined and an amino acid sequence was deduced (Japanese Patent Un-examined Publication [Kokai] No. 6-239893/1994). As a result, it has been revealed that the primary structure of the rat TPK1 corresponds to that of the enzyme known as rat GSK-3 β (glycogen synthase kinase 3 β, FEBS Lett., 325, 167 (1993)).

It has been reported that A β, the main component of senile plaques, is neurotoxic (Science, 250, 279 (1990)). However, various theories have been proposed as for the reason why A β causes the cell death, and any authentic theory has not yet been established. Takashima et al. observed that the cell death was caused by A β treatment of fetal rat hippocampus primary culture system, and then found that the TPK1 activity was increased by A β treatment and the cell death by A β was inhibited by antisense of TPK1 (Proc. Natl. Acad. Sci. USA, 90, 7789 (1993); Japanese Patent Un-examined Publication [Kokai] No. 6-329551/1994).

In view of the foregoing, compounds which inhibit the TPK1 activity may possibly suppress the neurotoxicity of A β and the formation of PHF and inhibit the nerve cell death in the Alzheimer disease, thereby cease or defer the progress of the disease. The compounds may also be possibly used as a medicament for therapeutic treatment of ischemic cerebrovascular disorder, Down syndrome, cerebral amyloid angiopathy, cerebral bleeding due to Lewy body disease and the like by suppressing the cytotoxicity of A β. Furthermore, the compounds may possibly be used as a medicament for therapeutic treatment of neurodegenerative diseases such as progressive supranuclear palsy, subacute sclerosing panencephalitic parkinsonism, postencephalitic parkinsonism, pugilistic encephalitis, Guam parkinsonism-dementia complex, Lewy body disease, Pick's disease, corticobasal degeneration, frontotemporal dementia, vascular dementia, acute stroke and traumatic injuries, brain and spinal cord trauma, peripheral neuropathies, retinopathies and glaucoma; non-insulin dependent diabetes (such as diabetes type II), and obesity, manic depressive illness, schizophrenia, alopecia, cancers such as breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia and several virus-induced tumors.

As structurally similar compounds to the compounds of the present invention represented by formula (I) described later, compounds represented by the following formula (A) are known:

wherein R represents 2,6-dichlorobenzyl group, 2-(2-chlorophenyl)ethylamino group, 3-phenylpropylamino group, or 1-methyl-3-phenylpropylamino group (WO98/24782). The compounds represented by formula (A) are characterized to have 4-fluorophenyl group at the 5-position of the pyrimidine ring and a hydroxy group at the 4-position, and not falling within the scope of the present invention. Moreover, main pharmacological activity of the compounds represented by formula (A) is anti-inflammatory effect, whereas the compounds of the present invention represented by formula (I) are useful as a TPK1 inhibitor or a medicament for therapeutic treatment of neurodegenerative diseases, and therefore, their pharmacological activities are totally different to each other. Patent Document 1: WO 00/18758 Patent Document 2: WO 01/70728 Patent Document 3: WO 01/70729

DISCLOSURE OF THE INVENTION

An object of the present invention is to provide compounds useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases such as Alzheimer disease. More specifically, the object is to provide novel compounds useful as an active ingredient of a medicament that enables radical prevention and/or treatment of the neurodegenerative diseases such as Alzheimer disease by inhibiting the TPK1 activity to suppress the neurotoxicity of A β and the formation of the PHF and by inhibiting the death of nerve cells.

In order to achieve the foregoing object, the inventors of the present invention conducted screenings of various compounds having inhibitory activity against the phosphorylation of TPK1. As a result, they found that compounds represented by the following formula (I) had the desired activity and were useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of the aforementioned diseases. The present invention was achieved on the basis of these findings.

The present invention thus provides 3-substituted-4-pyrimidone derivatives represented by formula (I) or salts thereof, or solvates thereof or hydrates thereof:

wherein Q represents CH or nitrogen atom; R represents a C₁-C₁₂ alkyl group which may be substituted; the ring of:

represents piperazine ring or piperidine ring; each X independently represents X¹—X²— wherein X¹ represents an oxo group; a C₁-C₈ alkyl group which may be substituted; a C₃-C₈ cycloalkyl-group which may be substituted; an optionally partially hydrogenated C₆-C₁₀ aryl ring which may be substituted; an indan ring which may be substituted; an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom, and nitrogen atom, and having 5 to 10 ring-constituting atoms in total; an aralkyloxy group; a group represented by —N(Ra)(Rb) wherein Ra and Rb are the same or different and each is hydrogen, a C₁-C₄ alkyl group which may be substituted, an aralkyl group which may be substituted, a C₃-C₈ cycloalkyl group which may be substituted, an aryl group which may be substituted, C₁-C₈ alkylcarbonyl group which may be substituted, C₃-C₈ cycloalkylcarbonyl group which may be substituted, aralkycarbonyl group which may be substituted, C₆-C₁₀ arylcarbonyl group which may be substituted, C₁-C₈ alkysulfonyl group which may be substituted, C₃-C₈ cycloalkylsulfonyl group which may be substituted, aralkysulfonyl group which may be substituted, C₆-C₁₀ arylsulfonyl group which may be substituted, C₁-C₈ alkyloxycarbonyl group which may be substituted, C₃-C₈ cycloalkyloxycarbonyl group which may be substituted, aralkyoxycarbonyl group which may be substituted, C₆-C₁₀ aryloxycarbonyl group which may be substituted, aminocarbonyl, N—C₁-C₈ alkylaminocarbonyl group which may be substituted, N,N′-C₁-C₈ dialkylaminocarbonyl group which may be substituted, N—C₁-C₈ alkyl-N′-C₃-C₈ cycloalkylaminocarbonyl group which may be substituted, N—C₁-C₈ alkyl-N′-aralkylaminocarbonyl group which may be substituted, N—C₁-C₈ alkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted, C₃-C₈ cycloalkylaminocarbonyl group which may be substituted, N,N′-C₃-C₈ dicycloalkylaminoycarbonyl group which may be substituted, N—C₃-C₈ cycloalkyl-N′-aralkylaminocarbonyl group which may be substituted, N—C₃-C₈ cycloalkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted, aralkylaminocarbonyl group which may be substituted, N,N′-diaralkylaminocarbonyl group which may be substituted, N-aralkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted, C₆-C₁₀ arylaminocarbonyl group which may be substituted, N,N′-C₆-C₁₀ diarylaminocarbonyl group which may be substituted, or an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom, and nitrogen atom, and having 5 to 10 ring-constituting atoms in total; or Ra and Rb together with the adjacent nitrogen atom form a 4 to 7 membered heterocyclic ring which may further contain 1 to 4 groups selected from an oxygen atom, a sulfur atom, N-Rc (wherein Rc represents a hydrogen atom, a C₁-C₄ alkyl group which may be substituted, an aralkyl group which may be substituted, C₃-C₈ cycloalkyl group which may be substituted or an aryl group which may be substituted, C₁-C₈ alkylcarbonyl group which may be substituted, C₃-C₈ cycloalkylcarbonyl group which may be substituted, aralkycarbonyl group which may be substituted, C₆-C₁₀ arylcarbonyl group which may be substituted, C₁-C₈ alkysulfonyl group which may be substituted, C₃-C₈ cycloalkylsulfonyl group which may be substituted, aralkysulfonyl group which may be substituted, C₆-C₁₀ arylsulfonyl group which may be substituted, C₁-C₈ alkyloxycarbonyl group which may be substituted, C₃-C₈ cycloalkyloxycarbonyl group which may be substituted, aralkyoxycarbonyl group which may be substituted, C₆-C₁₀ aryloxycarbonyl group which may be substituted, aminocarbonyl, N—C₁-C₈ alkylaminocarbonyl group which may be substituted, N,N′-C₁-C₈ dialkylaminocarbonyl group which may be substituted, N—C₁-C₈ alkyl-N′-C₃-C₈ cycloalkylaminocarbonyl group which may be substituted, N—C₁-C₈ alkyl-N′-aralkylaminocarbonyl group which may be substituted, N—C₁-C₈ alkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted, C₃-C₈ cycloalkylaminocarbonyl group which may be substituted, N,N′-C₃-C₈ dicycloalkylaminoycarbonyl group which may be substituted, N—C₃-C₈ cycloalkyl-N′-aralkylaminocarbonyl group which may be substituted, N—C₃-C₈ cycloalkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted, aralkylaminocarbonyl group which may be substituted, N,N′-diaralkylaminocarbonyl group which may be substituted, N-aralkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted, C₆-C₁₀ arylaminocarbonyl group which may be substituted, N,N′-C₆-C₁₀ diarylaminocarbonyl group which may be substituted, or an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom, and nitrogen atom, and having 5 to 10 ring-constituting atoms in total), a carbonyl group, a sulfinyl group or a sulfonyl group in the ring, and said 4 to 7 membered heterocyclic ring may optionally be fused with an aryl group which may be substituted; X² represents a bond, a carbonyl group, a sulfinyl group, a sulfonyl group, an oxygen atom, a sulfur atom, a C₁-C₄ alkylene group which may be substituted or N-Rd (Rd represents a hydrogen atom, a C₁-C₄ alkyl group which may be substituted, an aralkyl group which may be substituted, C₃-C₈ cycloalkyl group which may be substituted or an aryl group which may be substituted, C₁-C₈ alkylcarbonyl group which may be substituted, C₃-C₈ cycloalkylcarbonyl group which may be substituted, aralkycarbonyl group which may be substituted, C₆-C₁₀ arylcarbonyl group which may be substituted, C₁-C₈ alkysulfonyl group which may be substituted, C₃-C₈ cycloalkylsulfonyl group which may be substituted, aralkysulfonyl group which may be substituted, C₆-C₁₀ arylsulfonyl group which may be substituted, C₁-C₈ alkyloxycarbonyl group which may be substituted, C₃-C₈ cycloalkyloxycarbonyl group which may be substituted, aralkyoxycarbonyl group which may be substituted, C₆-C₁₀ aryloxycarbonyl group which may be substituted, aminocarbonyl, N—C₁-C₈ alkylaminocarbonyl group which may be substituted, N,N′-C₁-C₈ dialkylaminocarbonyl group which may be substituted, N—C₁-C₈ alkyl-N′-C₃-C₈ cycloalkylaminocarbonyl group which may be substituted, N—C₁-C₈ alkyl-N′-aralkylaminocarbonyl group which may be substituted, N—C₁-C₈ alkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted, C₃-C₈ cycloalkylaminocarbonyl group which may be substituted, N,N′-C₃-C₈ dicycloalkylaminoycarbonyl group which may be substituted, N—C₃-C₈ cycloalkyl-N′-aralkylaminocarbonyl group which may be substituted, N—C₃-C₈ cycloalkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted, aralkylaminocarbonyl group which may be substituted, N,N′-diaralkylaminocarbonyl group which may be substituted, N-aralkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted, C₆-C₁₀ arylaminocarbonyl group which may be substituted, N,N′-C₆-C₁₀ diarylaminocarbonyl group which may be substituted, or an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom, and nitrogen atom, and having 5 to 10 ring-constituting atoms in total); m represents an integer of 1 to 3; each Y independently represents a halogen atom, a hydroxy group, a cyano group, Y¹-Y³—wherein Y¹ represents a C₁-C₈ alkyl group which may be substituted; a C₃-C₈ cycloalkyl group which may be substituted or a C₆-C₁₀ aryl ring which may be substituted; Y³ represents a carbonyl group, a sulfinyl group, a sulfonyl group, an oxygen atom, a sulfur atom, a C₁-C₄ alkylene group which may be substituted or N-Re (Re represents a hydrogen atom, a C₁-C₄ alkyl group which may be substituted, an aralkyl group which may be substituted, C₃-C₈ cycloalkyl group which may be substituted or an aryl group which may be substituted, C₁-C₈ alkylcarbonyl group which may be substituted, C₃-C₈ cycloalkylcarbonyl group which may be substituted, aralkycarbonyl group which may be substituted, C₆-C₁₀ arylcarbonyl group which may be substituted, C₁-C₈ alkysulfonyl group which may be substituted, C₃-C₈ cycloalkylsulfonyl group which may be substituted, aralkysulfonyl group which may be substituted, C₆-C₁₀ arylsulfonyl group which may be substituted, C₁-C₈ alkyloxycarbonyl group which may be substituted, C₃-C₈ cycloalkyloxycarbonyl group which may be substituted, aralkyoxycarbonyl group which may be substituted, C₆-C₁₀ aryloxycarbonyl group which may be substituted, aminocarbonyl, N—C₁-C₈ alkylaminocarbonyl group which may be substituted, N,N′-C₁-C₈ dialkylaminocarbonyl group which may be substituted, N—C₁-C₈ alkyl-N′-C₃-C₈ cycloalkylaminocarbonyl group which may be substituted, N—C₁-C₈ alkyl-N′-aralkylaminocarbonyl group which may be substituted, N—C₁-C₈ alkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted, C₃-C₈ cycloalkylaminocarbonyl group which may be substituted, N,N′-C₃-C₈ dicycloalkylaminoycarbonyl group which may be substituted, N—C₃-C₈ cycloalkyl-N′-aralkylaminocarbonyl group which may be substituted, N—C₃-C₈ cycloalkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted, aralkylaminocarbonyl group which may be substituted, N,N′-diaralkylaminocarbonyl group which may be substituted, N-aralkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted, C₆-C₁₀ arylaminocarbonyl group which may be substituted, N,N′-C₆-C₁₀ diarylaminocarbonyl group which may be substituted, or an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom, and nitrogen atom, and having 5 to 10 ring-constituting atoms in total), n represents an integer of 0 to 8; when X and Y or two Y groups are attached on the same carbon atom, they may combine to each other to form a C₂-C₆ alkylene group; and when m is 1, n is 0, and X is X¹—CO—,

-   -   (1) X does not bind to 3-position of unsubstituted 1-piperazinyl         group or does not bind to 3-position of a 4-alkyl-1-piperazinyl         group; or     -   (2) X does not bind to 3-position or 4-position of         non-substituted 1-piperidinyl group.

According to another aspect of the present invention, there is provided a medicament comprising as an active ingredient a substance selected from the group consisting of the 3-substituted-4-pyrimidone derivatives represented by formula (I) and the physiologically acceptable salts thereof, and the solvates thereof and the hydrates thereof. As preferred embodiments of the medicament, there are provided the aforementioned medicament which is used for preventive and/or therapeutic treatment of diseases caused by tau protein kinase 1 hyperactivity, and the aforementioned medicament which is used for preventive and/or therapeutic treatment of neurodegenerative diseases.

As further preferred embodiments of the present invention, there are provided the aforementioned medicament wherein the diseases are selected from the group consisting of Alzheimer disease, ischemic cerebrovascular accidents, Down syndrome, cerebral bleeding due to cerebral amyloid angiopathy, progressive supranuclear palsy, subacute sclerosing panencephalitic parkinsonism, postencephalitic parkinsonism, pugilistic encephalitis, Guam parkinsonism-dementia complex, Lewy body disease, Pick's disease, corticobasal degeneration and frontotemporal dementia, vascular dementia, acute stroke and traumatic injuries, brain and spinal cord trauma, peripheral neuropathies, retinopathies and glaucoma, non-insulin dependent diabetes (such as diabetes type II), and obesity, manic depressive illness, schizophrenia, alopecia, cancers such as breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia and several virus-induced tumors; and the aforementioned medicament in the form of pharmaceutical composition containing the above substance as an active ingredient together with one or more pharmaceutical additives.

The present invention further provides an inhibitor of tau protein kinase 1 comprising as an active ingredient a substance selected from the group consisting of the 3-substituted-4-pyrimidone derivatives of formula (I) and the salts thereof, and the solvates thereof and the hydrates thereof.

According to further aspects of the present invention, there are provided a method for preventive and/or therapeutic treatment of diseases caused by tau protein kinase 1 hyperactivity, which comprises the step of administering to a patient a preventively and/or therapeutically effective amount of a substance selected from the group consisting of the 3-substituted-4-pyrimidone derivatives of formula (I) and the physiologically acceptable salts thereof, and the solvates thereof and the hydrates thereof, and a use of a substance selected from the group consisting of the 3-substituted-4-pyrimidone derivatives of formula (I) and the physiologically acceptable salts thereof, and the solvates thereof and the hydrates thereof for the manufacture of the aforementioned medicament.

BEST MODE FOR CARRYING OUT THE INVENTION

In the present specification, each group has the following meanings.

The alkyl group used herein may be either linear or branched.

The C₁-C₁₂ alkyl group represented by R may be, for example, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group, isopentyl group, neopentyl group, 1,1-dimethylpropyl group, n-hexyl group, isohexyl group, or a linear or branched heptyl group, octyl group, nonyl group, decyl group, undecyl group or dodecyl group. Particularly preferred R is methyl group.

In the specification, when a functional group is defined as “which may be substituted” or “optionally substituted”, the number of substituents as well as their types and substituting positions are not particularly limited, and when two or more substituents are present, they may be the same or different.

When the C₁-C₁₂ alkyl group represented by R has one or more substituents, the alkyl group may have one or more substituents selected from, for example, the groups consisting of a C₃-C₈ cycloalkyl group such as cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, cyclooctyl group; a C₁-C₅ alkoxy group such as methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, tert-butoxy group; C₁-C₈ alkylamino group or C₂-C₆ dialkylamino group; a C₆-C₁₀ aryl group such as phenyl group, 1-naphthyl group, and 2-naphthyl group.

The C₁-C₈ alkyl group may be, for example, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group, isopentyl group, neopentyl group, 1,1-dimethylpropyl group, n-hexyl group, isohexyl group, or a linear or branched heptyl group or octyl group.

The C₁-C₄ alkyl group may be, for example, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group or tert-butyl group.

The C₃-C₈ cycloalkyl group may be, for example, cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group or cyclooctyl group.

The optionally partially hydrogenated C₆-C₁₀ aryl ring may be, for example a benzene ring, a naphthalene ring, an indan ring or a 1,2,3,4-tetrahydronaphthalene ring.

The heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom, and nitrogen atom, and having 5 to 10 ring-constituting atoms in total may be, for example, furan ring, dihydrofuran ring, tetrahydrofuran ring, pyran ring, dihydropyran ring, tetrahydropyran ring, benzofuran ring, dihydrobenzofuran, isobenzofuran ring, benzodioxol ring, chromene ring, chroman ring, isochroman ring, thiophene ring, benzothiophene ring, pyrrole ring, pyrroline ring, pyrrolidine ring, 2-oxopyrrolidine ring, imidazole ring, imidazoline ring, imidazolidine ring, pyrazole ring, pyrazoline ring, pyrazolidine ring, triazole ring, tetrazole ring, pyridine ring, pyridine oxide ring, piperidine ring, 4-oxopiperidine ring, pyrazine ring, piperazine ring, homopiperazine ring, pyrimidine ring, pyridazine ring, indole ring, indoline ring, isoindole ring, isoindoline ring, indazole ring, benzimidazole ring, benzotriazole ring, tetrahydroisoquinoline ring, benzothiazolinone ring, benzoxazolinone ring, purine ring, quinolizine ring, quinoline ring, phthalazine ring, naphthyridine ring, quinoxaline ring, quinazoline ring, cinnoline ring, pteridine ring, oxazole ring, oxazolidine ring, isoxazole ring, isoxazolidine ring, oxadiazole ring, thiazole ring, benzothiazole ring, thiazylidine ring, isothiazole ring, isothiazolidine ring, benzodioxole ring, dioxane ring, benzodioxane ring, dithian ring, morpholine ring, thiomorpholine ring, or phthalimide ring.

The aralkyl group may be, for example, benzyl group, 2-phenylethyl group, 3-phenylpropyl group or 4-phenylbutyl group.

The C₁-C₄ alkylene group may be, for example, methylene, ethylene, trimethylene or tetramethylene.

The 4 to 7 membered heterocyclic ring which may further contain 1 to 4 groups may be, for example, pyrrolidine, piperidine, morpholine, thiomorpholine, piperazine, homopiperazine, 2-oxopyrrolidine, pyrrole, imidazoline, imidazole, pyrazole, pyrroline, pyrrolidine, imidazolidine, imidazolone, succinimide or glutarimide.

The C₆-C₁₀ aryl ring may be, for example, a benzene ring or a naphthalene ring, and the aryl group or the C₆-C₁₀ aryl group may be, for example, a phenyl group or naphthyl group.

When the ring represented by X or X¹ has one or more substituents, the ring may have one or more substituents selected from the group consisting of a C₁-C₅ alkyl group such as methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, neopentyl group, 1,1-dimethylpropyl group; C₃-C₆ cycloalkyl group such as cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group; a C₃-C₆ cycloalkyl-C₁-C₄ alkyl group such as cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl; a C₁-C₄ hydroxyalkyl group such as hydroxymethyl, hydroxyethyl, hydroxypropyl; a halogen atom such as fluorine atom, chlorine atom, bromine atom, and iodine atom; a C₁-C₅ halogenated alkyl group such as trifluoromethyl group; hydroxyl group; cyano group; nitro group; formyl group; a benzene ring which may be substituted; a naphthalene ring which may be substituted; an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and having 5 to 10 ring-constituting atoms in total (same as the above); an amino group; an N—C₃-C₆ cycloalkyl-N—C₁-C₄ alkylaminoalkyl group wherein said C₁-C₄ alkyl may be substituted by hydroxy group or C₁-C₄ alkoxy group such as N-cyclopropyl-N-methylaminomethyl group, N-cyclohexyl-N-methylaminomethyl group; a C₁-C₆ monoalkylaminomethyl group such as methylaminomethyl group, ethylaminomethyl group, propylaminomethyl group, isoproylaminomethyl group, butylaminomethyl group, isobutylaminomethyl group, tert-butylaminomethyl group, pentylaminomethyl group, isopentylaminomethyl group; a C₂-C₁₀ dialkylaminomethyl group such as dimethylaminomethyl group, diethylaminomethyl group, ethylmethylaminomethyl group, methylpropylaminomethyl group; pyrrolidinylmethyl group; piperidinylmethyl group; morpholinomethyl group; piperazinylmethyl group; pyrrolylmethyl group; imidazolylmethyl group; pyrazolylmethyl group; triazolylmethyl group; and a group of the formula -E-Rf wherein E represents O, S, SO, SO₂, CO or N(R⁴) and Rf represents a C₁-C₅ alkyl group (same as the above), a C₄-C₇ cycloalkyl group (same as the above), a C₄-C₇ cycloalkylalkl group (same as the above), a C₁-C₅ hydroxyalkyl group (same as the above), a benzene ring which may be substituted, a naphthalene ring which may be substituted, an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom and nitrogen atom, and having 5 to 10 ring-constituting atoms in total (same as the above), an N—C₃-C₆ cycloalkyl-N—C₁-C₄ alkylaminoalkyl group (same as the above), a C₁-C₅ monoalkylaminoalkyl group (same as the above), C₂-C₁₀ dialkylaminoalkyl group (same as the above), pyrrolidinylmethyl group, piperidinylmethyl group, morpholinomethyl group, piperazinylmethyl group, pyrrolylmethyl group, imidazolylmethyl group, pyrazolylmethyl group or triazolylmethyl group,

C₁-C₈ alkylcarbonyl group which may be substituted,

C₃-C₈ cycloalkylcarbonyl group which may be substituted,

aralkycarbonyl group which may be substituted,

C₆-C₁₀ arylcarbonyl group which may be substituted,

C₁-C₈ alkysulfonyl group which may be substituted,

C₃-C₈ cycloalkylsulfonyl group which may be substituted,

aralkysulfonyl group which may be substituted,

C₆-C₁₀ arylsulfonyl group which may be substituted,

C₁-C₈ alkyloxycarbonyl group which may be substituted,

C₃-C₈ cycloalkyloxycarbonyl group which may be substituted,

aralkyoxycarbonyl group which may be substituted,

C₆-C₁₀ aryloxycarbonyl group which may be substituted,

aminocarbonyl,

N—C₁-C₈ alkylaminocarbonyl group which may be substituted,

N,N′-C₁-C₈ dialkylaminocarbonyl group which may be substituted,

N—C₁-C₈ alkyl-N′-C₃-C₈ cycloalkylaminocarbonyl group which may be substituted,

N—C₁-C₈ alkyl-N′-aralkylaminocarbonyl group which may be substituted,

N—C₁-C₈ alkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted,

C₃-C₈ cycloalkylaminocarbonyl group which may be substituted,

N,N′-C₃-C₈ dicycloalkylaminoycarbonyl group which may be substituted,

N—C₃-C₈ cycloalkyl-N′-aralkylaminocarbonyl group which may be substituted,

N—C₃-C₈ cycloalkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted,

aralkylaminocarbonyl group which may be substituted,

N,N′-diaralkylaminocarbonyl group which may be substituted,

N-aralkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted,

C₆-C₁₀ arylaminocarbonyl group which may be substituted,

N,N′-C₆-C₁₀ diarylaminocarbonyl group which may be substituted,

and R⁴ represents a hydrogen atom, a C₁-C₄ alkyl group which may be substituted,

an aralkyl group which may be substituted, C₃-C₈ cycloalkyl group which may be substituted or an aryl group which may be substituted,

C₁-C₈ alkylcarbonyl group which may be substituted,

C₃-C₈ cycloalkylcarbonyl group which may be substituted,

aralkycarbonyl group which may be substituted,

C₆-C₁₀ arylcarbonyl group which may be substituted,

C₁-C₈ alkysulfonyl group which may be substituted,

C₃-C₈ cycloalkylsulfonyl group which may be substituted,

aralkysulfonyl group which may be substituted,

C₆-C₁₀ arylsulfonyl group which may be substituted,

C₁-C₈ alkyloxycarbonyl group which may be substituted,

C₃-C₈ cycloalkyloxycarbonyl group which may be substituted,

aralkyoxycarbonyl group which may be substituted,

C₆-C₁₀ aryloxycarbonyl group which may be substituted,

aminocarbonyl,

N—C₁-C₈ alkylaminocarbonyl group which may be substituted,

N,N′-C₁-C₈ dialkylaminocarbonyl group which may be substituted,

N—C₁-C₈ alkyl-N′-C₃-C₈ cycloalkylaminocarbonyl group which may be substituted,

N—C₁-C₈ alkyl-N′-aralkylaminocarbonyl group which may be substituted,

N—C₁-C₈ alkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted,

C₃-C₈ cycloalkylaminocarbonyl group which may be substituted,

N,N′-C₃-C₈ dicycloalkylaminoycarbonyl group which may be substituted,

N—C₃-C₈ cycloalkyl-N′-aralkylaminocarbonyl group which may be substituted,

N—C₃-C₈ cycloalkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted,

aralkylaminocarbonyl group which may be substituted,

N,N′-diaralkylaminocarbonyl group which may be substituted,

N-aralkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted,

C₆-C₁₀ arylaminocarbonyl group which may be substituted,

N,N′-C₆-C₁₀ diarylaminocarbonyl group which may be substituted,

or an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom, and nitrogen atom, and having 5 to 10 ring-constituting atoms in total.

When the C₆-C₁₀ aryl ring represented by Y¹ has one or more substituents, the ring may be substituted by one or more substituents selected from the groups consisting of halogen atoms, a C₁-C₅ alkyl group, a C₃-C₆ cycloalkyl group, a C₃-C₆ cycloalkyloxy group, a C₁-C₅ alkoxy group, a C₄-C₇ cycloalkylalkoxy, a C₁-C₅ alkylthio group, a C₁-C₅ alkylsulfonyl group, a C₁-C₅ halogenated alkyl, and a benzene ring.

When the ring represented by X, X¹ or Y¹ has one or more substituents, the substituent may further have one or more substituents selected from the group consisting of a C₁-C₅ alkyl group such as methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, neopentyl group, 1,1-dimethylpropyl group; C₃-C₆ cycloalkyl group such as cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group; a C₃-C₆ cycloalkyloxy group such as cyclopropyloxy group, cyclobutyloxy group, cyclopentyloxy group, cyclohexyloxy group; C₁-C₄ hydroxyalkyl group such as hydroxymethyl group, hydroxyethyl group, hydroxypropyl group, hydroxybutyl group; a C₁-C₅ alkoxy group such as methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, tert-butoxy group, pentyloxy group, and isopentyloxy group; a C₄-C₇ cycloalkylalkoxy group such as cyclopropylmethoxy group, cyclopentylmethoxy group; a C₁-C₅ alkylthio group such as methylthio group, ethylthio group, propylthio group, butylthio group, and pentylthio group; a C₁-C₅ alkylsulfonyl group such as methanesulfonyl group, ethanesulfonyl group, propanesulfonyl group, butanesulfonyl group, and pentanesulfonyl group; a halogen atom such as fluorine atom, chlorine atom, bromine atom, and iodine atom; a C₁-C₅ halogenated alkyl group such as trifluoromethyl group; a C₁-C₅ halogenated alkoxy group such as trifluoromethoxy group, 2,2,2-trifluoroethoxy group; hydroxyl group; cyano group; nitro group; formyl group; a C₂-C₆ alkylcarbonyl group such as acetyl group, propionyl group, butyryl group, and valeryl group; amino group; a C₁-C₅ monoalkylamino group such as methylamino group, ethylamino group, propylamino group, isopropylamino group, butylamino group, isobutylamino group, tert-butylamino group, pentylamino group, and isopentylamino group; a C₂-C₁₀ dialkylamino group such as dimethylamino group, ethylmethylamino group, diethylamino group, methylpropylamino group, and diisopropylamino group; a cyclic amino group such as pyrrolidinyl group, piperidino group, morpholino group; a C₂-C₁₀ monoalkylaminomethyl group such as methylaminomethyl group, ethylaminomethyl group, propylaminomethyl group, isoproylaminomethyl group, butylaminomethyl group, isobutylaminomethyl group, tert-butylaminomethyl group, pentylaminomethyl group, isopentylaminomethyl; a C₃-C₁₁ dialkylaminomethyl group such as dimethylaminomethyl group, diethylaminomethyl group, ethylmethylaminomethyl group, methylpropylaminomethyl group; a phenyl group; an aralkyloxy group such as benzyloxy, 2-phenylethyloxy, 3-phenylpropyloxy; an aralkyloxycarbonyl group such as benzyloxycarbonyl, 2-phenylehoxycarbonyl; an C₂-C₄ alkanoyloxy-C₁-C₄ alkyl group such as acetyloxymethyl, 2-acetyloxyethyl, 2-propionyloxyethyl; an alkanoylamino group such as acetylamino, propionylamino, butyrylamino; N—C₁-C₄ alkyl-N-alkanoylamino group such as N-methyl-N-acetylamino, N-ethyl-N-acetylamino, N-methyl-N-propionylamino, N-methyl-N-butyrylamino; a heterocyclic ring amino group such as pyridylamino, pyrimidinylamino, thienylamino, furylamino; N—C₁-C₄ alkyl-N-heterocyclic ring amino group such as N-methyl-N-pyridylamino, N-methyl-N-pyrimidinylamino, N-methyl-N-thienylamino, N-methyl-N-furylamino; a diheterocyclic ring amino group such as dipyridylamino, dipyrimidinylamino, dithienylamino, difurylamino, and the like.

R may preferably be a C₁-C₃ alkyl group, more preferably a methyl group or an ethyl group. The substituent of the alkyl group may preferably be a C₃-C₈ alkyl group.

X may preferably be a benzene ring which may be substituted, a benzyl group which may be substituted, a naphthyl group which may be substituted, a benzofuran ring which may be substituted, a dihydrobenzofuran ring which may be substituted, a benzoxazole ring which may be substituted, a benzisoxazole ring which may be substituted, a benzothiophene ring which may be substituted, a benzothiazole ring which may be substituted, a benzisothiazole ring which may be substituted, and a benzopyrazole ring which may be substituted; more preferably a benzene ring which may be substituted, a benzyl group which may be substituted. Substituent of X may preferably be selected from the group consisting of a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a hydroxy group, a nitro group, a cyano group, a perhalogenated C₁-C₄ alkyl group, a carboxyl group, a C₁-C₄ alkoxycarbonyl group, a C₁-C₄ alkylthio group, a C₁-C₄ alkoxysulfonyl group, amino group which may be substituted by a C₁-C₄ alkyl group, a benzene ring which may be substituted, and a cyclic amino group which may be substituted.

The compounds represented by the aforementioned formula (I) may form a salt. Examples of the salt include, when an acidic group exists, salts of alkali metals and alkaline earth metals such as lithium, sodium, potassium, magnesium, and calcium; salts of ammonia and amines such as methylamine, dimethylamine, trimethylamine, dicyclohexylamine, tris(hydroxymethyl)aminomethane, N,N-bis(hydroxyethyl)piperazine, 2-amino-2-methyl-1-propanol, ethanolamine, N-methylglucamine, and L-glucamine; or salts with basic amino acids such as lysine, δ-hydroxylysine, and arginine. When a basic group exists, examples include salts with mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid; salts with organic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, acetic acid, propionic acid, tartaric acid, fumaric acid, maleic acid, malic acid, oxalic acid, succinic acid, citric acid, benzoic acid, mandelic acid, cinnamic acid, lactic acid, glycolic acid, glucuronic acid, ascorbic acid, nicotinic acid, and salicylic acid; or salts with acidic amino acids such as aspartic acid, and glutamic acid.

In addition to the 3-substituted-4-pyrimidone derivatives represented by the aforementioned formula (I) and salts thereof, their solvates and hydrates also fall within the scope of the present invention. The 3-substituted-4-pyrimidone derivatives represented by the aforementioned formula (I) may have one or more asymmetric carbon atoms. As for the stereochemistry of such asymmetric carbon atoms, they may independently be in either (R) and (S) configuration, and the pyrimidone derivative may exist as stereoisomers such as optical isomers, or diastereoisomers. Any stereoisomers in a pure form, any mixtures of stereoisomers, racemates and the like fall within the scope of the present invention.

Preferred compounds of the present invention are represented by formula (II):

wherein Q, R, X, Y are the same as those defined above; p is 0 or 1; q is 0 or 1; r is an integer of 0 to 6; p+q is 1 or 2; and Z represents N or CZ¹ wherein Z¹ represents hydrogen atom or Y.

Examples of more preferred classes of compounds represented by formula (II) include:

(1) those wherein R represents a C₁-C₃ alkyl group which may be substituted by a C₃-C₈ cycloalkyl group;

(2) the compounds of the above (1) wherein R is methyl group or ethyl group; Y is in 3-, 4- or 5-position of the piperazine ring or the piperidine ring; p+q is 1; and r is an integer of 0 to 3;

(3) the compounds of the above (2) wherein X is a C₁-C₈ alkyl group which may be substituted or a C₆-C₁₀ aryl ring which may be substituted; Y is a C₁-C₆ alkyl group which may be substituted; p is 1; q is 0; r is an integer of 0 to 3; and Z is N or CH;

(4) the compounds of the above (3) wherein X is a benzene ring which may be substituted, a benzyl group which may be substituted; Y is a methyl group which may be substituted; Z is N and r is 0 or 1;

(5) the compounds of the above (2) wherein X is a benzene ring which may be substituted, a benzyl group which may be substituted, a benzoyl group which may be substituted, or a benzisothiazol ring which may be substituted; Y is a methyl group which may be substituted; Z is N and p is 0;

(6) the compounds of the above (2) wherein X is a C₁-C₈ alkyl group substituted by a benzene ring which may be substituted or a benzene ring which may be substituted;

Y is a hydroxy group, a cyano group, or Y¹—CO— wherein Y¹ is a C₁-C₈ alkyl group; Z is CH or C—Y and r is 0 or 1; and

(7) the compounds of the above (6) wherein X is a benzyl group which may be substituted or a benzene ring which may be substituted; Y is a hydroxy group, a cyano group, or an acetyl group; Z is CH or C—Y and r is 0 or 1.

Examples of particularly preferred classes of compounds represented by formula (II) include:

(1) those wherein R is methyl group, Y is CH₃O—CO— group or CH₃CH₂O—CO— group, Z is N, p is, 0, q is 1, r is 0 or 1 and Y is in 3-position of the piperazine ring;

(2) those wherein R is methyl group, Y is methyl group, benzyl group or acetyl group, Z is N, p is 1, q is 0, r is 0 or 1 and Y is in 4-position of the piperazine ring;

(3) those wherein R is methyl group, Y is methyl group, Z is N, p is 1, q is 0, r is 1 to 3 and Y is in 3-, 4-, or 5-position of the piperazine ring;

(4) those wherein R is methyl group, Y is hydroxyl group or cyano group, Z is CH, p is 1, q is 0, r is 0 or 1 and X and Y are attached on the same carbon atom;

(5) those wherein R is methyl group, Y is hydroxyl group, cyano group or acetyl group, Z is C—Y, p is 0, q is 1 and r is 1.

Examples of preferred compounds of the present invention are shown in the tables below. However, the scope of the present invention is not limited to the following compounds. TABLE 1

No. R1 R2 R3 R4 R5 R6 XA1 CH3— H H CH3— H H XA2 CH3— H H CH3CH2— H H XA3 CH3— H H

H H XA4 CH3— H H

H H XA5 CH3— H H

H H XA6 CH3— H H

H H XA7 CH3— H H

H H XA8 CH3— H H

H H XA9 CH3— H H

H H XA10 CH3— H H

H H XA11 CH3— H H

H H XA12 CH3— H H

H H XA13 CH3— H H

H H XA14 CH3— H H

H H XA15 CH3— H H

H H XA16 CH3— H H

H H XA17 CH3— H H n-C8H17— H H XA18 CH3— H H

H H XA19 CH3— H H

H H XA20 CH3— H H

H H XA21 CH3— H H

H H XA22 CH3— H H

H H XA23 CH3— H H

H H XA24 CH3— H H

H H XA25 CH3— H H

H H XA26 CH3— H H

H H XA27 CH3— H H

H H XA28 CH3— H H

H H XA29 CH3— H H

H H XA30 CH3— H H

H H XA31 CH3— H H

H H XA32 CH3— H H

H H XA33 CH3— H H

H H XA34 CH3— H H

H H XA35 CH3— H H

H H XA36 CH3— H H

H H XA37 CH3— H H

H H XA38 CH3— H H

H H XA39 CH3— H H

H H XA40 CH3— H H

H H XA41 CH3— H H

H H XA42 CH3— H H

H H XA43 CH3— H H

H H XA44 CH3— H H

H H XA45 CH3— H H

H H XA46 CH3— H H

H H XA47 CH3— H H

H H XA48 CH3— H H

H H XA49 CH3— H H

H H XA50 CH3— H H

H H XA51 CH3— H H

H H XA52 CH3— H H

H H XA53 CH3— H H

H H XA54 CH3— H H

H H XA55 CH3— H H

H H XA56 CH3— H H

H H XA57 CH3— H H

H H XA58 CH3— H H

H H XA59 CH3— H H

H H XA60 CH3— H H

H H XA61 CH3— H H

H H XA62 CH3— H H

H H XA63 CH3— H H

H H XA64 CH3— H H

H H XA65 CH3— H H

H H XA66 CH3— H H

H H XA67 CH3— H H

H H XA68 CH3— H H

H H XA69 CH3— H H

H H XA70 CH3— H H

H H XA71 CH3— H H

H H XA72 CH3— H H

H H XA73 CH3— H H

H H XA74 CH3— H H

H H XA75 CH3— H H

H H XA76 CH3— H H

H H XA77 CH3— H H

H H XA78 CH3— H H

H H XA79 CH3— H H

H H XA80 CH3— H H

H H XA81 CH3— H H

H H XA82 CH3— H H

H H XA83 CH3— H H

H H XA84 CH3— H H

H H XA85 CH3— H H

H H XA86 CH3— H H

H H XA87 CH3— H H

H H XA88 CH3— H H

H H XA89 CH3— H H

H H XA90 CH3— H H

H H XA91 CH3— H H

H H XA92 CH3— H H

H H XA93 CH3— H H

H H XA94 CH3— H H

H H XA95 CH3— H H

H H XA96 CH3— H H

H H XA97 CH3— H H

H H XA98 CH3— H H

H H XA99 CH3— H H

H H XA100 CH3— H H

H H XA101 CH3— H H

H H XA102 CH3— H H

H H XA103 CH3— H H

H H XA104 CH3— H H

H H XA105 CH3— H H

H H XA106 CH3— H H

H H XA107 CH3— H H

H H XA108 CH3— H H

H H XA109 CH3— H H

H H XA110 CH3— H H

H H XA111 CH3— H H

H H XA112 CH3— H H

H H XA113 CH3— H H

H H XA114 CH3— H H

H H XA115 CH3— H H

H H XA116 CH3— H H

H H XA117 CH3— H H

H H XA118 CH3— H H

H H XA119 CH3— H H

H H XA120 CH3— H H

H H XA121 CH3— H H

H H XA122 CH3— H H

H H XA123 CH3— H H

H H XA124 CH3— H H

H H XA125 CH3— H H

H H XA126 CH3— H H

H H XA127 CH3— H H

H H XA128 CH3— H H

H H XA129 CH3— H H

H H XA130 CH3— H H

H H XA131 CH3— H H

H H XA132 CH3— H H

H H XA133 CH3— H H

H H XA134 CH3— H H

H H XA135 CH3— H H

H H XA136 CH3— H H

H H XA137 CH3— H H

H H XA138 CH3— H H

H H XA139 CH3— H H

H H XA140 CH3— H H

H H XA141 CH3— H H

H H XA142 CH3— H H

H H XA143 CH3— H H

H H XA144 CH3— H H

H H XA145 CH3— H H

H H XA146 CH3— H H

H H XA147 CH3— H H

H H XA148 CH3— H H

H H XA149 CH3— H H

H H XA150 CH3— H H

H H XA151 CH3— H H

H H XA152 CH3— H H

H H XA153 CH3— H H

H H XA154 CH3— H H

H H XA155 CH3— H H

H H XA156 CH3— H H

H H XA157 CH3— H H

H H XA158 CH3— H H

H H XA159 CH3— H H

H H XA160 CH3— H H

H H XA161 CH3— H H

H H XA162 CH3— H H

H H XA163 CH3— H H

H H XA164 CH3— H H

H H XA165 CH3— H H

H H XA166 CH3— H H

H H XA167 CH3— H H

H H XA168 CH3— H H

H H XA169 CH3— H H

H H XA170 CH3— H H

H H XA171 CH3— H H

H H XA172 CH3— H H

H H XA173 CH3— H H

H H XA174 CH3— H H

H H XA175 CH3— H H

H H XA176 CH3— H H

H H XA177 CH3— H H

H H XA178 CH3— H H

H H XA179 CH3— H H

H H XA180 CH3— H H

H H XA181 CH3— H H

H H XA182 CH3— H H

H H XA183 CH3— H H

H H XA184 CH3— H H

H H XA185 CH3— H H

H H XA186 CH3— H H

H H XA187 CH3— H H

H H XA188 CH3— H H

H H XA189 CH3— H H

H H XA190 CH3— H H

H H XA191 CH3— H H

H H XA192 CH3— H H

H H XA193 CH3— H H

H H XA194 CH3— H H

H H XA195 CH3— H H

H H XA196 CH3— H H

H H XA197 CH3— H H

H H XA198 CH3— H H

H H XA199 CH3— H H

H H XA200 CH3— H H

H H XA201 CH3— H H

H H XA202 CH3— H H

H H XA203 CH3— H H

H H XA204 CH3— H H

H H XA205 CH3—

H H H H XA206 CH3—

H CH3— H H XA207 CH3—

H CH3CH2— H H XA208 CH3—

H

H H XA209 CH3—

H

H H XA210 CH3—

H

H H XA211 CH3—

H

H H XA212 CH3—

H

H H XA213 CH3—

H

H H XA214 CH3—

H

H H XA215 CH3—

H

H H XA216 CH3—

H

H H XA217 CH3—

H

H H XA218 CH3—

H

H H XA219 CH3—

H

H H XA220 CH3—

H

H H XA221 CH3—

H

H H XA222 CH3—

H n-C8H17— H H XA223 CH3—

H

H H XA224 CH3—

H

H H XA225 CH3—

H

H H XA226 CH3—

H

H H XA227 CH3—

H

H H XA228 CH3—

H

H H XA229 CH3—

H

H H XA230 CH3—

H

H H XA231 CH3—

H

H H XA232 CH3—

H

H H XA233 CH3—

H

H H XA234 CH3—

H

H H XA235 CH3—

H

H H XA236 CH3—

H

H H XA237 CH3—

H

H H XA238 CH3—

H

H H XA239 CH3—

H

H H XA240 CH3—

H

H H XA241 CH3—

H

H H XA242 CH3—

H

H H XA243 CH3—

H

H H XA244 CH3—

H

H H XA245 CH3—

H

H H XA246 CH3—

H

H H XA247 CH3—

H

H H XA248 CH3—

H

H H XA249 CH3—

H

H H XA250 CH3—

H

H H XA251 CH3—

H

H H XA252 CH3—

H

H H XA253 CH3—

H

H H XA254 CH3—

H

H H XA255 CH3—

H

H H XA256 CH3—

H

H H XA257 CH3—

H

H H XA258 CH3—

H

H H XA259 CH3—

H

H H XA260 CH3—

H

H H XA261 CH3—

H

H H XA262 CH3—

H

H H XA263 CH3—

H

H H XA264 CH3—

H

H H XA265 CH3—

H

H H XA266 CH3—

H

H H XA267 CH3—

H

H H XA268 CH3—

H

H H XA269 CH3—

H

H H XA270 CH3—

H H H H XA271 CH3—

H CH3— H H XA272 CH3—

H CH3CH2— H H XA273 CH3—

H

H H XA274 CH3—

H

H H XA275 CH3—

H

H H XA276 CH3—

H

H H XA277 CH3—

H

H H XA278 CH3—

H

H H XA279 CH3—

H

H H XA280 CH3—

H

H H XA281 CH3—

H

H H XA282 CH3—

H

H H XA283 CH3—

H

H H XA284 CH3—

H

H H XA285 CH3—

H

H H XA286 CH3—

H

H H XA287 CH3—

H n-C8H17— H H XA288 CH3—

H

H H XA289 CH3—

H

H H XA290 CH3—

H

H H XA291 CH3—

H

H H XA292 CH3—

H

H H XA293 CH3—

H

H H XA294 CH3—

H

H H XA295 CH3—

H

H H XA296 CH3—

H

H H XA297 CH3—

H

H H XA298 CH3—

H

H H XA299 CH3—

H

H H XA300 CH3—

H

H H XA301 CH3—

H

H H XA302 CH3—

H

H H XA303 CH3—

H

H H XA304 CH3—

H

H H XA305 CH3—

H

H H XA306 CH3—

H

H H XA307 CH3—

H

H H XA308 CH3—

H

H H XA309 CH3—

H

H H XA310 CH3—

H

H H XA311 CH3—

H

H H XA312 CH3—

H

H H XA313 CH3—

H

H H XA314 CH3—

H

H H XA315 CH3—

H

H H XA316 CH3—

H

H H XA317 CH3—

H

H H XA318 CH3—

H

H H XA319 CH3—

H

H H XA320 CH3—

H

H H XA321 CH3—

H

H H XA322 CH3—

H

H H XA323 CH3—

H

H H XA324 CH3—

H

H H XA325 CH3—

H

H H XA326 CH3—

H

H H XA327 CH3—

H

H H XA328 CH3—

H

H H XA329 CH3—

H

H H XA330 CH3—

H

H H XA331 CH3—

H

H H XA332 CH3—

H

H H XA333 CH3—

H

H H XA334 CH3—

H

H H XA335 CH3— CH3— H H H H XA336 CH3— CH3CH2— H H H H XA337 CH3—

H H H H XA338 CH3—

H H H H XA339 CH3—

H H H H XA340 CH3—

H H H H XA341 CH3—

H H H H XA342 CH3—

H H H H XA343 CH3—

H H H H XA344 CH3—

H H H H XA345 CH3—

H H H H XA346 CH3—

H H H H XA347 CH3—

H H H H XA348 CH3—

H H H H XA349 CH3—

H H H H XA350 CH3—

H H H H XA351 CH3— n-C8H17— H H H H XA352 CH3—

H H H H XA353 CH3—

H H H H XA354 CH3—

H H H H XA355 CH3—

H H H H XA356 CH3—

H H H H XA357 CH3—

H H H H XA358 CH3—

H H H H XA359 CH3—

H H H H XA360 CH3—

H H H H XA361 CH3—

H H H H XA362 CH3—

H H H H XA363 CH3—

H H H H XA364 CH3—

H H H H XA365 CH3—

H H H H XA366 CH3—

H H H H XA367 CH3—

H H H H XA368 CH3—

H H H H XA369 CH3—

H H H H XA370 CH3—

H H H H XA371 CH3—

H H H H XA372 CH3—

H H H H XA373 CH3—

H H H H XA374 CH3—

H H H H XA375 CH3—

H H H H XA376 CH3—

H H H H XA377 CH3—

H H H H XA378 CH3—

H H H H XA379 CH3—

H H H H XA380 CH3—

H H H H XA381 CH3—

H H H H XA382 CH3—

H H H H XA383 CH3—

H H H H XA384 CH3—

H H H H XA385 CH3—

H H H H XA386 CH3—

H H H H XA387 CH3—

H H H H XA388 CH3—

H H H H XA389 CH3—

H H H H XA390 CH3—

H H H H XA391 CH3—

H H H H XA392 CH3—

H H H H XA393 CH3—

H H H H XA394 CH3—

H H H H XA395 CH3—

H H H H XA396 CH3—

H H H H XA397 CH3—

H H H H XA398 CH3—

H H H H XA399 CH3—

H H H H XA400 CH3—

H H H H XA401 CH3—

H H H H XA402 CH3—

H H H H XA403 CH3—

H H H H XA404 CH3—

H H H H XA405 CH3—

H H H H XA406 CH3—

H H H H XA407 CH3—

H H H H XA408 CH3—

H H H H XA409 CH3—

H H H H XA410 CH3—

H H H H XA411 CH3—

H H H H XA412 CH3—

H H H H XA413 CH3—

H H H H XA414 CH3—

H H H H XA415 CH3—

H H H H XA416 CH3—

H H H H XA417 CH3—

H H H H XA418 CH3—

H H H H XA419 CH3—

H H H H XA420 CH3—

H H H H XA421 CH3—

H H H H XA422 CH3—

H H H H XA423 CH3—

H H H H XA424 CH3—

H H H H XA425 CH3—

H H H H XA426 CH3—

H H H H XA427 CH3—

H H H H XA428 CH3—

H H H H XA429 CH3—

H H H H XA430 CH3—

H H H H XA431 CH3—

H H H H XA432 CH3—

H H H H XA433 CH3—

H H H H XA434 CH3—

H H H H XA435 CH3—

H H H H XA436 CH3—

H H H H XA437 CH3—

H H H H XA438 CH3—

H H H H XA439 CH3—

H H H H XA440 CH3—

H H H H XA441 CH3—

H H H H XA442 CH3—

H H H H XA443 CH3—

H H H H XA444 CH3—

H H H H XA445 CH3—

H H H H XA446 CH3—

H H H H XA447 CH3—

H H H H XA448 CH3—

H H H H XA449 CH3—

H H H H XA450 CH3—

H H H H XA451 CH3—

H H H H XA452 CH3—

H H H H XA453 CH3—

H H H H XA454 CH3—

H H H H XA455 CH3—

H H H H XA456 CH3—

H H H H XA457 CH3—

H H H H XA458 CH3—

H H H H XA459 CH3—

H H H H XA460 CH3—

H H H H XA461 CH3—

H H H H XA462 CH3—

H H H H XA463 CH3—

H H H H XA464 CH3—

H H H H XA465 CH3—

H H H H XA466 CH3—

H H H H XA467 CH3—

H H H H XA468 CH3—

H H H H XA469 CH3—

H H H H XA470 CH3—

H H H H XA471 CH3—

H H H H XA472 CH3—

H H H H XA473 CH3—

H H H H XA474 CH3—

H H H H XA475 CH3—

H H H H XA476 CH3—

H H H H XA477 CH3—

H H H H XA478 CH3—

H H H H XA479 CH3—

H H H H XA480 CH3—

H H H H XA481 CH3—

H H H H XA482 CH3—

H H H H XA483 CH3—

H H H H XA484 CH3—

H H H H XA485 CH3—

H H H H XA486 CH3—

H H H H XA487 CH3—

H H H H XA488 CH3—

H H H H XA489 CH3—

H H H H XA490 CH3—

H H H H XA491 CH3—

H H H H XA492 CH3—

H H H H XA493 CH3—

H H H H XA494 CH3—

H H H H XA495 CH3—

H H H H XA496 CH3—

H H H H XA497 CH3—

H H H H XA498 CH3—

H H H H XA499 CH3—

H H H H XA500 CH3—

H H H H XA501 CH3—

H H H H XA502 CH3—

H H H H XA503 CH3—

H H H H XA504 CH3—

H H H H XA505 CH3—

H H H H XA506 CH3—

H H H H XA507 CH3—

H H H H XA508 CH3—

H H H H XA509 CH3—

H H H H XA510 CH3—

H H H H XA511 CH3—

H H H H XA512 CH3—

H H H H XA513 CH3—

H H H H XA514 CH3—

H H H H XA515 CH3—

H H H H XA516 CH3—

H H H H XA517 CH3—

H H H H XA518 CH3—

H H H H XA519 CH3—

H H H H XA520 CH3—

H H H H XA521 CH3—

H H H H XA522 CH3—

H H H H XA523 CH3—

H H H H XA524 CH3—

H H H H XA525 CH3—

H H H H XA526 CH3—

H H H H XA527 CH3—

H H H H XA528 CH3—

H H H H XA529 CH3—

H H H H XA530 CH3—

H H H H XA531 CH3—

H H H H XA532 CH3—

H H H H XA533 CH3—

H H H H XA534 CH3—

H H H H XA535 CH3—

H H H H XA536 CH3—

H H H H XA537 CH3—

H H H H XA538 CH3—

H H H H XA539 CH3—

H H H H XA540 CH3—

H H H H XA541 CH3—

H H H H XA542 CH3—

H H H H XA543 CH3—

H H H H XA544 CH3—

H H H H XA545 CH3—

H H H H XA546 CH3—

H H H H XA547 CH3—

H H H H XA548 CH3—

H H H H XA549 CH3—

H H H H XA550 CH3—

H H H H XA551 CH3—

H H H H XA552 CH3—

H H H H XA553 CH3—

H H H H XA554 CH3—

H H H H XA555 CH3—

H H H H XA556 CH3—

H H H H XA557 CH3—

H H H H XA558 CH3—

H H H H XA559 CH3—

H H H H XA560 CH3—

H H H H XA561 CH3—

H H H H XA562 CH3—

H H H H XA563 CH3—

H H H H XA564 CH3—

H H H H XA565 CH3—

H H H H XA566 CH3—

H H H H XA567 CH3—

H H H H XA568 CH3—

H H H H XA569 CH3—

H H H H XA570 CH3—

H H H H XA571 CH3—

H H H H XA572 CH3—

H H H H XA573 CH3—

H H H H XA574 CH3—

H H H H XA575 CH3—

H H H H XA576 CH3—

H H H H XA577 CH3—

H H H H XA578 CH3—

H H H H XA579 CH3—

H H H H XA580 CH3—

H H H H XA581 CH3—

H H H H XA582 CH3—

H H H H XA583 CH3—

H H H H XA584 CH3—

H H H H XA585 CH3—

H H H H XA586 CH3—

H H H H XA587 CH3—

H H H H XA588 CH3—

H H H H XA589 CH3—

H H H H XA590 CH3—

H H H H XA591 CH3—

H H H H XA592 CH3—

H H H H XA593 CH3—

H H H H XA594 CH3—

H H H H XA595 CH3—

H H H H XA596 CH3—

H H H H XA597 CH3—

H H H H XA598 CH3—

H H H H XA599 CH3—

H H H H XA600 CH3—

H H H H XA601 CH3—

H H H H XA602 CH3—

H H H H XA603 CH3—

H H H H XA604 CH3—

H H H H XA605 CH3—

H H H H XA606 CH3—

H H H H XA607 CH3—

H H H H XA608 CH3—

H H H H XA609 CH3—

H H H H XA610 CH3—

H H H H XA611 CH3—

H H H H XA612 CH3—

H H H H XA613 CH3—

H H H H XA614 CH3—

H H H H XA615 CH3—

H H H H XA616 CH3—

H H H H XA617 CH3—

H H H H XA618 CH3—

H H H H XA619 CH3—

H H H H XA620 CH3—

H H H H XA621 CH3—

H H H H XA622 CH3—

H H H H XA623 CH3— CH3— H CH3 H H XA624 CH3— CH3CH2— H CH3 H H XA625 CH3—

H CH3 H H XA626 CH3—

H CH3 H H XA627 CH3—

H CH3 H H XA628 CH3—

H CH3 H H XA629 CH3—

H CH3 H H XA630 CH3—

H CH3 H H XA631 CH3—

H CH3 H H XA632 CH3—

H CH3 H H XA633 CH3—

H CH3 H H XA634 CH3—

H CH3 H H XA635 CH3—

H CH3 H H XA636 CH3—

H CH3 H H XA637 CH3—

H CH3 H H XA638 CH3—

H CH3 H H XA639 CH3— n-C8H17— H CH3 H H XA640 CH3—

H CH3 H H XA641 CH3—

H CH3 H H XA642 CH3—

H CH3 H H XA643 CH3—

H CH3 H H XA644 CH3—

H CH3 H H XA645 CH3—

H CH3 H H XA646 CH3—

H CH3 H H XA647 CH3—

H CH3 H H XA648 CH3—

H CH3 H H XA649 CH3—

H CH3 H H XA650 CH3—

H CH3 H H XA651 CH3—

H CH3 H H XA652 CH3—

H CH3 H H XA653 CH3—

H CH3 H H XA654 CH3—

H CH3 H H XA655 CH3—

H CH3 H H XA656 CH3—

H CH3 H H XA657 CH3—

H CH3 H H XA658 CH3—

H CH3 H H XA659 CH3—

H CH3 H H XA660 CH3—

H CH3 H H XA661 CH3—

H CH3 H H XA662 CH3—

H CH3 H H XA663 CH3—

H CH3 H H XA664 CH3—

H CH3 H H XA665 CH3—

H CH3 H H XA666 CH3—

H CH3 H H XA667 CH3—

H CH3 H H XA668 CH3—

H CH3 H H XA669 CH3—

H CH3 H H XA670 CH3—

H CH3 H H XA671 CH3—

H CH3 H H XA672 CH3—

H CH3 H H XA673 CH3—

H CH3 H H XA674 CH3—

H CH3 H H XA675 CH3—

H CH3 H H XA676 CH3—

H CH3 H H XA677 CH3—

H CH3 H H XA678 CH3—

H CH3 H H XA679 CH3—

H CH3 H H XA680 CH3—

H CH3 H H XA681 CH3—

H CH3 H H XA682 CH3—

H CH3 H H XA683 CH3—

H CH3 H H XA684 CH3—

H CH3 H H XA685 CH3—

H CH3 H H XA686 CH3—

H CH3 H H XA687 CH3—

H CH3 H H XA688 CH3—

H CH3 H H XA689 CH3—

H CH3 H H XA690 CH3—

H CH3 H H XA691 CH3—

H CH3 H H XA692 CH3—

H CH3 H H XA693 CH3—

H CH3 H H XA694 CH3—

H CH3 H H XA695 CH3—

H CH3 H H XA696 CH3—

H CH3 H H XA697 CH3—

H CH3 H H XA698 CH3—

H CH3 H H XA699 CH3—

H CH3 H H XA700 CH3—

H CH3 H H XA701 CH3—

H CH3 H H XA702 CH3—

H CH3 H H XA703 CH3—

H CH3 H H XA704 CH3—

H CH3 H H XA705 CH3—

H CH3 H H XA706 CH3—

H CH3 H H XA707 CH3—

H CH3 H H XA708 CH3—

H CH3 H H XA709 CH3—

H CH3 H H XA710 CH3—

H CH3 H H XA711 CH3—

H CH3 H H XA712 CH3—

H CH3 H H XA713 CH3—

H CH3 H H XA714 CH3—

H CH3 H H XA715 CH3—

H CH3 H H XA716 CH3—

H CH3 H H XA717 CH3—

H CH3 H H XA718 CH3—

H CH3 H H XA719 CH3—

H CH3 H H XA720 CH3—

H CH3 H H XA721 CH3—

H CH3 H H XA722 CH3—

H CH3 H H XA723 CH3—

H CH3 H H XA724 CH3—

H CH3 H H XA725 CH3—

H CH3 H H XA726 CH3—

H CH3 H H XA727 CH3—

H CH3 H H XA728 CH3—

H CH3 H H XA729 CH3—

H CH3 H H XA730 CH3—

H CH3 H H XA731 CH3—

H CH3 H H XA732 CH3—

H CH3 H H XA733 CH3—

H CH3 H H XA734 CH3—

H CH3 H H XA735 CH3—

H CH3 H H XA736 CH3—

H CH3 H H XA737 CH3—

H CH3 H H XA738 CH3—

H CH3 H H XA739 CH3—

H CH3 H H XA740 CH3—

H CH3 H H XA741 CH3—

H CH3 H H XA742 CH3—

H CH3 H H XA743 CH3—

H CH3 H H XA744 CH3—

H CH3 H H XA745 CH3—

H CH3 H H XA746 CH3—

H CH3 H H XA747 CH3—

H CH3 H H XA748 CH3—

H CH3 H H XA749 CH3—

H CH3 H H XA750 CH3—

H CH3 H H XA751 CH3—

H CH3 H H XA752 CH3—

H CH3 H H XA753 CH3—

H CH3 H H XA754 CH3—

H CH3 H H XA755 CH3—

H CH3 H H XA756 CH3—

H CH3 H H XA757 CH3—

H CH3 H H XA758 CH3—

H CH3 H H XA759 CH3—

H CH3 H H XA760 CH3—

H CH3 H H XA761 CH3—

H CH3 H H XA762 CH3—

H CH3 H H XA763 CH3—

H CH3 H H XA764 CH3—

H CH3 H H XA765 CH3—

H CH3 H H XA766 CH3—

H CH3 H H XA767 CH3—

H CH3 H H XA768 CH3—

H CH3 H H XA769 CH3—

H CH3 H H XA770 CH3—

H CH3 H H XA771 CH3—

H CH3 H H XA772 CH3—

H CH3 H H XA773 CH3—

H CH3 H H XA774 CH3—

H CH3 H H XA775 CH3—

H CH3 H H XA776 CH3—

H CH3 H H XA777 CH3—

H CH3 H H XA778 CH3—

H CH3 H H XA779 CH3—

H CH3 H H XA780 CH3—

H CH3 H H XA781 CH3—

H CH3 H H XA782 CH3—

H CH3 H H XA783 CH3—

H CH3 H H XA784 CH3—

H CH3 H H XA785 CH3—

H CH3 H H XA786 CH3—

H CH3 H H XA787 CH3—

H CH3 H H XA788 CH3—

H CH3 H H XA789 CH3—

H CH3 H H XA790 CH3—

H CH3 H H XA791 CH3—

H CH3 H H XA792 CH3—

H CH3 H H XA793 CH3—

H CH3 H H XA794 CH3—

H CH3 H H XA795 CH3—

H CH3 H H

TABLE 1

No. R1 R2 R3 R4 R5 R6 XA796 CH3—

H CH3 H H XA797 CH3—

H CH3 H H XA798 CH3—

H CH3 H H XA799 CH3—

H CH3 H H XA800 CH3—

H CH3 H H XA801 CH3—

H CH3 H H XA802 CH3—

H CH3 H H XA803 CH3—

H CH3 H H XA804 CH3—

H CH3 H H XA805 CH3—

H CH3 H H XA806 CH3—

H CH3 H H XA807 CH3—

H CH3 H H XA808 CH3—

H CH3 H H XA809 CH3—

H CH3 H H XA810 CH3—

H CH3 H H XA811 CH3—

H CH3 H H XA812 CH3—

H CH3 H H XA813 CH3—

H CH3 H H XA814 CH3—

H CH3 H H XA815 CH3—

H CH3 H H XA816 CH3—

H CH3 H H XA817 CH3—

H CH3 H H XA818 CH3—

H CH3 H H XA819 CH3—

H CH3 H H XA820 CH3—

H CH3 H H XA821 CH3—

H CH3 H H XA822 CH3—

H CH3 H H XA823 CH3—

H CH3 H H XA824 CH3—

H CH3 H H XA825 CH3—

H CH3 H H XA826 CH3—

H CH3 H H XA827 CH3—

H CH3 H H XA828 CH3—

H CH3 H H XA829 CH3—

H CH3 H H XA830 CH3—

H CH3 H H XA831 CH3—

H CH3 H H XA832 CH3—

H CH3 H H XA833 CH3—

H CH3 H H XA834 CH3—

H CH3 H H XA835 CH3—

H CH3 H H XA836 CH3—

H CH3 H H XA837 CH3—

H CH3 H H XA838 CH3—

H CH3 H H XA839 CH3—

H CH3 H H XA840 CH3—

H CH3 H H XA841 CH3—

H CH3 H H XA842 CH3—

H CH3 H H XA843 CH3—

H CH3 H H XA844 CH3—

H CH3 H H XA845 CH3—

H CH3 H H XA846 CH3—

H CH3 H H XA847 CH3—

H CH3 H H XA848 CH3—

H CH3 H H XA849 CH3—

H CH3 H H XA850 CH3—

H CH3 H H XA851 CH3—

H CH3 H H XA852 CH3—

H CH3 H H XA853 CH3—

H CH3 H H XA854 CH3—

H CH3 H H XA855 CH3—

H CH3 H H XA856 CH3—

H CH3 H H XA857 CH3—

H CH3 H H XA858 CH3—

H CH3 H H XA859 CH3—

H CH3 H H XA860 CH3—

H CH3 H H XA861 CH3—

H CH3 H H XA862 CH3—

H CH3 H H XA863 CH3—

H CH3 H H XA864 CH3—

H CH3 H H XA865 CH3—

H CH3 H H XA866 CH3—

H CH3 H H XA867 CH3—

H CH3 H H XA868 CH3—

H CH3 H H XA869 CH3—

H CH3 H H XA870 CH3—

H CH3 H H XA871 CH3—

H CH3 H H XA872 CH3—

H CH3 H H XA873 CH3—

H CH3 H H XA874 CH3—

H CH3 H H XA875 CH3—

H CH3 H H XA876 CH3—

H CH3 H H XA877 CH3—

H CH3 H H XA878 CH3—

H CH3 H H XA879 CH3—

H CH3 H H XA880 CH3—

H CH3 H H XA881 CH3—

H CH3 H H XA882 CH3—

H CH3 H H XA883 CH— CH3— H

H H XA884 CH3— CH3CH2— H

H H XA885 CH3—

H

H H XA886 CH3—

H

H H XA887 CH3—

H

H H XA888 CH3—

H

H H XA889 CH3—

H

H H XA890 CH3—

H

H H XA891 CH3—

H

H H XA892 CH3—

H

H H XA893 CH3—

H

H H XA894 CH3—

H

H H XA895 CH3—

H

H H XA896 CH3—

H

H H XA897 CH3—

H

H H XA898 CH3—

H

H H XA899 CH3— n-C8H17— H

H H XA900 CH3—

H

H H XA901 CH3—

H

H H XA902 CH3—

H

H H XA903 CH3—

H

H H XA904 CH3—

H

H H XA905 CH3—

H

H H XA906 CH3—

H

H H XA907 CH3—

H

H H XA908 CH3—

H

H H XA909 CH3—

H

H H XA910 CH3—

H

H H XA911 CH3—

H

H H XA912 CH3—

H

H H XA913 CH3—

H

H H XA914 CH3—

H

H H XA915 CH3—

H

H H XA916 CH3—

H

H H XA917 CH3—

H

H H XA918 CH3—

H

H H XA919 CH3—

H

H H XA920 CH3—

H

H H XA921 CH3—

H

H H XA922 CH3—

H

H H XA923 CH3—

H

H H XA924 CH3—

H

H H XA925 CH3—

H

H H XA926 CH3—

H

H H XA927 CH3—

H

H H XA928 CH3—

H

H H XA929 CH3—

H

H H XA930 CH3—

H

H H XA931 CH3—

H

H H XA932 CH3—

H

H H XA933 CH3—

H

H H XA934 CH3—

H

H H XA935 CH3—

H

H H XA936 CH3—

H

H H XA937 CH3—

H

H H XA938 CH3—

H

H H XA939 CH3‘3

H

H H XA940 CH3—

H

H H XA941 CH3—

H

H H XA942 CH3—

H

H H XA943 CH3—

H

H H XA944 CH3—

H

H H XA945 CH3—

H

H H XA946 CH3—

H

H H XA947 CH3—

H

H H XA948 CH3—

H

H H XA949 CH3—

H

H H XA950 CH3—

H

H H XA951 CH3—

H

H H XA952 CH3—

H

H H XA953 CH3—

H

H H XA954 CH3—

H

H H XA955 CH3—

H

H H XA956 CH3—

H

H H XA957 CH3—

H

H H XA958 CH3—

H

H H XA959 CH3—

H

H H XA960 CH3—

H

H H XA961 CH3—

H

H H XA962 CH3—

H

H H XA963 CH3—

H

H H XA964 CH3—

H

H H XA965 CH3—

H

H H XA966 CH3—

H

H H XA967 CH3—

H

H H XA968 CH3—

H

H H XA969 CH3—

H

H H XA970 CH3—

H

H H XA971 CH3—

H

H H XA972 CH3—

H

H H XA973 CH3—

H

H H XA974 CH3—

H

H H XA975 CH3—

H

H H XA976 CH3—

H

H H XA977 CH3—

H

H H XA978 CH3—

H

H H XA979 CH3—

H

H H XA980 CH3—

H

H H XA981 CH3—

H

H H XA982 CH3—

H

H H XA983 CH3—

H

H H XA984 CH3—

H

H H XA985 CH3—

H

H H XA986 CH3—

H

H H XA987 CH3—

H

H H XA988 CH3—

H

H H XA989 CH3—

H

H H XA990 CH3—

H

H H XA991 CH3—

H

H H XA992 CH3—

H

H H XA993 CH3—

H

H H XA994 CH3—

H

H H XA995 CH3—

H

H H XA996 CH3—

H

H H XA997 CH3—

H

H H XA998 CH3—

H

H H XA999 CH3—

H

H H XA1000 CH3—

H

H H XA1001 CH3—

H

H H XA1002 CH3—

H

H H XA1003 CH3—

H

H H XA1004 CH3—

H

H H XA1005 CH3—

H

H H XA1006 CH3—

H

H H XA1007 CH3—

H

H H XA1008 CH3—

H

H H XA1009 CH3—

H

H H XA1010 CH3—

H

H H XA1011 CH3—

H

H H XA1012 CH3—

H

H H XA1013 CH3—

H

H H XA1014 CH3—

H

H H XA1015 CH3—

H

H H XA1016 CH3—

H

H H XA1017 CH3—

H

H H XA1018 CH3—

H

H H XA1019 CH3—

H

H H XA1020 CH3—

H

H H XA1021 CH3—

H

H H XA1022 CH3—

H

H H XA1023 CH3—

H

H H XA1024 CH3—

H

H H XA1025 CH3—

H

H H XA1026 CH3—

H

H H XA1027 CH3—

H

H H XA1028 CH3—

H

H H XA1029 CH3—

H

H H XA1030 CH3—

H

H H XA1031 CH3—

H

H H XA1032 CH3—

H

H H XA1033 CH3—

H

H H XA1034 CH3—

H

H H XA1035 CH3—

H

H H XA1036 CH3—

H

H H XA1037 CH3—

H

H H XA1038 CH3—

H

H H XA1039 CH3—

H

H H XA1040 CH3—

H

H H XA1041 CH3—

H

H H XA1042 CH3—

H

H H XA1043 CH3—

H

H H XA1044 CH3—

H

H H XA1045 CH3—

H

H H XA1046 CH3—

H

H H XA1047 CH3—

H

H H XA1048 CH3—

H

H H XA1049 CH3—

H

H H XA1050 CH3—

H

H H XA1051 CH3—

H

H H XA1052 CH3—

H

H H XA1053 CH3—

H

H H XA1054 CH3—

H

H H XA1055 CH3—

H

H H XA1056 CH3—

H

H H XA1057 CH3—

H

H H XA1058 CH3—

H

H H XA1059 CH3—

H

H H XA1060 CH3—

H

H H XA1061 CH3—

H

H H XA1062 CH3—

H

H H XA1063 CH3—

H

H H XA1064 CH3—

H

H H XA1065 CH3—

H

H H XA1066 CH3—

H

H H XA1067 CH3—

H

H H XA1068 CH3—

H

H H XA1069 CH3—

H

H H XA1070 CH3—

H

H H XA1071 CH3—

H

H H XA1072 CH3—

H

H H XA1073 CH3—

H

H H XA1074 CH3—

H

H H XA1075 CH3—

H

H H XA1076 CH3—

H

H H XA1077 CH3—

H

H H XA1078 CH3—

H

H H XA1079 CH3—

H

H H XA1080 CH3—

H

H H XA1081 CH3—

H

H H XA1082 CH3—

H

H H XA1083 CH3—

H

H H XA1084 CH3—

H

H H XA1085 CH3—

H

H H XA1086 CH3—

H

H H XA1087 CH3—

H

H H XA1088 CH3—

H

H H XA1089 CH3—

H

H H XA1090 CH3—

H

H H XA1091 CH3—

H

H H XA1092 CH3—

H

H H XA1093 CH3—

H

H H XA1094 CH3—

H

H H XA1095 CH3—

H

H H XA1096 CH3—

H

H H XA1097 CH3—

H

H H XA1098 CH3—

H

H H XA1099 CH3—

H

H H XA1100 CH3—

H

H H XA1101 CH3—

H

H H XA1102 CH3—

H

H H XA1103 CH3—

H

H H XA1104 CH3—

H

H H XA1105 CH3—

H

H H XA1106 CH3—

H

H H XA1107 CH3—

H

H H XA1108 CH3—

H

H H XA1109 CH3—

H

H H XA1110 CH3—

H

H H XA1111 CH3—

H

H H XA1112 CH3—

H

H H XA1113 CH3—

H

H H XA1114 CH3—

H

H H XA1115 CH3—

H

H H XA1116 CH3—

H

H H XA1117 CH3—

H

H H XA1118 CH3—

H

H H XA1119 CH3—

H

H H XA1120 CH3—

H

H H XA1121 CH3—

H

H H XA1122 CH3—

H

H H XA1123 CH3—

H

H H XA1124 CH3—

H

H H XA1125 CH3—

H

H H XA1126 CH3—

H

H H XA1127 CH3—

H

H H XA1128 CH3—

H

H H XA1129 CH3—

H

H H XA1130 CH3—

H

H H XA1131 CH3—

H

H H XA1132 CH3—

H

H H XA1133 CH3—

H

H H XA1134 CH3—

H

H H XA1135 CH3—

H

H H XA1136 CH3—

H

H H XA1137 CH3—

H

H H XA1138 CH3—

H

H H XA1139 CH3—

H

H H XA1140 CH3—

H

H H XA1141 CH3—

H

H H XA1142 CH3—

H

H H XA1143 CH3— CH3— H

H H XA1144 CH3— CH3CH2— H

H H XA1145 CH3—

H

H H XA1146 CH3—

H

H H XA1147 CH3—

H

H H XA1148 CH3—

H

H H XA1149 CH3—

H

H H XA1150 CH3—

H

H H XA1151 CH3—

H

H H XA1152 CH3—

H

H H XA1153 CH3—

H

H H XA1154 CH3—

H

H H XA1155 CH3—

H

H H XA1156 CH3—

H

H H XA1157 CH3—

H

H H XA1158 CH3—

H

H H XA1159 CH3— n-C8H17— H

H H XA1160 CH3—

H

H H XA1161 CH3—

H

H H XA1162 CH3—

H

H H XA1163 CH3—

H

H H XA1164 CH3—

H

H H XA1165 CH3—

H

H H XA1166 CH3—

H

H H XA1167 CH3—

H

H H XA1168 CH3—

H

H H XA1169 CH3—

H

H H XA1170 CH3—

H

H H XA1171 CH3—

H

H H XA1172 CH3—

H

H H XA1173 CH3—

H

H H XA1174 CH3—

H

H H XA1175 CH3—

H

H H XA1176 CH3—

H

H H XA1177 CH3—

H

H H XA1178 CH3—

H

H H XA1179 CH3—

H

H H XA1180 CH3—

H

H H XA1181 CH3—

H

H H XA1182 CH3—

H

H H XA1183 CH3‘3

H

H H XA1184 CH3—

H

H H XA1185 CH3—

H

H H XA1186 CH3—

H

H H XA1187 CH3—

H

H H XA1188 CH3—

H

H H XA1189 CH3—

H

H H XA1190 CH3—

H

H H XA1191 CH3—

H

H H XA1192 CH3—

H

H H XA1193 CH3—

H

H H XA1194 CH3—

H

H H XA1195 CH3—

H

H H XA1196 CH3—

H

H H XA1197 CH3—

H

H H XA1198 CH3—

H

H H XA1199 CH3—

H

H H XA1200 CH3—

H

H H XA1201 CH3—

H

H H XA1202 CH3—

H

H H XA1203 CH3—

H

H H XA1204 CH3—

H

H H XA1205 CH3—

H

H H XA1206 CH3—

H

H H XA1207 CH3—

H

H H XA1208 CH3—

H

H H XA1209 CH3—

H

H H XA1210 CH3—

H

H H XA1211 CH3—

H

H H XA1212 CH3—

H

H H XA1213 CH3—

H

H H XA1214 CH3—

H

H H XA1215 CH3—

H

H H XA1216 CH3—

H

H H XA1217 CH3—

H

H H XA1218 CH3—

H

H H XA1219 CH3—

H

H H XA1220 CH3—

H

H H XA1221 CH3—

H

H H XA1222 CH3—

H

H H XA1223 CH3—

H

H H XA1224 CH3—

H

H H XA1225 CH3—

H

H H XA1226 CH3—

H

H H XA1227 CH3—

H

H H XA1228 CH3—

H

H H XA1229 CH3—

H

H H XA1230 CH3—

H

H H XA1231 CH3—

H

H H XA1232 CH3—

H

H H XA1233 CH3—

H

H H XA1234 CH3—

H

H H XA1235 CH3—

H

H H XA1236 CH3—

H

H H XA1237 CH3—

H

H H XA1238 CH3—

H

H H XA1239 CH3—

H

H H XA1240 CH3—

H

H H XA1241 CH3—

H

H H XA1242 CH3—

H

H H XA1243 CH3—

H

H H XA1244 CH3—

H

H H XA1245 CH3—

H

H H XA1246 CH3—

H

H H XA1247 CH3—

H

H H XA1248 CH3—

H

H H XA1249 CH3—

H

H H XA1250 CH3—

H

H H XA1251 CH3—

H

H H XA1252 CH3—

H

H H XA1253 CH3—

H

H H XA1254 CH3—

H

H H XA1255 CH3—

H

H H XA1256 CH3—

H

H H XA1257 CH3—

H

H H XA1258 CH3—

H

H H XA1259 CH3—

H

H H XA1260 CH3—

H

H H XA1261 CH3—

H

H H XA1262 CH3—

H

H H XA1263 CH3—

H

H H XA1264 CH3—

H

H H XA1265 CH3—

H

H H XA1266 CH3—

H

H H XA1267 CH3—

H

H H XA1268 CH3—

H

H H XA1269 CH3—

H

H H XA1270 CH3—

H

H H XA1271 CH3—

H

H H XA1272 CH3—

H

H H XA1273 CH3—

H

H H XA1274 CH3—

H

H H XA1275 CH3—

H

H H XA1276 CH3—

H

H H XA1277 CH3—

H

H H XA1278 CH3—

H

H H XA1279 CH3—

H

H H XA1280 CH3—

H

H H XA1281 CH3—

H

H H XA1282 CH3—

H

H H XA1283 CH3—

H

H H XA1284 CH3—

H

H H XA1285 CH3—

H

H H XA1286 CH3—

H

H H XA1287 CH3—

H

H H XA1288 CH3—

H

H H XA1289 CH3—

H

H H XA1290 CH3—

H

H H XA1291 CH3—

H

H H XA1292 CH3—

H

H H XA1293 CH3—

H

H H XA1294 CH3—

H

H H XA1295 CH3—

H

H H XA1296 CH3—

H

H H XA1297 CH3—

H

H H XA1298 CH3—

H

H H XA1299 CH3—

H

H H XA1300 CH3—

H

H H XA1301 CH3—

H

H H XA1302 CH3—

H

H H XA1303 CH3—

H

H H XA1304 CH3—

H

H H XA1305 CH3—

H

H H XA1306 CH3—

H

H H XA1307 CH3—

H

H H XA1308 CH3—

H

H H XA1309 CH3—

H

H H XA1310 CH3—

H

H H XA1311 CH3—

H

H H XA1312 CH3—

H

H H XA1313 CH3—

H

H H XA1314 CH3—

H

H H XA1315 CH3—

H

H H XA1316 CH3—

H

H H XA1317 CH3—

H

H H XA1318 CH3—

H

H H XA1319 CH3—

H

H H XA1320 CH3—

H

H H XA1321 CH3—

H

H H XA1322 CH3—

H

H H XA1323 CH3—

H

H H XA1324 CH3—

H

H H XA1325 CH3—

H

H H XA1326 CH3—

H

H H XA1327 CH3—

H

H H XA1328 CH3—

H

H H XA1329 CH3—

H

H H XA1330 CH3—

H

H H XA1331 CH3—

H

H H XA1332 CH3—

H

H H XA1333 CH3—

H

H H XA1334 CH3—

H

H H XA1335 CH3—

H

H H XA1336 CH3—

H

H H XA1337 CH3—

H

H H XA1338 CH3—

H

H H XA1339 CH3—

H

H H XA1340 CH3—

H

H H XA1341 CH3—

H

H H XA1342 CH3—

H

H H XA1343 CH3—

H

H H XA1344 CH3—

H

H H XA1345 CH3—

H

H H XA1346 CH3—

H

H H XA1347 CH3—

H

H H XA1348 CH3—

H

H H XA1349 CH3—

H

H H XA1350 CH3—

H

H H XA1351 CH3—

H

H H XA1352 CH3—

H

H H XA1353 CH3—

H

H H XA1354 CH3—

H

H H XA1355 CH3—

H

H H XA1356 CH3—

H

H H XA1357 CH3—

H

H H XA1358 CH3—

H

H H XA1359 CH3—

H

H H XA1360 CH3—

H

H H XA1361 CH3—

H

H H XA1362 CH3—

H

H H XA1363 CH3—

H

H H XA1364 CH3—

H

H H XA1365 CH3—

H

H H XA1366 CH3—

H

H H XA1367 CH3—

H

H H XA1368 CH3—

H

H H XA1369 CH3—

H

H H XA1370 CH3—

H

H H XA1371 CH3—

H

H H XA1372 CH3—

H

H H XA1373 CH3—

H

H H XA1374 CH3—

H

H H XA1375 CH3—

H

H H XA1376 CH3—

H

H H XA1377 CH3—

H

H H XA1378 CH3—

H

H H XA1379 CH3—

H

H H XA1380 CH3—

H

H H XA1381 CH3—

H

H H XA1382 CH3—

H

H H XA1383 CH3—

H

H H XA1384 CH3—

H

H H XA1385 CH3—

H

H H XA1386 CH3—

H

H H XA1387 CH3—

H

H H XA1388 CH3—

H

H H XA1389 CH3—

H

H H XA1390 CH3—

H

H H XA1391 CH3—

H

H H XA1392 CH3—

H

H H XA1393 CH3—

H

H H XA1394 CH3—

H

H H XA1395 CH3—

H

H H XA1396 CH3—

H

H H XA1397 CH3—

H

H H XA1398 CH3—

H

H H XA1399 CH3—

H

H H XA1400 CH3—

H

H H XA1401 CH3—

H

H H XA1402 CH3—

H

H H XA1403 CH3— CH3— CH3— H H H XA1404 CH3— CH3CH2— CH3— H H H XA1405 CH3—

CH3— H H H XA1406 CH3—

CH3— H H H XA1407 CH3—

CH3— H H H XA1408 CH3—

CH3— H H H XA1409 CH3—

CH3— H H H XA1410 CH3—

CH3— H H H XA1411 CH3—

CH3— H H H XA1412 CH3—

CH3— H H H XA1413 CH3—

CH3— H H H XA1414 CH3—

CH3— H H H XA1415 CH3—

CH3— H H H XA1416 CH3—

CH3— H H H XA1417 CH3—

CH3— H H H XA1418 CH3—

CH3— H H H XA1419 CH3— n-C8H17— CH3— H H H XA1420 CH3—

CH3— H H H XA1421 CH3—

CH3— H H H XA1422 CH3—

CH3— H H H XA1423 CH3—

CH3— H H H XA1424 CH3—

CH3— H H H XA1425 CH3—

CH3— H H H XA1426 CH3—

CH3— H H H XA1427 CH3—

CH3— H H H XA1428 CH3—

CH3— H H H XA1429 CH3—

CH3— H H H XA1430 CH3—

CH3— H H H XA1431 CH3—

CH3— H H H XA1432 CH3—

CH3— H H H XA1433 CH3—

CH3— H H H XA1434 CH3—

CH3— H H H XA1435 CH3—

CH3— H H H XA1436 CH3—

CH3— H H H XA1437 CH3—

CH3— H H H XA1438 CH3—

CH3— H H H XA1439 CH3—

CH3— H H H XA1440 CH3—

CH3— H H H XA1441 CH3—

CH3— H H H XA1442 CH3—

CH3— H H H XA1443 CH3—

CH3— H H H XA1444 CH3—

CH3— H H H XA1445 CH3—

CH3— H H H XA1446 CH3—

CH3— H H H XA1447 CH3—

CH3— H H H XA1448 CH3—

CH3— H H H XA1449 CH3—

CH3— H H H XA1450 CH3—

CH3— H H H XA1451 CH3—

CH3— H H H XA1452 CH3—

CH3— H H H XA1453 CH3—

CH3— H H H XA1454 CH3—

CH3— H H H XA1455 CH3—

CH3— H H H XA1456 CH3—

CH3— H H H XA1457 CH3—

CH3— H H H XA1458 CH3—

CH3— H H H XA1459 CH3—

CH3— H H H XA1460 CH3—

CH3— H H H XA1461 CH3—

CH3— H H H XA1462 CH3—

CH3— H H H XA1463 CH3—

CH3— H H H XA1464 CH3—

CH3— H H H XA1465 CH3—

CH3— H H H XA1466 CH3—

CH3— H H H XA1467 CH3—

CH3— H H H XA1468 CH3—

CH3— H H H XA1469 CH3—

CH3— H H H XA1470 CH3—

CH3— H H H XA1471 CH3—

CH3— H H H XA1472 CH3—

CH3— H H H XA1473 CH3—

CH3— H H H XA1474 CH3—

CH3— H H H XA1475 CH3—

CH3— H H H XA1476 CH3—

CH3— H H H XA1477 CH3—

CH3— H H H XA1478 CH3—

CH3— H H H XA1479 CH3—

CH3— H H H XA1480 CH3—

CH3— H H H XA1481 CH3—

CH3— H H H XA1482 CH3—

CH3— H H H XA1483 CH3—

CH3— H H H XA1484 CH3—

CH3— H H H XA1485 CH3—

CH3— H H H XA1486 CH3—

CH3— H H H XA1487 CH3—

CH3— H H H XA1488 CH3—

CH3— H H H XA1489 CH3—

CH3— H H H XA1490 CH3—

CH3— H H H XA1491 CH3—

CH3— H H H XA1492 CH3—

CH3— H H H XA1493 CH3—

CH3— H H H XA1494 CH3—

CH3— H H H XA1495 CH3—

CH3— H H H XA1496 CH3—

CH3— H H H XA1497 CH3—

CH3— H H H XA1498 CH3— CH3— H H CH3— H XA1499 CH3— CH3CH2— H H CH3— H XA1500 CH3—

H H CH3— H XA1501 CH3—

H H CH3— H XA1502 CH3—

H H CH3— H XA1503 CH3—

H H CH3— H XA1504 CH3—

H H CH3— H XA1505 CH3—

H H CH3— H XA1506 CH3—

H H CH3— H XA1507 CH3—

H H CH3— H XA1508 CH3—

H H CH3— H XA1509 CH3—

H H CH3— H XA1510 CH3—

H H CH3— H XA1511 CH3—

H H CH3— H XA1512 CH3—

H H CH3— H XA1513 CH3—

H H CH3— H XA1514 CH3— n-C8H17— H H CH3— H XA1515 CH3—

H H CH3— H XA1516 CH3—

H H CH3— H XA1517 CH3—

H H CH3— H XA1518 CH3—

H H CH3— H XA1519 CH3—

H H CH3— H XA1520 CH3—

H H CH3— H

TABLE 1

No. R1 R2 R3 R4 R5 R6 XA1521 CH3—

H H CH3— H XA1522 CH3—

H H CH3— H XA1523 CH3—

H H CH3— H XA1524 CH3—

H H CH3— H XA1525 CH3—

H H CH3— H XA1526 CH3—

H H CH3— H XA1527 CH3—

H H CH3— H XA1528 CH3—

H H CH3— H XA1529 CH3—

H H CH3— H XA1530 CH3—

H H CH3— H XA1531 CH3—

H H CH3— H XA1532 CH3—

H H CH3— H XA1533 CH3—

H H CH3— H XA1534 CH3—

H H CH3— H XA1535 CH3—

H H CH3— H XA1536 CH3—

H H CH3— H XA1537 CH3—

H H CH3— H XA1538 CH3—

H H CH3— H XA1539 CH3—

H H CH3— H XA1540 CH3—

H H CH3— H XA1541 CH3—

H H CH3— H XA1542 CH3—

H H CH3— H XA1543 CH3—

H H CH3— H XA1544 CH3—

H H CH3— H XA1545 CH3—

H H CH3— H XA1546 CH3—

H H CH3— H XA1547 CH3—

H H CH3— H XA1548 CH3—

H H CH3— H XA1549 CH3—

H H CH3— H XA1550 CH3—

H H CH3— H XA1551 CH3—

H H CH3— H XA1552 CH3—

H H CH3— H XA1553 CH3—

H H CH3— H XA1554 CH3—

H H CH3— H XA1555 CH3—

H H CH3— H XA1556 CH3—

H H CH3— H XA1557 CH3—

H H CH3— H XA1558 CH3—

H H CH3— H XA1559 CH3—

H H CH3— H XA1560 CH3—

H H CH3— H XA1561 CH3—

H H CH3— H XA1562 CH3—

H H CH3— H XA1563 CH3—

H H CH3— H XA1564 CH3—

H H CH3— H XA1565 CH3—

H H CH3— H XA1566 CH3—

H H CH3— H XA1567 CH3—

H H CH3— H XA1568 CH3—

H H CH3— H XA1569 CH3—

H H CH3— H XA1570 CH3—

H H CH3— H XA1571 CH3—

H H CH3— H XA1572 CH3—

H H CH3— H XA1573 CH3—

H H CH3— H XA1574 CH3—

H H CH3— H XA1575 CH3—

H H CH3— H XA1576 CH3—

H H CH3— H XA1577 CH3—

H H CH3— H XA1578 CH3—

H H CH3— H XA1579 CH3—

H H CH3— H XA1580 CH3—

H H CH3— H XA1581 CH3—

H H CH3— H XA1582 CH3—

H H CH3— H XA1583 CH3—

H H CH3— H XA1584 CH3—

H H CH3— H XA1585 CH3—

H H CH3— H XA1586 CH3—

H H CH3— H XA1587 CH3—

H H CH3— H XA1588 CH3—

H H CH3— H XA1589 CH3—

H H CH3— H XA1590 CH3—

H H CH3— H XA1591 CH3—

H H CH3— H XA1592 CH3—

H H CH3— H XA1593 CH3— CH3— H H CH3— CH3— XA1594 CH3— CH3CH2— H H CH3— CH3— XA1595 CH3—

H H CH3— CH3— XA1596 CH3—

H H CH3— CH3— XA1597 CH3—

H H CH3— CH3— XA1598 CH3—

H H CH3— CH3— XA1599 CH3—

H H CH3— CH3— XA1600 CH3—

H H CH3— CH3— XA1601 CH3—

H H CH3— CH3— XA1602 CH3—

H H CH3— CH3— XA1603 CH3—

H H CH3— CH3— XA1604 CH3—

H H CH3— CH3— XA1605 CH3—

H H CH3— CH3— XA1606 CH3—

H H CH3— CH3— XA1607 CH3—

H H CH3— CH3— XA1608 CH3—

H H CH3— CH3— XA1609 CH3— n-C8H17— H H CH3— CH3— XA1610 CH3—

H H CH3— CH3— XA1611 CH3—

H H CH3— CH3— XA1612 CH3—

H H CH3— CH3— XA1613 CH3—

H H CH3— CH3— XA1614 CH3—

H H CH3— CH3— XA1615 CH3—

H H CH3— CH3— XA1616 CH3—

H H CH3— CH3— XA1617 CH3—

H H CH3— CH3— XA1618 CH3—

H H CH3— CH3— XA1619 CH3—

H H CH3— CH3— XA1620 CH3—

H H CH3— CH3— XA1621 CH3—

H H CH3— CH3— XA1622 CH3—

H H CH3— CH3— XA1623 CH3—

H H CH3— CH3— XA1624 CH3—

H H CH3— CH3— XA1625 CH3—

H H CH3— CH3— XA1626 CH3—

H H CH3— CH3— XA1627 CH3—

H H CH3— CH3— XA1628 CH3—

H H CH3— CH3— XA1629 CH3—

H H CH3— CH3— XA1630 CH3—

H H CH3— CH3— XA1631 CH3—

H H CH3— CH3— XA1632 CH3—

H H CH3— CH3— XA1633 CH3—

H H CH3— CH3— XA1634 CH3—

H H CH3— CH3— XA1635 CH3—

H H CH3— CH3— XA1636 CH3—

H H CH3— CH3— XA1637 CH3—

H H CH3— CH3— XA1638 CH3—

H H CH3— CH3— XA1639 CH3—

H H CH3— CH3— XA1640 CH3—

H H CH3— CH3— XA1641 CH3—

H H CH3— CH3— XA1642 CH3—

H H CH3— CH3— XA1643 CH3—

H H CH3— CH3— XA1644 CH3—

H H CH3— CH3— XA1645 CH3—

H H CH3— CH3— XA1646 CH3—

H H CH3— CH3— XA1647 CH3—

H H CH3— CH3— XA1648 CH3—

H H CH3— CH3— XA1649 CH3—

H H CH3— CH3— XA1650 CH3—

H H CH3— CH3— XA1651 CH3—

H H CH3— CH3— XA1652 CH3—

H H CH3— CH3— XA1653 CH3—

H H CH3— CH3— XA1654 CH3—

H H CH3— CH3— XA1655 CH3—

H H CH3— CH3— XA1656 CH3—

H H CH3— CH3— XA1657 CH3—

H H CH3— CH3— XA1658 CH3—

H H CH3— CH3— XA1659 CH3—

H H CH3— CH3— XA1660 CH3—

H H CH3— CH3— XA1661 CH3—

H H CH3— CH3— XA1662 CH3—

H H CH3— CH3— XA1663 CH3—

H H CH3— CH3— XA1664 CH3—

H H CH3— CH3— XA1665 CH3—

H H CH3— CH3— XA1666 CH3—

H H CH3— CH3— XA1667 CH3—

H H CH3— CH3— XA1668 CH3—

H H CH3— CH3— XA1669 CH3—

H H CH3— CH3— XA1670 CH3—

H H CH3— CH3— XA1671 CH3—

H H CH3— CH3— XA1672 CH3—

H H CH3— CH3— XA1673 CH3—

H H CH3— CH3— XA1674 CH3—

H H CH3— CH3— XA1675 CH3—

H H CH3— CH3— XA1676 CH3—

H H CH3— CH3— XA1677 CH3—

H H CH3— CH3— XA1678 CH3—

H H CH3— CH3— XA1679 CH3—

H H CH3— CH3— XA1680 CH3—

H H CH3— CH3— XA1681 CH3—

H H CH3— CH3— XA1682 CH3—

H H CH3— CH3— XA1683 CH3—

H H CH3— CH3— XA1684 CH3—

H H CH3— CH3— XA1685 CH3—

H H CH3— CH3— XA1686 CH3—

H H CH3— CH3— XA1687 CH3—

H H CH3— CH3— XA1688 CH3— CH3— H CH3— CH3— CH3— XA1689 CH3— CH3CH2— H CH3— CH3— CH3— XA1690 CH3—

H CH3— CH3— CH3— XA1691 CH3—

H CH3— CH3— CH3— XA1692 CH3—

H CH3— CH3— CH3— XA1693 CH3—

H CH3— CH3— CH3— XA1694 CH3—

H CH3— CH3— CH3— XA1695 CH3—

H CH3— CH3— CH3— XA1696 CH3—

H CH3— CH3— CH3— XA1697 CH3—

H CH3— CH3— CH3— XA1698 CH3—

H CH3— CH3— CH3— XA1699 CH3—

H CH3— CH3— CH3— XA1700 CH3—

H CH3— CH3— CH3— XA1701 CH3—

H CH3— CH3— CH3— XA1702 CH3—

H CH3— CH3— CH3— XA1703 CH3—

H CH3— CH3— CH3— XA1704 CH— n-C8H17— H CH3— CH3— CH3— XA1705 CH3—

H CH3— CH3— CH3— XA1706 CH3—

H CH3— CH3— CH3— XA1707 CH3—

H CH3— CH3— CH3— XA1708 CH3—

H CH3— CH3— CH3— XA1709 CH3—

H CH3— CH3— CH3— XA1710 CH3—

H CH3— CH3— CH3— XA1711 CH3—

H CH3— CH3— CH3— XA1712 CH3—

H CH3— CH3— CH3— XA1713 CH3—

H CH3— CH3— CH3— XA1714 CH3—

H CH3— CH3— CH3— XA1715 CH3—

H CH3— CH3— CH3— XA1716 CH3—

H CH3— CH3— CH3— XA1717 CH3—

H CH3— CH3— CH3— XA1718 CH3—

H CH3— CH3— CH3— XA1719 CH3—

H CH3— CH3— CH3— XA1720 CH3—

H CH3— CH3— CH3— XA1721 CH3—

H CH3— CH3— CH3— XA1722 CH3—

H CH3— CH3— CH3— XA1723 CH3—

H CH3— CH3— CH3— XA1724 CH3—

H CH3— CH3— CH3— XA1725 CH3—

H CH3— CH3— CH3— XA1726 CH3—

H CH3— CH3— CH3— XA1727 CH3—

H CH3— CH3— CH3— XA1728 CH3—

H CH3— CH3— CH3— XA1729 CH3—

H CH3— CH3— CH3— XA1730 CH3—

H CH3— CH3— CH3— XA1731 CH3—

H CH3— CH3— CH3— XA1732 CH3—

H CH3— CH3— CH3— XA1733 CH3—

H CH3— CH3— CH3— XA1734 CH3—

H CH3— CH3— CH3— XA1735 CH3—

H CH3— CH3— CH3— XA1736 CH3—

H CH3— CH3— CH3— XA1737 CH3—

H CH3— CH3— CH3— XA1738 CH3—

H CH3— CH3— CH3— XA1739 CH3—

H CH3— CH3— CH3— XA1740 CH3—

H CH3— CH3— CH3— XA1741 CH3—

H CH3— CH3— CH3— XA1742 CH3—

H CH3— CH3— CH3— XA1743 CH3—

H CH3— CH3— CH3— XA1744 CH3—

H CH3— CH3— CH3— XA1745 CH3—

H CH3— CH3— CH3— XA1746 CH3—

H CH3— CH3— CH3— XA1747 CH3—

H CH3— CH3— CH3— XA1748 CH3—

H CH3— CH3— CH3— XA1749 CH3—

H CH3— CH3— CH3— XA1750 CH3—

H CH3— CH3— CH3— XA1751 CH3—

H CH3— CH3— CH3— XA1752 CH3—

H CH3— CH3— CH3— XA1753 CH3—

H CH3— CH3— CH3— XA1754 CH3—

H CH3— CH3— CH3— XA1755 CH3—

H CH3— CH3— CH3— XA1756 CH3—

H CH3— CH3— CH3— XA1757 CH3—

H CH3— CH3— CH3— XA1758 CH3—

H CH3— CH3— CH3— XA1759 CH3—

H CH3— CH3— CH3— XA1760 CH3—

H CH3— CH3— CH3— XA1761 CH3—

H CH3— CH3— CH3— XA1762 CH3—

H CH3— CH3— CH3— XA1763 CH3—

H CH3— CH3— CH3— XA1764 CH3—

H CH3— CH3— CH3— XA1765 CH3—

H CH3— CH3— CH3— XA1766 CH3—

H CH3— CH3— CH3— XA1767 CH3—

H CH3— CH3— CH3— XA1768 CH3—

H CH3— CH3— CH3— XA1769 CH3—

H CH3— CH3— CH3— XA1770 CH3—

H CH3— CH3— CH3— XA1771 CH3—

H CH3— CH3— CH3— XA1772 CH3—

H CH3— CH3— CH3— XA1773 CH3—

H CH3— CH3— CH3— XA1774 CH3—

H CH3— CH3— CH3— XA1775 CH3—

H CH3— CH3— CH3— XA1776 CH3—

H CH3— CH3— CH3— XA1777 CH3—

H CH3— CH3— CH3— XA1778 CH3—

H CH3— CH3— CH3— XA1779 CH3—

H CH3— CH3— CH3— XA1780 CH3—

H CH3— CH3— CH3— XA1781 CH3—

H CH3— CH3— CH3— XA1782 CH3—

H CH3— CH3— CH3— XA1783 CH3CH2— CH3— H H H H XA1784 CH3CH2— CH3CH2— H H H H XA1785 CH3CH2—

H H H H XA1786 CH3CH2—

H H H H XA1787 CH3CH2—

H H H H XA1788 CH3CH2—

H H H H XA1789 CH3CH2—

H H H H XA1790 CH3CH2—

H H H H XA1791 CH3CH2—

H H H H XA1792 CH3CH2—

H H H H XA1793 CH3CH2—

H H H H XA1794 CH3CH2—

H H H H XA1795 CH3CH2—

H H H H XA1796 CH3CH2—

H H H H XA1797 CH3CH2—

H H H H XA1798 CH3CH2—

H H H H XA1799 CH3CH2— n-C8H17— H H H H XA1800 CH3CH2—

H H H H XA1801 CH3CH2—

H H H H XA1802 CH3CH2—

H H H H XA1803 CH3CH2—

H H H H XA1804 CH3CH2—

H H H H XA1805 CH3CH2—

H H H H XA1806 CH3CH2—

H H H H XA1807 CH3CH2—

H H H H XA1808 CH3CH2—

H H H H XA1809 CH3CH2—

H H H H XA1810 CH3CH2—

H H H H XA1811 CH3CH2—

H H H H XA1812 CH3CH2—

H H H H XA1813 CH3CH2—

H H H H XA1814 CH3CH2—

H H H H XA1815 CH3CH2—

H H H H XA1816 CH3CH2—

H H H H XA1817 CH3CH2—

H H H H XA1818 CH3CH2—

H H H H XA1819 CH3CH2—

H H H H XA1820 CH3CH2—

H H H H XA1821 CH3CH2—

H H H H XA1822 CH3CH2—

H H H H XA1823 CH3CH2—

H H H H XA1824 CH3CH2—

H H H H XA1825 CH3CH2—

H H H H XA1826 CH3CH2—

H H H H XA1827 CH3CH2—

H H H H XA1828 CH3CH2—

H H H H XA1829 CH3CH2—

H H H H XA1830 CH3CH2—

H H H H XA1831 CH3CH2—

H H H H XA1832 CH3CH2—

H H H H XA1833 CH3CH2—

H H H H XA1834 CH3CH2—

H H H H XA1835 CH3CH2—

H H H H XA1836 CH3CH2—

H H H H XA1837 CH3CH2—

H H H H XA1838 CH3CH2—

H H H H XA1839 CH3CH2—

H H H H XA1840 CH3CH2—

H H H H XA1841 CH3CH2—

H H H H XA1842 CH3CH2—

H H H H XA1843 CH3CH2—

H H H H XA1844 CH3CH2—

H H H H XA1845 CH3CH2—

H H H H XA1846 CH3CH2—

H H H H XA1847 CH3CH2—

H H H H XA1848 CH3CH2—

H H H H XA1849 CH3CH2—

H H H H XA1850 CH3CH2—

H H H H XA1851 CH3CH2—

H H H H XA1852 CH3CH2—

H H H H XA1853 CH3CH2—

H H H H XA1854 CH3CH2—

H H H H XA1855 CH3CH2—

H H H H XA1856 CH3CH2—

H H H H XA1857 CH3CH2—

H H H H XA1858 CH3CH2—

H H H H XA1859 CH3CH2—

H H H H XA1860 CH3CH2—

H H H H XA1861 CH3CH2—

H H H H XA1862 CH3CH2—

H H H H XA1863 CH3CH2—

H H H H XA1864 CH3CH2—

H H H H XA1865 CH3CH2—

H H H H XA1866 CH3CH2—

H H H H XA1867 CH3CH2—

H H H H XA1868 CH3CH2—

H H H H XA1869 CH3CH2—

H H H H XA1870 CH3CH2—

H H H H XA1871 CH3CH2—

H H H H XA1872 CH3CH2—

H H H H XA1873 CH3CH2—

H H H H XA1874 CH3CH2—

H H H H XA1875 CH3CH2—

H H H H XA1876 CH3CH2—

H H H H XA1877 CH3CH2—

H H H H XA1878 CH3CH2— CH3— H CH3— H H XA1879 CH3CH2— CH3CH2— H CH3— H H XA1880 CH3CH2—

H CH3— H H XA1881 CH3CH2—

H CH3— H H XA1882 CH3CH2—

H CH3— H H XA1883 CH3CH2—

H CH3— H H XA1884 CH3CH2—

H CH3— H H XA1885 CH3CH2—

H CH3— H H XA1886 CH3CH2—

H CH3— H H XA1887 CH3CH2—

H CH3— H H XA1888 CH3CH2—

H CH3— H H XA1889 CH3CH2—

H CH3— H H XA1890 CH3CH2—

H CH3— H H XA1891 CH3CH2—

H CH3— H H XA1892 CH3CH2—

H CH3— H H XA1893 CH3CH2—

H CH3— H H XA1894 CH3CH2— n-C8H17— H CH3— H H XA1895 CH3CH2—

H CH3— H H XA1896 CH3CH2—

H CH3— H H XA1897 CH3CH2—

H CH3— H H XA1898 CH3CH2—

H CH3— H H XA1899 CH3CH2—

H CH3— H H XA1900 CH3CH2—

H CH3— H H XA1901 CH3CH2—

H CH3— H H XA1902 CH3CH2—

H CH3— H H XA1903 CH3CH2—

H CH3— H H XA1904 CH3CH2—

H CH3— H H XA1905 CH3CH2—

H CH3— H H XA1906 CH3CH2—

H CH3— H H XA1907 CH3CH2—

H CH3— H H XA1908 CH3CH2—

H CH3— H H XA1909 CH3CH2—

H CH3— H H XA1910 CH3CH2—

H CH3— H H XA1911 CH3CH2—

H CH3— H H XA1912 CH3CH2—

H CH3— H H XA1913 CH3CH2—

H CH3— H H XA1914 CH3CH2—

H CH3— H H XA1915 CH3CH2—

H CH3— H H XA1916 CH3CH2—

H CH3— H H XA1917 CH3CH2—

H CH3— H H XA1918 CH3CH2—

H CH3— H H XA1919 CH3CH2—

H CH3— H H XA1920 CH3CH2—

H CH3— H H XA1921 CH3CH2—

H CH3— H H XA1922 CH3CH2—

H CH3— H H XA1923 CH3CH2—

H CH3— H H XA1924 CH3CH2—

H CH3— H H XA1925 CH3CH2—

H CH3— H H XA1926 CH3CH2—

H CH3— H H XA1927 CH3CH2—

H CH3— H H XA1928 CH3CH2—

H CH3— H H XA1929 CH3CH2—

H CH3— H H XA1930 CH3CH2—

H CH3— H H XA1931 CH3CH2—

H CH3— H H XA1932 CH3CH2—

H CH3— H H XA1933 CH3CH2—

H CH3— H H XA1934 CH3CH2—

H CH3— H H XA1935 CH3CH2—

H CH3— H H XA1936 CH3CH2—

H CH3— H H XA1937 CH3CH2—

H CH3— H H XA1938 CH3CH2—

H CH3— H H XA1939 CH3CH2—

H CH3— H H XA1940 CH3CH2—

H CH3— H H XA1941 CH3CH2—

H CH3— H H XA1942 CH3CH2—

H CH3— H H XA1943 CH3CH2—

H CH3— H H XA1944 CH3CH2—

H CH3— H H XA1945 CH3CH2—

H CH3— H H XA1946 CH3CH2—

H CH3— H H XA1947 CH3CH2—

H CH3— H H XA1948 CH3CH2—

H CH3— H H XA1949 CH3CH2—

H CH3— H H XA1950 CH3CH2—

H CH3— H H XA1951 CH3CH2—

H CH3— H H XA1952 CH3CH2—

H CH3— H H XA1953 CH3CH2—

H CH3— H H XA1954 CH3CH2—

H CH3— H H XA1955 CH3CH2—

H CH3— H H XA1956 CH3CH2—

H CH3— H H XA1957 CH3CH2—

H CH3— H H XA1958 CH3CH2—

H CH3— H H XA1959 CH3CH2—

H CH3— H H XA1960 CH3CH2—

H CH3— H H XA1961 CH3CH2—

H CH3— H H XA1962 CH3CH2—

H CH3— H H XA1963 CH3CH2—

H CH3— H H XA1964 CH3CH2—

H CH3— H H XA1965 CH3CH2—

H CH3— H H XA1966 CH3CH2—

H CH3— H H XA1967 CH3CH2—

H CH3— H H XA1968 CH3CH2—

H CH3— H H XA1969 CH3CH2—

H CH3— H H XA1970 CH3CH2—

H CH3— H H XA1971 CH3CH2—

H CH3— H H XA1972 CH3CH2—

H CH3— H H No. STRUTURE XA1973

XA1974

XA1975

XA1976

XA1977

XA1978

XA1979

XA1980

XA1981

XA1982

XA1983

XA1984

XA1985

XA1986

XA1987

XA1988

XA1989

XA1990

XA1991

XA1992

XA1993

XA1994

XA1995

XA1996

XA1997

XA1998

XA1999

XA2000

XA2001

XA2002

XA2003

XA2004

XA2005

XA2006

XA2007

XA2008

XA2009

XA2010

XA2011

XA2012

XA2013

XA2014

XA2015

XA2016

XA2017

XA2018

XA2019

XA2020

XA2021

XA2022

XA2023

XA2024

XA2025

XA2026

XA2027

XA2028

XA2029

XA2030

XA2031

XA2032

XA2033

XA2034

XA2035

XA2036

XA2037

XA2038

XA2039

XA2040

XA2041

XA2042

XA2043

XA2044

XA2045

XA2046

XA2047

XA2048

XA2049

XA2050

XA2051

XA2052

XA2053

XA2054

XA2055

TABLE 2

No R1 R2 R3 R4 R5 XB1 CH3— CH3— H H H XB2 CH3— CH3CH2— H H H XB3 CH3—

H H H XB4 CH3—

H H H XB5 CH3—

H H H XB6 CH3—

H H H XB7 CH3—

H H H XB8 CH3—

H H H XB9 CH3—

H H H XB10 CH3—

H H H XB11 CH3—

H H H XB12 CH3—

H H H XB13 CH3—

H H H XB14 CH3—

H H H XB15 CH3—

H H H XB16 CH3—

H H H XB17 CH3—

H H H XB18 CH3—

H H H XB19 CH3—

H H H XB20 CH3—

H H H XB21 CH3—

H H H XB22 CH3—

H H H XB23 CH3—

H H H XB24 CH3—

H H H XB25 CH3—

H H H XB26 CH3—

H H H XB27 CH3—

H H H XB28 CH3—

H H H XB29 CH3—

H H H XB30 CH3—

H H H XB31 CH3—

H H H XB32 CH3—

H H H XB33 CH3—

H H H XB34 CH3—

H H H XB35 CH3—

H H H XB36 CH3—

H H H XB37 CH3—

H H H XB38 CH3—

H H H XB39 CH3—

H H H XB40 CH3—

H H H XB41 CH3—

H H H XB42 CH3—

H H H XB43 CH3—

H H H XB44 CH3—

H H H XB45 CH3—

H H H XB46 CH3—

H H H XB47 CH3—

H H H XB48 CH3—

H H H XB49 CH3—

H H H XB50 CH3—

OH H H XB51 CH3—

OH H H XB52 CH3—

OH H H XB53 CH3—

OH H H XB54 CH3—

OH H H XB55 CH3—

OH H H XB56 CH3—

OH H H XB57 CH3—

OH H H XB58 CH3—

OH H H XB59 CH3—

OH H H XB60 CH3—

OH H H XB61 CH3—

OH H H XB62 CH3—

OH H H XB63 CH3—

OH H H XB64 CH3—

OH H H XB65 CH3—

OH H H XB66 CH3—

OH H H XB67 CH3—

OH H H XB68 CH3—

OH H H XB69 CH3—

OH H H XB70 CH3—

OH H H XB71 CH3—

OH H H XB72 CH3—

OH H H XB73 CH3—

OH H H XB74 CH3—

OH H H XB75 CH3—

OH H H XB76 CH3—

OH H H XB77 CH3—

OH H H XB78 CH3—

OH H H XB79 CH3—

OH H H XB80 CH3—

CN H H XB81 CH3—

CN H H XB82 CH3—

CN H H XB83 CH3—

CN H H XB84 CH3—

CN H H XB85 CH3—

CN H H XB86 CH3—

CN H H XB87 CH3—

CN H H XB88 CH3—

CN H H XB89 CH3—

CN H H XB90 CH3—

CN H H XB91 CH3—

CN H H XB92 CH3—

CN H H XB93 CH3—

CN H H XB94 CH3—

CN H H XB95 CH3—

CN H H XB96 CH3—

CN H H XB97 CH3—

CN H H XB98 CH3—

CN H H XB99 CH3—

CN H H XB100 CH3—

CN H H XB101 CH3—

CN H H XB102 CH3—

CN H H XB103 CH3—

CN H H XB104 CH3—

CN H H XB105 CH3—

CN H H XB106 CH3—

CN H H XB107 CH3—

CN H H XB108 CH3—

CN H H XB109 CH3—

CN H H XB110 CH3— H H CH3— H XB111 CH3— H H CH3CH2— H XB112 CH3— H H

H XB113 CH3— H H

H XB114 CH3— H H

H XB115 CH3— H H

H XB116 CH3— H H

H XB117 CH3— H H

H XB118 CH3— H H

H XB119 CH3— H H

H XB120 CH3— H H

H XB121 CH3— H H

H XB122 CH3— H H

H XB123 CH3— H H

H XB124 CH3— H H

H XB125 CH3— H H

H XB126 CH3— H H

H XB127 CH3— H H

H XB128 CH3— H H

H XB129 CH3— H H

H XB130 CH3— H H

H XB131 CH3— H H

H XB132 CH3— H H

H XB133 CH3— H H

H XB134 CH3— H H

H XB135 CH3— H H

H XB136 CH3— H H

H XB137 CH3— H H

H XB138 CH3— H H

H XB139 CH3— H H

H XB140 CH3— H H

H XB141 CH3— H H

H XB142 CH3— H H

H XB143 CH3— H H

H XB144 CH3— H H

H XB145 CH3— H H

H XB146 CH3— H H

H XB147 CH3— H H

H XB148 CH3— H H

H XB149 CH3— H H

H XB150 CH3— H H

H XB151 CH3— H H

H XB152 CH3— H H

H XB153 CH3— H H

H XB154 CH3— H H

H XB155 CH3— H H

H XB156 CH3— H H

H XB157 CH3— H H

H XB158 CH3— H H

H XB159 CH3— H H

H XB160 CH3— H H

H XB161 CH3— H H

H XB162 CH3— H H

H XB163 CH3— H H

H XB164 CH3— H H

H XB165 CH3— H H

H XB166 CH3— H H

H XB167 CH3— H H

H XB168 CH3— H H

H XB169 CH3— H H

OH XB170 CH3— H H

OH XB171 CH3— H H

OH XB172 CH3— H H

OH XB173 CH3— H H

OH XB174 CH3— H H

OH XB175 CH3— H H

OH XB176 CH3— H H

OH XB177 CH3— H H

OH XB178 CH3— H H

OH XB179 CH3— H H

OH XB180 CH3— H H

OH XB181 CH3— H H

OH XB182 CH3— H H

OH XB183 CH3— H H

OH XB184 CH3— H H

OH XB185 CH3— H H

OH XB186 CH3— H H

OH XB187 CH3— H H

OH XB188 CH3— H H

OH XB189 CH3— H H

OH XB190 CH3— H H

OH XB191 CH3— H H

OH XB192 CH3— H H

OH XB193 CH3— H H

OH XB194 CH3— H H

OH XB195 CH3— H H

OH XB196 CH3— H H

OH XB197 CH3— H H

OH XB198 CH3— H H

CN XB199 CH3— H H

CN XB200 CH3— H H

CN XB201 CH3— H H

CN XB202 CH3— H H

CN XB203 CH3— H H

CN XB204 CH3— H H

CN XB205 CH3— H H

CN XB206 CH3— H H

CN XB207 CH3— H H

CN XB208 CH3— H H

CN XB209 CH3— H H

CN XB210 CH3— H H

CN XB211 CH3— H H

CN XB212 CH3— H H

CN XB213 CH3— H H

CN XB214 CH3— H H

CN XB215 CH3— H H

CN XB216 CH3— H H

CN XB217 CH3— H H

CN XB218 CH3— H H

CN XB219 CH3— H H

CN XB220 CH3— H H

CN XB221 CH3— H H

CN XB222 CH3— H H

CN XB223 CH3— H H

CN XB224 CH3— H H

CN XB225 CH3— H H

CN XB226 CH3— H H

CN XB227 CH3— H H

XB228 CH3— H H

XB229 CH3— H H

XB230 CH3— H H

XB231 CH3— H H

XB232 CH3— H H

XB233 CH3— H H

XB234 CH3— H H

XB235 CH3— H H

XB236 CH3— H H

XB237 CH3— H H

XB238 CH3— H H

XB239 CH3— H H

XB240 CH3— H H

XB241 CH3— H H

XB242 CH3— H H

XB243 CH3— H H

XB244 CH3— H H

XB245 CH3— H H

XB246 CH3— H H

XB247 CH3— H H

XB248 CH3— H H

XB249 CH3— H H

XB250 CH3— H H

XB251 CH3— H H

XB252 CH3— H H

XB253 CH3— H H

XB254 CH3— H H

XB255 CH3— H H

No. STRUCTURE XB256

XB257

XB258

XB259

XB260

XB261

XB262

XB263

XB264

XB265

XB266

XB267

XB268

XB269

XB270

XB271

XB272

XB273

XB274

XB275

XB276

XB277

XB278

XB279

XB280

XB281

XB282

XB283

XB284

XB285

XB286

XB287

XB288

XB289

XB290

XB291

XB292

XB293

XB294

XB295

XB296

XB297

XB298

XB299

XB300

XB301

XB302

TABLE-3

No. R1 R2 R3 R4 YA0001 CH3— H H CH3— YA0002 CH3— H H CH3CH2— YA0003 CH3— H H

YA0004 CH3— H H

YA0005 CH3— H H

YA0006 CH3— H H

YA0007 CH3— H H

YA0008 CH3— H H

YA0009 CH3— H H

YA0010 CH3— H H

YA0011 CH3— H H

YA0012 CH3— H H

YA0013 CH3— H H

YA0014 CH3— H H

YA0015 CH3— H H

YA0016 CH3— H H

YA0017 CH3— H H

YA0018 CH3— H H

YA0019 CH3— H H

YA0020 CH3— H H

YA0021 CH3— H H

YA0022 CH3— H H

YA0023 CH3— H H

YA0024 CH3— H H

YA0025 CH3— H H

YA0026 CH3— H H

YA0027 CH3— H H

YA0028 CH3— H H

YA0029 CH3— H H

YA0030 CH3— H H

YA0031 CH3— H H

YA0032 CH3— H H

YA0033 CH3— H H

YA0034 CH3— H H

YA0035 CH3— H H

YA0036 CH3— H H

YA0037 CH3— H H

YA0038 CH3— H H

YA0039 CH3— H H

YA0040 CH3— H H

YA0041 CH3— H H

YA0042 CH3— H H

YA0043 CH3— H H

YA0044 CH3— H H

YA0045 CH3— H H

YA0046 CH3— H H

YA0047 CH3— H H

YA0048 CH3— H H

YA0049 CH3— H H

YA0050 CH3— H H

YA0051 CH3— H H

YA0052 CH3— H H

YA0053 CH3— H H

YA0054 CH3— H H

YA0055 CH3— H H

YA0056 CH3— H H

YA0057 CH3— H H

YA0058 CH3— H H

YA0059 CH3— H H

YA0060 CH3— H H

YA0061 CH3— H H

YA0062 CH3— H H

YA0063 CH3— H H

YA0064 CH3— H H

YA0065 CH3— H H

YA0066 CH3— H H

YA0067 CH3— H H

YA0068 CH3— H H

YA0069 CH3— H H

YA0070 CH3— H H

YA0071 CH3— H H

YA0072 CH3— H H

YA0073 CH3— H H

YA0074 CH3— H H

YA0075 CH3— H H

YA0076 CH3— H H

YA0077 CH3— H H

YA0078 CH3— H H

YA0079 CH3— H H

YA0080 CH3— H H

YA0081 CH3— H H

YA0082 CH3— H H

YA0083 CH3— H H

YA0084 CH3— H H

YA0085 CH3— H H

YA0086 CH3— H H

YA0087 CH3— H H

YA0088 CH3— H H

YA0089 CH3— H H

YA0090 CH3— H H

YA0091 CH3— H H

YA0092 CH3— H H

YA0093 CH3— H H

YA0094 CH3— H H

YA0095 CH3— H H

YA0096 CH3— H H

YA0097 CH3— H H

YA0098 CH3— H H

YA0099 CH3— H H

YA0100 CH3— H H

YA0101 CH3— H H

YA0102 CH3— H H

YA0103 CH3— H H

YA0104 CH3— H H

YA0105 CH3— H H

YA0106 CH3— H H

YA0107 CH3— H H

YA0108 CH3— H H

YA0109 CH3— H H

YA0110 CH3— H H

YA0111 CH3— H H

YA0112 CH3— H H

YA0113 CH3— H H

YA0114 CH3— H H

YA0115 CH3— H H

YA0116 CH3— H H

YA0117 CH3— H H

YA0118 CH3— H H

YA0119 CH3— H H

YA0120 CH3— H H

YA0121 CH3— H H

YA0122 CH3— H H

YA0123 CH3—

H H YA0124 CH3—

H CH3— YA0125 CH3—

H CH3CH2— YA0126 CH3—

H

YA0127 CH3—

H

YA0128 CH3—

H

YA0129 CH3—

H

YA0130 CH3—

H

YA0131 CH3—

H

YA0132 CH3—

H

YA0133 CH3—

H

YA0134 CH3—

H

YA0135 CH3—

H

YA0136 CH3—

H

YA0137 CH3—

H

YA0138 CH3—

H

YA0139 CH3—

H

YA0140 CH3—

H

YA0141 CH3—

H

YA0142 CH3—

H

YA0143 CH3—

H

YA0144 CH3—

H

YA0145 CH3—

H

YA0146 CH3—

H

YA0147 CH3—

H

YA0148 CH3—

H

YA0149 CH3—

H

YA0150 CH3—

H

YA0151 CH3—

H

YA0152 CH3—

H

YA0153 CH3—

H

YA0154 CH3—

H

YA0155 CH3—

H

YA0156 CH3—

H

YA0157 CH3—

H

YA0158 CH3—

H

YA0159 CH3—

H

YA0160 CH3—

H

YA0161 CH3—

H

YA0162 CH3—

H

YA0163 CH3—

H

YA0164 CH3—

H

YA0165 CH3—

H

YA0166 CH3—

H

YA0167 CH3—

H

YA0168 CH3—

H

YA0169 CH3—

H

YA0170 CH3—

H

YA0171 CH3—

H

YA0172 CH3—

H

YA0173 CH3—

H

YA0174 CH3—

H

YA0175 CH3—

H

YA0176 CH3—

H

YA0177 CH3—

H

YA0178 CH3—

H H YA0179 CH3—

H CH3— YA0180 CH3—

H CH3CH2— YA0181 CH3—

H

YA0182 CH3—

H

YA0183 CH3—

H

YA0184 CH3—

H

YA0185 CH3—

H

YA0186 CH3—

H

YA0187 CH3—

H

YA0188 CH3—

H

YA0189 CH3—

H

YA0190 CH3—

H

YA0191 CH3—

H

YA0192 CH3—

H

YA0193 CH3—

H

YA0194 CH3—

H

YA0195 CH3—

H

YA0196 CH3—

H

YA0197 CH3—

H

YA0198 CH3—

H

YA0199 CH3—

H

YA0200 CH3—

H

YA0201 CH3—

H

YA0202 CH3—

H

YA0203 CH3—

H

YA0204 CH3—

H

YA0205 CH3—

H

YA0206 CH3—

H

YA0207 CH3—

H

YA0208 CH3—

H

YA0209 CH3—

H

YA0210 CH3—

H

YA0211 CH3—

H

YA0212 CH3—

H

YA0213 CH3—

H

YA0214 CH3—

H

YA0215 CH3—

H

YA0216 CH3—

H

YA0217 CH3—

H

YA0218 CH3—

H

YA0219 CH3—

H

YA0220 CH3—

H

YA0221 CH3—

H

YA0222 CH3—

H

YA0223 CH3—

H

YA0224 CH3—

H

YA0225 CH3—

H

YA0226 CH3—

H

YA0227 CH3—

H

YA0228 CH3—

H

YA0229 CH3—

H

YA0230 CH3—

H

YA0231 CH3—

H

YA0232 CH3—

H

YA0233 CH3— CH3— H H YA0234 CH3— CH3CH2—H H YA0235 CH3—

H H YA0236 CH3—

H H YA0237 CH3—

H H YA0238 CH3—

H H YA0239 CH3—

H H YA0240 CH3—

H H YA0241 CH3—

H H YA0242 CH3—

H H YA0244 CH3—

H H YA0245 CH3—

H H YA0246 CH3—

H H YA0247 CH3—

H H YA0248 CH3—

H H YA0249 CH3—

H H YA0250 CH3—

H H YA0251 CH3—

H H YA0252 CH3—

H H YA0253 CH3—

H H YA0254 CH3—

H H YA0255 CH3—

H H YA0256 CH3—

H H YA0257 CH3—

H H YA0258 CH3—

H H YA0259 CH3—

H H YA0260 CH3—

H H YA0261 CH3—

H H YA0262 CH3—

H H YA0263 CH3—

H H YA0264 CH3—

H H YA0265 CH3—

H H YA0266 CH3—

H H YA0267 CH3—

H H YA0268 CH3—

H H YA0269 CH3—

H H YA0270 CH3—

H H YA0271 CH3—

H H YA0272 CH3—

H H YA0273 CH3—

H H YA0274 CH3—

H H YA0275 CH3—

H H YA0276 CH3—

H H YA0277 CH3—

H H YA0278 CH3—

H H YA0279 CH3—

H H YA0280 CH3—

H H YA0281 CH3—

H H YA0282 CH3—

H H YA0283 CH3—

H H YA0284 CH3—

H H YA0285 CH3—

H H YA0286 CH3—

H H YA0287 CH3—

H H YA0288 CH3—

H H YA0289 CH3—

H H YA0290 CH3—

H H YA0291 CH3—

H H YA0292 CH3—

H H YA0293 CH3—

H H YA0294 CH3—

H H YA0295 CH3—

H H YA0296 CH3—

H H YA0297 CH3—

H H YA0298 CH3—

H H YA0299 CH3—

H H YA0300 CH3—

H H YA0301 CH3—

H H YA0302 CH3—

H H YA0303 CH3—

H H YA0304 CH3—

H H YA0305 CH3—

H H YA0306 CH3—

H H YA0307 CH3—

H H YA0308 CH3—

H H YA0309 CH3—

H H YA0310 CH3—

H H YA0311 CH3—

H H YA0312 CH3—

H H YA0313 CH3—

H H YA0314 CH3—

H H YA0315 CH3—

H H YA0316 CH3—

H H YA0317 CH3—

H H YA0318 CH3—

H H YA0319 CH3—

H H YA0320 CH3—

H H YA0321 CH3—

H H YA0322 CH3—

H H YA0323 CH3—

H H YA0324 CH3—

H H YA0325 CH3—

H H YA0326 CH3—

H H YA0327 CH3—

H H YA0328 CH3—

H H YA0329 CH3—

H H YA0330 CH3—

H H YA0331 CH3—

H H YA0332 CH3—

H H YA0333 CH3—

H H YA0334 CH3—

H H YA0335 CH3—

H H YA0336 CH3—

H H YA0337 CH3—

H H YA0338 CH3—

H H YA0339 CH3—

H H YA0340 CH3—

H H YA0341 CH3—

H H YA0342 CH3—

H H YA0343 CH3—

H H YA0344 CH3—

H H YA0345 CH3—

H H YA0346 CH3—

H H YA0347 CH3—

H H YA0348 CH3—

H H YA0349 CH3—

H H YA0350 CH3—

H H YA0351 CH3—

H H YA0352 CH3—

H H YA0353 CH3—

H H YA0354 CH3—

H H YA0355 CH3—

H H YA0356 CH3—

H H YA0357 CH3—

H H YA0358 CH3—

H H YA0359 CH3—

H H YA0360 CH3—

H H YA0361 CH3—

H H YA0362 CH3—

H H YA0363 CH3—

H H YA0364 CH3—

H H YA0365 CH3—

H H YA0306 CH3—

H H YA0367 CH3—

H H YA0368 CH3—

H H YA0369 CH3—

H H YA0370 CH3—

H H YA0371 CH3—

H H YA0372 CH3—

H H YA0373 CH3—

H H YA0374 CH3—

H H YA0375 CH3—

H H YA0376 CH3—

H H YA0377 CH3—

H H YA0378 CH3—

H H YA0379 CH3—

H H YA0380 CH3—

H H YA0381 CH3—

H H YA0382 CH3—

H H YA0383 CH3—

H H YA0384 CH3—

H H YA0385 CH3—

H H YA0386 CH3—

H H YA0387 CH3—

H H YA0388 CH3—

H H YA0389 CH3—

H H YA0390 CH3—

H H YA0391 CH3—

H H YA0392 CH3—

H H YA0393 CH3—

H H YA0394 CH3—

H H YA0395 CH3—

H H YA0396 CH3—

H H YA0397 CH3—

H H YA0398 CH3—

H H YA0399 CH3—

H H YA0400 CH3—

H H YA0401 CH3—

H H YA0402 CH3—

H H YA0403 CH3—

H H YA0404 CH3—

H H YA0405 CH3—

H H YA0406 CH3—

H H YA0407 CH3—

H H YA0408 CH3—

H H YA0409 CH3—

H H YA0410 CH3—

H H YA0411 CH3—

H H YA0412 CH3—

H H YA0413 CH3—

H H YA0414 CH3—

H H YA0415 CH3—

H H YA0416 CH3—

H H YA0417 CH3—

H H YA0418 CH3—

H H YA0419 CH3—

H H YA0420 CH3—

H H

No. R1 R2 R3 R4 YA0421 CH3—

H H YA0422 CH3—

H H YA0423 CH3—

H H YA0424 CH3—

H H YA0425 CH3—

H H YA0426 CH3—

H H YA0427 CH3—

H H YA0428 CH3—

H H YA0429 CH3—

H H YA0430 CH3—

H H YA0431 CH3—

H H YA0432 CH3—

H H YA0433 CH3—

H H YA0434 CH3—

H H YA0435 CH3—

H H YA0436 CH3—

H H YA0437 CH3—

H H YA0438 CH3—

H H YA0439 CH3—

H H YA0440 CH3—

H H YA0441 CH3—

H H YA0442 CH3—

H H YA0443 CH3—

H H YA0444 CH3—

H H YA0445 CH3—

H H YA0446 CH3—

H H YA0447 CH3—

H H YA0448 CH3—

H H YA0449 CH3—

H H YA0450 CH3—

H H YA0451 CH3—

H H YA0452 CH3—

H H YA0453 CH3—

H H YA0454 CH3—

H H YA0455 CH3—

H H YA0456 CH3—

H H YA0457 CH3—

H H YA0458 CH3—

H H YA0459 CH3—

H H YA0460 CH3—

H H YA0461 CH3—

H H YA0462 CH3—

H H YA0463 CH3—

H H YA0464 CH3—

H H YA0465 CH3—

H H YA0466 CH3—

H H YA0467 CH3—

H H YA0468 CH3—

H H YA0469 CH3—

H H YA0470 CH3—

H H YA0471 CH3—

H H YA0472 CH3—

H H YA0473 CH3—

H H YA0474 CH3—

H H YA0475 CH3—

H H YA0476 CH3—

H H YA0477 CH3—

H H YA0478 CH3—

H H YA0479 CH3—

H H YA0480 CH3—

H H YA0481 CH3—

H H YA0482 CH3—

H H YA0483 CH3—

H H YA0484 CH3—

H H YA0485 CH3—

H H YA0486 CH3—

H H YA0487 CH3—

H H YA0488 CH3—

H H YA0489 CH3—

H H YA0490 CH3—

H H YA0491 CH3—

H H YA0492 CH3—

H H YA0493 CH3—

H H YA0494 CH3—

H H YA0495 CH3—

H H YA0496 CH3—

H H YA0497 CH3—

H H YA0498 CH3—

H H YA0499 CH3—

H H YA0500 CH3—

H H YA0501 CH3—

H H YA0502 CH3—

H H YA0503 CH3—

H H YA0504 CH3—

H H YA0505 CH3—

H H YA0506 CH3—

H H YA0507 CH3—

H H YA0508 CH3—

H H YA0509 CH3—

H H YA0510 CH3—

H H YA0511 CH3—

H H YA0512 CH3—

H H YA0513 CH3—

H H YA0514 CH3—

H H YA0515 CH3—

H H YA0516 CH3—

H H YA0517 CH3—

H H YA0518 CH3—

H H YA0519 CH3—

H H YA0520 CH3—

H H YA0521 CH3— CH3— H CH3 YA0522 CH3— CH3CH2— H CH3 YA0523 CH3—

H CH3 YA0524 CH3—

H CH3 YA0525 CH3—

H CH3 YA0526 CH3—

H CH3 YA0527 CH3—

H CH3 YA0528 CH3—

H CH3 YA0529 CH3—

H CH3 YA0530 CH3—

H CH3 YA0531 CH3—

H CH3 YA0532 CH3—

H CH3 YA0533 CH3—

H CH3 YA0534 CH3—

H CH3 YA0535 CH3—

H CH3 YA0536 CH3—

H CH3 YA0537 CH3—

H CH3 YA0538 CH3—

H CH3 YA0539 CH3—

H CH3 YA0540 CH3—

H CH3 YA0541 CH3—

H CH3 YA0542 CH3—

H CH3 YA0543 CH3—

H CH3 YA0544 CH3—

H CH3 YA0545 CH3—

H CH3 YA0546 CH3—

H CH3 YA0547 CH3—

H CH3 YA0548 CH3—

H CH3 YA0549 CH3—

H CH3 YA0550 CH3—

H CH3 YA0551 CH3—

H CH3 YA0552 CH3—

H CH3 YA0553 CH3—

H CH3 YA0554 CH3—

H CH3 YA0555 CH3—

H CH3 YA0556 CH3—

H CH3 YA0557 CH3—

H CH3 YA0558 CH3—

H CH3 YA0559 CH3—

H CH3 YA0560 CH3—

H CH3 YA0561 CH3—

H CH3 YA0562 CH3—

H CH3 YA0563 CH3—

H CH3 YA0564 CH3—

H CH3 YA0565 CH3—

H CH3 YA0566 CH3—

H CH3 YA0567 CH3—

H CH3 YA0568 CH3—

H CH3 YA0569 CH3—

H CH3 YA0570 CH3—

H CH3 YA0571 CH3—

H CH3 YA0572 CH3—

H CH3 YA0573 CH3—

H CH3 YA0574 CH3—

H CH3 YA0575 CH3—

H CH3 YA0576 CH3—

H CH3 YA0577 CH3—

H CH3 YA0578 CH3—

H CH3 YA0579 CH3—

H CH3 YA0580 CH3—

H CH3 YA0581 CH3—

H CH3 YA0582 CH3—

H CH3 YA0583 CH3—

H CH3 YA0584 CH3—

H CH3 YA0585 CH3—

H CH3 YA0586 CH3—

H CH3 YA0587 CH3—

H CH3 YA0588 CH3—

H CH3 YA0589 CH3—

H CH3 YA0590 CH3—

H CH3 YA0591 CH3—

H CH3 YA0592 CH3—

H CH3 YA0593 CH3—

H CH3 YA0594 CH3—

H CH3 YA0595 CH3—

H CH3 YA0596 CH3—

H CH3 YA0597 CH3—

H CH3 YA0598 CH3—

H CH3 YA0599 CH3—

H CH3 YA0600 CH3—

H CH3 YA0601 CH3—

H CH3 YA0602 CH3—

H CH3 YA0603 CH3—

H CH3 YA0604 CH3—

H CH3 YA0605 CH3—

H CH3 YA0606 CH3—

H CH3 YA0607 CH3—

H CH3 YA0608 CH3—

H CH3 YA0609 CH3—

H CH3 YA0610 CH3—

H CH3 YA0611 CH3—

H CH3 YA0612 CH3—

H CH3 YA0613 CH3—

H CH3 YA0614 CH3—

H CH3 YA0615 CH3—

H CH3 YA0616 CH3—

H CH3 YA0617 CH3—

H CH3 YA0618 CH3—

H CH3 YA0619 CH3—

H CH3 YA0620 CH3—

H CH3 YA0621 CH3—

H CH3 YA0622 CH3—

H CH3 YA0623 CH3—

H CH3 YA0624 CH3—

H CH3 YA0625 CH3—

H CH3 YA0626 CH3—

H CH3 YA0627 CH3—

H CH3 YA0628 CH3—

H CH3 YA0629 CH3—

H CH3 YA0630 CH3—

H CH3 YA0631 CH3—

H CH3 YA0632 CH3—

H CH3 YA0633 CH3—

H CH3 YA0634 CH3—

H CH3 YA0635 CH3—

H CH3 YA0636 CH3—

H CH3 YA0637 CH3—

H CH3 YA0638 CH3—

H CH3 YA0639 CH3—

H CH3 YA0640 CH3—

H CH3 YA0641 CH3—

H CH3 YA0642 CH3—

H CH3 YA0643 CH3—

H CH3 YA0644 CH3—

H CH3 YA0645 CH3—

H CH3 YA0646 CH3—

H CH3 YA0647 CH3—

H CH3 YA0648 CH3—

H CH3 YA0649 CH3—

H CH3 YA0650 CH3—

H CH3 YA0651 CH3—

H CH3 YA0652 CH3—

H CH3 YA0653 CH3—

H CH3 YA0654 CH3—

H CH3 YA0655 CH3—

H CH3 YA0656 CH3—

H CH3 YA0657 CH3—

H CH3 YA0658 CH3—

H CH3 YA0659 CH3—

H CH3 YA0660 CH3—

H CH3 YA0661 CH3—

H CH3 YA0662 CH3—

H CH3 YA0663 CH3—

H CH3 YA0664 CH3—

H CH3 YA0665 CH3—

H CH3 YA0666 CH3—

H CH3 YA0667 CH3—

H CH3 YA0668 CH3—

H CH3 YA0669 CH3—

H CH3 YA0670 CH3—

H CH3 YA0671 CH3—

H CH3 YA0672 CH3—

H CH3 YA0673 CH3—

H CH3 YA0674 CH3—

H CH3 YA0675 CH3—

H CH3 YA0676 CH3—

H CH3 YA0677 CH3—

H CH3 YA0678 CH3—

H CH3 YA0679 CH3—

H CH3 YA0680 CH3—

H CH3 YA0681 CH3—

H CH3 YA0682 CH3—

H CH3 YA0683 CH3—

H CH3 YA0684 CH3—

H CH3 YA0685 CH3—

H CH3 YA0686 CH3—

H CH3 YA0687 CH3—

H CH3 YA0688 CH3—

H CH3 YA0689 CH3—

H CH3 YA0690 CH3—

H CH3 YA0691 CH3—

H CH3 YA0692 CH3—

H CH3 YA0693 CH3—

H CH3 YA0694 CH3—

H CH3 YA0695 CH3—

H CH3 YA0696 CH3—

H CH3 YA0697 CH3—

H CH3 YA0698 CH3—

H CH3 YA0699 CH3—

H CH3 YA0700 CH3—

H CH3 YA0701 CH3—

H CH3 YA0702 CH3—

H CH3 YA0703 CH3—

H CH3 YA0704 CH3—

H CH3 YA0705 CH3—

H CH3 YA0706 CH3—

H CH3 YA0707 CH3—

H CH3 YA0708 CH3—

H CH3 YA0709 CH3—

H CH3 YA0710 CH3—

H CH3 YA0711 CH3—

H CH3 YA0712 CH3—

H CH3 YA0713 CH3—

H CH3 YA0714 CH3—

H CH3 YA0715 CH3—

H CH3 YA0716 CH3—

H CH3 YA0717 CH3—

H CH3 YA0718 CH3—

H CH3 YA0719 CH3—

H CH3 YA0720 CH3—

H CH3 YA0721 CH3—

H CH3 YA0722 CH3—

H CH3 YA0723 CH3—

H CH3 YA0724 CH3—

H CH3 YA0725 CH3—

H CH3 YA0726 CH3—

H CH3 YA0727 CH3—

H CH3 YA0728 CH3—

H CH3 YA0729 CH3—

H CH3 YA0730 CH3—

H CH3 YA0731 CH3— CH3— H

YA0732 CH3— CH3CH2— H

YA0733 CH3—

H

YA0734 CH3—

H

YA0735 CH3—

H

YA0736 CH3—

H

YA0737 CH3—

H

YA0738 CH3—

H

YA0739 CH3—

H

YA0740 CH3—

H

YA0741 CH3—

H

YA0742 CH3—

H

YA0743 CH3—

H

YA0744 CH3—

H

YA0745 CH3—

H

YA0746 CH3—

H

YA0747 CH3—

H

YA0748 CH3—

H

YA0749 CH3—

H

YA0750 CH3—

H

YA0751 CH3—

H

YA0752 CH3—

H

YA0753 CH3—

H

YA0754 CH3—

H

YA0755 CH3—

H

YA0756 CH3—

H

YA0757 CH3—

H

YA0758 CH3—

H

YA0759 CH3—

H

YA0760 CH3—

H

YA0761 CH3—

H

YA0762 CH3—

H

YA0763 CH3—

H

YA0764 CH3—

H

YA0765 CH3—

H

YA0766 CH3—

H

YA0767 CH3—

H

YA0768 CH3—

H

YA0769 CH3—

H

YA0770 CH3—

H

YA0771 CH3—

H

YA0772 CH3—

H

YA0773 CH3—

H

YA0774 CH3—

H

YA0775 CH3—

H

YA0776 CH3—

H

YA0777 CH3—

H

YA0778 CH3—

H

YA0779 CH3—

H

YA0780 CH3—

H

YA0781 CH3—

H

YA0782 CH3—

H

YA0783 CH3—

H

YA0784 CH3—

H

YA0785 CH3—

H

YA0786 CH3—

H

YA0787 CH3—

H

YA0788 CH3—

H

YA0789 CH3—

H

YA0790 CH3—

H

YA0791 CH3—

H

YA0792 CH3—

H

YA0793 CH3—

H

YA0794 CH3—

H

YA0795 CH3—

H

YA0796 CH3—

H

YA0797 CH3—

H

YA0798 CH3—

H

YA0799 CH3—

H

YA0800 CH3—

H

YA0801 CH3—

H

YA0802 CH3—

H

YA0803 CH3—

H

YA0804 CH3—

H

YA0805 CH3—

H

YA0806 CH3—

H

YA0807 CH3—

H

YA0808 CH3—

H

YA0809 CH3—

H

YA0810 CH3—

H

YA0811 CH3—

H

YA0812 CH3—

H

YA0813 CH3—

H

YA0814 CH3—

H

YA0815 CH3—

H

YA0816 CH3—

H

YA0817 CH3—

H

YA0818 CH3—

H

YA0819 CH3—

H

YA0820 CH3—

H

YA0821 CH3—

H

YA0822 CH3—

H

YA0823 CH3—

H

YA0824 CH3—

H

YA0825 CH3—

H

YA0826 CH3—

H

YA0827 CH3—

H

YA0828 CH3—

H

YA0829 CH3—

H

YA0830 CH3—

H

YA0831 CH3—

H

YA0832 CH3—

H

YA0833 CH3—

H

YA0834 CH3—

H

YA0835 CH3—

H

YA0836 CH3—

H

YA0837 CH3—

H

YA0838 CH3—

H

YA0839 CH3—

H

YA0840 CH3—

H

YA0841 CH3—

H

YA0842 CH3—

H

YA0843 CH3—

H

YA0844 CH3—

H

YA0845 CH3—

H

YA0846 CH3—

H

YA0847 CH3—

H

YA0848 CH3—

H

YA0849 CH3—

H

YA0850 CH3—

H

YA0851 CH3—

H

YA0852 CH3—

H

YA0853 CH3—

H

YA0854 CH3—

H

YA0855 CH3—

H

No. R1 R2 R3 R4 YA0856 CH3—

H

YA0857 CH3—

H

YA0858 CH3—

H

YA0859 CH3—

H

YA0860 CH3—

H

YA0861 CH3—

H

YA0862 CH3—

H

YA0863 CH3—

H

YA0864 CH3—

H

YA0865 CH3—

H

YA0866 CH3—

H

YA0867 CH3—

H

YA0868 CH3—

H

YA0869 CH3—

H

YA0870 CH3—

H

YA0871 CH3—

H

YA0872 CH3—

H

YA0873 CH3—

H

YA0874 CH3—

H

YA0875 CH3—

H

YA0876 CH3—

H

YA0877 CH3—

H

YA0878 CH3—

H

YA0879 CH3—

H

YA0880 CH3—

H

YA0881 CH3—

H

YA0882 CH3—

H

YA0883 CH3—

H

YA0884 CH3—

H

YA0885 CH3—

H

YA0886 CH3—

H

YA0887 CH3—

H

YA0888 CH3—

H

YA0889 CH3—

H

YA0890 CH3—

H

YA0891 CH3—

H

YA0892 CH3—

H

YA0893 CH3—

H

YA0894 CH3—

H

YA0895 CH3—

H

YA0896 CH3—

H

YA0897 CH3—

H

YA0898 CH3—

H

YA0899 CH3—

H

YA0900 CH3—

H

YA0901 CH3—

H

YA0902 CH3—

H

YA0903 CH3—

H

YA0904 CH3—

H

YA0905 CH3—

H

YA0906 CH3—

H

YA0907 CH3—

H

YA0908 CH3—

H

YA0909 CH3—

H

YA0910 CH3—

H

YA0911 CH3—

H

YA0912 CH3—

H

YA0913 CH3—

H

YA0914 CH3—

H

YA0915 CH3—

H

YA0916 CH3—

H

YA0917 CH3—

H

YA0918 CH3—

H

YA0919 CH3—

H

YA0920 CH3—

H

YA0921 CH3—

H

YA0922 CH3—

H

YA0923 CH3—

H

YA0924 CH3—

H

YA0925 CH3—

H

YA0926 CH3—

H

YA0927 CH3—

H

YA0928 CH3—

H

YA0929 CH3—

H

YA0930 CH3—

H

YA0931 CH3—

H

YA0932 CH3—

H

YA0933 CH3—

H

YA0934 CH3—

H

YA0935 CH3—

H

YA0936 CH3—

H

YA0937 CH3—

H

YA0938 CH3—

H

YA0939 CH3—

H

YA0940 CH3—

H

YA0941 CH3— CH3— H

YA0942 CH3— CH3CH2— H

YA0943 CH3—

H

YA0944 CH3—

H

YA0945 CH3—

H

YA0946 CH3—

H

YA0947 CH3—

H

YA0948 CH3—

H

YA0949 CH3—

H

YA0950 CH3—

H

YA0951 CH3—

H

YA0952 CH3—

H

YA0953 CH3—

H

YA0954 CH3—

H

YA0955 CH3—

H

YA0956 CH3—

H

YA0957 CH3—

H

YA0958 CH3—

H

YA0959 CH3—

H

YA0960 CH3—

H

YA0961 CH3—

H

YA0962 CH3—

H

YA0963 CH3—

H

YA0964 CH3—

H

YA0965 CH3—

H

YA0966 CH3—

H

YA0967 CH3—

H

YA0968 CH3—

H

YA0969 CH3—

H

YA0970 CH3—

H

YA0971 CH3—

H

YA0972 CH3—

H

YA0973 CH3—

H

YA0974 CH3—

H

YA0975 CH3—

H

YA0976 CH3—

H

YA0977 CH3—

H

YA0978 CH3—

H

YA0979 CH3—

H

YA0980 CH3—

H

YA0981 CH3—

H

YA0982 CH3—

H

YA0983 CH3—

H

YA0984 CH3—

H

YA0985 CH3—

H

YA0986 CH3—

H

YA0987 CH3—

H

YA0988 CH3—

H

YA0989 CH3—

H

YA0990 CH3—

H

YA0901 CH3—

H

YA0992 CH3—

H

YA0993 CH3—

H

YA0994 CH3—

H

YA0995 CH3—

H

YA0996 CH3—

H

YA0997 CH3—

H

YA0998 CH3—

H

YA0999 CH3—

H

YA1000 CH3—

H

YA1001 CH3—

H

YA1002 CH3—

H

YA1003 CH3—

H

YA1004 CH3—

H

YA1005 CH3—

H

YA1006 CH3—

H

YA1007 CH3—

H

YA1008 CH3—

H

YA1009 CH3—

H

YA1010 CH3—

H

YA1011 CH3—

H

YA1012 CH3—

H

YA1013 CH3—

H

YA1014 CH3—

H

YA1015 CH3—

H

YA1016 CH3—

H

YA1017 CH3—

H

YA1018 CH3—

H

YA1019 CH3—

H

YA1020 CH3—

H

YA1021 CH3—

H

YA1022 CH3—

H

YA1023 CH3—

H

YA1024 CH3—

H

YA1025 CH3—

H

YA1026 CH3—

H

YA1027 CH3—

H

YA1028 CH3—

H

YA1029 CH3—

H

YA1030 CH3—

H

YA1031 CH3—

H

YA1032 CH3—

H

YA1033 CH3—

H

YA1034 CH3—

H

YA1035 CH3—

H

YA1036 CH3—

H

YA1037 CH3—

H

YA1038 CH3—

H

YA1039 CH3—

H

YA1040 CH3—

H

YA1041 CH3—

H

YA1042 CH3—

H

YA1043 CH3—

H

YA1044 CH3—

H

YA1045 CH3—

H

YA1046 CH3—

H

YA1047 CH3—

H

YA1048 CH3—

H

YA1049 CH3—

H

YA1050 CH3—

H

YA1051 CH3—

H

YA1052 CH3—

H

YA1053 CH3—

H

YA1054 CH3—

H

YA1055 CH3—

H

YA1056 CH3—

H

YA1057 CH3—

H

YA1058 CH3—

H

YA1059 CH3—

H

YA1060 CH3—

H

YA1061 CH3—

H

YA1062 CH3—

H

YA1063 CH3—

H

YA1064 CH3—

H

YA1065 CH3—

H

YA1066 CH3—

H

YA1067 CH3—

H

YA1068 CH3—

H

YA1069 CH3—

H

YA1070 CH3—

H

YA1071 CH3—

H

YA1072 CH3—

H

YA1073 CH3—

H

YA1074 CH3—

H

YA1075 CH3—

H

YA1076 CH3—

H

YA1077 CH3—

H

YA1078 CH3—

H

YA1079 CH3—

H

YA1080 CH3—

H

YA1081 CH3—

H

YA1082 CH3—

H

YA1083 CH3—

H

YA1084 CH3—

H

YA1085 CH3—

H

YA1086 CH3—

H

YA1087 CH3—

H

YA1088 CH3—

H

YA1089 CH3—

H

YA1090 CH3—

H

YA1091 CH3—

H

YA1092 CH3—

H

YA1093 CH3—

H

YA1094 CH3—

H

YA1095 CH3—

H

YA1096 CH3—

H

YA1097 CH3—

H

YA1098 CH3—

H

YA1099 CH3—

H

YA1100 CH3—

H

YA1101 CH3—

H

YA1102 CH3—

H

YA1103 CH3—

H

YA1104 CH3—

H

YA1105 CH3—

H

YA1106 CH3—

H

YA1107 CH3—

H

YA1108 CH3—

H

YA1109 CH3—

H

YA1110 CH3—

H

YA1111 CH3—

H

YA1112 CH3—

H

YA1113 CH3—

H

YA1114 CH3—

H

YA1115 CH3—

H

YA1116 CH3—

H

YA1111 CH3—

H

YA1118 CH3—

H

YA1119 CH3—

H

YA1120 CH3—

H

YA1121 CH3—

H

YA1122 CH3—

H

YA1123 CH3—

H

YA1124 CH3—

H

YA1125 CH3—

H

YA1126 CH3—

H

YA1127 CH3—

H

YA1128 CH3—

H

YA1129 CH3—

H

YA1130 CH3—

H

YA1131 CH3—

H

YA1132 CH3—

H

YA1133 CH3—

H

YA1134 CH3—

H

YA1135 CH3—

H

YA1136 CH3—

H

YA1137 CH3—

H

YA1138 CH3—

H

YA1139 CH3—

H

YA1140 CH3—

H

YA1141 CH3—

H

YA1142 CH3—

H

YA1143 CH3—

H

YA1144 CH3—

H

YA1145 CH3—

H

YA1146 CH3—

H

YA1147 CH3—

H

YA1148 CH3—

H

YA1149 CH3—

H

YA1150 CH3—

H

YA1151 CH3—

H

YA1152 CH3—

H

YA1153 CH3—

H

YA1154 CH3— CH3— CH3— H YA1155 CH3— CH3CH2— CH3— H YA1156 CH3—

CH3— H YA1157 CH3—

CH3— H YA1158 CH3—

CH3— H YA1159 CH3—

CH3— H YA1160 CH3—

CH3— H YA1161 CH3—

CH3— H YA1162 CH3—

CH3— H YA1163 CH3—

CH3— H YA1104 CH3—

CH3— H YA1165 CH3—

CH3— H YA1166 CH3—

CH3— H YA1181 CH3—

CH3— H YA1168 CH3—

CH3— H YA1169 CH3—

CH3— H YA1170 CH3—

CH3— H YA1171 CH3—

CH3— H YA1172 CH3—

CH3— H YA1173 CH3—

CH3— H YA1174 CH3—

CH3— H YA1175 CH3—

CH3— H YA1176 CH3—

CH3— H YA1177 CH3—

CH3— H YA1178 CH3—

CH3— H YA1179 CH3—

CH3— H YA1180 CH3—

CH3— H YA1181 CH3—

CH3— H YA1182 CH3—

CH3— H YA1183 CH3—

CH3— H YA1184 CH3—

CH3— H YA1185 CH3—

CH3— H YA1186 CH3—

CH3— H YA1187 CH3—

CH3— H YA1188 CH3—

CH3— H YA1189 CH3—

CH3— H YA1190 CH3—

CH3— H YA1191 CH3—

CH3— H YA1192 CH3—

CH3— H YA1193 CH3—

CH3— H YA1194 CH3—

CH3— H YA1195 CH3—

CH3— H YA1196 CH3—

CH3— H YA1197 CH3—

CH3— H YA1198 CH3—

CH3— H YA1199 CH3—

CH3— H YA1200 CH3—

CH3— H YA1201 CH3—

CH3— H YA1202 CH3—

CH3— H YA1203 CH3—

CH3— H YA1204 CH3—

CH3— H YA1205 CH3—

CH3— H YA1206 CH3—

CH3— H YA1207 CH3—

CH3— H YA1208 CH3—

CH3— H YA1209 CH3—

CH3— H YA1210 CH3—

CH3— H YA1211 CH3—

CH3— H YA1212 CH3—

CH3— H YA1213 CH3—

CH3— H YA1214 CH3—

CH3— H YA1215 CH3—

CH3— H YA1216 CH3—

CH3— H YA1217 CH3—

CH3— H YA1218 CH3—

CH3— H YA1219 CH3—

CH3— H YA1220 CH3—

CH3— H YA1221 CH3—

CH3— H YA1222 CH3—

CH3— H YA1223 CH3—

CH3— H YA1224 CH3—

CH3— H YA1225 CH3—

CH3— H YA1226 CH3—

CH3— H YA1227 CH3—

CH3— H YA1228 CH3—

CH3— H YA1229 CH3—

CH3— H YA1230 CH3—

CH3— H YA1231 CH3—

CH3— H YA1232 CH3—

CH3— H YA1233 CH3—

CH3— H YA1234 CH3—

CH3— H YA1235 CH3—

CH3— H YA1236 CH3—

CH3— H YA1237 CH3—

CH3— H YA1238 CH3—

CH3— H YA1239 CH3—

CH3— H YA1240 CH3—

CH3— H YA1241 CH3—

CH3— H YA1242 CH3—

CH3— H YA1243 CH3—

CH3— H YA1244 CH3—

CH3— H YA1245 CH3—

CH3— H YA1246 CH3—

CH3— H YA1247 CH3—

CH3— H YA1248 CH3—

CH3— H YA1249 CH3— CH3— H CH3— YA1250 CH3— CH3CH2— H CH3— YA1251 CH3—

H CH3— YA1252 CH3—

H CH3— YA1253 CH3—

H CH3— YA1254 CH3—

H CH3— YA1255 CH3—

H CH3— YA1256 CH3—

H CH3— YA1257 CH3—

H CH3— YA1258 CH3—

H CH3— YA1259 CH3—

H CH3— YA1260 CH3—

H CH3— YA1261 CH3—

H CH3— YA1262 CH3—

H CH3— YA1263 CH3—

H CH3— YA1264 CH3—

H CH3— YA1265 CH3—

H CH3— YA1266 CH3—

H CH3— YA1267 CH3—

H CH3— YA1268 CH3—

H CH3— YA1269 CH3—

H CH3— YA1270 CH3—

H CH3— YA1271 CH3—

H CH3— YA1272 CH3—

H CH3— YA1273 CH3—

H CH3— YA1274 CH3—

H CH3— YA1275 CH3—

H CH3— YA1276 CH3—

H CH3— YA1277 CH3—

H CH3— YA1278 CH3—

H CH3— YA1279 CH3—

H CH3— YA1280 CH3—

H CH3— YA1281 CH3—

H CH3— YA1282 CH3—

H CH3— YA1283 CH3—

H CH3— YA1284 CH3—

H CH3— YA1285 CH3—

H CH3— YA1286 CH3—

H CH3— YA1287 CH3—

H CH3— YA1288 CH3—

H CH3— YA1289 CH3—

H CH3— YA1290 CH3—

H CH3— YA1291 CH3—

H CH3— YA1292 CH3—

H CH3— YA1293 CH3—

H CH3— YA1294 CH3—

H CH3— YA1295 CH3—

H CH3— YA1296 CH3—

H CH3— YA1297 CH3—

H CH3— YA1298 CH3—

H CH3— YA1299 CH3—

H CH3— YA1300 CH3—

H CH3— YA1301 CH3—

H CH3— YA1302 CH3—

H CH3— YA1303 CH3—

H CH3— YA1304 CH3—

H CH3— YA1305 CH3—

H CH3— YA1306 CH3—

H CH3— YA1307 CH3—

H CH3— YA1308 CH3—

H CH3— YA1309 CH3—

H CH3— YA1310 CH3—

H CH3— YA1311 CH3—

H CH3— YA1312 CH3—

H CH3— YA1313 CH3—

H CH3— YA1314 CH3—

H CH3— YA1315 CH3—

H CH3— YA1316 CH3—

H CH3— YA1317 CH3—

H CH3— YA1318 CH3—

H CH3— YA1319 CH3—

H CH3— YA1320 CH3—

H CH3— YA1321 CH3—

H CH3— YA1322 CH3—

H CH3— YA1323 CH3—

H CH3— YA1324 CH3—

H CH3— YA1325 CH3—

H CH3— YA1326 CH3—

H CH3— YA1327 CH3—

H CH3— YA1328 CH3—

H CH3— YA1329 CH3—

H CH3— YA1330 CH3—

H CH3— YA1331 CH3—

H CH3— YA1332 CH3—

H CH3— YA1333 CH3—

H CH3— YA1334 CH3—

H CH3— YA1335 CH3—

H CH3— YA1336 CH3—

H CH3— YA1337 CH3—

H CH3— YA1338 CH3—

H CH3— YA1339 CH3—

H CH3— YA1340 CH3—

H CH3— YA1341 CH3—

H CH3— YA1342 CH3—

H CH3— YA1343 CH3—

H CH3— YA1344 CH3CH2— CH3— H H YA1345 CH3CH2— CH3CH2— H H YA1346 CH3CH2—

H H YA1347 CH3CH2—

H H YA1348 CH3CH2—

H H YA1349 CH3CH2—

H H YA1350 CH3CH2—

H H YA1351 CH3CH2—

H H YA1352 CH3CH2—

H H YA1353 CH3CH2—

H H YA1354 CH3CH2—

H H YA1355 CH3CH2—

H H YA1356 CH3CH2—

H H YA1357 CH3CH2—

H H YA1358 CH3CH2—

H H YA1359 CH3CH2—

H H YA1360 CH3CH2—

H H YA1361 CH3CH2—

H H YA1362 CH3CH2—

H H YA1363 CH3CH2—

H H YA1364 CH3CH2—

H H YA1365 CH3CH2—

H H YA1366 CH3CH2—

H H YA1367 CH3CH2—

H H YA1368 CH3CH2—

H H YA1369 CH3CH2—

H H YA1370 CH3CH2—

H H YA1371 CH3CH2—

H H YA1372 CH3CH2—

H H YA1373 CH3CH2—

H H YA1374 CH3CH2—

H H YA1375 CH3CH2—

H H YA1376 CH3CH2—

H H YA1377 CH3CH2—

H H YA1378 CH3CH2—

H H YA1379 CH3CH2—

H H YA1380 CH3CH2—

H H YA1381 CH3CH2—

H H YA1382 CH3CH2—

H H YA1383 CH3CH2—

H H YA1384 CH3CH2—

H H YA1385 CH3CH2—

H H YA1386 CH3CH2—

H H YA1387 CH3CH2—

H H YA1388 CH3CH2—

H H YA1389 CH3CH2—

H H YA1390 CH3CH2—

H H YA1391 CH3CH2—

H H YA1392 CH3CH2—

H H YA1393 CH3CH2—

H H YA1394 CH3CH2—

H H YA1395 CH3CH2—

H H YA1396 CH3CH2—

H H YA1397 CH3CH2—

H H YA1398 CH3CH2—

H H YA1399 CH3CH2—

H H YA1400 CH3CH2—

H H YA1401 CH3CH2—

H H YA1402 CH3CH2—

H H YA1403 CH3CH2—

H H YA1404 CH3CH2—

H H YA1405 CH3CH2—

H H YA1406 CH3CH2—

H H YA1407 CH3CH2—

H H YA1408 CH3CH2—

H H YA1409 CH3CH2—

H H YA1410 CH3CH2—

H H YA1411 CH3CH2—

H H YA1412 CH3CH2—

H H YA1413 CH3CH2—

H H YA1414 CH3CH2—

H H YA1415 CH3CH2—

H H YA1416 CH3CH2—

H H YA1417 CH3CH2—

H H YA1418 CH3CH2—

H H YA1419 CH3CH2—

H H YA1420 CH3CH2—

H H YA1421 CH3CH2—

H H YA1422 CH3CH2—

H H YA1423 CH3CH2—

H H YA1424 CH3CH2—

H H YA1425 CH3CH2—

H H YA1426 CH3CH2—

H H YA1427 CH3CH2—

H H YA1428 CH3CH2—

H H YA1429 CH3CH2—

H H YA1430 CH3CH2—

H H YA1431 CH3CH2—

H H YA1432 CH3CH2—

H H YA1433 CH3CH2—

H H YA1434 CH3CH2—

H H YA1435 CH3CH2—

H H YA1436 CH3CH2—

H H YA1437 CH3CH2—

H H YA1438 CH3CH2—

H H YA1439 CH3CH2— CH3— H CH3— YA1440 CH3CH2— CH3CH2— H CH3— YA1441 CH3CH2—

H CH3— YA1442 CH3CH2—

H CH3— YA1443 CH3CH2—

H CH3— YA1444 CH3CH2—

H CH3— YA1445 CH3CH2—

H CH3— YA1446 CH3CH2—

H CH3— YA1447 CH3CH2—

H CH3— YA1448 CH3CH2—

H CH3— YA1449 CH3CH2—

H CH3— YA1450 CH3CH2—

H CH3— YA1451 CH3CH2—

H CH3— YA1452 CH3CH2—

H CH3— YA1453 CH3CH2—

H CH3— YA1454 CH3CH2—

H CH3— YA1455 CH3CH2—

H CH3— YA1456 CH3CH2—

H CH3— YA1457 CH3CH2—

H CH3— YA1458 CH3CH2—

H CH3— YA1459 CH3CH2—

H CH3— YA1460 CH3CH2—

H CH3— YA1461 CH3CH2—

H CH3— YA1462 CH3CH2—

H CH3— YA1463 CH3CH2—

H CH3— YA1464 CH3CH2—

H CH3— YA1465 CH3CH2—

H CH3— YA1466 CH3CH2—

H CH3— YA1467 CH3CH2—

H CH3— YA1468 CH3CH2—

H CH3— YA1469 CH3CH2—

H CH3— YA1470 CH3CH2—

H CH3— YA1471 CH3CH2—

H CH3— YA1472 CH3CH2—

H CH3— YA1473 CH3CH2—

H CH3— YA1474 CH3CH2—

H CH3— YA1475 CH3CH2—

H CH3— YA1476 CH3CH2—

H CH3— YA1477 CH3CH2—

H CH3— YA1478 CH3CH2—

H CH3— YA1479 CH3CH2—

H CH3— YA1480 CH3CH2—

H CH3— YA1481 CH3CH2—

H CH3— YA1482 CH3CH2—

H CH3— YA1483 CH3CH2—

H CH3— YA1484 CH3CH2—

H CH3— YA1485 CH3CH2—

H CH3— YA1486 CH3CH2—

H CH3— YA1487 CH3CH2—

H CH3— YA1488 CH3CH2—

H CH3— YA1489 CH3CH2—

H CH3— YA1490 CH3CH2—

H CH3— YA1491 CH3CH2—

H CH3— YA1492 CH3CH2—

H CH3— YA1493 CH3CH2—

H CH3— YA1494 CH3CH2—

H CH3— YA1495 CH3CH2—

H CH3— YA1496 CH3CH2—

H CH3— YA1497 CH3CH2—

H CH3— YA1498 CH3CH2—

H CH3— YA1499 CH3CH2—

H CH3— YA1500 CH3CH2—

H CH3— YA1501 CH3CH2—

H CH3— YA1502 CH3CH2—

H CH3— YA1503 CH3CH2—

H CH3— YA1504 CH3CH2—

H CH3— YA1505 CH3CH2—

H CH3— YA1506 CH3CH2—

H CH3— YA1507 CH3CH2—

H CH3— YA1508 CH3CH2—

H CH3— YA1509 CH3CH2—

H CH3— YA1510 CH3CH2—

H CH3— YA1511 CH3CH2—

H CH3— YA1512 CH3CH2—

H CH3— YA1513 CH3CH2—

H CH3— YA1514 CH3CH2—

H CH3— YA1515 CH3CH2—

H CH3— YA1516 CH3CH2—

H CH3— YA1517 CH3CH2—

H CH3— YA1518 CH3CH2—

H CH3— YA1519 CH3CH2—

H CH3— YA1520 CH3CH2—

H CH3— YA1521 CH3CH2—

H CH3— YA1522 CH3CH2—

H CH3— YA1523 CH3CH2—

H CH3— YA1524 CH3CH2—

H CH3— YA1525 CH3CH2—

H CH3— YA1526 CH3CH2—

H CH3— YA1527 CH3CH2—

H CH3— YA1528 CH3CH2—

H CH3— YA1529 CH3CH2—

H CH3— YA1530 CH3CH2—

H CH3— YA1531 CH3CH2—

H CH3— YA1532 CH3CH2—

H CH3— YA1533 CH3CH2—

H CH3—

No. STRUCTURE YA1534

YA1535

YA1536

YA1537

YA1538

YA1539

YA1540

YA1541

YA1542

YA1543

YA1544

YA1545

YA1546

YA1547

YA1548

YA1549

YA1550

YA1551

YA1552

YA1553

YA1554

YA1555

YA1556

YA1557

YA1558

YA1559

YA1560

YA1561

YA1562

YA1563

YA1564

YA1565

YA1566

YA1567

YA1568

YA1569

YA1570

YA1571

YA1572

YA1573

YA1574

YA1575

YA1576

YA1577

YA1578

YA1579

YA1580

YA1581

YA1582

YA1583

YA1584

YA1585

YA1586

YA1587

YA1588

YA1589

YA1590

TABLE 4

No. R1 R2 R3 R4 R5 YB1 CH3— CH3— H H H YB2 CH3— CH3CH2— H H H YB3 CH3—

H H H YB4 CH3—

H H H YB5 CH3—

H H H YB6 CH3—

H H H YB7 CH3—

H H H YB8 CH3—

H H H YB9 CH3—

H H H YB10 CH3—

H H H YB11 CH3—

H H H YB12 CH3—

H H H YB13 CH3—

H H H YB14 CH3—

H H H YB15 CH3—

H H H YB16 CH3—

H H H YB17 CH3—

H H H YB18 CH3—

H H H YB19 CH3—

H H H YB20 CH3—

H H H YB21 CH3—

H H H YB22 CH3—

H H H YB23 CH3—

H H H YB24 CH3—

H H H YB25 CH3—

H H H YB26 CH3—

H H H YB27 CH3—

H H H YB28 CH3—

H H H YB29 CH3—

H H H YB30 CH3—

H H H YB31 CH3—

H H H YB32 CH3—

H H H YB33 CH3—

H H H YB34 CH3—

H H H YB35 CH3—

H H H YB36 CH3—

H H H YB37 CH3—

H H H YB38 CH3—

H H H YB39 CH3—

H H H YB40 CH3—

H H H YB41 CH3—

H H H YB42 CH3—

H H H YB43 CH3—

H H H YB44 CH3—

H H H YB45 CH3—

H H H YB46 CH3—

H H H YB47 CH3—

H H H YB48 CH3—

H H H YB49 CH3—

H H H YB50 CH3—

H H H YB51 CH3—

H H H YB52 CH3—

OH H H YB53 CH3—

OH H H YB54 CH3—

OH H H YB55 CH3—

OH H H YB56 CH3—

OH H H YB57 CH3—

OH H H YB58 CH3—

OH H H YB59 CH3—

OH H H YB60 CH3—

OH H H YB61 CH3—

OH H H YB62 CH3—

OH H H YB63 CH3—

OH H H YB64 CH3—

OH H H YB65 CH3—

OH H H YB66 CH3—

OH H H YB67 CH3—

OH H H YB68 CH3—

OH H H YB69 CH3—

OH H H YB70 CH3—

OH H H YB71 CH3—

OH H H YB72 CH3—

OH H H YB73 CH3—

OH H H YB74 CH3—

OH H H YB75 CH3—

OH H H YB76 CH3—

OH H H YB77 CH3—

OH H H YB78 CH3—

OH H H YB79 CH3—

OH H H YB80 CH3—

OH H H YB81 CH3—

OH H H YB82 CH3—

CN H H YB83 CH3—

CN H H YB84 CH3—

CN H H YB85 CH3—

CN H H YB86 CH3—

CN H H YB87 CH3—

CN H H YB88 CH3—

CN H H YB89 CH3—

CN H H YB90 CH3—

CN H H YB91 CH3—

CN H H YB92 CH3—

CN H H YB93 CH3—

CN H H YB94 CH3—

CN H H YB95 CH3—

CN H H YB96 CH3—

CN H H YB97 CH3—

CN H H YB98 CH3—

CN H H YB99 CH3—

CN H H YB100 CH3—

CN H H YB101 CH3—

CN H H YB102 CH3—

CN H H YB103 CH3—

CN H H YB104 CH3—

CN H H YB105 CH3—

CN H H YB106 CH3—

CN H H YB107 CH3—

CN H H YB108 CH3—

CN H H YB109 CH3—

CN H H YB110 CH3—

CN H H YB111 CH3—

CN H H YB112 CH3— H H CH3— H YB113 CH3— H H CH3CH2— H YB114 CH3— H H

H YB115 CH3— H H

H YB116 CH3— H H

H YB117 CH3— H H

H YB118 CH3— H H

H YB119 CH3— H H

H YB120 CH3— H H

H YB121 CH3— H H

H YB122 CH3— H H

H YB123 CH3— H H

H YB124 CH3— H H

H YB125 CH3— H H

H YB126 CH3— H H

H YB127 CH3— H H

H YB128 CH3— H H

H YB129 CH3— H H

H YB130 CH3— H H

H YB131 CH3— H H

H YB132 CH3— H H

H YB133 CH3— H H

H YB134 CH3— H H

H YB135 CH3— H H

H YB136 CH3— H H

H YB137 CH3— H H

H YB138 CH3— H H

H YB139 CH3— H H

H YB140 CH3— H H

H YB141 CH3— H H

H YB142 CH3— H H

H YB143 CH3— H H

H YB144 CH3— H H

H YB145 CH3— H H

H YB146 CH3— H H

H YB147 CH3— H H

H YB148 CH3— H H

H YB149 CH3— H H

H YB150 CH3— H H

H YB151 CH3— H H

H YB152 CH3— H H

H YB153 CH3— H H

H YB154 CH3— H H

H YB155 CH3— H H

H YB156 CH3— H H

H YB157 CH3— H H

H YB158 CH3— H H

H YB159 CH3— H H

H YB160 CH3— H H

H YB161 CH3— H H

H YB162 CH3— H H

H YB163 CH3— H H

H YB164 CH3— H H

OH YB165 CH3— H H

OH YB166 CH3— H H

OH YB167 CH3— H H

OH YB168 CH3— H H

OH YB169 CH3— H H

OH YB170 CH3— H H

OH YB171 CH3— H H

OH YB172 CH3— H H

OH YB173 CH3— H H

OH YB174 CH3— H H

OH YB175 CH3— H H

OH YB176 CH3— H H

OH YB177 CH3— H H

OH YB178 CH3— H H

OH YB179 CH3— H H

OH YB180 CH3— H H

OH YB181 CH3— H H

OH YB182 CH3— H H

OH YB183 CH3— H H

OH YB184 CH3— H H

OH YB185 CH3— H H

OH YB186 CH3— H H

OH YB187 CH3— H H

OH YB188 CH3— H H

OH YB189 CH3— H H

OH YB190 CH3— H H

OH YB191 CH3— H H

OH YB192 CH3— H H

OH YB193 CH3— H H

CN YB194 CH3— H H

CN YB195 CH3— H H

CN YB196 CH3— H H

CN YB197 CH3— H H

CN YB198 CH3— H H

CN YB199 CH3— H H

CN YB200 CH3— H H

CN YB201 CH3— H H

CN YB202 CH3— H H

CN YB203 CH3— H H

CN YB204 CH3— H H

CN YB205 CH3— H H

CN YB206 CH3— H H

CN YB207 CH3— H H

CN YB208 CH3— H H

CN YB209 CH3— H H

CN YB210 CH3— H H

CN YB211 CH3— H H

CN YB212 CH3— H H

CN YB213 CH3— H H

CN YB214 CH3— H H

CN YB215 CH3— H H

CN YB216 CH3— H H

CN YB217 CH3— H H

CN YB218 CH3— H H

CN YB219 CH3— H H

CN YB220 CH3— H H

CN YB221 CH3— H H

CN YB222 CH3— H H

YB223 CH3— H H

YB224 CH3— H H

YB225 CH3— H H

YB226 CH3— H H

YB227 CH3— H H

YB228 CH3— H H

YB229 CH3— H H

YB230 CH3— H H

YB231 CH3— H H

YB232 CH3— H H

YB233 CH3— H H

YB234 CH3— H H

YB235 CH3— H H

YB236 CH3— H H

YB237 CH3— H H

YB238 CH3— H H

YB239 CH3— H H

YB240 CH3— H H

YB241 CH3— H H

YB242 CH3— H H

YB243 CH3— H H

YB244 CH3— H H

YB245 CH3— H H

YB246 CH3— H H

YB247 CH3— H H

YB248 CH3— H H

YB249 CH3— H H

YB250 CH3— H H

No. STRUCTURE YB251

YB252

YB253

YB254

YB255

YB256

YB257

YB258

YB259

YB260

YB261

YB262

YB263

YB264

YB265

YB266

YB267

YB268

YB269

YB270

YB271

YB272

YB273

YB274

YB275

YB276

YB277

YB278

Particularly preferred compounds of the present invention represented by formula (I) include:

-   2-(3-Phenylpiperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(4-Fluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(3-Fluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(2-Fluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(4-Chlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   (S)-2-(3-(4-Chlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   (R)-2-(3-(4-Chlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(3-Chlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(2-Chlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(4-Bromophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(3-Bromophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(2-Bromophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(4-Methylphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(3-Methylphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(2-Methylphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(4-Cyanophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(3-Cyanophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(2-Cyanophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(4-Methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(3-Methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(2-Methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(2-Ethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(5-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(4-Fluoro-3-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   (S)-2-(3-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   (R)-2-(3-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(4-Chloro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(4-Fluoro-2-methylphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(2-Fluoro-6-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(5-Bromo-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(2-Bromo-4-fluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(2-Chloro-6-fluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(2,4-Difluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(2,6-Difluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(2,6-Dichlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(2,4-Dimethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(3,4-Dimethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(2,5-Dimethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(2,6-Dimethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(2,4-Difluoro-6-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(5-Cyano-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(4-Cyano-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(1-Naphthyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(2-Naphthyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(2,3-Dihydrobenzofuran-7-yl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(Benzofuran-2-yl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   (S)-2-(3-(Benzofuran-2-yl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(4-(Pyrrolidin-1-yl-methyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(4-(Pyrrolidin-1-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(2-methoxy-4-(pyrrolidin-1-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(2-methoxy-5-(pyrrolidin-1-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(4-(Phenyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(4-(4-Fluorophenyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(4-(4-Methoxyphenyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(4-(2-Methoxyphenyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(4-(Morpholin-4-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(4-(4-Methylpiperazin-1-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(4-Phenylpiperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(4-Benzylpiperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(4-Benzoylpiperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(4-(1,2-Benzisothiazol-3-yl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(4-Methyl-3-phenylpiperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(4-Fluoro-2-methoxyphenyl)-4-methylpiperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   (S)-2-(3-(4-Fluoro-2-methoxyphenyl)-4-methylpiperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   (R)-2-(3-(4-Fluoro-2-methoxyphenyl)-4-methylpiperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(4-Acetyl-3-(4-fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(4-Benzyl-3-(4-fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(4-Benzyl-3-(ethoxycarbonyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(4-methyl-3-(1-naphthyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(5,5-Dimethyl-3-(2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-Phenylpiperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(4-Fluorophenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(3-Fluorophenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(2-Fluorophenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(4-Chlorophenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(4-Bromophenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(4-Methoxyphenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(3-Methoxyphenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(2-Methoxyphenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(4-((Pyrrolidin-1-yl)methyl)phenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   (S)-2-(3-(4-(Pyrrolidin-1-yl-methyl)phenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   (R)-2-(3-(4-(Pyrrolidin-1-yl-methyl)phenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-Hydroxy-3-phenylpiperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-Phenylpiperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(4-Fluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(3-Fluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(2-Fluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(4-Chlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(3-Chlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(2-Chlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(4-Bromophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(3-Bromophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(2-Bromophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(4-Cyanophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(3-Cyanophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(2-Cyanophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(4-Methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(3-Methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(2-Methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(2-Ethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(6-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(5-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   (S)-2-(3-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   (R)-2-(3-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(4-Chloro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(5-Bromo-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(2,6-Dichlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(2,4-Dimethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; -   2-(3-(3,4-Dimethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(2,5-Dimethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(2,6-Dimethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(2,4-Difluoro-6-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(1-Naphthyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(2-Naphthyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(2,3-Dihydrobenzofuran-7-yl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(Benzofuran-2-yl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(4-(Pyrrolidin-1-yl-methyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(4-(Pyrrolidin-1-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H     pyrimidin-4-one; -   2-(3-(2-methoxy-4-(pyrrolidin-1-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(2-methoxy-5-(pyrrolidin-1-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(4-(Phenyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(4-(4-Fluorophenyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(4-(4-Methoxyphenyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(4-(2-Methoxyphenyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(4-(Morpholin-4-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(4-(4-Methylpiperazin-1-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(4-Fluoro-2-methoxyphenyl)-4-methylpiperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   (S)-2-(3-(4-Fluoro-2-methoxyphenyl)-4-methylpiperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   (R)-2-(3-(4-Fluoro-2-methoxyphenyl)-4-methylpiperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(4-Acetyl-3-(4-fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(4-Benzyl-3-(4-fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(4-(4-Fluorophenyl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(4-Cyano-4-phenylpiperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(4-(6-Fluorobenofuran-3-yl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(Benzoisoxazol-3-yl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   (S)-2-(3-(Benzoisoazol-3-yl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   (R)-2-(3-(Benzoisoxazol-3-yl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(3-(6-Fluorobenzoisoxazol-3-yl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(4-(6-Fluorobenzoisoxazol-3-yl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; -   2-(4-(5-Methylbenzofuran-3-yl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one;     and -   2-(4-(6-Fluorobenzothiophene-3-yl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one.

Salts of the aforementioned preferred compound, and solvates or hydrates of the aforementioned compounds and salts thereof are also preferred.

The 3-substituted-4-pyrimidone compounds represented by the aforementioned formula (I) can be prepared, for example, according to the method explained below.

(In the above scheme, definitions of Q, R, X and Y are the same as those already described.)

The 2-thiopyrimidone represented by the above formula (III) is prepared easily by a modification of the method described in EP 354,179. The reaction may be carried out in the presence of a base such as sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, potassium tert-butoxide, sodium carbonate, sodium hydrogencarbonate, potassium carbonate, triethylamine, diisopropylethylamine, and 1,8-diazabicyclo[5,4,0]undec-7-en for 1 to 100 hours at a suitable temperature ranging from 0° C. to 200° C. under nitrogen or argon atmosphere or under ordinary air to afford the desired compound (III). Examples of a solvent for the reactions include, for example, alcoholic solvent such as methanol, ethanol, 1-propanol, isopropanol, tert-butanol, ethylene glycol, propylene glycol; etheric solvents such as diethyl ether, tert-butyl methyl ether, tetrahydrofuran, isopropyl ether; hydrocarbonic solvents such as benzene, toluene, xylene; halogenated hydrocarbonic solvents such as dichloromethane, chloroform, dichloroethane; aprotic polar solvents such as formamide, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, sulfolane, hexamethylphosphoric triamide, water and the like. Generally, a single solvent or a mixture of two or more solvents may be used so as to be suitable to a base used.

Then the 2-thiopyrimidone derivative (III) is transformed into the 2-chloropyrimidone (IV) by a chlorinating agent. The reaction time and temperature depend on the chlorinating agent used. Examples of a chlorinating agent for the reactions include, for example, thionyl chloride, thionyl chloride and dimethylformamide, phosphorus oxychloride, phosphorus oxychloride and dimethylformamide, oxalyl chloride, phosphorous oxychloride and dimethylformamide, and phosphorus pentachloride.

The amine represented by the above formula (V) may be prepared by a modification of the method described in Japanese Patent Unexamined Publication [Kokai] No. 52-139085/1977 or according to well-known methods of one skilled in the art.

Then the chloride derivative (IV) is allowed to react with the amine (V) or salts thereof in the presence of a base such as sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, sodium carbonate, sodium hydrogencarbonate, potassium carbonate, triethylamine, diisopropylethylamine, and 1,8-diazabicyclo[5,4,0]undec-7-en for 0.1 to 100 hours at a suitable temperature ranging from 0° C. to 200° C. under nitrogen or argon atmosphere or under ordinary air to afford the desired compound (II).

Examples of a solvent for the reactions include, for example, alcoholic solvent such as methanol, ethanol, 1-propanol, isopropanol, tert-butanol, ethylene glycol, propylene glycol; etheric solvents such as diethyl ether, tert-butyl methyl ether, tetrahydrofuran, isopropyl ether; hydrocarbonic solvents such as benzene, toluene, xylene; halogenated hydrocarbonic solvents such as dichloromethane, chloroform, dichloroethane; aprotic polar solvents such as formamide, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, dimethyl sulfoxide, sulfolane, hexamethylphosphoric triamide, water and the like. Generally, a single solvent or a mixture of two or more solvents may be used so as to be suitable to a base used.

The compounds of the present invention have inhibitory activity against TPK1, and they inhibit TPK1 activity in neurodegenerative diseases like Alzheimer disease, thereby suppress the neurotoxicity of A β and the formation of PHF and inhibit the nerve cell death. Accordingly, the compounds of the present invention are useful as an active ingredient of a medicament which radically enables preventive and/or therapeutic treatment of Alzheimer disease. In addition, the compounds of the present invention are also useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of ischemic cerebrovascular accidents, Down syndrome, cerebral bleeding due to solitary cerebral amyloid angiopathy, progressive supranuclear palsy, subacute sclerosing panencephalitis, postencephalitic parkinsonism, pugilistic encephalosis, Guam parkinsonism-dementia complex, Lewy body disease, Pick's disease, corticobasal degeneration frontotemporal dementia, vascular dementia, acute stroke and traumatic injuries, brain and spinal cord trauma, peripheral neuropathies, retinopathies and glaucoma, non-insulin dependent diabetes (such as diabetes type II), and obesity, manic depressive illness, schizophrenia, alopecia, cancers such as breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia and several virus-induced tumors.

As the active ingredient of the medicament of the present invention, a substance may be used which is selected from the group consisting of the compound represented by the aforementioned formula (I) and pharmacologically acceptable salts thereof, and solvates thereof and hydrates thereof. The substance, per se, may be administered as the medicament of the present invention, however, it is desirable to administer the medicament in a form of a pharmaceutical composition which comprises the aforementioned substance as an active ingredient and one or more of pharmaceutical additives. As the active ingredient of the medicament of the present invention, two or more of the aforementioned substance may be used in combination. The above pharmaceutical composition may be supplemented with an active ingredient of other medicament for the treatment of, for example, Alzheimer disease, vascular dementia, acute stroke and traumatic injuries, brain and spinal cord trauma, peripheral neuropathies, retinopathies and glaucoma, non-insulin dependent diabetes (such as diabetes type II), and obesity, manic depressive illness, schizophrenia, alopecia, cancers such as breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia and several virus-induced tumors.

A type of the pharmaceutical composition is not particularly limited, and the composition may be provided as any formulation for oral or parenteral administration. For example, the pharmaceutical composition may be formulated, for example, in the form of pharmaceutical compositions for oral administration such as granules, fine granules, powders, hard capsules, soft capsules, syrups, emulsions, suspensions, solutions and the like, or in the form of pharmaceutical compositions for parenteral administrations such as injections for intravenous, intramuscular, or subcutaneous administration, drip infusions, transdermal preparations, transmucosal preparations, nasal drops, inhalants, suppositories and the like. Injections or drip infusions may be prepared as powdery preparations such as in the form of lyophilized preparations, and may be used by dissolving just before use in an appropriate aqueous medium such as physiological saline. Sustained-release preparations such as those coated with a polymer may be directly administered intracerebrally.

Types of pharmaceutical additives used for the manufacture of the pharmaceutical composition, content rations of the pharmaceutical additives relative to the active ingredient, and methods for preparing the pharmaceutical composition may be appropriately chosen by those skilled in the art. Inorganic or organic substances, or solid or liquid substances may be used as pharmaceutical additives. Generally, the pharmaceutical additives may be incorporated in a ratio ranging from 1% by weight to 90% by weight based on the weight of an active ingredient.

Examples of excipients used for the preparation of solid pharmaceutical compositions include, for example, lactose, sucrose, starch, talc, cellulose, dextrin, kaolin, calcium carbonate and the like. For the preparation of liquid compositions for oral administration, a conventional inert diluent such as water or a vegetable oil may be used. The liquid composition may contain, in addition to the inert diluent, auxiliaries such as moistening agents, suspension aids, sweeteners, aromatics, colorants, and preservatives. The liquid composition may be filled in capsules made of an absorbable material such as gelatin. Examples of solvents or suspension mediums used for the preparation of compositions for parenteral administration, e.g. injections, suppositories, include water, propylene glycol, polyethylene glycol, benzyl alcohol, ethyl oleate, lecithin and the like. Examples of base materials used for suppositories include, for example, cacao butter, emulsified cacao butter, lauric lipid, witepsol.

Dose and frequency of administration of the medicament of the present invention are not particularly limited, and they may be appropriately chosen depending on conditions such as a purpose of preventive and/or therapeutic treatment, a type of a disease, the body weight or age of a patient, severity of a disease and the like. Generally, a daily dose for oral administration to an adult may be 0.01 to 1,000 mg (the weight of an active ingredient), and the dose may be administered once a day or several times a day as divided portions, or once in several days. When the medicament is used as an injection, administrations may preferably be performed continuously or intermittently in a daily dose of 0.001 to 100 mg (the weight of an active ingredient) to an adult.

EXAMPLES

The present invention will be explained more specifically with reference to examples. However, the scope of the present invention is not limited to the following examples. The compound numbers in the examples correspond to those in the table above.

Reference Example 1 Synthesis of 2-mercapto-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one

A solution of ethyl 3-oxo-3-(4-pyridyl)propionate (29.0 g, 150 mmol), N-methyl thiourea (40.6 g, 450 mmol) and 1,8-diazabicyclo[5,4,0]-7-undecene (22.4 ml, 150 mmol) was refluxed for 4 hours and the solution of methanesulfonic acid (14.4 g, 150 mmol) in water (50 ml) was added after cooling by ice-water. The precipitate was washed with water, filtered and dried to give the title compound (23.7 g, 72%).

¹H-NMR (DMSO-d₆) δ: 3.58(s, 3H), 6.40(s, 1H), 7.72(dd, J=1.8, 4.5 Hz, 2H), 8.73(dd, J=1.5, 4.8 Hz, 2H), 12.92(brd, 1H).

Reference Example 2 Synthesis of 2-chloro-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one

Phosphorous oxychloride (26.11 g, 170 mmol) was added to dimethyl-formamide (180 ml) and stirred 20 min. 2-Mercapto-3-methyl-6-(4-pyridyl)-pyrimidine-4-one (24.15 g, 110 mmol) was added to the solution and stirred 5 min and then stirred at 70° C. for 2 hours. Ethyl acetate (630 ml) was added to the ice-cooled solution and precipitate was collected by filtration after stirring for 20 minutes. After drying, the precipitate was dissolved in water (400 ml) and pH was adjusted to 10 by using aqueous sodium hydroxide. The precipitate was washed with water, filtered and dried to give the title compound (18.82 g, 77%).

¹H-NMR (CDCl₃) δ: 3.72(s, 3H), 6.90(s, 1H), 7.78(dd, J=1.7, 4.5 Hz, 2H), 8.75(dd, J=1.6, 4.5 Hz, 2H).

Reference Example 3 Synthesis of 2-mercapto-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one

A solution of ethyl 3-oxo-3-(4-pyrimidyl)propionate (34.1 g, 176 mmol), N-methyl thiourea (47.5 g, 527 mmol) and 1,8-diazabicyclo[5,4,0]-7-undecene (26.3 ml, 176 mmol) in ethanol (340 ml) was refluxed for 2 hours and the solution of methanesulfonic acid (16.9 g, 176 mmol) in water (70 ml) was added after cooling by ice-water. The precipitate was washed with water, filtered and dried to give the title compound (30.2 g, 78%).

¹H-NMR (DMSO-d₆) δ: 3.56(s, 3H), 6.88(s, 1H), 8.24(dd, J=1.2, 5.4 Hz, 2H), 9.05 (dd, J=5.4 Hz, 1H), 11.94(s, 1H).

Reference Example 4 Synthesis of 2-chloro-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one

Phosphorous oxychloride (4.60 g, 30 mmol) was added to dimethyl-formamide (32 ml) and stirred for 20 min at 0° C. 2-Mercapto-3-methyl-6-(4-pyrimidyl)-3H-pyrimidine-4-one (4.40 g, 20 mmol) was added to the solution and stirred 5 min and then stirred at 70° C. for 2 hours. The reaction mixture was poured into ice water, neutralized by solid potassium carbonate, and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, and evaporated under reduced pressure. Purification of the residue by silica gel chromatography (ethyl acetate) gave the title compound (1.20 g, 27%).

¹H-NMR (CDCl₃) δ: 3.74(s, 3H), 7.56(s, 1H), 8.18(d, J=5.1 Hz, 1H), 8.92(d, J=5.1 Hz, 1H), 9.30(s, 1H).

MS[M+H]⁺: 223.

Example 1 Synthesis of 2-(2-(4-fluoro-2-methoxyphenyl)piperazin-4-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one dihydrochloride (No. XA468)

A solution of 2-bromo-5-fluoroanisole (11.8 g, 57.6 mmol) in tetrahydrofuran (60 ml) was dropped into the magnesium (1.40 g, 57.6 mmol) in refluxed tetrahydrofuran (32 ml) containing small amount of 1,2-dibromoethane and refluxed for 15 min. After addition of tetrehydrofuran (50 ml), the solution was cooled to −78° C. and diethyl oxalate (7.41 g, 50.7 mmol) in diethyl ether (50 ml) was dropped into the solution. After stirring at same temperature for 30 min, the solution was warmed to −10° C. and 1N aqueous hydrogen chloride (50 ml) and water were added. Organic layer was extracted with diethyl ether, washed with brine and dried over magnesium sulfate. After removal of the solvent under reduced pressure, purification of the residue by silica gel column chromatography (eluent: hexane/ethyl acetate=5/2) gave ethyl 2-(4-fluoro-2-methoxyphenyl)-2-ozoacetate (6.80 g, 59%)

¹H-NMR (CDCl₃) δ: 1.40(3H, t, J=7.1 Hz), 3.87(3H, s), 4.89(2H, q, J=7.1 Hz), 6.68(1H, d, J=10.5 Hz), 6.77-6.81(1H, m), 7.91-7.95(1H, m).

Ethylenediamine (0.60 g, 10.0 mmol) was added to a solution of ethyl 2-(4-fluoro-2-methoxyphenyl)-2-oxoacetate (2.26 g, 10.0 mmol) in ethanol (30 ml) and refluxed 4 hr. After removal of the solvent under reduced pressure, residue was washed with ethanol-diethyl ether to give 5,6-dihydro-3-(4-fluoro-2-methoxyphenyl)pyrazinone (1.76 g, 79%).

¹H-NMR (CDCl₃) δ: 3.50-3.56 (2H, m), 3.81 (3H, s), 3.88-3.92 (2H, m), 6.65(1H, d, J=11.0 Hz), 6.70-6.76 (1H, m), 6.89(1H, bs), 7.36-7.40(1H, m).

5,6-Dihydro-3-(4-fluoro-2-methoxyphenyl)pyrazinone was added to the solution of lithium aluminium hydride (0.46 g, 12 mmol) in diethyl ether (25 ml) and refluxed for 6 hr. Water (0.48 ml), 15% sodium hydroxide solution (0.48 ml) and again water (1.21 ml) were added to the ice-cooled solution and the precipitate was filtered and washed with dichloromethane. Combined organic layer was evaporated to give 2-(4-fluoro-2-methoxyphenyl)piperazine (0.83 g, 99%).

¹H-NMR (CDCl₃) δ: 2.02(2H, s), 2.57-2.63 (1H, m), 2.80-2.89 (1H, m), 2.92-2.99 (2H, m), 3.06-3.12 (2H, m), 3.80(3H, s), 4.06 (1H, d, J=10.0 Hz), 6.56-6.65 (2H, m), 7.40 (1H, t, J=7.8 Hz).

2-Chloro-3-methyl-6-(4-pyridyl)-pyrimidin-4-one (222 mg, 1.0 mmol) was added to an ice-cooled solution of 2-(4-fluoro-2-methoxyphenyl)piperazine (210 mg, 1.0 mmol), triethylamine (0.15 ml, 1.1 mmol) in N,N-dimethylformamide (10 ml) and stirred at that temperature for 1 hr and then at room temperature for 2 hr. Next day, reaction was quenched by ice-water and the filtrate was washed with water and dried to give 2-(2-(4-fluoro-2-methoxyphenyl)piperazin-4-yl)-3-methyl-6-(4-pyridyl)-pyrimidin-4-one (246 mg, 62%).

¹H-NMR (CDCl₃) δ: 2.89-2.96 (1H, m), 3.19-3.31 (3H, m), 3.59 (3H, s), 3.62-3.74 (2H, m), 3.85 (3H, s), 4.39-4.44 (1H, m), 6.63-6.71 (2H, m), 6.67 (1H, s), 7.51-7.55 (1H, m), 7.81 (2H, dd, J=1.7, 4.6 Hz), 8.71 (2H, dd, J=1.7, 4.6 Hz).

4N Hydrogen chloride in 1,4-dioxane (0.4 ml) was added to the solution of 2-(2-(4-fluoro-2-methoxyphenyl)piperazin-4-yl)-3-methyl-6-(4-pyridyl)-pyrimidin-4-one (217 mg, 0.6 mmol) in dichloromethane (5 ml) and stirred for 15 min. After addition of diethyl ether, filtration and wash with diethyl ether and dryness gave the title compound (260 mg, quant.).

Example 2 Synthesis of 2-(2-(4-methoxyphenyl)-piperazine-4-yl)-3-methyl-6-(4-pyridyl)pyrimidin-4-one dihydrochloride (No. XA393)

Dimethylslufoxide (50 ml) solution of 4-methyoxyphenacylbromide (9.94 g, 43.4 mmol) and water (1.6 ml, 88.8 mmol) were stirred at 50° C. for 2.5 hr. Water was added and the solution was extracted with ethyl acetate 3 times and washed with brine and then dried over sodium sulfate. Removal of the solvent gave 4-methoxyphenylglyoxal (8.30 g, quant.).

¹H-NMR (DMSO) δ: 3.84 (3H, s), 6.60-6.69 (1H, m), 7.04 (2H, d, J=8.8 Hz), 8.05 (2H, d, J=9.1 Hz).

Methanol (5 ml) solution of ethylenediamine (3.74 g, 62.29 mmol) was added to the ice-cooled solution of 4-methoxyphenylglyoxal (8.30 g, 45.5 mmol) in methanol (100 ml) and tetrahydrofuran (50 ml) and stirred for 10 min. After cooling to 0° C., sodium tetrahydroborate (6.14 g, 162.2 mmol) and additional methanol (50 ml) was added and stirred overnight. After removal of the solvent, aqueous sodium hydroxide was added and was extracted with dichloromethane three times and washed with brine and dried over sodium sulfate. After removal of the solvent, purification of the residue by silica gel column chromatography (eluent; dichloromethane/ethanol/diethylamine=20/2/1) gave 2-(4-methoxypheny)-piperazine (3.96 g, 45%).

¹H-NMR (CDCl₃) δ: 2.69(1H, dd, J=10.3, 11.9 Hz), 2.80-3.01(4H, m), 3.07-3.11 (1H, m), 3.68-3.73(1H, m), 3.79(3H, s), 6.84-6.88 (2H, m), 7.27-7.32 (2H, m).

A solution of triethylamine (697 mg, 6.9 mmol), 2-(4-methoxyphenyl)-piperazine (430 mg, tetrahydrofuran (10 ml) was stirred at room temperature for 30 min and at 50° C. for 3 hr. Solvent was removed under reduced pressure, and 1N aqueous sodium hydroxide solution was added to the residue and extracted by dichloromethane three times and washed with brine and dried over sodium sulfate. After removal of the solvent under reduced pressure, the residue was purified by silica gel column chromatography (eluent; dichloromethane/ethanol=10/1) to give 2-(2-(4-methoxyphenyl)-piperazine-4-yl)-3-methyl-6-(4-pyridyl)pyrimidin-4-one (594 mg, 76%)

¹H-NMR (CDCl₃) δ: 3.02 (1H, dd, J=10.8, 12.7 Hz), 3.18-3.25 (3H, m), 3.55 (3H, s), 3.57-3.67 (2H, m), 3.82 (3H, s), 3.98(1H, dd, J=2.7, 10.8 Hz), 6.67 (1H, s), 6.92 (2H, d, J=8.7 Hz), 7.37 (2H, d, J=8.7 Hz), 7.80 (2H, d, J=6.0 Hz), 8.71 (2H, d, J=6.0 Hz).

4N Hydrogen chloride in ethyl acetate (5 ml) was added to the solution of 2-(2-(4-methoxyphenyl)-piperazine-4-yl)-3-methyl-6-(4-pyridyl)pyrimidin-4-one (594 mg, 1.6 mmol) in dichloromethane (5 ml) and stirred for 1 hr. Wash with ethyl acetate after removal of the solvent and dryness gave the title compound (683 mg, 96%).

Example 3 Synthesis of 2-(2-(4-chlorophenyl)-piperazine-4-yl)-3-methyl-6-(4-pyridyl)pyrimidin-4-one hydrochloride (No. XA371)

Mixture of methyl(4-chlorophenyl)acetate (5.10 g, 27.6 mmol) and N-bromosuccinimide (5.16 g, 29 mmol) in carbon tetrachloride was treated by Hg lamp. After filtration, solvent was removed under reduced pressure and the residue was dissolved in methanol. Ethylenediamine (2.03 ml, 30.4 mmol) and triethylamine (2.06 ml, 14.8 mmol) and di-tert-butyldicarbonate (3.10 ml, 13.5 mmol) were added to the solution of 3-(4-chlorophenyl)piperazin-2-one (2.60 g, 12.3 mmol) in dichloromethane (100 ml) and stirred. The reaction mixture was washed with 1N aqueous hydrogen chloride, water, brine and then dried. After removal of the solvent under reduced pressure, residue was purified by silica gel column chromatography to give 4-(tert-butoxycarbonyl)-3-(4-chlorophenyl)-piperazin-2-one.

¹H-NMR (CDCl₃) δ: 1.44 (9H, s), 3.21-3.32 (2H, m), 3.48 (1H, m), 4.04 (1H, brs), 5.66 (1H, brs), 7.10 (1H, brs), 7.30-7.38 (4H, m).

Solution of 4-(tert-butoxycarbonyl)-3-(4-chlorophenyl)-piperazin-2-one (500 mg, 1.6 mmol) and acetic acid (929 μl, 16 mmol) were added to a refluxed solution of sodium borohydride (608 mg, 16 mmol) in 1,4-dioxane (5 ml) and reflux was continued. The reaction was quenched by water and extracted with dichloromethane and washed with brine and dried. After removal of the solvent, residue was purified by silica gel column chromatography to give 4-(tert-butoxycarbonyl)-3-(4-chlorophenyl)piperazine (330 mg, 69%).

¹H-NMR (CDCl₃) δ: 1.46(9H, s), 2.76-2.99(3H, m), 3.13(1H, dd, J=13.0 Hz, 4.3 Hz), 3.45-3.49(2H, m), 3.92(1H, m), 5.15(1H, s), 7.27-7.33(4H, m).

A solution of 4-(tert-butoxycarbonyl)-3-(4-chlorophenyl)piperazine (330 mg, 1.1 mmol), 2-chloro-3-methyl-6-(4-pyridyl)pyrimidin-4-one (246 mg, 1.1 mmol) and triethylamine (170 μl, 1.22 mmol) in tetrahydrofuran were refluxed. Usual workup and purification by silica gel column chromatography gave 2-(1-(tert-butoxy-carbonyl)-2-(4-chlorophenyl)-piperazine-4-yl)-3-methyl-6-(4-pyridyl)pyrimidin-4-one (500 mg, 93%).

¹H-NMR (CDCl₃) δ: 1.45(9H, s), 3.09(1H, m), 3.35(3H, s), 3.40-3.63(4H, m), 3.96-4.19(2H, m), 5.43(1H, s), 6.68(1H, s), 7.23(2H, d, J=8.3 Hz), 7.32(2H, d, J=8.3 Hz), 7.78(2H, d, J=5.9 Hz), 8.72(2H, d, J=5.9 Hz).

4N Hydrogen chloride in ethyl acetate was added to the solution of 2-(1-(tert-butoxycarbonyl)-2-(4-chlorophenyl)-piperazine-4-yl)-3-methyl-6-(4-pyridyl)pyrimidin-4-one (500 mg, 1.0 mmol) in ethyl acetate and stirred. Filtration and successive dryness gave the title compound (373 mg, 79%).

Example 4 Synthesis of 3-methyl-2-(3-(4-((1-pyrrolidinyl)methyl)phenyl)piperidine-1-yl)-6-(4-pyridyl)pyrimidin-4-one fumarate (No. XB43)

Tetrakis(triphenylphosphine)palladium (0.65 g, 0.56 mmol), 4-formylphenylboric acid (2.81 g, 18.7 mmol), 2M aqueous sodium carbonate (18.7 ml, 37.4 mmol) and ethanol were added to the nitrogen-saturated solution of 3-bromopyridine (2.66 g, 16.8 mmol) in toluene and refluxed under nitrogen for 8 hrs. Water was added to the solution and extracted with ethyl acetate, washed with water and brine and dried. Solvents were removed under reduced pressure and the residue was purified by silica gel column chromatography (eluent; hexane/ethyl acetate=1/1.5) to give 4-(3-pyridyl)benzaldehyde (0.78 g, 25%).

Methyl iodide (0.8 ml, 12.9 mmol) was added to a solution of 4-(3-pyridyl)benzaldehyde (0.78 g, 4.3 mmol) in dichloromethane and stirred 2 days. Additional methyl iodide (0.8 ml, 12.9 mmol) was added and stirred for 3 hr. After removal of the solvent, methanol was added to the residue and ice-cooled. Sodium tetrahydroborate (6.4 g, 17.0 mmol) was added to the solution and stirred for 1.5 hr with warming to room temperature. Organic solvents were removed under reduced pressure after addition of water and extracted with ethyl acetate, washed with water and brine and dried over sodium sulfate. After removal of the solvent under reduced pressure, residue was purified by silica gel chromatography (eluent ethyl acetate to methanol) to give 3-(4-hydroxymethylphenyl)-1-methyl-1,2,5,6-tetrahydropyridine (0.63 g, 72%).

Triethylamine (1.29 ml, 9.2 mmol), acetic anhydride (0.35 ml, 3.7 mmol) were added to a solution of 4-(hydroxymethyl)phenyl-1-methyl-1,2,5,6-tetrahydropyridine (0.63 g, 3.1 mmol) in dichloromethane and stirred overnight. Organic solvents were removed under reduced pressure after addition of water and extracted with ethyl acetate, washed with water and brine and dried over sodium sulfate. Removal of the solvent under reduced pressure gave 3-(4-acetozymethylphenyl)-1-methyl-1,2,5,6-tetrahydropyridine (0.67 g, 89%).

A solution of 3-(4-acetoxymethylphenyl)-1-methyl-1,2,5,6-tetrahydropyridine (0.67 g, 2.7 mmol) and 1-chloroethyl chloroformate (0.36 ml, 3.3 mmol) in dichloroethane was refluxed for 2 hr. Organic solvents were removed under reduced pressure after addition of water and extracted with ethyl acetate, washed with water and brine and dried over sodium sulfate. After removal of the solvent, methanol was added and refluxed for 1.5 hr. Tetrahydrofuran and water were added to the residue after removal of the solvent under reduced pressure and triethylamine (1.9 ml, 13.6 mmol) and di-tert-butyl dicarbonate (0.66 g, 3.0 mmol) were added and stirred. Organic solvents were removed under reduced pressure after addition of water and extracted with ethyl acetate, washed with water and brine and dried over sodium sulfate. Removal of the solvent under reduced pressure and the residue was purified by silica gel chromatography to give 3-(4-acetoxymethylphenyl)-1-(tert-butoxycarbonyl)-1,2,5,6-tetrahydropyridine (0.71 g, 78%).

Palladium on charcoal was added to the solution of 3-(4-acetoxymethylphenyl)-1-(tert-butoxycarbonyl)-1,2,5,6-tetrahydropyridine (0.71 g, 2.1 mmol) in ethyl acetate and stirred under hydrogen atmosphere. After filtration with celite and removal of the solvent under reduced pressure, methanol and 1N aqueous sodium hydroxide were added and stirred. Organic solvents were removed under reduced pressure after addition of water and extracted with ethyl acetate, washed with water and brine and dried over sodium sulfate. Removal of the solvent under reduced pressure and the residue was purified by silica gel chromatography (eluent; hexane/ethyl acetate=3/1) to give 3-(4-hydroxymethylphenyl)-1-(tert-butoxycarbonyl)piperidine (0.39 g, 62%).

Triethylamine (0.47 g, 3.4 mmol) and methanesulfonyl chloride (0.12 ml, 1.6 mmol) were added to an ice-cooled solution of 3-(4-hydroxymethylphenyl)-1-(tert-butoxycarbonyl)piperidine (0.39 g, 1.34 mmol) in dichloromethane and stirred for 7.5 hr. Pyrrolidine (1.0 ml, 12 mmol) was added to the solution and stirred overnight. Organic solvents were removed under reduced pressure after addition of water and extracted with ethyl acetate, washed with water and brine and dried over sodium sulfate. Removal of the solvent under reduced pressure and the residue was purified by silica gel chromatography (eluent; ethyl acetate to ethyl acetate/methanol=1/1, then methanol only) to give 3-(4-(1-pyrrolidinyl)methylphenyl)-1-(tert-butoxycarbonyl)piperidine (0.26 g, 56%).

4N Hydrogen chloride in ethyl acetate was added to 3-(4-(1-pyrrolidinyl)-methylphenyl)-1-(tert-butoxycarbonyl)piperidine (0.26 g, 0.75 mmol) and stirred overnight. After filtration and dryness, triethylamine (0.5 ml, 3.6 mmol), 2-chloro-3-methyl-6-(4-pyridyl)-pyrimidin-4-one (0.14 g, 0.63 mmol) and tetrahydrofuran were added and stirred at 70° C. Organic solvents were removed under reduced pressure after addition of water and extracted with ethyl acetate, washed with water and brine and dried over sodium sulfate. Removal of the solvent under reduced pressure and the residue was dissolved into ethyl acetate. A solution of fumaric acid (0.095 g, 0.82 mmol) in acetone was added and the resulting precipitate was filtered and dried to give the title compound (0.29 g, 76%).

Example 5 Synthesis of (R)-2-(2-(4-chlorophenyl)piperazin-4-yl)-3-methyl-6-(4-pyridyl)-pyrimidin-4-one (No. XA372)

To a solution of (S)-2-methyl-CBS-oxazaborolidine (27.6 mL, 1.0 M solution in toluene, 27.6 mmol) was added borane-tetrahydrofuran complex (166 ml, 1.0 M solution in tetrahydrofuran, 166 mmol) at −40° C. To the resulting solution was added a solution of 4′-chlorophenacyl bromide (32.25 g, 138.1 mmol) in tetrahydrofuran (200 ml) through dropping funnel over 1 h at 40° C. After stirring for 3 hours below-0° C., methanol (ca. 50 ml) was added dropwise. After stirring the resulting solution for additional 30 min at room temperature, solvent was removed under reduced pressure. The residue, dissolved in ethyl acetate, was treated with 1 N hydrochloric acid to form white precipitate, which was filtered off. The layers of the filtrate was separated, and the organic layer was washed with hydrochloric acid and brine successively, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was used for the next reaction without further purification.

The residue was dissolved in ether (250 ml), and stirred with potassium hydroxide (15.5 g, 276 mmol) in water (250 ml) vigorously. After consumption of the starting material, the layers were separated. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was used for the next reaction without further purification.

The residue was heated with benzylamine (37,7 ml, 345 mmol) at 80° C. for 4.5 h. After cooling at room temperature, the resulting white crystals was washed with ether/hexane and collected to afford (S)-2-benzylamino-1-(4-chlorophenyl)ethanol (23.8 g, 65.8%). The excess benzylamine in the filtrate was distilled off at 120° C. under reduced pressure. From the residue, another (S)-2-benzylamino-1-(4-chlorophenyl)ethanol (2.41 g, 6.7%) was obtained.

¹H NMR (CDCl₃)™: 2.68(1H, dd, J=12.3, 8.9 Hz), 2.92(1H, dd, J=12.3, 3.7 Hz), 3.80(1H, d, J=11.9 Hz), 3.86(1H, d, J=11.9 Hz), 4.68(1H, dd, J=8.9, 3.7 Hz), 7.30(9H, m).

To a suspension of (S)-2-benzylamino-1-(4-chlorophenyl)ethanol (15.76 g, 60.21 mmol) and triethylamine (33.6 ml, 241 mmol) in dichloromethane (300 ml) was added a solution of thionyl chloride (4.83 ml, 66.2 mmol) in dichloromethane (20 ml) at −78° C. over 20 min. The resulting suspension was stirred at −78° C. for 20 min and at 0° C. for additional 20 min. The reaction mixture was partitioned between ether and water, and the organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: 10-20% ethyl acetate-hexane) to afford (2RS,5S)-3-benzyl-5-(4-chlorophenyl)-1,2,3-oxathiazolidine 2-oxide (16.2 g 87.4%) as a pale yellow solid.

The resulting product was obtained as a mixture of two diastereomers due to the S-oxide.

major isomer: ¹H NMR (CDCl₃) δ: 3.31(1H, dd, J=10.5, 9.9 Hz), 3.55(1H, dd, J=9.0, 6.3 Hz), 3.88(1H, d, J=13.2 Hz), 4.37(1H, d, J=13.2 Hz), 5.49(1H, dd, J=10.5, 6.3 Hz), 7.22-7.43(9H, m).

minor isomer: ¹H NMR (CDCl₃) δ: 3.21(1H, dd, J=13.5, 4.5 Hz), 3.77(1H, dd, J=13.5, 11.4 Hz), 4.05(1H, d, J=13.5 Hz), 4.38(1H, d, J=13.5 Hz), 5.99(1H, dd, J=11.4, 4.5 Hz), 7.22-7.43(9H, m).

A solution of (2RS,5S)-3-benzyl-5-(4-chlorophenyl)-1,2,3-oxathiazolidine 2-oxide (16.2 g, 52.6 mmol) and sodium azide (17.11 g, 263.2 mmol) in N,N-dimethylformamide (100 ml) was heated at 70° C. for 24 hours. The reaction mixture was partitioned between ether and water, and the organic layer was washed with water and brine successively, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: 10-20% ethyl acetate-hexane) to afford (R)-N-benzyl-2-azido-2-(4-chlorophenyl)ethylamine (12.7 g, 83.8%) as a yellow oil.

¹H NMR (CDCl₃) δ: 2.81(1H, dd, J=12.5, 5.1 Hz), 2.89(1H, dd, J=12.5, 8.5 Hz), 3.82(2H, s), 4.64(1H, dd, J=8.5, 5.1 Hz), 7.23-7.36(9H, m).

A solution of (R)-N-benzyl-2-azido-2-(4-chlorophenyl)ethylamine (12.7 g, 44.1 mmol) in tetrahydrofuran (176 mL) was treated with triphenylphosphine (13.9 g, 52.9 mmol) at room temperature. After addition of water (20 ml), the reaction mixture was heated at 60° C. for 1 h. The reaction mixture was condensed, and partitioned between ether and 1 N hydrochloric acid. The aqueous layer was treated with 1 N aqueous sodium hydroxide solution until the solution became basic. The resulting solution was extracted with dichlromethane thoroughly. The combined organic layer was washed with water, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was used for the nest reaction without further purification.

The residue was heated with diethyl oxalate (18 ml, 132 mmol) at 120° C. for 1.5 h. The resulting white precipitate was washed with ether and collected to afford (R)-1-benzyl-5-(4-chlorophenyl)-2,3-dioxopiperazine (11.4 g, 82.2%).

¹H NMR (CDCl₃) δ: 3.46(1H, dd, J=12.9, 8.1 Hz), 3.60(1H, dd, J=12.9, 3.8 Hz), 4.48(1H, d, J=14.7 Hz), 4.79(1H, d, J=14.7 Hz), 4.80(1H, dd, J=8.9, 3.8 Hz), 6.83(1H, s), 7.13(4H, m), 7.27(5H, m).

To a suspension of (R)-1-benzyl-5-(4-chlorophenyl)-2,3-dioxopiperazine (11.4 g, 36.3 mmol) in tetrahydrofuran (300 ml) was added borane-tetrahydrofuran complex (181 mL, 1.0 M solution in tetrahydrofuran, 181 mmol) at room temperature. After stirring for 24 hours, the reaction mixture was quenched with methanol (50 ml) at 0° C., and concentrated under reduced pressure. The residue was treated with 10% aqueous sodium hydroxide solution (300 ml) and heated at 100° C. for 2 hours. After cooling at room temperature, the mixture was extracted with dichloromethane thoroughly. The combined organic layer was dried over anhydrous sodium sulfated, filtered, and concentrated under reduced pressure. The residue was used for the next reaction without further purification.

To a solution of the residue and triethylamine (7.58 ml, 54.4 mmol) in dichloromethane (150 ml) was added di-tert-butyl dicarbonate (9.49 g, 43.5 mmol) at room temperature. After stirring for 45 min, the resulting mixture was partitioned between dichloromethane and water, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: 10-20% ethyl acetate-hexane) to afford (R)-1-benzyl-4-(tert-butoxycarbonyl)-3-(4-chlorophenyl)piperazine (11.6 g, 82.8%) as an oil.

¹H NMR (CDCl₃) δ: 1.43(9H, s), 2.16(1H, dt, J=4.4, 11.7 Hz), 2.40(1H, dd, J=4.4, 11.7 Hz), 2.78(1H, dd, J=4.4, 11.7 Hz), 2.98(1H, dt, J=4.4, 11.7 Hz), 3.20(1H, d, J=12.8 Hz), 3.42(1H, d, J=12.9 Hz), 3.57(1H, d, J=12.9 Hz), 3.89(1H, d, J=12.8 Hz), 5.17(1H, s), 7.24-7.36(9H, m).

To a solution of (R)-1-benzyl-4-(tert-butoxycarbonyl)-3-(4-chlorophenyl)piperazine (11.6 g, 30.1 mmol) in 1,2-dichloroethane (80 ml) was added 1-chloroethyl chloroformate (4.91 ml, 45.1 mmol) at room temperature. Upon disappearance of the starting material, the reaction mixture was concentrated under reduced pressure. The residue was then dissolved in methanol (100 ml) and refluxed for 30 min. The resulting white precipitate was filtered and washed with methanol to afford (R)-2-(4-chlorophenyl)piperazine dihydrochloride, which was liberated with aqueous sodium hydroxide solution, and extracted with dichloromethane to afford (R)-2-(4-chlorophenyl)piperazine (3.04 g, 51.4%) as white solid.

¹H NMR (CDCl₃) δ: 2.65(1H, dd, J=12.0, 10.5 Hz), 2.82-3.04(4H, m), 3.09(1H, d, J=12.6 Hz), 3.73(1H, dd, J=10.1, 2.7 Hz), 7.29(4H, m)

The filtrate was concentrated under reduced pressure and partitioned between ether and 1 N hydrochloric acid. The aqueous layer was neutralized with 1 N aqueous sodium hydroxide solution, and extracted with dichloromethane thoroughly. The combined organic extracts were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified after Boc-protection (Boc₂O, Et₃N, CH₂Cl₂) to furnish (R)-1,4-di(tert-butoxycarbonyl)-2-(4-chlorophenyl)piperazine (2.70 g, 22.6%) as pale yellow solid.

¹H NMR (CDCl₃) δ: 1.43(9H, s), 1.46(9H, s), 2.96(2H, m), 3.32(1H, dd, J=13.8, 4.2 Hz), 3.74(1H, m), 3.94(1H, d, J=11.4 Hz), 4.40(1H, d, J=13.2 Hz), 5.23(1H, s), 7.25(2H, m)

To a suspension of (R)-2-(4-chlorophenyl)piperazine dihydrochloride (1.09 g, 4.05 mmol) in tetrahydrofuran (24 ml) was added triethylamine (2.82 ml, 20.3 mmol). After stirring for 15 min at room temperature, 2-chloro-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one (748 mg, 3.38 mmol) was added portionwise. Upon disappearance of the chloropyrimidone, the reaction mixture was condensed under reduced pressure. The residue was partitioned between saturated aqueous sodium bicarbonate solution and dichloromethane. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give pale yellow solid, which was recrystallized from ethanol to afford (R)-2-(2-(4-chlorophenyl)piperazin-4-yl)-3-methyl-6-(4-pyridyl)-pyrimidin-4-one (998 mg, 77.4%) as white crystals. The enantiomer excess was determined by HPLC (>99% ee). The crystals were converted into its dihydrochloride salt.

¹H NMR (DMSO-d₆) δ: 3.40(3H, m), 3.46(3H, s), 3.62(1H, dd, J=12.0, 13.2 Hz), 3.72(1H, m), 3.92(1H, t, J=15.5 Hz), 4.68(1H, t, J=10.1 Hz), 7.18(1H, s), 7.58(2H, d, J=8.6 Hz), 7.83(2H, d, J=8.6 Hz), 8.57(2H, d, J=6.6 Hz), 9.01(2H, d, J=6.6 Hz), 10.20(1H, d, J=7.8 Hz), 10.76(1H, br s) MS: 382(M+H)

[α]D²⁴=+62.2° (c 1.00, H₂O)

Example 6 Synthesis of (S)-2-(2-(4-chlorophenyl)piperazin-4-yl)-3-methyl-6-(4-pyridyl)-pyrimidin-4-one (No. XA373)

(S)-isomer was prepared same as above by using (R)-2-methyl-CBS-oxazaborolidine instead of (S)-2-methyl-CBS-oxazaborolidine.

¹H NMR (DMSO-d₆) δ: 3.40 (3H, m), 3.45 (3H, s), 3.53-3.96 (3H, m), 4.68 (1H, t, J=13.5 Hz), 7.10 (1H, s), 7.60 (2H, d, J=8.3 Hz), 7.76 (2H, d, J=8.3 Hz), 8.38 (1H, br s), 8.91 (1H, d, J=4.8 Hz), 9.88 (1H, br s), 10.31 (1H, br s)

MS: 382(M+H)

[α]D²⁴=−63.3° (c 1.00, H₂O)

Example 7 Synthesis of 2-(2-(4-fluoro-2-methoxyphenyl)piperazin-4-yl)-3-methyl-6-(4-pyrimidyl)-pyrimidin-4-one (No. YA0366)

A solution of 2-bromo-5-fluoroanisole (11.8 g, 57.6 mmol) in tetrahydrofuran (60 ml) was dropped into the magnesium (1.40 g, 57.6 mmol) in refluxed tetrahydrofuran (32 ml) containing small amount of 1,2-dibromoethane and refluxed for 15 min. After addition of tetrahydrofuran (50 ml), the solution was cooled to −78° C. and diethyl oxalate (7.41 g; 50.7 mmol) in diethyl ether (50 ml) was dropped into the solution. After stirring at the same temperature for 30 min, the solution was warmed to −10° C. and 1N aqueous hydrogen chloride (50 ml) and water were added. Organic layer was extracted with diethyl ether, washed with brine and dried over magnesium sulfate. After removal of the solvent under reduced pressure, purification of the residue by silica gel column chromatography (eluent: hexane/ethyl acetate=5/2) gave ethyl 2-(4-fluoro-2-methoxyphenyl)-2-oxoacetate (6.80 g, 59%)

¹H-NMR (CDCl₃) δ: 1.40(3H, t, J=7.1 Hz), 3.87(3H, s), 4.89(2H, q, J=7.1 Hz), 6.68(1H, d, J=10.5 Hz), 6.77-6.81(1H, m), 7.91-7.95(1H, m).

Ethylenediamine (0.60 g, 10.0 mmol) was added to a solution of ethyl 2-(4-fluoro-2-methoxyphenyl)-2-oxoacetate (2.26 g, 10.0 mmol) in ethanol (30 ml) and refluxed 4 hr; After removal of the solvent under reduced pressure, residue was washed with ethanol-diethyl ether to give 5,6-dihydro-3-(4-fluoro-2-methoxyphenyl)pyrazinone (1.76 g, 79%).

¹H-NMR (CDCl₃) δ: 3.50-3.56 (2H, m), 3.81 (3H, s), 3.88-3.92 (2H, m), 6.65(1H, d, J=11.0 Hz), 6.70-6.76 (1H, m), 6.89(1H, bs), 7.36-7.40(1H, m).

5,6-Dihydro-3-(4-fluoro-2-methoxyphenyl)pyrazinone was added to the solution of lithium aluminium hydride (0.46 g, 12 mmol) in diethyl ether (25 ml) and refluxed for 6 hr. Water (0.48 ml), 15% sodium hydroxide solution (0.48 ml) and again water (1.21 ml) were added to the ice-cooled solution and the precipitate was filtered and washed with dichloromethane. Combined organic layer was evaporated to give 2-(4-fluoro-2-methoxyphenyl)piperazine (0.83 g, 99%).

¹H-NMR (CDCl₃) δ: 2.02(2H, s), 2.57-2.63 (1H, m), 2.80-2.89 (1H, m), 2.92-2.99 (2H, m), 3.06-3.12 (2H, m), 3.80(3H, s), 4.06 (1H, d, J=10.0 Hz), 6.56-6.65 (2H, m), 7.40 (1H, t, J=7.8 Hz).

2-Chloro-3-methyl-6-(4-pyrimidyl)-pyrimidin-4-one (223 mg, 1:0 mmol) was added to an ice-cooled solution of 2-(4-fluoro-2-methoxyphenyl)piperazine (210 mg, 1.0 mmol), triethylamine (0.15 ml, 1.1 mmol) in N,N-dimethylformamide (10 ml) and stirred at that temperature for 0.5 hr and then at room temperature for 3 hours. Reaction was quenched by ice-water and the filtrate was washed with water and dried to give 2-(2-(4-fluoro-2-methoxyphenyl)piperazin-4-yl)-3-methyl-6-(4-pyrimidyl)-pyrimidin-4-one (262 mg, 66%).

¹H-NMR (CDCl₃) δ: 2.89-2.98 (1H, m), 3.22-3.31 (3H, m), 3.60 (3H, s), 3.62-3.71 (2H, m), 3.86 (3H, s), 4.39-4.44 (1H, m), 6.43-6.73 (2H, m), 7.33 (1H, s), 7.52-7.56 (1H, m), 8.19 (1H, d, J=5.1 Hz), 8.87 (1H, d, J=5.2 Hz), 9.28 (1H, d, J=1.2 Hz).

4N Hydrogen chloride in 1,4-dioxane (0.2 ml) was added to the solution of 2-(2-(4-fluoro-2-methoxyphenyl)piperazin-4-yl)-3-methyl-6-(4-pyrimidyl)-pyrimidin-4-one (238 mg, 0.6 mmol) in dichloromethane (5 ml) and stirred for 15 min. Wash with methanol and ethyl acetate after removal of the solvent and dryness gave the title compound (223 mg, 86%).

Example 8 Synthesis of 2-(2-(4-chlorophenyl)-piperazine-4-yl)-3-methyl-6-(4-pyrimidyl)pyrimidin-4-one (No. YA0269)

Dimethyl sulfoxide (60 ml) solution of 4-chlorophenacylbromide (11.11 g, 65.9 mmol) and water (1.7 ml) were stirred. The solution was extracted with ethyl acetate 3 times and washed with water twice and brine and then dried over sodium sulfate. After removal of the solvent, the residue was washed with hexane-ethyl acetate and dried to give 4-chlorophenylglyoxal (4.43 g, 50%).

¹H-NMR (CDCl₃) δ: 4.02-4.16(2H, m), 5.90-5.95(1H, m), 7.45-7.53(2H, m), 8.05-8.11(2H, m).

A methanol (10 ml) solution of ethylenediamine (1.90 g, 31.6 mmol) was added to the ice-cooled solution of 4-chlorophenylglyozal (4.43 g, 26.3 mmol) in methanol (100 ml) and tetrahydrofuran (30 ml) and stirred for 10 min. After addition of sodium tetrahydroborate (3.26 g, 86.3 mmol), additional methanol (50 ml) was added and stirred overnight. After removal of the solvent, diluted hydrochloric acid was added and extracted with ether twice. After addition of sodium hydroxide, basic aqueous layer was extracted with dichloromethane three times and washed with brine and dried over sodium sulfate. After removal of the solvent by filtration, purification of the residue by silica gel column chromatography (eluent; dichloromethane/ethanol=10/1 to dichloromethane/ethanol/diethylamine=20/2/1) to give 2-(4-chlorophenyl)-piperazine (0.43 g, 9%)

¹H-NMR (CDCl₃) δ: 2.67(1H, dd, J=10.5, 12.0 Hz), 2.87-3.03(4H, m), 3.07-3.13(1H, m), 3.77(1H, dd, J=2.7, 10.2 Hz), 7.27-7.36(4H, m).

Triethylamine (528 mg, 5.2 mmol) was added to a solution of 4-(chlorophenyl)piperazine (216 mg, 1.1 mmol) and 2-chloro-3-methyl-6-(4-pyrimidyl)pyrimidin-4-one and stirred at 50° C. for 2 hr. Solvent was removed under reduced pressure, and 1N aqueous sodium hydroxide solution was added to the residue and extracted by dichloromethane. After washing with brine and dryness by sodium sulfate, solvent was removed under reduced pressure, and the residue was purified using ISOLUTE(registered trade mark) SI (International Sorvent Technology, UK) (eluent; dichloromethane/ethanol=10/1) to give the title compound (396 mg, 95%).

Example 9 Synthesis of 2-(2-(4-chlorophenyl)-6,6-dimethyl-piperazin-4-yl)-3-methyl-6-pyridin-4-yl-3H-pyrimidin-4-one dihydrochloride (No. XA1986)

A solution of 4′-chloro-2-bromoacetophenone (25.0 g, 107 mmol), water (1.92 mL, 107 mmol) and 47% hydrobromic acid (0.20 mL) in dimethylsulfoxide (160 mL) was stirred at 80° C. for 5 h. After the reaction mixture was poured into water, the precipitate was filtered, washed with diethylether and dried, affording 4′-chloro-2,2-dihydroxyacetophenone (14.0 g, 70%). ¹H NMR (300 MHz, CDCl₃), δ 5.92(1H, s), 7.45-7.52(2H, m), 8.05-8.20(2H, m).

2,2-dimethly-ethylenediamine (2.10 mL, 20.0 mmol) was added to a solution of 4′-chloro-2,2-dihydroxyacetophenone (3.70 g, 20.0 mmol) in methanol (120 mL) and tetrahydrofuran (30 mL) at room temperature. After 2 h, sodium borohydride (1.50 g, 40.0 mmol) was added to the reaction mixture at 0° C. The reaction mixture was stirred overnight, then quenched with 1N hydrochloric acid and evaporated in vacuo. The acidic solution was extracted with ethyl acetate, then basified to pH 11 using 15% aqueous sodium hydroxide, and extracted with dichloromethane. The extract was dried over sodium sulfate and concentrated in vacuo. Di-t-butyldicarbonate (6.40 mL, 27.9 mmol) was added to the solution of the residue in 1N aqueous sodium hydroxide (40 mL) and tetrahydrofuran (60 mL). The resulting suspension was heated at 40° C. for 8 h, then diluted with ethyl acetate and water. The organic layer was extracted with additional ethyl acetate, dried and concentrated in vacuo. The crude product was purified by flash column chromatography, affording 2-(4-chlorophenyl)-4-t-butoxycarbonyl-6,6-dimethylpiperazine (1.69 g, 28%, 2 steps). ¹H NMR (300 MHz, CDCl₃), δ 1.15(3H, s), 1.21(3H, s), 2.47-2.70(2H, m), 3.72-4.16(3H, m), 7.26-7.37(4H, m).

4 M Hydrogen chloride in ethyl acetate (5.0 mL, 20.0 mmol) was added to a solution of 2-(4-chlorophenyl)-4-t-butoxycarbonyl-6,6-dimethyl-piperazine (1.69 g, 5.2 mmol). After 12 h, removing the solvent, filtrating and washing the precipitate with ethyl acetate gave 2-(4-chlorophenyl)-6,6-dimethyl-piperazine dihydrochloride (1.43 g, 95%). ¹H NMR (300 MHz, DMSO-d₆), δ 1.40 (3H, s), 1.58(3H, s), 3.24-3.99(4H, m), 4.73(1H, m), 7.69(2H, d, J=8.4 Hz), 7.79(2H, m), 9.99-10.12(2H, m).

A solution of 2-(4-chlorophenyl)-6,6-dimethyl-piperazine hydrochloride (155 mg, 0.52 mmol), 2-chloro-3-methyl-6-(4-pyridyl)-pyrimidine-4-one (111 mg, 0.50 mmol) and triethylamine (0.42 mL, 2.50 mmol) in tetrahydrofuran (5 mL) was stirred at room temperature for 6 h. The whole was evaporated in vacuo and the residue was extracted with dichloromethane. The organic layer was washed with water, dried and concentrated in vacuo. The residue was dissolved in methanol (5 mL) and treated with 4M hydrogen chloride in ethyl acetate (0.50 mL, 2.0 mmol) for 20 min. After removing the solvent, filtrating and washing the precipitate with ethanol gave 2-(2-(4-chlorophenyl)-6,6-dimethyl-piperazin-4-yl)-3-methyl-6-pyridin-4-yl-3H-pyrimidin-4-one dihydrochloride (235 mg, 97%).

Example 10 Synthesis of 2-(2S-(4-bromophenyl)-piperazin-1-yl)-3-methyl-6-pyridin-4-yl-3H-pyrimidin-4-one (No. XA2051)

Benzyl chloroformate (2.40 mL, 15.0 mmol) was added to a solution of 2S-(4-bromophenyl)-piperazine dihydrochloride in 1N aqueous sodium hydroxide (30 mL) and dichloromethane (60 mL). The resulting suspension was stirred at room temperature for 1.5 h. After partitioned between ethyl-acetate, the organic layer was extracted with additional ethyl acetate, dried and concentrated in vacuo. The precipitate was washed with ether, affording 2S-(4-bromophenyl)-4-benzyloxycarbonyl-piperazine (2.92 g, 57%). ¹H NMR (300 MHz, CDCl₃), δ 2.87-3.01(2H, m), 3.47(2H, m), 3.93-3.97(1H, m), 4.20(2H, m), 5.16(2H, s), 7.36(5H, m), 7.42-7.61(4H, m).

A solution of 2S-(4-bromophenyl)-4-benzyloxycarbonyl-piperazine (788 mg, 2.10 mmol), 2-chloro-3-methyl-6-(4-pyridyl)-pyrimidine-4-one (444 mg, 2.00 mmol) and diisopropylethylamine (0.70 mL, 4.00 mmol) in dimethylformamide (20 mL) was stirred at 80° C. for 3 h. The reaction mixture was poured into water and the whole was extracted with ethyl acetate. The organic layer was washed with brine, dried and concentrated in vacuo. Chromatographic purification of the residue provided 2-(2S-(4-bromophenyl)-4-benzyloxycarbonyl-piperazin-1-yl)}-3-methyl-6-pyridin-4-yl-3H-pyrimidin-4-one (601 mg, 54%). ¹H NMR (300 MHz, CDCl₃), δ 3.05(1H, m), 3.30-3.48(3H, m), 3.64(3H, s), 4.08-4.22(2H, m), 4.68(1H, m), 5.15(1H, d, J=12.3 Hz), 5.21(1H, d, J=12.6 Hz), 6.63(1H, s), 7.21(2H, d, J=8.4 Hz), 7.28-7.39(7H, m), 7.59(2H, d, J=6.3 Hz), 8.68(2H, d, J=6.3 Hz).

Potassium hydroxide (168 mg, 3.0 mmol) was added to a solution of 2-{2S-(4-bromophenyl)-4-benzyloxycarbonyl-piperazin-1-yl}-3-methyl-6-pyridin-4-yl-3H-pyrimidin-4-one in ethanol (2.0 mL). After stirring for 8 h at room temperature, purifying by preparative HPLC gave 2-(2S-(4-bromophenyl)-piperazin-1-yl)-3-methyl-6-pyridin-4-yl-3H-pyrimidin-4-one (40 mg, 26%).

Example 11 Synthesis of (S)-3-methyl-6-(4-pyridyl)-2-(3-(4-(3-(pyrrolidin-1-yl) pyrrolidin-1-yl)phenyl)piperazin-1-yl)pyrimidin-4-one (No. XA2032)

A suspension of (S)-2-(4-bromophenyl)-1,4-di(t-butoxycarbonyl) piperazine (1.33 g, 3.00 mmol), (R)-3-pyrrolidinol (520 mg, 4.20 mmol), palladium acetate (27 mg, 0.12 mmol), 2-(di-t-butylphosphino)biphenyl (72 mg, 0.24 mmol), and sodium t-butoxide (808 mg, 8.41 mmol) in tert-butanol (20 mL) was heated at 90° C. for 3.5 h. After dilution with ethyl acetate, the resulting mixture was passed through a Celite column. The filtrate was concentrated in vacuo, and the residue was purified by silica gel column chromatography eluting 10-50% ethyl acetate-hexane to afford (S)-1,4-di-(t-butoxycarbonyl)-2-(4-((R)-3-hydroxypyrrolidino) phenyl)piperazine (733 mg, 54.5%) as a yellow foam.

To a solution of (S)-1,4-di(t-butoxycarbonyl)-2-(4-((R)-3-hydroxy pyrrolidino)phenyl)piperazine (733 mg, 1.64 mmol) and triethylamine (0.34 mL, 2.46 mmol) in dichloromethane (20 mL) was added methanesulfonyl chloride (0.152 mL, 1.97 mmol) at 0° C. After stirring for 20 min, the reaction mixture was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated in vacuo to afford (S)-1,4-di(t-butoxycarbonyl)-2-(4-((R)-3-(methansulfonyloxy)pyrrolidin-1-yl) phenyl)piperazine (877 mg, quant.) as a brown solid.

To a solution of (S)-1,4-di(t-butoxycarbonyl)-2-(4-((R)-3-methansulfonyloxy-pyrrolidino)phenyl)piperazine (877 mg, 1.64 mmol) in toluene (10 mL) was added pyrrolidine (0.64 mL, 8.19 mmol), and the resulting solution was heated at 90° C. for 8 h. After checking consumption of the starting material with TLC, the reaction mixture was partitioned between ethyl acetate and saturated sodium bicarbonate aqueous solution. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting 30-100% ethyl acetate-hexane and then 3-10% methanol-ethyl acetate to afford (S)-1,4-di(t-butoxycarbonyl)-2-(4-((S)-3-(pyrrolidin-1-yl)pyrrolidin-1-yl)phenyl)piperazine (479 mg, 58%) as a pale yellow powder.

To a solution of (S)-1,4-di(t-butoxycarbonyl)-2-(4-((S)-3-(pyrrolidin-1-yl) pyrrolidin-1-yl)phenyl)piperazine (479 mg, 0.957 mmol) in dichloromethane (4 mL) was added 4 N hydrogen chloride in ethyl acetate (4 mL) at room temperature. After stirring for 3 h, the resulting precipitate was collected and dried in vacuo to afford (S)-2-(4-((S)-3-(pyrrolidin-1-yl)pyrrolidin-1-yl)phenyl)piperazine tetrahydrochloride (370 mg, 87%) as a white solid.

To a suspension of (S)-2-(4-((S)-3-(pyrrolidin-1-yl)pyrrolidin-1-yl)phenyl) piperazine tetrahydrochloride (98 mg, 0.22 mmol) in tetrahydrofuran (5 mL) was added triethylamine (0.20 mL, 1.40 mmol) and 2-chloro-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one (44 mg, 0.20 mmol) at room temperature. After stirring for 24 h, the reaction mixture was concentrated in vacuo. The residue was dissolved in dichloromethane and sodium bicarbonate aqueous solution, and the solution was passed through CHEM ELUT CE1010 (manufactured by VARIAN). The filtrate was concentrated, and the resulting crystals were washed in a mixture of diisopropyl ether and ethanol to afford (S)-2-(3-(4-(3-(pyrrolidin-1-yl)pyrrolidin-1-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)pyrimidin-4-one (80 mg, 82%) as a pale yellow solid.

Example 12 Synthesis of (S)-3-methyl-6-(4-pyrimidinyl)-2-(3-(4-(3-(pyrrolidin-1-yl) pyrrolidin-1-yl)phenyl)piperazin-1-yl)pyrimidin-4-one (No. YA1577)

To a suspension of (S)-2-(4-((S)-3-(pyrrolidin-1-yl)pyrrolidin-1-yl)phenyl) piperazine tetrahydrochloride (99 mg, 0.22 mmol) in tetrahydrofuran (5 mL) was added triethylamine (0.20 mL, 1.40 mmol) and 2-chloro-3-methyl-6-(4-pyrimidinyl)-3H-pyrimidin-4-one (45 mg, 0.20 mmol) at room temperature. After stirring for 24 h, the reaction mixture was concentrated in vacuo. The residue was dissolved in dichloromethane and sodium bicarbonate aqueous solution, and the solution was passed through CHEM ELUT CE1010 (manufactured by VARIAN). The filtrate was concentrated, and the resulting crystals were washed in a mixture of diisopropyl ether and ethanol to afford (S)-3-methyl-6-(4-pyrimidinyl)-2-(3-(4-(3-(pyrrolidin-1-yl)pyrrolidin-1-yl)phenyl)piperazin-1-yl)-pyrimidin-4-one (65 mg, 66%) as a pale yellow solid.

Example 13 Synthesis of (S)-2-(3-(4-(N-cyclohexyl-N-methylamino)phenyl) piperazin-1-yl)-3-methyl-6-(4-pyridyl)pyrimidin-4-one (No. XA1999)

A suspension of (S)-2-(4-bromophenyl)-1,4-di(t-butoxycarbonyl) piperazine (1.21 g, 2.75 mmol), N-methylcyclohexylamine (0.43 mL, 3.30 mmol), palladium acetate (25 mg, 0.11 mmol), 2-(di-t-butylphosphino)biphenyl (66 mg, 0.22 mmol), and sodium t-butoxide (370 mg, 3.85 mmol) in t-butanol (15 mL) was heated at 80° C. for 8 h. The resulting solution was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting 10-15% ethyl acetate-hexane to afford (S)-1,4-di(t-butoxycarbonyl)-2-(4-(N-cyclohexyl-N-methylamino)phenyl)piperazine (917 mg) as white crystals.

To a solution of (S)-1,4-di(t-butoxycarbonyl)-2-(4-(N-cyclohexyl-N-methylamino)phenyl)piperazine in dichloromethane (4 mL) was added 4 N hydrogen chloride in ethyl acetate (4 mL). After stirring for 40 min, the white precipitate was collected, which included impurities. The mixture was purified by a reverse phase chromatography eluting 0.05% TFA in water-acetonitrile to afford (S)-2-(4-(N-cyclohexyl-N-methylamino)phenyl)piperazine (59 mg 8% in 2 steps) as a clear oil.

To a solution of (S)-2-(4-(N-cyclohexyl-N-methylamino)phenyl) piperazine (50 mg, 0.183 mmol) and triethylamine (0.077 mL, 0.55 mmol) was added 2-chloro-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one (37 mg, 0.17 mmol) at room temperature. After stirring for 4.5 h, the reaction mixture was concentrated in vacuo. The residue was partitioned between dichloromethane and saturated sodium bicarbonate aqueous solution. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by a reverse phase chromatography eluting 0.05% TFA in water-acetonitrile to afford (S)-2-(3-(4-(N-cyclohexyl-N-methylamino)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)pyrimidin-4-one (67 mg, 88%) as a oil, which was dissolved in ethyl acetate and treated with 4 N hydrogen chloride in ethyl acetate to yield its trihydrochloride.

Example 14 Synthesis of (S)-2-(3-(4-(N,N-dimethylamino)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)pyrimidin-4-one trihydrochloride (No. XA2017)

A suspension of (S)-2-(4-bromophenyl)-1,4-di(t-butoxycarbonyl) piperazine (1.14 g, 2.59 mmol), N,N-dimethylamine hydrochloride (422 mg, 5.17 mmol), palladium acetate (23 mg, 0.10 mmol), 2-(di-t-butylphosphino)biphenyl(62 mg, 0.21 mmol), and sodium t-butoxide (845 mg, 8.80 mmol) in t-butanol (15 mL) was heated at 90° C. for 3 h. After dilution with ethyl acetate, the resulting solution was passed through a Celite column. The filtrate was concentrated, and the residue was purified by silica gel column chromatography eluting 10-20% ethyl acetate-hexane to afford (S)-1,4-di(t-butoxycarbonyl)-2-(4-(N,N-dimethylamino) phenyl)piperazine (556 mg, 53%) as white crystals.

To a solution of (S)-1,4-di(t-butoxycarbonyl)-2-(4-(N,N-dimethylamino) phenyl)piperazine (556 mg, 1.37 mmol) in dichloromethane (4 mL) was added 4 N hydrogen chloride in ethyl acetate (4 mL). After stirring for 8.5 h, the white precipitate was collected and dried in vacuo to afford (S)-2-(4-(N,N-dimethylamino) phenyl)piperazine trihydrochloride (413 mg, 96%) as white crystals.

To a suspension of (S)-2-(4-(N,N-dimethylamino)phenyl)piperazine trihydrochloride (115 mg, 0.365 mmol) in tetrahydrofuran (5 mL) was added triethylamine (0.28 mL, 2.0 mmol) and then 2-chloro-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one (74 mg, 0.33 mmol) at room temperature. After stirring for 10 h, the resulting mixture was concentrated in vacuo. The residue was dissolved in dichloromethane and saturated sodium bicarbonate aqueous solution, and the solution was passed through CHEM ELUT CE1010 (manufactured by VARIAN). The filtrate was concentrated in vacuo to yield crystals, which were washed with diisopropyl ether. After the crystals were dissolved in ethyl acetate, the solution was treated with 4 N hydrogen chloride in ethyl acetate. White precipitate was collected and dried in vacuo to afford (S)-2-(3-(4-(N,N-dimethylamino)phenyl) piperazin-1-yl)-3-methyl-6-(4-pyridyl)pyrimidin-4-one trihydrochloride (135 mg, 81%).

Example 15 Synthesis of (S)-2-(3-(4-methoxybiphen-4-yl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)pyrimidin-4-one (No. XA1991)

A mixture of (S)-2-(4-bromophenyl)-1,4-di(t-butoxycarbonyl)piperazine (1.82 g, 4.11 mmol), 4-methoxyphenylboronic acid (937 mg, 6.17 mmol), sodium carbonate (2.18 g, 20.6 mmol), and tetrakis(triphenylphosphine)palladium(0) (238 mg, 0.206 mmol) was dissolved in dimethoxyethane (20 mL) and water (20 mL), and the resulting solution was refluxed for 3 h. After cooling to room temperature, the mixture was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The resulting solid was washed with ethyl acetate to afford (S)-1,4-di(t-butoxycarbonyl)-2-(4′-methoxybiphen-4-yl)piperazine (1.46 g, 75.9%) as a white solid.

To a solution of (S)-1,4-di(t-butoxycarbonyl)-2-(4′-methoxybiphen-4-yl)-piperazine (1.46 g, 3.12 mmol) in dichloromethane (8 mL) was added 4 N hydrogen chloride in ethyl acetate (8 mL) at room temperature. After stirring for 1 h, the precipitate was collected and dried in vacuo to afford (S)-2-(4′-methoxybiphen-4-yl) piperazine dihydrochloride (1.00 g, 94%) as white solid.

To a suspension of (S)-2-(4′-methoxybiphen-4-yl)-piperazine dihydrochloride (237 mg, 0.694 mmol) in tetrahydrofuran (5 mL) was added triethylamine (0.40 mL, 2.9 mmol) and then 2-chloro-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one (128 mg, 0.579 mmol) at room temperature. After stirring for 28 h, the resulting mixture was concentrated in vacuo. The residue was partitioned between dichloromethane and saturated sodium bicarbonate aqueous solution, and the organic layer was dried over anhydrous sodium sulfate and then concentrated in vacuo. The resulting solid was washed with hot ethanol to afford (S)-2-(3-(4-methoxybiphen-4-yl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)pyrimidin-4-one (252 mg, 96%), which was treated with 4 N hydrogen chloride in ethyl acetate to yield its dihydrochloride salt (252 mg) as pale yellow crystals.

Example 16 Synthesis of (S)-2-(3-benzylpiperazin-1-yl)-3-methyl-6-(4-pyridyl) pyrimidin-4-one (No. XA2004)

To a solution of L-phenylalanine ethyl ester hydrochloride (3.875 g, 16.87 mmol), Boc-glycine (2.815 g, 16.07 mmol) in dichloromethane (100 mL) was added triethylamine (2.35 mL, 16.87 mmol) and then 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (3.23 g, 16.87 mmol) at room temperature. After the resulting mixture was stirred for 2.5 h, it was partitioned between ethyl acetate and water. The organic layer was washed with 1 N hydrochloric acid, brine, and then saturated sodium bicarbonate aqueous solution, dried over anhydrous sodium sulfate, and concentrated in vacuo to afford Boc-glyclylphenylalanine ethyl ester (5.96 g).

To a solution of Boc-glycylphenylalanine ethyl ester (5.96 g) in dichloromethane (20 ml) was added trifluoroacetic acid (20 mL) at room temperature. After stirring 1.5 h, the resulting solution was concentrated in vacuo. The residue was dissolved in water, into which sodium bicarbonate was added until the pH was 9. After the solution was stirred for several hours, the resulting white crystals were collected and dried in vacuo to afford (S)-3-benzyl-2,5-dioxopiperazine (2.29 g, 70% in 2 steps) as a white powder.

To a suspension of (S)-3-benzyl-2,5-dioxopiperazine (2.284 g, 11.18 mmol) in tetrahydrofuran (20 mL) was added borane-tetrahydrofuran complex (49 mL, 1.0 M solution in THF, 49 mmol) at room temperature. The resulting mixture was refluxed for several hours before it was quenched with methanol at 0° C. After concentration in vacuo, the residue was treated with 10% sodium hydroxide aqueous solution, which was extracted with dichloromethane thoroughly. The organic layer was washed with water, dried over anhydrous sodium sulfate, and concentrated in vacuo to afford white crystals, which were washed with ether to yield (S)-2-benzylpiperazine (795 mg, 40.3%).

To a solution of (S)-2-benzylpiperazine (48 mg, 0.27 mmol) in tetrahydrofuran (5 mL) was added triethylamine (0.10 mL, 0.74 mmol) and then 2-chloro-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one (55 mg, 0.248 mmol) at room temperature. After refluxing for 24 h, the resulting mixture was concentrated in vacuo. The residue was partitioned between dichloromethane and saturated sodium bicarbonate aqueous solution, and the organic layer was dried over anhydrous sodium sulfate and then concentrated in vacuo. The residue was purified by a reverse phase chromatography eluting 0.05% TFA in water-acetonitrile to afford (S)-2-(3-benzylpiperazin-1-yl)-3-methyl-6-(4-pyridyl) pyrimidin-4-one (73 mg 81%), which was treated with 4 N hydrogen chloride in ethyl acetate to yield its dihydrochloride salt as a yellow powder.

Example 17 Synthesis of (S)-3-methyl-2-(3-(4-(1,2,4-oxadiazol-3-yl)phenyl) piperazin-1-yl)-6-(4-pyridyl)pyrimidin-4-one (No. XA2039)

To a solution of 4-cyanoacetophenone (11.32 g, 77.98 mmol) in dichloromethane (200 mL) was added bromine (4.00 mL, 78.0 mmol) dropwise at room temperature. After stirring several minutes, the reaction mixture was washed with water, dried over anhydrous sodium sulfate, and concentrated in vacuo to afford 4-cyanophenacyl bromide (17.73 g) as a white solid.

A solution of 4-cyanophenacyl bromide (11.20 g, 49.99 mmol) in dimethylsulfoxide (83 mL) was treated with water (0.90 mL, 49.99 mmol). After stirring for 24 h at room temperature, it was poured into ice-water, and extracted with ether. The organic layer was washed with water and then brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The residue was purified by a silica gel column chromatography eluting 20-50% ethyl acetate in hexane to afford 4-cyanophenylglyoxal (5.10 g, 64.1%) as a yellow solid.

To a solution of 4-cyanophenylglyoxal (2.21 g, 12.5 mmol) in methanol (30 mL) and tetrahydrofuran (10 mL) was added ethylenediamine (1.00 mL, 14.96 mmol) at room temperature. After the mixture was stirred at room temperature for 1 h, sodium borohydride (943 mg, 24.92 mmol) was added at 0° C. The solution was warmed up to room temperature and stirred for another 2 h before it was quenched with 1 N hydrochloric acid. After concentration in vacuo, the mixture was partitioned between ether and water. The aqueous layer was alkalized with sodium hydroxide, and extracted with dichloromethane. The extract was dried over anhydrous sodium sulfate, and then concentrated in vacuo to afford reddish oil (1.69 g). The oil was dissolved in dichloromethane (30 mL), into which triethylamine (3.82 mL, 27.41 mmol) and di-tert-butyl dicarbonate (5.98 g, 27.41 mmol) at room temperature. The reaction mixture was stirred for several hours before it was partitioned between ethyl acetate and water. The organic layer was dried over anhydrous sodium sulfate, and then concentrated in vacuo. The residue was purified by a silica gel column chromatography eluting 5-20% ethyl acetate in hexane to afford 1,4-di(t-butoxycarbonyl)-2-(4-cyanophenyl)piperazine (2.46 g, 50.9%) as white crystals.

A solution of 1,4-di(t-butoxycarbonyl)-2-(4-cyanophenyl)piperazine (558 mg, 1.44 mmol), hydroxylamine hydrochloride (300 mg, 4.23 mmol), and sodium carbonate (763 mg, 7.20 mmol) in ethanol (3 mL) and water (3 mL) was heated at 80° C. for 2.5 h before it was partitioned between dichloromethane and water. The aqueous layer was extracted with dichloromethane. The combined organic layer was dried over sodium sulfate, and concentrated in vacuo to afford white foam (680 mg), which was dissolved in toluene (5 mL) and treated with triethyl orthoformate (2.4 mL, 14.4 mmol) and p-toluenesulfonic acid (27 mg, 0.14 mmol). The solution was heated at 90° C. for 1 h before it was partitioned between dichloromethane and saturated sodium bicarbonate aqueous solution. The organic layer was dried over anhydrous sodium sulfate, and concentrated in vacuo. The resulting white crystals were washed with ethyl acetate, and dried in vacuo to afford 1,4-di(t-butoxycarbonyl)-2-(4-(1,2,4-oxadiazol-3-yl)phenyl)piperazine (464 mg, 75% in 2 steps).

To a solution of 1,4-di(t-butoxycarbonyl)-2-(4-(1,2,4-oxadiazol-3-yl) phenyl)piperazine (464 mg, 1.08 mmol) in dichloromethane (2 mL) was added 4 N hydrogen chloride in ethyl acetate (3 mL) at room temperature. After stirring for 1.5 h, the precipitate was collected and dried in vacuo to afford 2-(4-(1,2,4-oxadiazol-3-yl)phenyl)piperazine dihydrochloride (321 mg, 98%) as a white powder.

To a suspension of 2-(4-(1,2,4-oxadiazol-3-yl)phenyl)piperazine dihydrochloride (102 mg, 0.34 mmol) in tetrahydrofuran (6 mL) was added triethylamine (0.23 mL, 1.65 mmol) and then 2-chloro-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one (73 mg, 0.33 mmol) at room temperature. After stirring for 24 h, the resulting mixture was concentrated in vacuo. The residue was dissolved in dichloromethane and saturated sodium bicarbonate aqueous solution, and the solution was passed through CHEM ELUT CE1010 (manufactured by VARIAN). The filtrate was concentrated in vacuo to yield crystals, which were washed with diisopropyl ether and ethanol to afford (S)-2-(3-(4-(1,2,4-oxadiazol-3-yl)phenyl) piperazin-1-yl)-3-methyl-6-(4-pyridyl)pyrimidin-4-one (102 mg 74%) as a white powder.

Example 18 Synthesis of 2-[4-(2-Methoxyphenylamino)-piperidin-1-yl]-3-methyl-6-(pyridin-4-yl)-3H-pyrimidin-4-one (No. XB276)

To a solution of anisidine (3.1 g, 25.2 mmol) and 4-oxo-piperidine-1-carboxylic acid tert-butyl ester (5.0 g, 25.1 mmol) in methanol (100 mL) was added sodium triacetoxyborohydride (13.4 g, 63.2 mmol) at room temperature. After stirring for 6 h, the resulting suspension was partitioned between ethyl acetate and 1N sodium hydroxide. The aqueous layer was extracted with ethyl acetate. The combined organic layer was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel chromatography eluting 10-20% ethyl acetate in hexane to furnish 4-(2-methoxyphenylamino)-piperidine-1-carboxylic acid tert-butyl ester (2.7 g, 8.8 mmol, 35%) as a pale yellow oil.

To a solution of 4-(2-methoxyphenylamino)-piperidine-1-carboxylic acid tert-butyl ester (2.7 g, 8.8 mmol) in methanol (30 mL) was added 4N hydrochloric acid in ethyl acetate (20 mL) at room temperature. After stirring for 1 h, the resulting suspension was concentrated in vacuo. The residue was partitioned between chloroform and 1N sodium hydroxide. The aqueous layer was extracted with chloroform. The combined organic layer was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel chromatography eluting 10-20% methanol in chloroform to furnish 4-(2-methoxyphenylamino)-piperidine (1.8 g, 8.7 mmol, 99%) as white crystals.

To a solution of 4-(2-methoxyphenylamino)-piperidine (0.8 g, 3.87 mmol) and triethylamine (1.3 g, 12.8 mmol) in tetrahydrofuran (20 mL) was added 2-chloro-3-methyl-6-(pyridin-4-yl)-3H-pyrimidin-4-one (0.8 g, 3.61 mmol) portionwise. After stirring for 12 h, the resulting suspension was partitioned between chloroform and 1N sodium hydroxide. The aqueous layer was extracted with chloroform. The combined organic layer was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel chromatography eluting 5-10% methanol in chloroform to furnish 2-(4-(2-methoxyphenylamino)-piperidin-1-yl)-3-methyl-6-(pyridin-4-yl)-3H-pyrimidin-4-one (1.2 g, 3.07 mmol, 85%) as white crystals.

Example 19 Synthesis of 3-Methyl-2-(3-(4-(4-methylpiperazin-1-yl)-phenyl)-piperidin-1-yl)-6-(pyridin-4-yl)-3H-pyrimidin-4-one (No. XB278)

A solution of (4-bromo-phenyl)-acetic acid ethyl ester (2.31 g, 9.50 mmol) in dimethylsulfoxide (6 mL) was added to the suspension of sodium hydride (407 mg, 60% in oil, 10.17 mmol) and stirred 3 min. A solution of (3-bromo-propyl)-carbamic acid tert-butyl ester (2.03 g, 8.52 mmol) in dimethylsulfoxide (6 mL) was added to the solution and stirred at 50° C. for 30 min. The resulting solution was partitioned between ethyl acetate and saturated aqueous ammonium chloride. The aqueous layer was extracted with ethyl acetate. The combined organic layer was washed with water and brine, dried by passing through Celite column, and concentrated in vacuo. The residue was purified by silica gel chromatography eluting ethyl acetate/hexane (4/1 to 3/1, v/v) to afford 3-(4-Bromo-phenyl)-6-tert-butoxycarbonylamino-hexanoic acid ethyl ester (2.43 g, 74%).

To a solution of 3-(4-Bromo-phenyl)-6-tert-butoxycarbonylamino-hexanoic acid ethyl ester (2.43 g, 6.32 mmol) in ethyl acetate (3 mL) was added 4 N hydrogen chloride in ethyl acetate (6 mL) at room temperature. Removal of the solvent in vacuo after stirring for 30 min afforded 6-Amino-3-(4-bromo-phenyl)-hexanoic acid ethyl ester hydrochloride that was used in the next step without further purification.

A solution of 6-amino-3-(4-bromo-phenyl)-hexanoic acid ethyl ester hydrochloride, potassium carbonate (1039 mg, 7.52 mmol) in ethanol (50 ml) was refluxed for 20 hr. Solvent was removed in vacuo after addition of dilute hydrochloric acid and water was added to the residue. Filtration, wash with water and dryness afforded 3-(4-Bromo-phenyl)-piperidin-2-one (1387 mg, 86%, 2 steps).

To an ice-cooled solution of 3-(4-bromo-phenyl)-piperidin-2-one (37.97 g, 149 mmol) in tetrahydrofuran (250 ml) was added borane-tetrahydrofuran complex (335 ml, 1.0 M solution in THF, 335 mmol). The solution was stirred overnight at room temperature, and then refluxed 1.5 hr after addition of 10% aqueous hydrochloric acid. Solvents was removed in vacuo, and the residue was partitioned between dichloromethane and 1N sodium hydroxide. The aqueous layer was extracted with dichlorometane. The combined organic layer was washed with water and brine, dried over sodium sulfate, and concentrated in vacuo. The residue was dissolved in water (100 mL) and concentrated hydrochloric acid (100 mL) and refluxed for 3 hr. Sodium hydroxide was added to the solution and the resulting solution was extracted with dichlorometane. The organic layer was washed with water and brine, dried over sodium sulfate Concentration in vacuo afforded 3-(4-bromo-phenyl)-piperidine (32 18 g, 90%).

To a suspension of 3-(4-bromophenyl)-piperidine (25.2 g, 105 mmol), and triethylamine (13 g, 128 mmol) in tetrahydrofuran (250 mL) was added di-tert-butyl-dicarbonate (25.2 g, 105 mmol) at room temperature. After stirring for 1 h, the resulting suspension was partitioned between ethyl acetate and 1N sodium hydroxide. The aqueous layer was extracted with ethyl acetate. The combined organic layer was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was washed by hexane to furnish 3-(4-bromophenyl)-piperidine-1-carboxylic acid tert-butyl ester (35.7 g, 105 mmol, 100%) as white crystals.

To a suspension of 3-(4-bromophenyl)-piperidine-1-carboxylic acid tert-butyl ester (3.0 g, 8.8 mmol), palladium acetate (80 mg, 0.36 mmol), 2-(di-t-butyl phosphino)biphenyl (210 mg, 0.70 mmol), and sodium t-butoxide (1.2 g, 125 mmol) in toluene (30 mL) was added N-methylpiperazine (1.3 g, 13.0 mmol) at room temperature. After heating at 90° C. for 5 h, the resulting suspension was passed through a Celite column. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel chromatography eluting 5-25% of ethyl acetate in hexane to afford 3-(4-(4-methylpiperazin-1-yl)-phenyl)-piperidine-1-carboxylic acid tert-butyl ester (2.0 g, 5.56 mmol, 63%) as white crystals.

To a solution of 3-(4-(4-methylpiperazin-1-yl)-phenyl)-piperidine-1-carboxylic acid tert-butyl ester (2.0 g, 5.56 mmol) in methanol (20 mL) was added 4N hydrochloric acid in ethyl acetate (20 mL) at room temperature. After stirring for 1 h, the resulting suspension was concentrated in vacuo. The residue was washed with ethyl acetate to furnish 3-(4-(4-methylpiperazin-1-yl)-phenyl)-piperidine trihydrochloride (1.84 g, 4.99 mmol, 90%) as white crystals.

To a solution of 3-(4-(4-methylpiperazin-1-yl)-phenyl)-piperidine trihydrochloride salt (0.4 g, 1.08 mmol) and triethylamine (0.6 g, 5.93 mmol) in tetrahydrofuran (10 mL) was added 2-chloro-3-methyl-6-(pyridin-4-yl)-3H-pyrimidin-4-one (0.22 g, 0.99 mmol) portionwise. After stirring for 12 h, the resulting suspension was partitioned between chloroform and 1N sodium hydroxide. The aqueous layer was extracted with chloroform. The combined organic layer was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel chromatography eluting 5-10% methanol in chloroform to furnish 3-methyl-2-(3-(4-(4-methylpiperazin-1-yl)-phenyl)-piperidin-1-yl)-6-(piridin-4-yl)-3H-pyrimidin-4-one (0.31 g, 0.70 mmol; 71%) as white crystals.

Example 20 Synthesis of 2-(3-(4-cyclohexylaminophenyl)-piperidin-1-yl)-3-methyl-6-(pyridin-4-yl)-3H-pyrimidin-4-one (No. XB301)

To a suspension of 3-(4-bromophenyl)-piperidine-1-carboxylic acid tert-butyl ester (8.0 g, 23.5 mmol), palladium acetate (210 mg, 0.94 mmol), 2-(di-t-butyl phosphino)biphenyl (560 mg, 1.88 mmol), and sodium t-butoxide (3.2 g, 33.3 mmol) in toluene (80 mL) was added cyclohexylamine (2.8 g, 28.2 mmol) at room temperature. After heating at 90° C. for 5 h, the resulting suspension was passed through a Celite column. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel chromatography eluting 5-25% of ethyl acetate in hexane to afford 3-(4-cyclohexylaminophenyl)-piperidine-1-carboxylic acid tert-butyl ester (6.74 g, 18.8 mmol, 80%) as white crystals.

To a solution of 3-(4-cyclohexylaminophenyl)-piperidine-1-carboxylic acid tert-butyl ester (6.74 g, 18.8 mmol) in methanol (50 mL) was added 4N hydrochloric acid in ethyl acetate (40 mL) at room temperature. After stirring for 1 h, the resulting suspension was concentrated in vacuo. The residue was washed with ethyl acetate to furnish 3-(4-cyclohexylaminophenyl)-piperidine dihydrochloride (5.84 g, 17.6 mmol, 94%) as white crystals.

To a solution of 3-(4-cyclohexylaminophenyl)-piperidine dihydrochloride salt (1.0 g, 3.02 mmol) and triethylamine (1.5 g, 14.8 mmol) in tetrahydrofuran (20 mL) was added 2-chloro-3-methyl-6-(pyridin-4-yl)-3H-pyrimidin-4-one (0.64 g, 2.89 mmol) portionwise. After stirring for 12 h, the resulting suspension was partitioned between chloroform and 1N sodium hydroxide. The aqueous layer was extracted with chloroform. The combined organic layer was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel chromatography eluting 5-10% methanol in chloroform to furnish 2-(3-(4-cyclohexylaminophenyl)-piperidin-1-yl)-3-methyl-6-(pyridin-4-yl)-3H-pyrimidin-4-one (1.23 g, 2.77 mmol, 96%) as white crystals.

Example 21 Synthesis of 2-(4-(4-Bromo-phenyl)-piperidin-1-yl)-3-methyl-6-pyridin-4-yl-3H-pyrimidin-4-one (No. XB267)

Mixture of 4-bromobenzaldehyde (22.40 g, 121.1 mmol), dimethyl malonate (19.37 g, 146.6 mmol), cat. acetic acid and cat. piperidine in toluene (100 ml) were refluxed for 6 h with azeotropically removal of water. Resulting solution was partitioned between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate. The combined organic layer was washed with water, saturated aqueous sodium bicarbonate and brine, dried over sodium sulfate. Concentration of the organic solvent in vacuo afforded 2-(4-bromo-benzylidene)-malonic acid diethyl ester as an oil that was used in the next step without further purification.

To an ice-cooled solution of dimethyl malonate (19.35 g, 146.5 mmol) and sodium methoxide (30.12 g in 28% methanol solution, 156.1 mmol) in methanol (300 ml) was added 2-(4-bromo-benzylidene)-malonic acid diethyl ester in methanol (50 ml). After stirring for 3 h, the solvent was removed in vacuo and the residue was partitioned between ethyl acetate and dilute hydrochloric acid. The aqueous layer was extracted with ethyl acetate. The combined organic layer was washed with brine, dried over sodium sulfate. Concentration of the organic solvent in vacuo afforded 3-(4-bromo-phenyl)-2,4-bis-ethoxycarbonyl-pentanedioic acid diethyl ester as an oil that was used in the next step without further purification.

A solution of 3-(4-bromo-phenyl)-2,4-bis-ethoxycarbonyl-pentanedioic acid diethyl ester in concentrated hydrochloric acid (100 ml) and acetic acid (100 ml) was refluxed for 8 h. Removal of the solvent in vacuo and recrystallization of the residue from acetonitrile yielded 3-(4-bromo-phenyl)-pentanedioic acid (22.84 g in 1^(st) crop, 65%, 3.84 g in 2^(nd) crop, 11.05% from 4-bromobenzaldehyde).

A solution 3-(4-bromo-phenyl)-pentanedioic acid (26.68 g, 92.9 mmol) in acetic anhydride (100 ml) was refluxed for 1.5 hr. Removal of the solvent in vacuo, and remaining solvent were azeotropically removed using toluene. Teterahydrofuran (200 ml) and aqueous ammonia (28%, 50 ml) was added to the residue and stirred overnight. After removal of the solvent in vacuo, acetic anhydride (100 ml) was added and refluxed for 4 hr. After removal of the solvent in vacuo and succeeding azeotropic distillation with toluene, residue was partitioned between ethyl ether and water. Filtration of the suspension and dryness afforded the 4-(4-bromo-phenyl)-piperidine-2,6-dione (12.53 g, 50%) as a solid.

To an ice-cooled solution of lithium tetrahydroborate (4.13 g, 189.6 mmol) in tetrahydrofuran (200 ml) was added chlorotrimethylsilane (41.52 g, 382.2 mmol). After stirring 5 min, a solution of 4-(4-bromo-phenyl)-piperidine-2,6-dione (12.53 g, 46.7 mmol) was added and stirred overnight. The resulting solution was concentrated in vacuo after addition of 10% aqueous hydrochloric acid. The residue was dissolved in aqueous sodium hydroxide solution and methanol, and a solution of di-tert-butyl dicarbonate (11.45 g, 52.5 mmol) in methanol (10 ml) was added and stirred for 6 h. After removal of the solvent in vacuo, concentrated hydrochloric acid wad added and stirred overnight. After extraction of the solution by diethyl ether, sodium hydroxide was added to the aqueous layer to turn basic, and extracted with dichloromethane. The organic layer was washed with brine, dried over sodium sulfate. The residue of the diethyl ether and dichloromethane after removal of the solvents under reduced pressure was mixed and dissolved in tetrahydrofuran (200 ml). A solution of di-tert-butyl dicarbonate (7.45 g, 34.1 mmol) in tetrahydrofuran (10 ml) and triethylamine were added and stirred overnight. The resulting solution was concentrated in vacuo. Purification of the residue by silica gel chromatography eluting hexane/ethyl acetate (5/1, v/v) furnished 4-(4-bromo-phenyl)-piperidine-1-carboxylic acid tert-butyl ester (14.4 g, 91%) as a solid.

To a solution of furnished 4-(4-bromophenyl)-piperidine-1-carboxylic acid tert-butyl ester (1114 mg, 3.27 mmol) in ethyl acetate (1 mL) was added 4 N hydrogen chloride in ethyl acetate (2 mL) at room temperature. After stirring for 5 h, solvent was removed in vacuo, and the resulting solid was washed with ethyl acetate and dried in vacuo to afford (4-(4-bromophenyl)-piperidine hydrochloride (884 mg, 98%) as a white solid.

A solution of (4-(4-bromophenyl)-piperidine hydrochloride (279 mg, 1.01 mmol) and triethylamine (554 mg, 5.47 mmol), 2-chloro-3-methyl-6-(pyridin-4-yl)-3H-pyrimidin-4-one (206 mg, 0.929 mmol) in tetrahydrofuran (20 mL) was stirred for 3 hr. The resulting solution was diluted with tetrahydrofuran and filtrated. After removal of the solvents under reduced pressure and the purification of the resulting residue by CHEM ELUT CE1010 (manufactured by VARIAN) eluting dichloromethane/ethanol (15/1, v/v) and wash with ethyl acetate afforded 2-(4-(4-Bromophenyl)-piperidin-1-yl)-3-methyl-6-pyridin-4-yl-3H-pyrimidin-4-one (368 mg, 93%) as a solid.

Example 22 Synthesis of 3-Methyl-6-pyridin-4-yl-2-[4-(4-pyrrolidin-1-yl-phenyl)-piperidin-1-yl]-3H-pyrimidin-4-one (No. XB269)

A suspension of 4-(4-Bromophenyl)-piperidine-1-carboxylic acid tert-butyl ester (1.97 g, 5.79 mmol), palladium acetate (54 mg, 0.24 mmol), 2-(di-t-butylphosphino)biphenyl (154 mg, 0.52 mmol), and sodium t-butoxide (846 mg, 8.80 mmol), pyrrolidine (587 mg, 8.25 mmol) in toluene (80 mL) was heated at 90° C. for 3 h under nitrogen atmosphere. The resulting suspension was passed through a Celite column and partitioned between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate. The combined organic layer was washed with brine, dried over sodium sulfate, and concentrated in vacuo. Purification of the residue by HPLC afforded 4-(4-pyrrolidin-1-yl-phenyl)-piperidine-1-carboxylic acid tert-butyl ester as a solid that was used in the next step without further purification.

To a solution of furnished 4-(4-Pyrrolidin-1-yl-phenyl)-piperidine-1-carboxylic acid tert-butyl ester in ethyl acetate (5 mL) was added 4 N hydrogen chloride in ethyl acetate (10 mL) at room temperature. After stirring for 3 h, solvent was removed in vacuo, and the resulting solid was purified by HPLC. Sodium hydroxide was added to the resulting fractions and the aqueous layer was extracted by dichloromethane. Organic layer was washed with brine, and passed through Cerite. Removal of the solvent under reduced pressure afforded 4-(4-pyrrolidin-1-yl-phenyl)-piperidine (1.01 g, 76%).

A solution of 4-(4-pyrrolidin-1-yl-phenyl)-piperidine (215 mg, 0.933 mmol) and triethylamine (391 mg, 3.86 mmol), 2-chloro-3-methyl-6-(pyridin-4-yl)-3H-pyrimidin-4-one (187 mg, 0.844 mmol) in tetrahydrofuran (10 mL) was refluxed for 5 hr. The resulting solution was diluted with tetrahydrofuran and filtrated. After removal of the solvents under reduced pressure and the purification of the resulting residue by CHEM ELUT CE1010 (manufactured by VARIAN) eluting dichloromethane/ethanol (15/1, v/v) and wash with ethyl acetate afforded 3-methyl-6-pyridin-4-yl-2-(4-(4-pyrrolidin-1-yl-phenyl)-piperidin-1-yl)-3H-pyrimidin-4-one (284 mg, 81%) as a solid.

Example 23 Synthesis of 2-(4-(6-Fluorobenzo[b]thiophen-3-yl)piperidin-1-yl)-1-methyl-1H-[4,4′]bipyrimidinyl-6-one (No. YB253)

The key intermediate 4-(6-fluorobenzo[b]thiophen-3-yl)piperidine hydrochloride of 2-[4-(6-fluorobenzo[b]thiophen-3-yl)piperidin-1-yl]-1-methyl-1H-[4,4′]bipyrimidinyl-6-one was synthesized from 1-acetylpipridine-4-carboxylic acid which was prepared according to the method reported by Watanabe (J. Heterocyclic Chem., 30, 445 (1993)).

To a solution of 1-benzoylpiperidine-4-carboxylic acid (66 g, 285 mmol) in dichloromethane (160 mL) was added thionyl chloride (26 mL, 388 mmol). After stirring at 60° C. for 1 h, the mixture was added portionwise to a stirred suspension of 2,4-difluorobenzene (45 g, 397 mmol) and anhydrous aluminum chloride (88 g, 666 mmol) in dichloromethane (245 mL), and the reaction mixture was refluxed for 5 h. The reaction mixture was poured into a mixture of ice and concentrated hydrochloric acid and extracted with chloroform. The organic layer was dried over sodium sulfate and the solvent was evaporated under reduced pressure. Recrystallization from hexane gave 1-benzoyl-4-(2,4-difluorobenzoyl)piperidine (46 g, 50%) as colorless crystals.

A solution of 1-benzoyl-4-(2,4-difluorobenzoyl)piperidine (40 g, 120 mmol), methyl thioglycolate (12 mL, 130 mmol) in dimethylformamide (500 mL) was stirred at room temperatute for 12 h. The solvent was evaporated off in vacuo and the residue treated with water and ethyl acetate. The organic layer was dried over sodium sulfate and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography eluting hexane/ethyl acetate to give 3-(1-benzoylpiperidin-4-yl)-6-fluorobenzo[b]thiophene-2-carboxylic acid (11.8 g, 26%) as an oil.

3-(1-Benzoylpiperidin-4-yl)-6-fluorobenzo[b]thiophene-2-carboxylic acid (10 g, 26 mmol) was suspended in quinoline (100 mL) and cupper powder (0.5 g) was added. After stirring at 200° C. for 1 h, the mixture was cooled to room temperature and partitioned between ethyl acetate and water. The organic layer was dried over magnesium sulfate and evaporated. The obtained residue was purified by silica gel column chromatography eluting hexane/ethyl acetate to give (4-(6-fluorobenzo[b]thiophen-3-yl)piperidin-1-yl)phenylmethanone (5.0 g, 48%) as yellow crystals.

A solution of (4-(6-fluorobenzo[b]thiophen-3-yl)piperidin-1-yl) phenylmethanone (6.5 g, 19 mmol) in acetic acid (100 mL) and concentrated hydrochloric acid (100 mL) was stirred at 90° C. for 10 h. To a solution of reaction mixture was added ethyl acetate. The precipitated crystals were collected by filtration and washed with ethyl acetate to give 4-(6-fluorobenzo[b]thiophen-3-yl)piperidine hydrochloride (4.8 g, 89%) as yellow crystals.

To a solution of 4-(6-fluorobenzo[b]thiophen-3-yl)piperidine hydrochloride (200 mg, 0.74 mmol) and 2-chloro-1-methyl-1H-[4,4′]bipyrimidinyl-6-one (160 mg, 0.70 mmol) in tetrahydrofuran (10 mL) was added triethylamine (212 mg, 2.1 mmol). The mixture was stirred at 90° C. for 6 h. The solvent was evaporated off in vacuo and the residue was treated with water and chloroform. The organic layer was dried over sodium sulfate and the solvent was evaporated under reduced pressure. Recrystallization from ethyl acetate gave 2-[4-(6-fluorobenzo[b]thiophen-3-yl)piperidin-1-yl]-1-methyl-1H-[4,4′]bipyrimidinyl-6-one (220 mg, 96%) as colorless crystals.

Example 24 Synthesis of 2-(4-(Biphenyl-2-yl)piperazin-1-yl)-1-methyl-1H-[4,4′]bipyrimidinyl-6-one (No. YA1552)

To a solution of 1-biphenyl-2-yl-piperazine dihydrochloride (311 mg, 1.0 mmol) and 2-chloro-1-methyl-1H-[4,4′]bipyrimidinyl-6-one (202 mg, 0.91 mmol) in tetrahydrofuran (20 mL) was added triethylamine (404 mg, 4.0 mmol). The mixture was stirred at 90° C. for 4 h. The solvent was evaporated off in vacuo and the residue treated with water and chloroform. The organic layer was dried over sodium sulfate and the solvent was evaporated under reduced pressure. Recrystallization from ethyl acetate gave 2-[4-(biphenyl-2-yl)piperazin-1-yl]-1-methyl-1H-[4,4′]bipyrimidinyl-6-one (250 mg, 65%) as colorless crystals.

The compounds in the following table were prepared in the same manner as the methods described above. The compound numbers in the following table correspond to those shown in the above-described table of preferred compounds. TABLE 5 NO NMR Exact-MS XA19 2.51-2.89(4H, m), 3.31-3.34(4H, m), 362 3.39(3H, s), 3.56(2H, s), 6.80(1H, s), 7.25-7.31(1H, m), 7.31-7.36(4H, m), 7.98(2H, dd, J=1.5, 4.8Hz), 8.68(2H, dd, J=1.5, 4.5Hz) (DMSO-d6) XA25 3.32-3.34(4H, m), 3.46(3H, s), 3.48-3.51(4H, 348 m), 6.80-6.85(1H, m), 6.84(1H, s), 7.01(2H, d, J=8.0Hz), 7.23-7.28(2H, m), 8.00(2H, dd, J=1.3, 4.6Hz), 8.70(2H, dd, J=1.5, 4.5Hz) (DMSO-d6) XA156 3.47(3H, s), 3.51-3.60(4H, m), 3.62-3.71(4H, 405 m), 6.85(1H, s), 7.41-7.49(1H, m), 7.56-7.61(1H, m), 8.02(2H, dd, J=1.5, 4.5Hz), 8.09(1H, d, J=8.1Hz), 8.16(1H, d, J=8.1Hz), 8.70(2H, dd, J=1.5, 4.8Hz) (DMSO-d6) XA289 1.11-1.28(3H, m), 2.98-3.16(1H, m), 434 3.28-3.41(1H, m), 3.39(3H, s), 3.54-3.80(3H, m), 3.88-3.99(1H, m), 4.08-4.26(4H, m), 4.32-4.45(1H, m), 7.13(1H, s), 7.37-7.53(5H, m), 8.45(2H, d, J=5.8Hz), 8.96(2H, d, J=6.0Hz) (DMSO-d6) XA361 3.44(3H, s), 3.54-3.95(6H, m), 4.64(1H, brs), 348 7.11(1H, s), 7.42-7.51(3H, m), 7.74(2H, d, J=6.6Hz), 8.46(2H, d, J=5.7Hz), 8.94(2H, d, J=5.7Hz), 9.98(1H, brs), 10.46(1H, brs) (DMSO-d6). XA364 (DMSO-d6): 3.41-3.76(4H, m), 3.48(3H, s), 366 3.89-4.01(2H, m), 4.96(1H, m), 7.16(1H, s), 7.33-7.58(3H, m), 8.11(1H, dd, J=7.2, 7.2Hz), 8.52(2H, d, J=6.6Hz), 8.97(2H, d, J=6.6Hz), 10.04(1H, m), 10.66(1H, m). XA365 3.43(s, 3H), 3.51-3.96(m, 6H), 4.70(m, 1H), 366 7.00(s, 1H), 7.25(m, 1H), 7.54(m, 2H), 7.60(m, 1H), 8.20(d, J=5.7Hz, 2H), 8.80(d, J=5.7Hz, 2H) (CDCl3) XA366 2.27-2.85(1H, m), 2.94-3.08(3H, m), 366 3.43(3H, s), 3.59-3.67(2H, m), 3.94-3.97(1H, m), 6.81(1H, s), 7.19(2H, t, J=8.9Hz), 7.50-7.55(2H, m), 7.96(2H, dd, J=1.6, 4.5Hz), 8.68(2H, dd, J=1.5, 4.6Hz) (DMSO-d6) XA366 3.35-3.50(2H, m), 3.46(3H, s), 3.58-3.75(2H, 366 (HCl) m), 3.86-3.97(2H, m), 4.68(1H, t, J=9.3Hz), 7.15(1H, s), 7.35(2H, t, J=9.0Hz), 7.82-7.87(2H, m), 8.48(2H, d, J=6.6Hz), 8.96(2H, d, J=6.3Hz), 9.55-10.08(1H, m), 10.54-10.70(1H, m) (DMSO-d6) XA369 (CDCl3): 2.81(1H, dd, J=10.4, 12.5Hz), 382 3.18-3.40(3H, m), 3.50-3.80(5H, m), 4.50(1H, dd, J=2.5, 10.1Hz), 6.67(1H, s), 7.20-7.45(3H, m), 7.74(1H, dd, J=1.9, 7.6Hz), 7.81(2H, dd, J=1.4, 4.6Hz), 8.70(2H, dd, J=1.4, 4.6Hz). XA370 (CDCl3): 3.01(1H, dd, J=10.4, 12.5Hz), 382 3.10-3.30(3H, m), 3.50-3.80(5H, m), 4.04(1H, dd, J=2.7, 10.8Hz), 6.67(1H, s), 7.20-7.45(4H, m), 7.50(1H, s), 7.80(2H, dd, J=1.5, 4.8Hz), 8.71(2H, dd, J=1.5, 5.1Hz). XA371 3.44(3H, s), 3.44-3.71(7H, m), 3.90(2H, m), 382 4.66(1H, brs), 7.11(1H, s), 7.55(2H, d, J=8.4Hz), 7.78(2H, d, J=8.4Hz), 8.50(2H, d, J=5.7Hz), 8.95(2H, d, J=5.7Hz), 10.13(1H, brs), 10.60(1H, brs) (DMSO-d6) XA376 (DMSO-d6): 3.45(3H, s), 3.50-4.20(6H, m), 426 4.66(1H, br s), 7.12(1H, s), 7.72(4H, s), 8.44(2H, d, J=6.6Hz), 8.94(2H, d, J=6.6Hz), 10.00(1H, br s), 10.05(1H, br s) XA391 3.37-3.93(6H, m), 3.48(3H, s), 3.87(3H, s), 378 4.89-4.95(1H, m), 7.04-7.12(2H, m), 7.17(1H, d, J=8.5Hz), 7.45-7.51(1H, m), 7.75-7.81(1H, m), 8.29-8.38(2H, m), 8.83-8.91(2H, m), 9.66-9.77(1H, m), 9.91-10.10(1H, m) (DMSO) XA392 (DMSO-d6): 3.30-3.58(5H, m), 378 3.58-3.80(2H, m), 3.81(3H, s), 3.85-4.00(2H, m), 4.58-4.75(1H, m), 7.03(1H, dd, J=1.8, 8.1Hz), 7.11(1H, s), 7.26(1H, d, J=7.8Hz), 7.35-7.50(2H, m), 8.41(2H, d, J=5.7Hz), 8.92(2H, d, J=6.0Hz), 9.80-10.00(1H, brd), 10.30-10.60(1H, brd). XA393 3.40-3.43(5H, m), 3.51-3.63(2H, m), 378 3.78(3H, s), 3.93(2H, m), 4.58(1H, br), 7.02-7.06(3H, m), 7.64(2H, d, J=8.7Hz), 8.34(2H, d, J=6.3Hz), 8.88(2H, d, J=8.7Hz), 9.76(1H, br), 10.16(1H, br) (DMSO-d6) XA396 1.30(3H, t, J=6.9Hz), 3.38-3.54(1H, m), 392 3.49(3H, s), 3.65-3.79(1H, m), 3.84-3.98(2H, m), 4.02-4.18(2H, m), 4.84(1H, t, J=10.5Hz), 7.04-7.16(2H, m), 7.15(1H, s), 7.39-7.45(1H, m), 7.89(1H, d, J=6.6Hz), 8.49(2H, d, J=6.3Hz), 8.95(2H, d, J=6.6Hz), 9.92(1H, d, J=9.3Hz), 10.51-10.64(1H, m) (DMSO-d6) XA406 (DMSO-d6): 3.64(2H, m), 373 3.94(2H, t, J=11.4Hz), 4.02-4.40(5H, m), 4.78(1H, t, J=10.4Hz), 7.06(1H, s), 7.98(2H, d, J=8.3Hz), 8.01(2H, d, J=8.3Hz), 8.23(1H, dd, J=1.2, 5.1Hz), 9.02(1H, d, J=5.1Hz), 9.31(1H, d, J=1.2Hz), 10.03(1H, d, J=8.7Hz), 10.57(1H, s). XA433 (CDCl3): 2.00(4H, m), 417 3.03(1H, dd, J=10.8, 12.0Hz), 3.21(3H, m), 3.29(4H, m), 3.57(3H, s), 3.62(2H, m), 3.90(1H, dd, J=2.7, 10.8Hz), 6.57(2H, d, J=8.7Hz), 6.66(1H, s), 7.29(2H, d, J=8.7Hz), 7.80(2H, d, J=4.8Hz), 8.70(2H, d, J=4.8Hz). XA439 (CDCl3): 3.02(1H, dd, J=10.7, 12.4Hz), 434 3.18(7H, m), 3.55(3H, s), 3.62(2H, m), 3.87(4H, m), 3.96(1H, dd, J=2.5, 11.1Hz), 6.66(1H, S), 6.93(2H, d, J=8.7Hz), 7.36(2H, d, J=8.7Hz), 7.79(2H, d, J=4.5Hz), 8.70(2H, d, J=4.5Hz). XA442 (CDCl3): 2.36(3H, s), 2.59(4H, m), 446 3.02(1H, t, J=11.6Hz), 3.22(7H, m), 3.55(3H, s), 3.63(2H, m), 3.94(1H, d, J=10.5Hz), 6.66(1H, s), 6.93(2H, d, J=8.7Hz), 7.34(2H, d, J=8.7Hz), 7.80(2H, d, J=4.5Hz), 8.70(2H, d, J=4.5Hz). XA463 3.41-3.54(3H, m), 3.48(3H, s), 3.69-3.73(1H, 408 m), 3.78(3H, s), 3.82(3H, s), 3.86-3.93(2H, m), 4.89(1H, t, J=10.5Hz), 6.97-7.01(1H, m), 7.08(1H, d, J=9.0Hz), 7.15(1H, s), 7.66(1H, d, J=3.0Hz), 8.51(2H, d, J=6.3Hz), 8.96(2H, d, J=6.3Hz), 9.93(1H, d, J=9.0Hz), 10.60-10.73(1H, m) (DMSO-d6) XA464 (DMSO-d6): 3.45(3H, s), 3.38-3.81(6H, m), 408 3.88(6H, s), 5.06(1H, m), 6.82(2H, d, J=8.7Hz), 7.04(1H, s), 7.44(1H, t, J=8.4Hz), 8.20(1H, m), 8.30(2H, d, J=6.3Hz), 8.87(2H, d, J=6.3Hz), 10.07(1H, m). XA468 3.40-3.50(4H, m), 3.47(3H, s), 3.83-3.94(2H, 396 m), 3.88(3H, s), 4.81-4.91(1H, m), 6.92-6.99(1H, m), 7.07-7.10(1H, m), 7.12(1H, s), 7.79-7.91(1H, m), 8.30-8.40(2H, m), 8.85-8.92(2H, m), 9.70-9.79(1H, m), 10.02-10.23(1H, m) (DMSO) XA469/ (DMSO-d6): 3.38-3.60(6H, m), 396 XA470 3.60-3.80(1H, m) 3.80-4.00(5H, m), 4.80-4.97(1H, m), 6.85-7.00(1H, m), 7.09(1H, dd, J=2.4, 11.4Hz), 7.13(1H, s), 7.95(1H, dd, J=6.9, 8.7Hz), 8.46(2H, d, J=6.6Hz), 8.94(2H, d, J=6.3Hz), 9.80-10.00(1H, brd), 10.35-10.60(1H, brd). XA472 3.36-4.00(6H, m), 3.46(3H, s), 3.94(3H, s), 396 4.94-5.02(1H, m), 6.96-7.01(1H, m), 7.05(1H, d, J=8.6Hz), 7.14(1H, s), 7.49-7.58(1H, m), 8.44-8.50(2H, m), 8.52-8.64(1H, m), 8.96(2H, d, J=6.6Hz), 10.49-10.60(1H, m) (DMSO) XA480 2.78(1H, dd, J=10.0, 12.1Hz), 3.18-3.27(3H, 412 m), 3.59(3H, s), 3.64-3.74(2H, m), 3.86(3H, s), 4.37(1H, dd, J=2.4, 10.1Hz), 6.67(1H, s), 6.89(1H, d, J=2.1Hz), 6.99(1H, dd, J=1.7, 8.0Hz), 7.50(1H, d, J=8.2Hz), 7.82(2H, dd, J=1.5, 4.8Hz), 8.71(2H, dd, J=1.8, 4.5Hz) (CDCl3) XA490 3.35-3.94(6H, m), 3.49(3H, s), 4.71-4.80(1H, 380 (2HCl) m), 7.02-7.11(1H, m), 7.18-7.28(2H, m), 7.98-8.10(1H, m), 8.31-8.48(2H, m), 8.87-8.97(2H, m), 9.79-9.92(1H, m), 10.18-10.39(1H, m) (DMSO) XA501 (CDCl3): 2.77(1H, dd, J=10.2, 12.0Hz), 456 3.15-3.35(3H, m), 3.50-3.80(5H, m), 3.84(3H, s), 4.39(1H, d, J=7.8Hz), 6.67(1H, s), 6.78(1H, d, J=8.8Hz), 7.39(1H, dd, J=2.4, 8.7Hz), 7.71(1H, d, J=2.3Hz), 7.82(2H, d, J=6.0Hz), 8.71(2H, d, J=6.0Hz). XA510 (CDCl3): 1.98-2.05(4H, m), 2.85(1H, dd, 447 J=12, 10.5Hz), 3.17-3.24(7H, m), 3.58(3H, s), 3.65-3.72(2H, m), 3.85(3H, s), 4.28(1H, dd, 10.5, 2.7Hz), 6.10(1H, d, J=2.1Hz), 6.18(1H, dd, J=8.7, 2.1Hz), 6.65(1H, s), 7.33(1H, d, J=8.4Hz), 7.83(2H, dd, J=4.5, 1.8Hz), 8.70(2H, dd, J=4.5, 1.5Hz). XA511 (CDCl3): 1.90-2.05(4H, m), 447 2.93(1H, t, J=12.0Hz), 3.15-3.40(7H, m), 3.59(3H, s), 3.65-3.85(5H, m), 4.11(1H, dd, J=2.1, 10.2HZ), 6.49(1H, dd, J=3.0, 9.0Hz), 6.66(1H, s), 7.83(2H, dd, J=1.8, 4.5Hz), 8.70(2H, dd, J=1.5, 4.5Hz). XA516 (DMSO-d6): 3.20-3.70(4H, m), 3.70(1H, m), 414 3.98(3H, s), 3.99(3H, s), 4.00(1H, m), 4.96(1H, d, J=10.2Hz), 7.01(1H, s), 7.03(2H, m), 8.26(2H, d, J=6.1Hz), 8.53(1H, s), 8.84(2H, d, J=6.1Hz), 10.25(1H, d, J=10.7Hz) XA525 (DMSO-d6): 3.30-3.50(2H, m), 3.48(3H, s), 454 3.55-3.78(2H, m), 3.78(3H, s), 3.96(2H, d, J=13.5Hz), 4.69(1H, t, J=10.4Hz), 7.06(1H, t, J=7.4Hz), 7.12(1H, s), 7.14(1H, d, J=7.4Hz), 7.31(1H, d, J=7.4Hz), 7.39(1H, t, J=7.4Hz), 7.59(2H, d, J=8.3Hz), 7.77(2H, d, J=8.3Hz), 8.43(2H, d, J=6.5Hz), 8.93(2H, d, J=6.5Hz), 9.89(1H, d, J=8.7Hz), 10.34(1H, s). XA527 (DMSO-d6): 3.40=4.10(9H, m), 3.81(3H, s), 454 4.69(1H, m), 7.05(1H, s), 7.05(2H, d, J=9.0Hz), 7.67(2H, d, J=9.0Hz) 7.75(4H, s), 8.27(2H, d, J=5.7Hz), 8.85(2H, d, J=5.7Hz), 9.75(1H, s), 10.04(1H, s). XA536 (DMSO-d6): 3.40-3.60(2H, m), 3.47(3H, s), 443 3.68(2H, m), 3.95(2H, m), 4.71(1H, t, J=9.9Hz), 7.16(1H, s), 7.33(2H, t, J=8.85Hz), 7.78(6H, m), 8.50(2H, d, J=6.3Hz), 8.97(2H, d, J=6.3Hz), 10.02(1H, s), 10.50(1H, s). XA543 3.52(s, 3H), 3.57-4.10(m, 6H), 5.57(m, 1H), 398 7.02(s, 1H), 7.53-7.70(m, 2H), 8.06(d, J=7.2Hz, 2H), 8.21-8.34(m, 3H), 8.82(d, J=6.3Hz, 2H), 9.88-9.92(m, 1H), 10.58-10.61(m, 1H) (DMSO d6) XA544 3.41-3.59(2H, m), 3.49(3H, s), 3.68-3.76(2H, 398 m), 3.97-4.02(2H, m), 4.78-4.89(1H, m), 7.15(1H, s), 7.58-7.63(2H, m), 7.89-8.07(4H, m), 8.30(1H, s), 8.49(2H, d, J=6.3Hz), 8.95(2H, d, J=6.3Hz), 10.17(1H, d, J=8.4Hz), 10.57-10.70(1H, m) (DMSO-d6) XA619 (CDCl3): 2.98(1H, dd, J=12.6, 10.8Hz), 390 3.17-3.28(5H, m), 3.58(3H, s), 3.62(1H, m), 3.79(1H, m), 4.26(1H, dd, 10.5, 2.7Hz), 4.62(2H, m), 6.66(1H, s), 6.88(1H, t, J=7.5Hz), 7.16(1H, d, J=7.2Hz), 7.27(1H, m), 7.84(2H, d, J=6.0), 8.70(2H, dd, J=4.8, 1.2Hz). XA626 3.33-3.41(4H, m), 3.42(3H, s), 3.47-3.87(4H, 376 m), 6.84(1H, s), 7.44-7.49(5H, m), 7.99(2H, dd, J=1.5, 4.5Hz), 8.69(2H, dd, J=1.4, 4.8Hz) (DMSO-d6) XA649 3.44(3H, s), 3.37-4.04(9H, m), 4.67(1H, 362 d, J=9.6Hz), 7.10(1H, s), 7.45-7.55(3H, m), 7.83(2H, d, J=6.0Hz), 8.47(2H d, J=6.6Hz), 8.95(2H, d, J=6.6Hz), 12.15(1H, brs) (DMSO-d6) XA756 (CDCl3): 2.50-2.61(1H, m), 2.80-2.95(1H, m), 410 3.05-3.20(1H, m), 3.25-3.40(1H, m), 3.50-3.60(1H, m), 3.57(3H, s), 3.65-3.75(1H, m), 3.75-3.80(1H, m), 3.85(3H, s), 6.60-6.80(3H, m), 7.47(1H, dd, J=7.2, 8.4Hz), 7.82(2H, dd, J=1.5, 4.5Hz), 8.71(2H, dd, J=1.5, 4.5Hz). XA757/ (DMSO-d6): 2.54(3H, s), 3.40-3.79(3H, m), 410 XA758 3.46(3H, s), 3.80-4.10(6H, m), 4.83-5.10(1H, m), 6.90-7.05(1H, m), 7.08(1H, s), 7.13(1H, dd, J=2.7, 11.4Hz), 8.00-8.25(1H, brd), 8.37(2H, d, J=6.3Hz), 8.91(2H, d, J=6.6Hz), 11.80-12.20(1H, brd). XA831 2.55(s, 3H), 3.51(s, 3H), 3.67-3.82(m, 4H), 412 4.04-4.08(m, 2H), 5.64(m, 1H), 7.05(s, 1H), 7.59-7.72(m, 3H), 8.06-8.11(m, 2H), 8.35(d, J=6.6Hz, 2H), 8.41(d, J=7.8Hz, 1H), 8.49(d, J=6.9Hz, 1H), 8.84(d, J=6.6Hz, 2H) (DMSO d6) XA1016 (DMSO-d6): 3.15-3.35(1H, m), 486 3.38-3.60(4H, m), 3.75-4.15(8H, m), 4.18-4.25(1H, m), 4.90-5.20(1H, m), 7.00-7.20(3H, m), 7.30-7.55(6H, m), 8.50-8.70(3H, m), 9.00(2H, d, J=6.3Hz). XA1276 (CDCl3): 1.80-2.42(3H, m), 3.08-3.39(4H, 438 m), 3.40-3.62(1H, m), 3.65-4.23(6.8H, m), 4.63-4.90(0.6H, m), 5.40-5.62(0.7H, m), 5.80-6.00(0.1H, m), 6.52-6.78(3H, m), 6.90-7.2(1H, m), 7.68-7.90(2H, m), 8.64-8.80(2H, m) XA1649 1.48(3H, s), 1.57(3H, s), 3.50(3H, s), 406 3.51-3.66(2H, m), 3.72-3.76(1H, m), 3.90(3H, s), 3.99(1H, d, J=13.4Hz), 5.15-5.23(1H, m), 7.08-7.12(2H, m), 7.18(1H, d, J=8.6Hz), 7.46-7.49(1H, m), 8.04-8.11(1H, m), 8.37-8.45(2H, m), 8.89-8.97(2H, m), 9.49-9.60(1H, m), 9.95-10.11(1H, m) (DMSO) XA1973 3.01(1H, dd, J=10.8, 12.9Hz), 382 3.10-3.30(3H, m), 3.50-3.75(5H, m), 4.04(1H, dd, J=2.7, 10.8Hz), 6.67(1H, s), 7.20-7.40(4H, m), 7.50(1H, s), 7.80(2H, dd, J=1.5, 4.8Hz), 8.71(2H, dd, J=1.5, 5.1Hz) (CDCl3) XA1974 2.80(1H, dd, J=10.3, 12.2Hz), 426 3.15-3.30(3H, m), 3.50-3.80(5H, m), 4.44(1H, dd, J=2.6, 10.3Hz), 6.67(1H, s), 7.10-7.20(1H, m), 7.25-7.40(1H, m), 7.58(1H, dd, J=1.0, 8.1Hz), 7.73(1H, dd, J=1.6, 7.8Hz), 7.81(2H, dd, J=1.6, 4.5Hz), 8.70(2H, dd, J=1.6, 4.5Hz) (CDCl3) XA1975 2.95-3.10(1H, m), 3.10-3.35(3H, m), 407 3.56(3H, s), 3.60-3.70(2H, m), 3.80-4.05(7H, m), 6.67(1H, s), 6.87(1H, d, J=8.1Hz), 6.90-7.10(2H, m), 7.80(2H, dd, J=1.8, 6.3Hz), 8.71(2H, dd, J=1.5, 4.8Hz) (CDCl3) XA1976 3.40(3H, m), 3.45(3H, s), 3.53-3.96(3H, m), 382 4.68(1H, t, J=13.5Hz), 7.10(1H, s), 7.60(2H, d, J=8.3Hz), 7.76(2H, d, J=8.3Hz), 8.38(1H, br s), 8.91(1H, d, J=4.8Hz), 9.88(1H, br s), 10.31(1H, br s) (DMSO-d6) XA1977 3.40(3H, m), 3.46(3H, s), 3.62(1H, dd, 382 J=12.0, 13.2Hz), 3.72(1H, m), 3.92(1H, t, J=15.5Hz), 4.68(1H, t, J=10.1Hz), 7.18(1H, s), 7.58(2H, d, J=8.6Hz), 7.83(2H, d, J=8.6Hz), 8.57(2H, d, J=6.6Hz), 9.01(2H, d, J=6.6Hz), 10.20(1H, d, J=7.8Hz), 10.76(1H, br s) (DMSO-d6) XA1978 2.98(1H, t, J=10.9Hz), 3.22(m, 3H), 3.56(3H, s), 3.60(2H, m), 4.03(1H, d, J=8.7Hz), 6.68(1H, s), 7.28(1H, d, J=8.2Hz), 7.46(1H, d, J=8.2Hz), 7.61(1H, s), 7.79(2H, d, J=5.6Hz), 8.71(2H, d, J=5.6Hz) (CDCl3) XA1979 3.31(1H, dd, J=13.8, 8.9Hz), 3.46(3H, s), 396 3.85(1H, dd, J=13.8, 3.6Hz), 4.10(1H, d, J=17.7Hz), 4.19(1H, d, J=17.7Hz), 4.91(1H, dd, J=8.9, 3.6Hz), 6.11(1H, s), 6.74(1H, s), 7.32(2H, d, J=8.4Hz), 7.42(2H, d, J=8.4Hz), 7.79(2H, dd, J=4.8, 1.5Hz), 8.74(2H, dd, J=4.8, 1.5Hz) (CDCl3) XA1980 1.97(4H, m), 3.26(4H, m), 3.38(2H, m), 417 3.45(3H, s), 3.60(2H, m), 3.80(1H, d, J=13.8Hz), 3.92(1H, d, J=14.1Hz), 4.48(1H, t, J=10.4Hz), 6.65(2H, d, J=8.7Hz), 7.16(1H, s), 7.54(2H, d, J=8.7Hz), 8.57(2H, d, J=6.6Hz), 9.00(2H, d, J=6.6Hz), 9.83(1H, d, J=9.3Hz), 10.32(1H, br s) (DMSO-d6) XA1981 3.21(4H, m), 3.40(2H, m), 3.46(3H, s), 433 3.65(2H, m), 3.78(4H, m), 3.91(2H, t, J=13.7Hz), 4.55(1H, t, J=10.1Hz), 7.14(2H, d, J=8.7Hz), 7.20(1H, s), 7.64(2H, d, J=8.7Hz), 8.60(2H, d, J=6.6Hz), 9.02(2H, d, J=6.6Hz), 9.93(1H, d, J=9.0Hz), 10.47(1H, br s) (DMSO-d6) XA1982 2.80(3H, d, J=4.5Hz), 3.15(4H, m), 446 3.44(4H, m), 3.45(3H, s), 3.60(2H, m), 3.82(1H, d, J=13.5Hz), 3.90(3H, m), 4.54(1H, t, J=10.5), 7.10(2H, d, J=8.7Hz), 7.17(1H, s), 7.64(2H, d, J=8.7Hz), 8.54(2H, d, J=6.3Hz), 8.99(2H, d, J=6.3Hz), 9.94(1H, d, J=8.7Hz), 10.47(1H, br s), 11.26(1H, br s) (DMSO-d6) XA1983 1.27(3H, t, J=6.6Hz), 3.46-4.14(8H, m), 396 4.70(1H, m), 7.11(1H, s), 7.60(2H, d, J=8.4Hz), 7.76(2H, d, J=8.4Hz), 8.32(2H, d, J=6Hz), 8.89(2H, d, J=6.0Hz), 9.87(1H, m), 10.23(1H, m), (DMSO-d6) XA1984 1.27(6H, dd, J=6.9, 6.9Hz), 3.37-4.36(6H, 410 m), 4.66-4.79(2H, m), 7.03(1H, s), 7.62(2H, d, J=8.7Hz), 7.78(2H, d, J=8.7Hz), 8.33(2H, d, J=6Hz), 8.90(2H, d, J=6.0Hz), 9.93(1H, m), 10.25(1H, m), (DMSO-d6) XA1985 1.40(3H, d, J=6.3Hz), 3.44-4.04(5H, m), 396 3.48(3H, s), 4.69(1H, m), 7.08(1H, s), 7.60(2H, d, J=8.4Hz), 7.79(2H, d, J=8.4Hz), 8.33(2H, d, J=6.3Hz), 8.90(2H, d, J=6.3Hz), 9.83(1H, m), 10.00(1H, m), (DMSO-d6) XA1986 1.57(6H, s), 3.50(3H, s), 3.51-3.93(4H, m), 410 4.98(1H, m), 7.11(1H, s), 7.60(2H, d, J=7.4Hz), 7.94(2H, d, J=7.4Hz), 8.41(2H, d, J=6.0Hz), 8.93(2H, d, J=6.0Hz), 9.88(1H, m), 10.05(1H, m), (DMSO-d6) XA1987 1.43(3H, d, J=6.6Hz), 3.38-3.93(5H, m), 396 3.48(3H, s), 4.72(1H, m), 7.12(1H, s), 7.59(2H, d, J=8.4Hz), 7.84(2H, d, J=8.4Hz), 8.43(2H, d, J=6.6Hz), 8.95(2H, d, J=6.6Hz), 9.65(1H, m), 10.23(1H, m), (DMSO-d6) XA1988 2.34(1H, m), 2.42(1H, m), 2.80(3H, d, J=5.6Hz), 460 2.81(3H, d, J=5.6Hz), 3.28(1H, q, J=8.8Hz), 3.43(2H, m), 3.45(3H, s), 3.57(5H, m), 3.80(1H, d, J=11.4Hz), 3.96(2H, m), 4.50(1H, t, J=10.4Hz), 6.69(2H, d, J=8.4Hz), 7.14(1H, s), 7.55(2H, d, J=8.4Hz), 8.47(2H, d, J=5.6Hz), 8.96(2H, d, J=5.6Hz), 9.75(1H, d, J=8.0Hz), 10.16(1H, br s), 11.40(1H, br s) (DMSO-d6) XA1989 1.65(2H, br s), 1.91(4H, br s), 3.46(9H, s), 431 3.70(2H, m), 3.92(2H, t, J=16.6Hz), 4.66(1H, br s), 7.16(1H, s), 7.85(4H, br s), 8.50(2H, d, J=6.4Hz), 8.97(2H, d, J=6.4Hz), 10.01(1H, br s), 10.59(1H, br s) (DMSO-d6) XA1990 2.32(1H, m), 2.42(1H, m), 2.79(3H, d, J=5.2Hz), 460 2.81(3H, d, J=5.2Hz), 3.27(1H, m), 3.39(2H, m), 3.45(3H, s), 3.59(5H, m), 3.79(1H, d, J=13.3Hz), 3.95(2H, m), 4.50(1H, t, J=11.6Hz), 6.69(2H, d, J=8.4Hz), 7.16(1H, s), 7.56(2H, d, J=8.4Hz), 8.50(2H, s), 8.98(2H, d, J=5.6Hz), 9.78(1H, br s), 10.19(1H, br s), 11.44(1H, br s) (DMSO-d6) XA1991 3.47(3H, s), 3.61(3H, m), 3.81(3H, s), 454 4.02(3H, m), 4.69(1H, t, J=10.6Hz), 7.05(2H, d, J=8.8Hz), 7.10(1H, s), 7.67(2H, d, J=8.8Hz), 7.77(4H, s), 8.38(2H, br s), 8.91(2H, d, J=5.2Hz), 9.90(1H, br s), 10.28(1H, br s) (DMSO-d6) XA1992 1.26(3H, t, J=6.9Hz), 1.41(3H, d, J=6.3Hz), 410 3.43-4.06(7H, m), 4.74(1H, m), 7.09(1H, s), 7.58(2H, d, J=8.4Hz), 7.84(2H, d, J=8.4Hz), 8.32(2H, d, J=6.6Hz), 8.90(2H, d, J=6.6Hz), 9.90(1H, m), 10.03(1H, m), (DMSO-d6) XA1993 1.41(3H, t, J=6.3Hz), 1.55(6H, dd, J=6.6, 6.6Hz), 424 3.49-3.73(5H, m), 4.64(1H, m), 4.78(1H, m), 6.99(1H, s), 7.58(2H, d, J=8.7Hz), 7.81(2H, d, J=8.7Hz), 8.28(2H, d, J=6.3Hz), 8.87(2H, d, J=6.3Hz), 9.91(2H, m) (DMSO-d6) XA1994 1.27(3H, t, J=6.9Hz), 1.55(3H, s), 1.60(3H, 424 s), 3.42-4.14(6H, m), 5.04(1H, m), 7.13(1H, s), 7.60(2H, d, J=8.4Hz), 7.91(2H, d, J=8.4Hz), 8.32(2H, d, J=6.3Hz), 8.89(2H, d, J=6.3Hz), 9.80-9.84(2H, m) (DMSO-d6) XA1995 1.52(3H, d, J=6.6Hz), 1.58(6H, s), 1.59(3H, 438 d, J=6.6Hz), 3.40-3.68(4H, m), 4.75(1H, m), 5.09(1H, m), 7.03(1H, s), 7.60(2H, d, J=8.4Hz), 7.93(2H, d, J=8.4Hz), 8.33(2H, d, J=6.0Hz), 8.89(2H, d, J=6.0Hz), 9.89(2H, m) (DMSO-d6) XA1996 1.29(3H, t, J=6.8Hz), 3.47(2H, br s), 468 3.66(3H, m), 3.81(3H, s), 3.83(1H, m), 4.04(2H, m), 4.71(1H, d, J=10.6Hz), 7.05(2H, d, J=8.8Hz), 7.12(1H, s), 7.67(2H, d, J=8.8Hz), 7.75(2H, d, J=8.4Hz), 7.79(2H, d, J=8.4Hz), 8.36(2H, d, J=6.4Hz), 8.91(2H, d, J=6.4Hz), 9.92(1H, d, J=8.8Hz), 10.29(1H, br s) (DMSO-d6) XA1997 1.56(3H, d, J=6.4Hz), 1.58(3H, d, J=6.4Hz), 482 3.47(2H, br s), 3.60(1H, m), 3.77(2H, m), 3.81(3H, s), 4.72(3H, m), 7.05(2H, d, J=8.8Hz), 7.06(1H, s), 7.68(2H, d, J=8.8Hz), 7.76(2H, d, J=8.4Hz), 7.80(2H, d, J=8.4Hz), 8.42(2H, d, J=6.4Hz), 8.94(2H, d, J=6.4Hz), 10.02(1H, d, J=9.6Hz), 10.39(1H, br s) (DMSO-d6) XA1998 1.24(1H, m), 1.39(4H, m), 1.72(1H, m), 430 1.79(4H, m), 2.55(1H, m), 3.45(3H, s), 4.00-3.45(6H, m), 4.61(1H, t, J=11.2Hz), 7.09(1H, s), 7.35(2H, d, J=8.4Hz), 7.62(2H, d, J=8.4Hz), 8.37(2H, d, J=4.0Hz), 8.90(2H, d, J=4.0Hz), 9.75(1H, d, J=9.6Hz), 10.17(1H, br s), (DMSO-d6) XA1999 1.04(1H, m), 1.17(2H, m), 1.43(2H, m), 459 1.60(1H, m), 1.79(4H, m), 2.96(3H, br s), 3.45(3H, s), 4.18-3.44(6H, m), 4.62(1H, br s), 7.13(1H, s), 7.75(4H, br s), 8.46(1H, br s), 8.95(1H, br s), 9.87(1H, br s), 10.40(1H, br s) (DMSO-d6) XA2000 1.40(3H, d, J=6.6Hz), 3.44-4.04(5H, m), 396 3.48(3H, s), 4.72(1H, m), 7.05(1H, s), 7.61(2H, d, J=8.4Hz), 7.78(2H, d, J=8.4Hz), 8.29(2H, d, J=6.0Hz), 8.90(2H, d, J=6.0Hz), 9.78-10.00(2H, m), (DMSO-d6) XA2001 1.26(3H, t, J=6.9Hz), 1.41(3H, d, J=6.0Hz), 410 3.43-4.06(7H, m), 4.74(1H, m), 7.08(1H, s), 7.58(2H, d, J=8.4Hz), 7.81(2H, d, J=8.4Hz), 8.29(2H, d, J=6.3Hz), 8.88(2H, d, J=6.3Hz), 9.84-10.00(2H, m), (DMSO-d6) XA2002 1.41(3H, t, J=6.0Hz), 1.56(6H, dd, J=6.6, 6.6Hz), 424 3.49-3.73(5H, m), 4.62(1H, m), 4.78(1H, m), 7.00(1H, s), 7.59(2H, d, J=8.4Hz), 7.81(2H, d, J=8.4Hz), 8.30(2H, d, J=6.3Hz), 8.88(2H, d, J=6.3Hz), 9.91(2H, m) (DMSO-d6) XA2003 3.03(4H, td, J=4.6Hz), 3.26(4H, t, J=4.5Hz), 425 3.48(3H, s), 6.65(1H, s), 7.10(2H, m), 7.20-7.45(5H, m), 7.65(2H, d, J=8.5Hz), 7.79(2H, d, J=6.3Hz), 8.71(2H, d, J=1.5, 4.8Hz) (CDCl3), XA2004 2.93(1H, m), 3.20(2H, m), 3.30(3H, s), 362 3.36(1H, d, J=12.8Hz), 3.46(1H, t, J=12.0Hz), 3.73(4H, m), 7.03(1H, s), 7.33(2H, m), 7.42(3H, m), 8.16(2H, d, J=6.4Hz), 8.86(2H, d, J=6.4Hz), 9.61(1H, d, J=10.0Hz), 9.95(1H, d, J=8.4Hz) (DMSO-d6) XA2005 2.93(1H, dd, J=14.8, 8.4Hz), 3.07(1H, m), 396 3.19(1H, m), 3.33(3H, s), 3.41(3H, s), 3.69(1H, m), 3.80(2H, d, J=14.0Hz), 6.96(1H, br s), 7.39(2H, d, J=8.0Hz), 7.49(2H, d, J=8.0Hz), 8.00(2H, br s), 8.77(2H, br s), 9.24(1H, s), 9.54(1H, s) (DMSO-d6) XA2006 3.39(2H, m), 3.46(3H, s), 3.56(2H, m), 508 3.85(1H, d, J=13.2Hz), 3.93(1H, d, J=13.6Hz), 4.55(1H, t, J=10.4Hz), 6.94(1H, br s), 7.13(1H, s), 7.14(4H, m), 7.30(2H, m), 7.59(2H, d, J=8.0Hz), 8.45(2H, s), 8.95(2H, s), 9.73(1H, br s), 10.10(1H, br s) (DMSO-d6) XA2007 1.39(1H, m), 1.80(8H, m), 2.18(2H, d, J=11.2Hz), 514 2.76(2H, t, J=11.4Hz), 3.90(2H, m), 3.33(1H, m), 3.40(3H, m), 3.45(3H, s), 3.58(2H, m), 3.82(1H, d, J=13.3Hz), 3.93(3H, m), 4.53(1H, t, J=10.4Hz), 7.09(2H, d, J=8.8Hz), 7.11(1H, s), 7.56(2H, d, J=8.8Hz), 8.40(2H, d, J=6.0Hz), 8.92(2H, d, J=6.0Hz), 9.75(1H, d, J=8.8Hz), 10.14(1H, br s), 10.39(1H, br s) (DMSO-d6) XA2008 2.82-2.90(1H, m), 3.01-3.05(4H, m), 426 3.22(3H, s), 3.44(3H, s), 3.58-3.66(2H, m), 4.08(1H, dd, J=1.2, 10.2Hz), 6.81(1H, s), 7.77(2H, d, J=7.2Hz), 7.92-7.98(4H, m), 8.69(2H, d, J=4.2Hz) (DMSO-d6) XA2009 1.21(3H, d, J=6.6Hz), 3.17-3.45(4H, m), 396 3.52(3H, s), 4.02(1H, m), 4.69(1H, m), 7.20(1H, s), 7.54(2H, d, J=8.4Hz), 7.70(2H, d, J=8.4Hz), 8.26(2H, d, J=6.3Hz), 8.88(2H, d, J=6.3Hz), 9.90(1H, m), 10.16(1H, m), (DMSO-d6) XA2010 1.21(3H, d, J=6.0Hz), 3.17-3.45(4H, m), 396 3.53(3H, s), 4.02(1H, m), 4.70(1H, m), 7.24(1H, s), 7.54(2H, d, J=8.7Hz), 7.73(2H, d, J=8.7Hz), 8.33(2H, d, J=5.7Hz), 8.93(2H, d, J=5.7Hz), 10.04(1H, m), 1037(1H, m), (DMSO-d6) XA2011 3.02(1H, t, J=11.9Hz), 3.17(6H, m), 433 3.55(3H, s), 3.63(2H, m), 3.86(4H, m), 3.96(1H, d, J=10.2Hz), 6.66(1H, s), 6.92(2H, d, J=8.4Hz), 7.35(2H, d, J=8.4Hz), 7.80(2H, d, J=5.1Hz), 8.70(2H, d, J=5.1Hz) (CDCl3) XA2012 2.31(3.6H, s), 3.16(4H, t, J=4.8Hz), 433 3.44(3H, s), 3.45(4H, m), 3.75(4H, t, J=4.8Hz), 3.86(1H, d, J=14.0Hz), 3.92(1H, d, J=12.4Hz), 4.56(1H, d, J=10.4Hz), 6.95(1H, s), 7.06(2H, d, J=8.8Hz), 7.43(2H, d, J=8.8Hz), 8.06(2H, d, J=6.0Hz), 8.75(2H, d, J=6.0Hz), 9.03(1H, s), 9.33(1H, d, J=10.0Hz) (DMSO-d6) XA2013 1.82(4H, m), 1.97(2H, m), 2.12(2H, m), 500 2.77(2H, t, J=11.6Hz), 3.01(2H, m), 3.27(1H, m), 3.40(2H, m), 3.45(3H, s), 3.49(2H, m), 3.57(1H, m), 3.63(1H, m), 3.84(1H, d, J=13.6Hz), 3.92(3H, d, J=12.8Hz), 4.53(1H, t, J=11.2Hz), 7.12(2H, d, J=8.4Hz), 7.14(1H, s), 7.58(2H, d, J=8.9Hz), 8.49(2H, d, J=5.2Hz), 8.97(2H, d, J=5.2Hz), 9.82(1H, br s), 10.24(1H, br s), 11.12(1H, br s) (DMSO-d6) XA2014 1.75(2H, m), 2.14(2H, m), 2.72(6H, d, J=4.5Hz), 474 2.74-2.80(3H, m), 3.30-3.95(8H, m), 3.45(3H, s), 4.54(1H, m), 7.10(2H, d, J=9.0Hz), 7.15(1H, s), 7.60(2H, d, J=9.0Hz), 8.51(2H, d, J=6.6Hz), 8.98(2H, d, J=6.6Hz), 9.86(1H, m), 10.32(1H, m), 10.93(1H, m), (DMSO-d6) XA2015 1.68(2H, m), 2.09(2H, m), 3.16-3.90(10H, 447 m), 3.45(3H, s), 4.60(1H, m), 7.13(1H, s), 7.45-7.71(4H, m), 8.45(2H, d, J=6.0Hz), 8.94(2H, d, J=6.0Hz), 9.83(1H, m), 10.22(1H, m) (DMSO-d6) XA2016 1.91-2.03(2H, m), 3.09(1H, m), 433 3.28-3.57(7H, m), 3.40(3H, s), 4.41(2H, m), 6.58(2H, d, J=8.7Hz), 7.13(1H, s), 7.46(2H, d, J=8.7Hz), 8.44(2H, d, J=6.3Hz), 8.94(2H, d, J=6.3Hz), 9.61(1H, m), 9.89(1H, m) (DMSO-d6) XA2017 2.97(6H, s), 3.45(3H, s), 4.20-3.30(6H, m), 391 4.53(1H, t, J=9.8Hz), 6.69(2H, br s), 7.14(1H, s), 7.57(2H, br s), 8.48(2H, br s), 8.96(2H, br s), 9.72(1H, br s), 10.09(1H, br s) (DMSO-d6) XA2018 3.18-3.22(1H, m), 3.44-3.80(15H, m), 566 4.51-4.55(1H, m), 5.11(2H, s), 7.04-7.07(3H, m), 7.32-7.39(5H, m), 7.52-7.55(2H, m), 8.33-8.35(2H, m), 8.82-8.87(2H, m), 9.65-9.75(2H, br) (DMSO-d6) XA2019 1.32(6H, d, J=6.8Hz), 3.04-3.88(18H, m), 474 4.52-4.55(1H, m), 7.09-7.12(3H, m), 7.62(2H, d, J=7.2Hz), 8.45(2H, d, J=4.2Hz), 8.94(2H, d, J=4.2Hz), 9.83-10.34(3H, br), 11.00-11.04(1H, br) (DMSO-d6) XA2020 1.32(6H, d, J=6.8Hz), 3.04-3.88(18H, m), 476 4.52-4.55(1H, m), 7.09-7.12(3H, m), 7.62(2H, d, J=7.2Hz), 8.45(2H, d, J=4.2Hz), 8.94(2H, d, J=4.2Hz), 9.83-10.34(3H, br), 11.00-11.04(1H, br) (DMSO-d6) XA2021 2.09(3H, s), 3.19-4.00(20H, m), 518 4.43-4.54(3H, m), 7.06-7.19(3H, m), 7.62(2H, d, J=7.2Hz), 8.44(2H, d, J=4.2Hz), 8.94(2H, d, J=4.2Hz), 9.82-9.85(1H, br), 10.26-10.30(1H, br), 11.30-11.40(1H, br) (DMSO-d6) XA2022 3.17-3.21(4H, m), 3.38-4.16(14H, m), 432 4.51-4.54(1H, m), 7.08-7.18(3H, m), 7.60(2H, d, J=7.2Hz), 8.43(2H, d, J=4.2Hz), 8.93(2H, d, J=4.2Hz), 9.26-9.34(2H, br), 9.81-84(1H, br), 10.25-10.30(1H, br) (DMSO-d6) XA2023 1.82(3H, m), 3.29(3H, m), 3.40-3.96(9H, m), 445 3.48(3H, s), 4.55(1H, m), 7.10(1H, s), 7.13(2H, d, J=8.4Hz), 7.56(2H, d, J=8.4Hz), 8.39(2H, d, J=6.0Hz), 8.91(2H, d, J=6.0Hz), 9.67(1H, m), 9.97(1H, m) (DMSO-d6) XA2024 1.89-2.03(2H, m), 2.95-3.07(5H, m), 433 3.29-3.83(5H, m), 3.40(3H, s), 4.40(1H, m), 4.94(1H, m), 6.49(2H, d, J=8.4Hz), 7.13(1H, s), 7.25(2H, d, J=8.4Hz), 7.95(2H, d, J=6.0Hz), 8.69(2H, d, J=6.0Hz) (DMSO-d6) XA2025 1.16(6H, d, J=6.3Hz), 2.28-2.36(2H, m), 460 2.97-3.21(6H, m), 3.54(3H, s), 3.55-3.62(4H, m), 3.95(1H, m), 6.66(1H, s), 6.93(2H, d, J=8.7Hz), 7.32(2H, d, J=8.7Hz), 7.80(2H, d, J=6.3Hz), 8.70(2H, d, J=6.3Hz) (CDCl3) XA2026 1.26(6H, d, J=6.3Hz), 2.42(2H, dd, J=11.1, 461 11.1Hz), 3.02(1H, dd, J=12.3, 10.8Hz), 3.17-3.22(3H, m), 3.45-3.63(4H, m), 3.55(3H, s), 3.81(1H, m), 3.95(1H, dd, J=13.2, 2.1Hz), 6.66(1H, s), 6.92(2H, d, J=8.4Hz), 7.34(2H, d, J=8.4Hz), 7.80(2H, d, J=6.0Hz), 8.70(2H, d, J=6.0Hz) (CDCl3) XA2027 2.91-3.09(5H, m), 3.26(3H, s), 3.46(3H, s), 502 3.69-3.73(2H, m), 4.07-4.11(1H, m), 6.81(1H, s), 7.64(2H, d, J=7.2Hz), 7.77(2H, d, J=7.2Hz), 7.94-8.02(6H, m), 8.68(1H, d, J=4.2Hz) (DMSO-d6) XA2028 3.28-3.32(4H, m), 3.46(3H, s), 3.86-3.91(2H, 449 m), 4.59-4.61(1H, m), 6.90(1H, s), 7.77-8.06(10H, m), 8.70(2H, d, J=4.2Hz), 9.36-9.44(1H, br) (DMSO-d6) XA2029 3.08(1H, dd, J=12.4, 10.4Hz), 3.25(3H, 508 m), 3.58(3H, s), 3.68(2H, m), 4.09(1H, dd, J=10.4, 2.4Hz), 6.68(1H, s), 7.29(2H, d, J=8.4Hz), 7.54(2H, d, J=8.4Hz), 7.56(2H, d, J=8.4Hz), 7.59(2H, d, J=8.4Hz), 7.81(2H, dd, J=4.4, 1.6Hz), 8.71(2H, dd, J=4.4, 1.6Hz) (CDCl3) XA2030 3.08(1H, dd, J=12.4, 10.4Hz), 3.27(3H, 492 m), 3.58(3H, s), 3.70(2H, m), 4.11(1H, dd, J=10.4, 2.4Hz), 6.68(1H, s), 7.57(2H, d, J=8.0Hz), 7.63(2H, d, J=8.0Hz), 7.70(4H, s), 7.81(2H, dd, J=4.8, 1.2Hz), 8.71(2H, dd, J=4.8, 1.2Hz) (CDCl3) XA2031 1.45(3H, t, J=12.4Hz), 3.08(1H, dd, J=12.4, 468 10.8Hz), 3.24(3H, m), 3.57(3H, s), 3.67(2H, m), 4.07(1H, m), 4.09(2H, q, J=7.0Hz), 6.67(1H, s), 6.97(2H, d, J=8.4Hz), 7.51(2H, d, J=8.4Hz), 7.51(2H, d, J=8.4Hz), 7.54(2H, d, J=8.4Hz), 7.57(2H, d, J=8.4Hz), 7.81(2H, dd, J=4.8, 1.2Hz), 8.71(2H, dd, J=4.8, 1.2Hz) (CDCl3) XA2032 1.94(4H, m), 2.02(1H, m), 2.21(1H, m), 468 2.62(4H, m), 2.91(1H, m), 3.03(1H, dd, J=12.4, 10.4Hz), 3.20(4H, m), 3.33(1H, m), 3.48(2H, m), 3.54(3H, s), 3.62(2H, m), 3.91(1H, dd, J=10.4, 2.4Hz), 6.55(2H, d, J=8.4Hz), 6.66(1H, s), 7.29(2H, d, J=8.4Hz), 7.81(2H, dd, J=4.4, 0.8Hz), 8.70(2H, dd, J=4.4, 0.8Hz) (CDCl3) XA2033 2.29(3H, s), 3.06(4H, t, J=4.8Hz), 3.38(4H, t, 427 J=4.8Hz), 3.51(3H, s), 5.70(1H, s), 6.67(1H, s), 7.24-7.29(5H, m), 7.83(2H, dd, J=1.6, 4.3Hz), 8.72(2H, dd, J=1.3, 4.5Hz) (CDCl3) XA2034 3.09(1H, dd, J=12.0, 10.8Hz), 3.23(3H, 484 m), 3.57(3H, s), 3.66(2H, m), 3.82(3H, s), 3.86(3H, s), 4.06(1H, dd, J=10.8, 2.4Hz), 6.58(2H, m), 6.67(1H, s), 7.24(2H, m), 7.47(2H, d, J=8.0Hz), 7.53(2H, d, J=8.0Hz), 7.82(2H, dd, J=4.8, 1.2Hz), 8.71(2H, dd, J=4.8, 1.2Hz) (CDCl3) XA2035 3.08(3H, dd, J=12.4, 10.8Hz), 3.25(3H, 484 m), 3.57(3H, s), 3.67(2H, m), 3.93(3H, s), 3.96(3H, s), 4.08(1H, dd, J=10.0, 2.0Hz), 6.68(1H, s), 6.95(1H, d, J=8.4Hz), 7.11(1H, d, J=2.4Hz), 7.16(1H, dd, J=8.4, 2.4Hz), 7.51(2H, d, J=8.0Hz), 7.58(2H, d, J=8.0Hz), 7.81(2H, dd, J=4.8, 1.2Hz), 8.71(2H, dd, J=4.8, 1.2Hz) (CDCl3) XA2036 3.08(1H, dd, J=12.4, 10.8Hz), 3.26(3H, 458 m), 3.57(3H, s), 3.67(2H, m), 4.09(1H, dd, J=10.0, 2.0Hz), 6.68(1H, s), 7.42(2H, d, J=8.4Hz), 7.53(4H, d, J=8.4Hz), 7.58(2H, d, J=8.4Hz), 7.80(2H, dd, J=4.8, 1.6Hz), 8.71(2H, dd, J=4.8, 1.6Hz) (CDCl3) XA2037 3.09(1H, dd, J=12.4, 10.8Hz), 3.25(3H, 492 m), 3.58(3H, s), 3.69(2H, m), 4.11(1H, dd, J=10.4, 2.4Hz), 6.68(1H, s), 7.28(2H, m), 7.44(2H, d, J=8.0Hz), 7.51(3H, m), 8.81(2H, dd, J=4.0, 1.2Hz), 8.72(2H, dd, J=4.0, 1.2Hz) (CDCl3) XA2038 3.07(1H, dd, J=12.3, 11.0Hz), 3.26(3H, 492 m), 3.57(3H, s), 3.67(2H, m), 4.10(1H, dd, J=10.2, 2.1Hz), 6.68(1H, s), 7.42(1H, dd, J=8.1, 2.2Hz), 7.55(5H, m), 7.68(1H, d, J=2.2Hz), 7.80(2H, dd, J=4.8, 1.3Hz), 8.71(2H, dd, J=4.8, 1.3Hz) (CDCl3) XA2039 3.06(1H, dd, J=12.0, 10.8Hz), 3.24(3H, 416 m), 3.58(3H, s), 3.67(2H, m), 4.13(1H, dd, J=10.4, 2.4Hz), 6.68(1H, s), 7.61(2H, d, J=8.4Hz), 7.80(2H, d, J=4.4Hz), 8.15(2H, d, J=8.4Hz), 8.71(2H, d, J=4.4Hz), 8.77(1H, s) (CDCl3) XA2040 3.04-3.26(4H, m), 3.57(3H, s), 3.66-3.71(2H, 530 m), 4.07(1H, m), 5.12(2H, s), 6.68(1H, s), 7.06(2H, d, J=8.7Hz), 7.40-7.59(11H, m), 7.81(2H, d, J=6.0Hz), 8.71(2H, d, J=6.0Hz) (CDCl3) XA2041 0.38(2H, m), 0.67(2H, m), 1.32(1H, m), 494 3.09(1H, dd, J=12.6, 11.1Hz), 3.22-3.28(3H, m), 3.58(3H, s), 3.67-3.71(2H, m), 3.86(2H, d, J=6.9Hz), 4.08(1H, m), 6.68(1H, s), 7.06(2H, d, J=9.0Hz), 7.49-7.60(6H, m), 7.82(2H, d, J=6.0Hz), 8.72(2H, d, J=6.0Hz) (CDCl3) XA2042 1.37(6H, d, J=6.0Hz), 3.08(1H, dd, J=12.3, 482 11.1Hz), 3.20-3.28(3H, m), 3.57(3H, s), 3.65-3.70(2H, m), 4.06(1H, m), 4.59(1H, m), 6.67(1H, s), 7.06(2H, d, J=9.0Hz), 7.48-7.59(6H, m), 7.81(2H, d, J=6.0Hz), 8.71(2H, d, J=6.0Hz) (CDCl3) XA2043 0.99(3H, t, J=7.5Hz), 1.40-1.85(4H, m), 496 3.05-3.30(4H, m), 3.57(3H, s), 3.65-3.70(2H, m), 4.00-4.10(3H, m), 6.67(1H, s), 6.97(2H, d, J=8.7Hz), 7.50-7.56(6H, m), 7.81(2H, d, J=6.0Hz), 8.71(2H, d, J=6.0Hz) (CDCl3) XA2044 1.66(1H, br.s), 2.52(3H, s), 3.05(1H, dd, 469 J=10.5, 12.6Hz), 3.20-3.26(3H, m), 3.57(3H, s), 3.62-3.72(2H, m), 4.07(1H, dd, J=2.1, 10.5Hz), 6.67(1H, s), 7.33(2H, d, J=8.4Hz), 7.50-7.61(6H, m), 7.81(2H, dd, J=1.6, 4.3Hz), 8.70(2H, dd, J=1.3, 4.5Hz) (CDCl3) XA2045 1.72(1H, br.s), 2.40(3H, s), 2.98-3.26(5H, 437 m), 3.57(3H, s), 3.57-3.67(1H, m), 4.07(1H, dd, J=2.1, 10.5Hz), 6.67(1H, s), 7.24(2H, d, J=8.1Hz), 7.49-7.52(4H, m), 7.60(2H, d, J=8.1Hz), 7.81(2H, dd, J=1.6, 4.3Hz), 8.70(2H, dd, J=1.3, 4.5Hz) (CDCl3) XA2046 1.36(9H, s), 1.72(1H, br.s), 3.06(1H, dd, 479 J=10.5, 12.4Hz), 3.20-3.28(3H, m), 3.57(3H, s), 3.57-3.67(2H, m), 4.07(1H, dd, J=2.1, 10.5Hz), 6.67(1H, s), 7.24(2H, d, J=8.1Hz), 7.43-7.56(6H, m), 7.81(2H, dd, J=1.6, 4.3Hz), 8.71(2H, dd, J=1.3, 4.5Hz) (CDCl3) XA2047 1.29(6H, d, J=6.9Hz), 1.73(1H, br.s), 465 2.96(1H, m), 3.06(1H, dd, J=10.5, 12.4Hz), 3.21-3.29(3H, m), 3.57(3H, s), 3.62-3.71(2H, m), 4.07(1H, dd, J=2.1, 10.5Hz), 6.67(1H, s), 7.31(2H, d, J=8.1Hz), 7.45-7.54(4H, m), 7.63(2H, d, J=8.1Hz), 7.81(2H, dd, J=1.6, 4.3Hz), 8.71(2H, dd, J=1.3, 4.5Hz), (CDCl3) XA2048 1.68(2H, br.s), 2.98(1H, dd, J=10.5, 12.6Hz), 438 3.20-3.27(2H, m), 3.56(3H, s), 3.64-3.74(1H, m), 4.04(1H, dd, J=3.3, 11.1Hz), 4.80(3H, s), 6.66(1H, s), 6.72(2H, d, J=8.5Hz), 7.49-7.52(4H, m), 7.63(2H, d, J=8.1Hz), 7.81(2H, dd, J=1.6, 4.3Hz), 8.70(2H, dd, J=1.3, 4.5Hz) (DMSO-d6) XA2049 2.67(3H, s), 3.06(1H, dd, J=12.4, 10.8Hz), 430 3.25(3H, m), 3.57(3H, s), 3.62(2H, m), 4.12(1H, dd, J=10.0, 2.0Hz), 6.68(1H, s), 7.59(2H, d, J=8.0Hz), 7.80(1H, dd, J=4.8, 1.2Hz), 8.09(1H, d, J=8.0Hz), 8.71(1H, dd, J=4.8, 1.2Hz) (CDCl3) XA2050 3.05(1H, m), 3.30-3.48(3H, m), 3.64(3H, s), 560 4.08-4.22(2H, m), 4.68(1H, m), 5.15(1H, d, J=12.3Hz), 5.21(1H, d, J=12.6Hz), 6.63(1H, s), 7.21(2H, d, J=8.4Hz), 7.28-7.39(7H, m), 7.59(2H, d, J=6.3Hz), 8.68(2H, d, J=6.3Hz) (CDCl3) XA2051 2.88-3.34(6H, m), 3.67(3H, s), 4.56(1H, dd, 426 J=9.9, 3.3Hz), 6.62(1H, s), 7.19(2H, d, J=10.8Hz), 7.36(2H, d, J=10.8Hz), 7.58(2H, dd, J=4.5, 1.5Hz), 8.67(2H, dd, J=4.5, 1.5Hz) (CDCl3) XA2052 3.04(1H, m), 3.29-3.48(3H, m), 3.64(3H, s), 560 4.10-4.15(2H, m), 4.68(1H, m), 5.15(1H, d, J=12.3Hz), 5.21(1H, d, J=12.6Hz), 6.63(1H, s), 7.21(2H, d, J=8.1Hz), 7.32-7.39(7H, m), 7.59(2H, d, J=6.0Hz), 8.68(2H, d, J=6.0Hz) (CDCl3) XA2053 3.01(1H, m), 3.29-3.41(3H, m), 3.66(3H, s), 527 4.05-4.13(2H, m), 4.67(1H, m), 6.64(1H, s), 7.23(2H, d, J=8.4Hz), 7.41(2H, d, J=8.4Hz), 7.60(2H, dd, J=4.5, 1.5Hz), 8.69(2H, dd, J=4.5, 1.5Hz) (CDCl3) XA2054 2.28(3H, s), 3.07(4H, m), 3.59(4H, m), 445 3.73(3H, s), 5.78(1H, s), 6.70(1H, s), 6.98(1H, m), 7.40(1H, m), 7.60-7.66(2H, m), 7.81(2H, dd, J=1.6, 4.3Hz), 8.72(2H, dd, J=1.3, 4.5Hz) (CDCl3) XA2055 2.31(3H, s), 3.19(4H, m), 3.46(4H, m), 428 3.54(3H, s), 5.79(1H, s), 6.69(1H, s), 7.18-7.23(1H, m), 7.79(2H, d, J=5.4Hz), 7.79-7.87(2H, m), 8.54(1H, d, J=5.2Hz), 8.72(2H, d, J=4.5Hz) (CDCl3) XB13 1.16-1.28(1H, m), 1.50-1.64(1H, m), 361 1.70-1.82(2H, m), 1.90-2.01(1H, m), 2.58(2H, d, J=7.3Hz), 2.64-2.72(1H, m), 2.89-2.97(1H, m), 3.28(3H, s), 3.57-3.67(2H, m), 6.93(1H, s), 7.20-7.35(5H, m), 8.26(2H, d, J=5.7Hz), 8.87(2H, d, J=5.9Hz) (DMSO-d6) XB16 1.75-2.16(4H, m), 2.96-3.08(3H, m, 3.55(3H, 347 s), 3.69-3.79(2H, m), 6.66(1H, s), 7.26-7.40(5H, m), 7.81(2H, d, J=6.0Hz), 8.70(2H, d, J=6.0Hz) (CDCl3) XB17 1.76-1.99(5H, m), 2.97-3.10(2H, m), 365 3.75(1H, d, J=12.4Hz), 6.81(1H, s), 7.18-7.24(2H, m), 7.28-7.35(1H, m), 7.47(1H, t, J=7.1Hz), 7.98(2H, d, J=5.8Hz), 8.68(2H, d, J=5.8Hz) (DMSO-d6) XB19 1.86-2.14(4H, m), 2.94-3.03(3H, m), 365 3.55(3H, s), 3.68-3.75(2H, m), 6.66(1H, s), 7.05(2H, m), 7.23(2H, m), 7.80(2H, d, J=6.3Hz), 8.70(2H, d, J=6.3Hz) (CDCl3) XB33 1.75-2.08(4H, m), 2.80(1H, m), 3.03(1H, m), 377 3.42(3H, s), 3.77(2H, m), 3.85(3H, s), 6.65(1H, s), 6.89-7.00(2H, m), 7.22-7.28(2H, m), 7.82(2H, d, J=6.0Hz), 8.70(2H, d, J=6.0Hz) (CDCl3) XB35 1.73-1.83(4H, m), 2.90-3.02(3H, m), 377 3.42(3H, s), 3.67-3.81(2H, m), 3.74(3H, s), 6.80(1H, s), 6.91(2H, d, J=8.7Hz), 7.27(2H, d, J=8.5Hz), 7.97(2H, d, J=5.9Hz), 8.69(2H, d, J=5.7Hz) (DMSO-d6) XB43 1.69-1.90(7H, m), 1.94-2.00(1H, m), 430 2.59-2.68(4H, m), 2.92-3.02(3H, m), 3.43(3H, s), 3.69-3.80(4H, m), 6.59(3H, s), 6.79(1H, s), 7.29-7.36(4H, m), 7.96(2H, d, J=5.9Hz), 8.68(2H, d, J=5.1Hz) (DMSO-d6) XB46 (CDCl3):1.95-2.09(3H, m), 2.39(1H, m), 388 3.15(1H, m), 3.45(1H, dd, J=12.9, 10.8Hz), 3.57(3H, s), 3.61-3.72(2H, m), 4.08(1H, m), 6.67(1H, s), 7.32(1H, m), 7.58-7.60(2H, m), 7.74(1H, d, J=7.8Hz), 7.80(2H, dd, J=4.5, 1.5Hz), 8.69(2H, dd, J=4.5, 1.5Hz). XB47 (CDCl3):1.90-2.06(3H, m), 2.36(1H, m), 406 3.14(1H, m), 3.42(1H, m), 3.57(3H, s), 3.61-3.71(2H, m), 4.06(1H, m), 6.68(1H, s), 7.09(1H, m), 7.28(1H, m), 7.68(1H, dd, J=8.8, 5.1Hz), 7.79(2H, d, J=4.7Hz), 8.69(2H, d, J=5.9Hz). XB48 1.90-2.10(3H, m), 2.32-2.44(1H, m), 388 3.11-3.20(1H, m), 3.45(1H, dd, J=10.5, 12.6Hz), 3.57(3H, s), 3.61-3.72(2H, m), 4.08(1H, d, J=11.1Hz), 6.67(1H, s), 7.30-7.35(1H, m), 7.56-7.62(2H, m), 7.74(1H, d, J=13.8Hz), 7.80(2H, dd, J=1.8, 4.5Hz), 8.70(2H, dd, J=1.8, 4.8Hz) (CDCl3) XB49 1.91-2.09(3H, m), 2.37-2.42(1H, m), 388 3.12-3.19(1H, m), 3.45(1H, dd, J=10.8, 12.9Hz), 3.57(3H, s), 3.60-3.72(2H, m), 4.08(1H, d, J=11.1Hz), 6.67(1H, s), 7.30-7.35(1H, m), 7.54-7.62(2H, m), 7.75(1H, d, J=8.1Hz), 7.80(2H, dd, J=1.5, 4.5Hz), 8.70(2H, dd, J=1.8, 4.5Hz) (CDCl3) XB50 1.59-1.67(1H, m), 1.72-1.81(1H, m), 363 2.08(1H, dt, J=3.4, 12.7Hz), 2.23-2.40(1H, m), 3.06-3.14(1H, m), 3.41-3.54(2H, m), 3.42(3H, s), 3.93(1H, d, J=14.0Hz), 7.02(1H, s), 7.24-7.29(1H, m), 7.34-7.39(2H, m), 7.56-7.59(2H, m), 8.55(2H, d, J=6.6Hz), 8.98(2H, d, J=6.5Hz) (DMSO-d6) XB80 2.21-2.36(4H, m), 3.19-3.31(2H, m), 372 3.46(3H, s), 3.88(2H, d, J=13.2Hz), 6.86(1H, s), 7.38-7.42(1H, m), 7.46-7.51(2H, m), 7.58-7.64(2H, m), 8.01(2H, d, J=5.1Hz), 8.70(2H, d, J=5.1Hz) (DMSO-d6) XB122 1.44(2H, m), 1.75-1.83(3H, m), 2.63(2H, d, J=6.9Hz), 361 2.90(2H, m), 3.51(3H, s), 3.64(2H, m), 6.65(1H, s), 7.17-7.34(5H, m), 7.80(2H, d, J=6.3Hz), 8.70(2H, d, J=6.3Hz) (CDCl3) XB123 1.44-2.16(5H, m), 2.86-2.97(2H, m), 395 3.49(3H, s), 3.62(1H, m), 3.72(1H, m), 4.48(1H, d, J=7.2Hz), 6.64(1H, s), 7.07(2H, m), 7.32(2H, m), 7.79(2H, d, J=6.3Hz), 8.69(2H, d, J=6.3Hz) (CDCl3) XB124 1.38-1.60(3H, m), 1.78(1H, m), 2.16(1H, m), 409 2.79-2.94(2H, m), 3.20(3H, s), 3.49(3H, s), 3.59(1H, m), 3.69(1H, m), 3.88(1H, d, J=7.5Hz, 1H), 6.64(1H, s), 7.08(2H, m), 7.25(2H, m), 7.79(2H, d, J=6.0Hz), 8.70(2H, d, J=6.0Hz) (CDCl3) XB127 1.87-2.06(4H, m), 2.79(1H, m), 3.10(2H, m), 347 3.57(3H, s), 3.78(2H, m), 6.68(1H, s), 7.23-7.29(3H, m), 7.34(2H, m), 7.84(2H, d, J=6.0Hz), 8.72(2H, d, J=6.0Hz) (CDCl3) XB130 1.81-2.03(4H, m), 2.78(1H, m), 3.09(2H, m), 365 3.57(3H, s), 3.79(2H, m), 6.69(1H, s), 7.03(2H, m), 7.23(2H, m), 7.84(2H, d, J=5.4Hz), 8.72(2H, br s) (CDCl3) XB134 1.78-1.95(4H, m), 2.80-2.91(1H, m), 415 2.96-3.09(2H, m), 3.45(3H, s), 3.81(2H, d, J=13.1Hz), 6.80(1H, s), 7.33(1H, dd, J=2.0, 8.3Hz), 7.56-7.60(2H, m), 7.99(2H, dd, J=1.6, 4.5Hz), 8.69(2H, dd, J=1.5, 4.5Hz) (DMSO-d6) XB145 1.82-2.02(4H, m), 3.09-3.27(3H, m), 377 3.57(3H, s), 3.79(2H, m), 3.86(3H, s), 6.67(1H, s), 6.89-6.99(2H, m), 7.21-7.26(2H, m), 7.84(2H, d, J=6.0Hz), 8.72(2H, d, J=6.0Hz) (CDCl3) XB157 1.85-2.07(2H, m), 2.17-2.30(2H, m), 405 2.91-3.10(1H, m), 3.10-3.24(2H, m), 3.57(3H, s), 3.71-3.88(2H, m), 6.69(1H, s), 6.99-7.06(1H, m), 7.21(1H, dd, J=2.1, 8.7Hz), 7.45(1H, s), 7.49-7.65(1H, m), 7.83(2H, dd, J=1.8, 4.5Hz), 8.72(2H, dd, J=1.2, 4.8Hz) (CDCl3) XB158 2.22-2.32(4H, m), 3.22(2H, m), 3.37(1H, m), 406 3.58(3H, s), 3.82(2H, m, 6.71(1H, s), 7.10(1H, m), 7.29(1H, m), 7.67(1H, m), 7.83(2H, d, J=6.3Hz), 8.72(2H, d, J=6.3Hz) (CDCl3) XB159 2.19-2.26(4H, m), 3.21(2H, m), 3.35(1H, m), 405 3.59(3H, s), 3.82(2H, m), 6.70(1H, s), 6.95(1H, dt, J=9.0, 2.1Hz), 7.13(1H, dd, J=9.0, 2.1Hz), 7.71(1H, m), 7.85(2H, d, J=6.3Hz), 8.72(2H, d, J=6.3Hz) (CDCl3) XB160 2.13-2.34(2H, m), 2.34-2.43(2H, m), 388 3.10-3.38(3H, m), 3.57(3H, s), 3.68-3.83(2H, m), 6.69(1H, s), 7.29-7.40(2H, m), 7.46-7.59(1H, m), 7.64-7.78(1H, m), 7.80-7.78(2H, m), 8.72(2H, d, J=6.0Hz) (CDCl3) XB161 2.19(2H, m), 2.38(2H, m), 3.18(2H, m), 404 3.39(1H, m), 3.58(3H, s), 3.80(2H, m), 6.70(1H, s), 7.39(1H, m), 7.50(1H, m), 7.83(2H, d, J=6.0Hz), 7.89(1H, d, J=7.2Hz), 8.01(1H, d, J=7.8Hz), 8.73(2H, d, J=6.0Hz) (CDCl3) XB162 1.96(2H, m), 2.88(2H, m), 3.15(2H, m), 420 3.60(3H, s), 3.85(2H, m), 4.63(1H, m), 6.73(1H, s), 7.13-7.23(3H, m), 7.46(1H, d, J=7.5Hz), 7.84(2H, d, J=6.3Hz), 8.73(2H, d, J=6.3Hz) (CDCl3) XB164 1.64(2H, m), 2.23(2H, m), 3.13(2H, m), 380 3.50(1H, m), 3.53(3H, s), 3.68(2H, m), 6.58(2H, m), 6.68(1H, s), 6.91(2H, m), 7.81(2H, d, J=6.0Hz), 8.72(2H, d, J=6.0Hz) (CDCl3) XB165 1.91-1.99(4H, m), 2.84(3H, s), 3.07(2H, m), 376 3.55(3H, s), 3.77(2H, m), 3.84(1H, m), 6.69(1H, s), 6.75-6.87(3H, m), 7.27(2H, m), 7.82(2H, d, J=6.3Hz), 8.72(2H, d, J=6.3Hz) (CDCl3) XB168 1.52(2H, m), 1.79(3H, s), 1.96(2H, m), 422 3.09(2H, m), 3.42(3H, s), 3.64(2H, m), 4.86(1H, m), 6.63(1H, s), 7.09-7.19(4H, m), 7.74(2H, d, J=6.0Hz), 8.70(2H, d, J=6.0Hz) (CDCl3) XB169 1.86(1H, br s), 1.95(2H, m), 2.30(2H, m), 363 3.47-3.63(7H, m), 6.68(1H, s), 7.30-7.44(3H, m), 7.54(2H, d, J=7.5Hz), 7.84(2H, d, J=6.0Hz), 8.71(2H, d, J=6.0Hz) (CDCl3) XB201 2.20-2.31(4H, m), 3.20-3.29(2H, m), 390 3.46(3H, s), 3.87(2H, d, J=13.8Hz), 6.86(1H, s), 7.29-7.35(2H, m), 7.64-7.69(2H, m), 8.01(2H, dd, J=1.5, 4.5Hz), 8.70(2H, dd, J=1.5, 4.5Hz) (DMSO-d6) XB227 2.16-2.25(2H, m), 2.48-2.58(2H, m), 389 3.14-3.21(2H, m), 3.40(3H, s), 3.41-3.50(2H, m), 6.79(1H, s), 7.28-7.33(1H, m), 7.39-7.46(4H, m), 7.97(2H, dd, J=1.5, 4.5Hz), 8.68(2H, dd, J=1.5, 4.5Hz) (DMSO-d6) XB256 1.77-1.85(8H, m), 2.10(1H, m), 2.51(4H, m), 430 2.97-3.02(3H, m), 3.58(3H, s), 3.55(3H, s), 3.62(2H, s), 3.74(1H, m), 6.66(1H, s), 7.16(2H, d, J=7.8Hz), 7.32(1H, d, J=7.8Hz), 7.80(2H, dd, J=1.5, 4.8Hz), 8.70(2H, dd, J=1.5, 4.8Hz) (CDCl3) XB257 1.77-1.85(8H, m), 2.10(1H, m), 2.51(4H, m), 430 2.97-3.02(3H, m), 3.58(3H, s), 3.55(3H, s), 3.62(2H, s), 3.74(1H, m), 6.66(1H, s), 7.16(2H, d, J=7.8Hz), 7.32(1H, d, J=7.8Hz), 7.80(2H, dd, J=1.5, 4.8Hz), 8.70(2H, dd, J=1.5, 4.8Hz) (CDCl3) XB258 1.86(4H, m), 1.99(4H, m), 3.03(5H, m), 429 3.35(4H, m), 3.43(3H, s), 3.73(2H, m), 4.30(2H, s), 6.81(1H, s), 7.43(2H, d, J=8.1Hz), 7.69(2H, d, J=8.1Hz), 7.97(2H, d, J=6.0Hz), 8.69(2H, d, J=6.0Hz), 11.01(1H, br s) (DMSO-d6) XB259 1.75(1H, m), 1.89(3H, m), 1.97(3H, m), 443 2.13(1H, d, J=13.6Hz), 3.02(3H, m), 3.46(2H, t, J=7.0Hz), 3.55(3H, s), 3.66(2H, t, J=7.0Hz), 3.75(2H, m), 6.66(1H, s), 7.30(2H, d, J=8.0Hz), 7.52(2H, d, J=8.0Hz), 7.80(2H, dd, J=6.0, 1.2Hz), 8.71(2H, dd, J=6.0, 1.2Hz) XB260 1.77-1.86(8H, m), 2.94-3.06(5H, m), 430 3.43(3H, s), 3.73-3.78(2H, m), 4.28-4.31(2H, m), 6.81(1H, s), 7.44(2H, d, J=7.3Hz), 7.57(2H, d, J=7.3Hz), 7.96(2H, d, J=4.2Hz), 8.63(2H, d, J=4.2Hz), 10.75-10.80(1H, br) (DMSO-d6) XB261 1.45-1.59(6H, m), 1.73-1.94(4H, m), 444 2.10-2.15(4H, m), 2.98-3.05(3H, m), 3.49(2H, m), 3.55(3H, s), 3.74-3.77(2H, m), 6.65(1H, s), 7.22(2H, d, J=8.4Hz), 7.33(2H, d, J=8.4Hz), 7.80(2H, d, J=6.0Hz), 8.70(2H, d, J=6.0Hz) (CDCl3) XB262 1.19-1.31(6H, m), 1.80-1.94(7H, m), 472 2.10(1H, m), 2.32(3H, s), 2.45(1H, m), 2.97-3.02(3H, m), 3.54(3H, s), 3.55(2H, m), 3.69-3.74(2H, m), 6.66(1H, s), 7.22(2H, d, J=8.4Hz), 7.33(2H, d, J=8.4Hz), 7.81(2H, d, J=6.0Hz), 8.71(2H, d, J=6.0Hz) (CDCl3) XB263 1.77-1.86(4H, m), 2.44(1H, m), 2.80(6H, s), 473 2.98-3.16(4H, m), 3.42(3H, s), 3.62-3.79(6H, m), 4.42(3H, m), 6.93(1H, s), 7.45(2H, d, J=8.4Hz), 7.58(2H, d, J=8.4Hz), 8.21(2H, d, J=6.0Hz), 8.82(2H, d, J=6.0Hz) (DMSO-d6) XB264 0.99(3H, t, J=7.2Hz), 1.20-1.24(6H, m), 486 1.80-1.93(7H, m), 2.10(1H, m), 2.50-2.55(2H, m), 2.97-3.00(3H, m), 3.55(3H, s), 3.60(2H, s), 3.69-3.74(2H, m), 6.65(1H, s), 7.18(2H, d, J=8.4Hz), 7.34(2H, d, J=8.4Hz), 7.80(2H, d, J=6.0Hz), 8.70(2H, d, J=6.0Hz) (CDCl3) XB265 1.02(6H, d, J=6.6Hz), 1.23-1.28(5H, m), 500 1.72-2.15(9H, m), 2.51(1H, m), 2 97-3.08(4H, m), 3.55(3H, s), 3.70(2H, s), 3.74-3.78(2H, m), 6.65(1H, s), 7.18(2H, d, J=7.8Hz), 7.34(2H, d, J=7.8Hz), 7.81(2H, d, J=6.0Hz), 8.70(2H, d, J=6.0Hz) (CDCl3) XB266 1.77-1.87(4H, m), 2.44(1H, m), 2.80(6H, s), 473 2.99-3.09(4H, m), 3.42(3H, s), 3.62-3.79(6H, m), 4.42(3H, m), 6.95(1H, s), 7.45(2H, d, J=8.1Hz), 7.58(2H, d, J=8.1Hz), 8.29(2H, d, J=6.0Hz), 8.86(2H, d, J=6.0Hz) (DMSO-d6) XB267 1.85-1.88(4H, m), 2.81(1H, m), 425 2.99-3.07(2H, m), 3.44(3H, s), 3.79-3.84(2H, m), 6.82(1H, s), 7.29(2H, d, J=8.4Hz), 7.51(2H, d, J=8.4Hz), 8.01(2H, d, J=6.0Hz), 8.70(2H, d, J=6.0Hz) (DMSO-d6) XB268 1.83-1.99(4H, m), 2.83(1H, m), 425 2.98-3.06(2H, m), 3.45(3H, s), 3.79-3.84(2H, m), 6.82(1H, s), 7.29-7.43(3H, m), 7.53(1H, s), 8.01(2H, d, J=6.0Hz), 8.70(2H, d, J=6.0Hz) (DMSO-d6) XB269 1.74-1.96(8H, m), 2.51(1H, m), 416 2.65-3.01(2H, m), 3.04-3.18(4H, m), 3.44(3H, s), 3.77-3.81(2H, m), 6.49(2H, d, J=8.4Hz), 6.80(1H, s), 7.09(2H, d, J=8.4Hz), 8.00(2H, dd, J=4.5, 1.8Hz), 8.69(2H, dd, J=4.5, 1.8Hz) (DMSO-d6) XB270 1.83-1.99(8H, m), 2.72(1H, m), 416 2.97-3.07(2H, m), 3.19-3.23(4H, m), 3.45(3H, s), 3.78-3.83(2H, m), 6.38(1H, d, J=7.8Hz) 6.44(1H, s), 6.53(1H, d, J=7.5Hz), 6.81(1H, s), 7.09(1H, dd, J=7.8, 7.8Hz), 8.00(2H, d, J=5.4Hz), 8.70(2H, d, J=5.7Hz) (DMSO-d6) XB271 1.81-1.92(2H, m), 2.07-2.15(2H, m), 404 3.02-3.21(3H, m), 3.51(3H, s), 3.79-3.83(2H, m), 6.80-6.86(2H, m), 7.10-7.17(2H, m), 7.58-7.63(1H, m), 8.00(2H, d, J=4.2Hz), 8.69(2H, d, J=4.2Hz), 10.90(1H, brs) (DMSO-d6) XB272 1.53-1.63(2H, m), 2.02-2.07(2H, m), 430 3.11-3.19(2H, m), 3.41(3H, s), 3.60-3.72(3H, m), 6.12(1H, d, J=8.2Hz), 6.79-6.80(2H, m), 6.88-6.91(2H, m), 7.25-7.31(1H, m), 8.00(2H, d, J=4.2Hz), 8.70(2H, d, J=4.2Hz) (DMSO-d6) XB273 1.47-1.57(2H, m), 2.00-2.07(2H, m), 405 2.71(6H, s), 3.04-3.12(2H, m), 3.37-3.42(4H, m), 3.67-3.71(2H, m), 4.87(1H, d, J=8.2Hz), 6.56-6.65(4H, m), 6.79(1H, s), 7.99(2H, d, J=4.2Hz), 8.69(2H, d, J=4.2Hz) (DMSO-d6) XB274 1.51-1.61(2H, m), 2.01-2.07(2H, m), 392 3.08-3.16(2H, m), 3.43(3H, s), 3.50-3.53(1H, m), 3.67(3H, s), 3.70-3.73(2H, m), 5.56(1H, d, J=8.2Hz), 6.09-6.24(3H, m), 6.78(1H, s), 6.96(1H, dd, J=7.2Hz, 7.3Hz), 7.99(2H, d, J=4.2Hz), 8.69(2H, d, J=4.2Hz) (DMSO-d6) XB275 1.48-1.59(2H, m), 2.00-2.07(2H, m), 392 3.06-3.13(2H, m), 3.40(3H, s), 3.44-3.46(1H, m), 3.64(3H, s), 3.66-3.71(2H, m), 5.07(1H, d, J=8.2Hz), 6.59(2H, d, J=7.2Hz), 6.70(2H, d, J=7.2Hz), 6.79(1H, s), 7.98(2H, d, J=4.2Hz), 8.68(2H, d, J=4.2Hz) (DMSO-d6) XB276 1.57-1.68(2H, m), 2.03-2.07(2H, m), 392 3.05-3.09(2H, m), 3.41(3H, s), 3.51-3.77(6H, m), 4.57(1H, d, J=8.2Hz), 6.53-6.58(1H, m), 6.66-6.69(1H, m), 6.74-6.82(3H, m), 7.99(2H, d, J=4.2Hz), 8.68(2H, d, J=4.2Hz) (DMSO-d6) XB277 1.78-1.92(4H, m), 2.94-3.07(5H, m), 406 3.41-3.86(10H, m), 6.88-6.92(1H, m), 7.04(1H, s), 7.21-7.24(2H, m), 7.39-7.44(1H, m), 8.48(2H, d, J=4.2Hz), 8.95(2H, d, J=4.2Hz) (DMSO-d6) XB278 1.68-2.08(4H, m), 2.90-2.96(2H, m), 406 3.15(3H, s), 3.38(3H, s), 3.81-4.04(7H, m), 7.03(1H, s), 7.13(2H, d, J=7.2Hz), 7.81(2H, d, J=7.2Hz), 8.45(2H, d, J=4.2Hz), 8.94(2H, d, J=4.2Hz) (DMSO-d6) XB279 1.76-1.85(4H, m), 2.65(3H, s), 2.85-2.94(2H, 406 m), 3.41-3.42(1H, m), 3.44(3H, s), 3.74-3.79(2H, m), 4.02(3H, s), 6.78(1H, s), 6.83-6.99(4H, m), 7.97(2H, d, J=4.2Hz), 8.68(2H, d, J=4.2Hz) (DMSO-d6) XB280 1.86-1.98(4H, m), 2.98(6H, s), 3.01-3.10(2H, 419 m), 3.40-3.92(11H, m), 7.00-7.13(2H, m), 7.42-7.50(2H, m), 8.51(2H, d, J=4.2Hz), , 8.97(2H, d, J=4.2Hz) (DMSO-d6) XB281 1.69-1.88(3H, m), 1.92-2.00(1H, m), 425 2.92-3.06(3H, m), 3.42(3H, s), 3.63-3.88(2H, m), 6.79(1H, s), 7.33(2H, d, J=8.4Hz), 7.54(2H, d, J=8.4Hz), 7.96(2H, d, J=5.7Hz), 8.68(2H, d, J=6.0Hz) (DMSO-d6) XB282 2.51-2.60(4H, m), 3.47(3H, s), 3.65-3.68(4H, 285 m), 6.54(1H, s), 8.00(2H, d, J=4.2Hz), 8.70(1H, d, J=4.2Hz) (DMSO-d6) XB283 1.71-1.82(4H, m), 2.40-2.49(2H, m), 475 2.50-2.53(4H, m), 2.86-2.94(3H, m), 3.06-3.09(4H, m), 3.41(3H, s), 3.50-3.68(4H, m), 4.43-4.46(1H, m), 6.78(1H, s), 6.89(2H, d, J=7.2Hz), 7.17(2H, d, J=7.2Hz), 7.95(2H, d, J=4.2Hz), 8.67(2H, d, J=4.2Hz) (DMSO-d6) XB284 1.71-1.93(4H, m), 2.86(6H, s), 2.88-2.97(3H, 390 m), 3.41(3H, s), 3.65-3.75(2H, m), 6.73(2H, d, J=7.2Hz), 6.78(1H, s), 7.15(2H, d, J=7.2Hz), 7.96(2H, d, J=4.2Hz), 8.68(2H, d, J=4.2Hz) (DMSO-d6) XB285 1.72-1.83(4H, m), 2.89-2.96(3H, m), 432 3.05-3.09(4H, m), 3.42(3H, s), 3.71-3.75(4H, m), 6.78(1H, s), 6.91(2H, d, J=7.2Hz), 7.20(2H, d, J=7.2Hz), 7.96(2H, d, J=4.2Hz), 8.68(2H, d, J=4.2Hz) (DMSO-d6) XB286 1.52-1.91(10H, m), 2.86-2.94(3H, m), 430 3.07-3.10(4H, m), 3.41(3H, s), 3.66-3.75(2H, m), 6.78(1H, s), 6.89(2H, d, J=7.2Hz), 7.16(2H, d, J=7.2Hz), 7.95(2H, d, J=4.2Hz), 8.68(2H, d, J=4.2Hz) (DMSO-d6) XB287 1.64-1.88(4H, m), 2.21(3H, s), 2.42-2.45(4H, 445 m), 2.89-2.94(3H, m), 3.07-3.11(4H, m), 3.41(3H, s), 3.69-3.75(2H, m), 6.78(1H, s), 6.90(2H, d, J=7.2Hz), 7.18(2H, d, J=7.2Hz), 7.96(2H, d, J=4.2Hz), 8.68(2H, d, J=4.2Hz) (DMSO-d6) XB288 1.43-1.47(2H, m), 1.71-1.90(6H, m), 473 2.19(6H, s), 2.58-2.66(2H, m), 2.87-2.95(2H, m), 2.87-2.98(3H, m), 3.30-3.32(1H, m), 3.41(3H, s), 3.64-3.75(4H, m), 6.78(1H, s), 6.90(2H, d, J=7.2Hz), 7.16(2H, d, J=7.2Hz), 7.96(2H, d, J=4.2Hz), 8.68(2H, d, J=4.2Hz) (DMSO-d6) XB289 1.72-1.94(4H, m), 2.92-2.99(3H, m), 565 3.08-3.11(4H, m), 3.41(3H, s), 3.52-3.56(4H, m), 3.66-3.75(2H, m), 5.11(2H, s), 6.78(1H, s), 6.93(2H, d, J=7.2Hz), 7.20(2H, d, J=7.2Hz), 7.28-7.39(5H, m), 7.95(2H, d, J=4.2Hz), 8.69(2H, d, J=4.2Hz) (DMSO-d6) XB290 1.53-1.63(2H, m), 1.85-1.89(2H, m), 369 2.14(3H, s), 2.31-2.46(8H, m), 2.86-2.94(2H, m), 3.34-3.35(1H, m), 3.39(3H, s), 3.70-3.74(2H, m), 6.79(1H, s), 7.98(2H, d, J=4.2Hz), 8.69(2H, d, J=4.2Hz) (DMSO-d6) XB291 1.52-1.63(2H, m), 1.85-1.90(2H, m), 399 2.34-2.42(11H, m), 2.86-2.94(2H, m), 3.39(3H, s), 3.45-3.50(2H, m), 3.70-3.74(2H, m), 4.38-4.40(1H, m), 6.80(1H, s), 7.98(2H, d, J=4.2Hz), 8.69(2H, d, J=4.2Hz) (DMSO-d6) XB292 1.71-1.83(4H, m), 2.81-3.00(11H, m), 431 3.28-3.30(1H, m), 3.41(3H, s), 3.66-3.75(2H, m), 6.78(1H, s), 6.89(2H, d, J=7.2Hz), 7.17(2H, d, J=7.2Hz), 7.96(2H, d, J=4.2Hz), 8.68(2H, d, J=4.2Hz) (DMSO-d6) XB293 1.43-1.53(2H, m), 1.93-1.98(3H, m), 406 2.63-2.66(1H, m), 2.92-3.00(2H, m), 3.39(3H, s), 3.62-3.79(7H, m), 6.78(1H, s), 6.88-6.97(2H, m), 7.18-7.22(1H, m), 7.35(1H, d, J=7.3Hz), 7.98(2H, d, J=4.2Hz), 8.68(2H, d, J=4.2Hz) (DMSO-d6) XB294 1.42-1.53(2H, m), 1.96-2.08(3H, m), 406 2.61-2.67(1H, m), 2.91-2.99(2H, m), 3.39(3H, s), 3.62-3.80(7H, m), 6.77(1H, s), 6.86(2H, d, J=7.2Hz), 7.25(2H, d, J=7.2Hz), 7.97(2H, d, J=4.2Hz), 8.68(2H, d, J=4.2Hz) (DMSO-d6) XB295 1.81-1.91(2H, m), 2.61-2.20(2H, m), 420 2.96-3.17(6H, m), 3.41-3.47(5H, m), 3.74-3.86(4H, m), 6.90-7.03(3H, m), 7.21-7.29(2H, m), 8.44(2H, d, J=4.2Hz), 8.93(2H, d, J=4.2Hz), 9.30-9.38(2H, br) (DMSO-d6) XB296 1.80-1.91(2H, m), 2.07-2.21(2H, m), 420 2.96-3.11(6H, m), 3.34-3.41(5H, m), 3.69-3.86(4H, m), 6.91(2H, d, J=7.2Hz), 7.05(1H, s), 7.20(2H, d, J=7.2Hz), 8.49(2H, d, J=4.2Hz), 8.96(2H, d, J=4.2Hz), 9.44-9.50(2H, br) (DMSO-d6) XB297 1.41-1.51(2H, m), 1.91-1.96(3H, m), 419 2.61-2.65(1H, m), 2.86(6H, s), 2.91-2.98(2H, m), 3.38(3H, s), 3.61-3.67(4H, m), 6.70(2H, d, J=7.2Hz), 6.77(1H, s), 7.20(2H, d, J=7.2Hz), 7.97(2H, d, J=4.2Hz), 8.68(2H, d, J=4.2Hz) (DMSO-d6) XB298 2.04(2H, d, J=13.1Hz), 2.34(3H, s), 2.53(2H, 426 m), 2.91(2H, m), 3.55(3H, s), 3.70(2H, d, J=13.1Hz), 4.27(1H, m), 6.08(1H, s), 6.86(1H, s), 7.36-7.48(5H, m), 7.80(2H, dd, J=1.6, 4.3Hz), 8.69(2H, dd, J=1.3, 4.5Hz) (CDCl3) XB299 2.06(2H, d, J=13.1Hz), 2.22(2H, m), 2.99(2H, 413 m), 3.13(1H, m), 3.54(3H, s), 3.70(2H, d, J=13.1Hz), 6.68(1H, s), 7.25(1H, s), 7.44-7.48(2H, m), 7.64-7.67(3H, m), 7.78(2H, dd, J=1.6, 4.3Hz), 8.69(2H, dd, J=1.3, 4.5Hz) (CDCl3) XB300 1.75-1.85(4H, m), 2.97-3.10(5H, m), 464 3.43(3H, s), 3.71-3.76(2H, m), 3.88-3.93(2H, m), 6.70(1H, dd, J=7.2, 7.3Hz), 6.79(1H, s), 7.02-7.06(2H, m), 7.15-7.23(3H, m), 7.31-7.35(2H, m), 7.97(2H, d, J=4.2Hz), 8.69(2H, d, J=4.2Hz) (DMSO-d6) XB301 1.09-1.34(5H, m), 1.57-1.88(9H, m), 444 2.78-2.93(3H, m), 3.08-3.18(1H, m), 3.41(3H, s), 3.62-3.74(2H, m), 5.27(1H, d, J=8.2Hz), 6.52(2H, d, J=7.2Hz), 6.79(1H, s), 7.01(2H, d, J=7.2Hz), 7.96(2H, d, J=4.2Hz), 8.68(2H, d, J=4.2Hz) (DMSO-d6) XB302 1.10-1.16(1H, m), 1.32-1.46(4H, m), 458 1.64-1.82(9H, m), 2.68(3H, s), 2.82-2.93(3H, m), 3.41(3H, s), 3.54-3.74(3H, m), 6.72(2H, d, J=7.2Hz), 6.78(1H, s), 7.12(2H, d, J=7.2Hz), 7.95(2H, d, J=4.2Hz), 8.68(2H, d, J=4.2Hz) (DMSO-d6) No. NMR MS[M+1] YA0262 (DMSO-d6): 3.47(3H, s), 3.48-3.66(4H, m), 367 3.89-4.02(2H, m), 4.98(1H, m), 7.06(1H, s), 7.35-7.59(3H, m), 7.99(1H, dd, J=7.2, 6.9Hz), 8.25(1H, dd, J=5.4, 1.2Hz), 9.01(1H, d, J=5.1Hz), 9.31(1H, s), 9.84(1H, m), 10.19(1H, m). YA0263 (CDCl3): 3.01(1H, dd, J=10.5, 12.4Hz), 367 3.10-3.35(3H, m), 3.57(3H, s), 3.55-3.65(2H, m), 4.05(1H, dd, J=2.4, 10.4Hz), 7.00-7.10(1H, m), 7.30(1H, s), 7.22(2H, m), 7.30-7.42(2H, m), 8.15(1H, dd, J=1.3, 5.2Hz), 8.86(1H, d, J=5.2Hz), 9.27(1H, d, J=1.0Hz). YA0264 2.83(1H, dd, J=11.0, 11.9Hz), 2.93(1H, s), 367 2.99-3.10(3H, m), 3.45(3H, s), 3.61-3.69(2H, m), 3.95(1H, dd, J=2.1, 10.3Hz), 6.97(1H, s), 7.19(2H, t, J=8.8Hz), 7.48-7.56(2H, m), 8.17(1H, dd, J=1.0, 5.0Hz), 8.99(1H, d, J=5.1Hz), 9.29(1H, d, J=1.0Hz) (DMSO-d6) YA0264 3.39-3.47(2H, m), 3.45(3H, s), 3.55-3.66(2H, m), 367 (HCl) 3.86-3.96(2H, m), 4.64-4.71(1H, m), 7.05(1H, s), 7.36(2H, t, J=8.7Hz), 7.77-7.81(2H, m), 8.23(1H, dd, J=1.2, 5.1Hz), 9.02(1H, d, J=5.1Hz), 9.32(1H, d, J=1.2Hz), 9.79(1H, d, J=10.2Hz), 10.13-10.28(1H, m) (DMSO-d6) YA0267 (CDCl3): 2.81(1H, dd, J=10.5, 12.6Hz), 383 3.15-3.40(3H, m), 3.50-3.65(4H, m), 3.65-3.80(1H, m), 4.51(1H, dd, J=2.7, 10.5Hz), 7.20-7.45(4H, m), 7.74(1H, dd, J=1.5, 7.5Hz), 8.15-8.20(1H, m), 8.85(1H, d, J=5.1Hz), 9.27(1H, s). YA0268 (CDCl3): 3.00(1H, dd, J=10.5, 12.6Hz), 383 3.10-3.35(3H, m), 3.50-3.70(5H, m), 4.03(1H, dd, J=2.4, 10.5Hz), 7.32(4H, m), 7.50(1H, s), 8.15(1H, dd, J=1.2, 5.1Hz), 8.87(1H, d, J=5.1Hz), 9.27(1H, d, J=1.5Hz). YA0269 3.40-3.50(2H, m), 3.45(3H, s), 3.53-3.65(2H, m), 383 3.87-3.97(2H, m), 4.68(1H, t, J=10.2Hz), 7.05(1H, s), 7.59(2H, d, J=11.1Hz), 7.75(2H, d, J=11.1Hz), 8.22(1H, dd, J=1.5, 5.4Hz), 9.02(1H, d, J=5.1Hz), 9.31(1H, s), 9.83(1H, d, J=9.6Hz), 10.11-10.25(1H, m) (DMSO-d6) YA0274 (DMSO-d6): 3.45(3H, s), 3.40-3.70(4H, m), 427 3.92(2H, t, J=14.1Hz), 4.67(1H, br s), 7.06(1H, s), 7.68(2H, d, J=10.0Hz), 7.72(2H, d, J=10.0Hz), 8.22(1H, d, J=4.8Hz), 9.03(1H, d, J=4.8Hz), 9.31(1H, s), 9.88(1H, br s), 10.22(1H, br s). YA0289 3.38-3.57(4H, m), 3.35(3H, s), 3.89(3H, s), 379 3.91-3.97(2H, m), 4.84-4.94(1H, m), 7.06(1H, s), 7.08-7.15(1H, m), 7.18(1H, d, J=8.4Hz), 7.41-7.49(1H, m), 7.68(1H, d, J=7.6Hz), 8.25(1H, d, J=4.9Hz), 9.04(1H, d, J=5.1Hz), 9.32(1H, s) (DMSO) YA0290 (DMSO-d6): 3.40-3.75(7H, m), 379 3.92(2H, t, J=13.2Hz), 4.64(1H, t, J=9.1Hz), 7.00-7.10(2H, m), 7.23(1H, d, J=7.6Hz), 7.35(1H, s), 7.42(1H, t, J=7.8Hz), 8.23(1H, d, J=5.6Hz), 9.02(1H, d, J=5.2Hz), 9.32(1H, s), 9.65-9.80(1H, brd), 9.90-10.15(1H, brd). YA0291 (DMSO-d6): 3.42(3H, s), 3.36-3.58(4H, m), 379 3.79(3H, s), 3.83-3.95(2H, m), 4.61(1H, m), 7.05(1H, s), 7.07(2H, d, J=8.1Hz), 7.60(2H, d, J=8.7Hz), 8.22(1H, dd, J=5.1, 1.2Hz), 9.02(1H, d, J=5.4Hz), 9.31(1H, s), 9.58-9.74(2H, m). YA0294 1.31(3H, t, J=6.8Hz), 3.44-3.59(2H, m), 3.48(3H, 393 s), 3.87-3.97(2H, m), 4.09-4.20(2H, m), 4.80-4.91(1H, m), 7.06(1H, s), 7.09-7.17(2H, m), 7.44(1H, t, J=7.4Hz), 7.64(1H, d, J=7.5Hz), 8.23(1H, d, J=5.3Hz), 9.03(1H, d, J=5.2Hz), 9.32(1H, s), 9.49-9.60(2H, m) (DMSO-d6) YA0304 (DMSO-d6): 3.45(3H, s), 3.64(3H, m), 3.93(3H, m), 374 4.78(1H, t, J=9.6Hz), 7.13(1H, s), 7.97(2H, d, J=8.7Hz), 8.01(2H, d, J=8.7Hz), 8.43(2H, d, J=6.2Hz), 8.93(2H, d, J=6.2Hz), 10.12(1H, s), 10.70(1H, s). YA0331 (CDCl3): 2.00(4H, m), 3.05(1H, t, J=11.7Hz), 418 3.18-3.30(3H, m), 3.29(4H, m), 3.56(3H, s), 3.62(2H, m), 3.91(1H, d, J=8.4Hz), 6.57(2H, d, J=8.7Hz), 7.31(3H, m), 8.17(1H, dd, J=1.2, 5.1Hz), 8.85(1H, d, J=5.1Hz), 9.27(1H, d, J=1.2Hz). YA0337 (CDCl3): 3.02(1H, dd, J=10.8, 12.6Hz), 434 3.18(8H, m), 3.56(3H, s), 3.61(1H, t, J=9.0Hz), 3.87(4H, m), 3.95(1H, dd, J=2.7, 10.8Hz), 6.93(2H, d, J=8.9Hz), 7.31(1H, s), 7.36(2H, d, J=8.9Hz), 8.16(1H, dd, J=1.5, 5.4Hz), 8.85(1H, d, J=5.4Hz), 9.27(1H, d, J=1.5Hz). YA0340 (CDCl3): 2.36(3H, s), 2.59(4H, m), 447 3.02(1H, t, J=11.4Hz), 3.16-3.29(7H, m), 3.26(3H, s), 3.61(2H, m), 3.94(1H, d, J=8.0Hz), 6.94(2H, d, J=8.7Hz), 7.31(1H, s), 7.34(2H, d, J=8.7Hz), 8.16(1H, d, J=5.1Hz), 8.85(1H, d, J=5.1Hz), 9.27(1H, s). YA0361 3.39-3.50(2H, m), 3.47(3H, s), 3.61-3.73(1H, m), 409 3.78(3H, s), 3.83(3H, s), 3.87-3.92(3H, m), 4.92(1H, t, J=10.5Hz), 6.99-7.11(3H, m), 7.57(1H, d, J=2.7Hz), 8.25(1H, dd, J=1.2, 5.1Hz), 9.03(1H, d, J=4.8Hz), 9.31(1H, d, J=0.9Hz), 9.78(1H, d, J=9.0Hz), 10.21-10.38(1H, m) (DMSO-d6) YA0362 (DMSO-d6): 3.47(3H, s), 3.37-4.04(6H, m), 409 3.94(6H, s), 5.09(1H, m), 6.82(2H, d, J=8.4Hz), 7.05(1H, s), 7.45(1H, t, J=8.4Hz), 8.22(1H, m), 8.24(1H, dd, J=5.4, 1.5Hz), 9.05(1H, d, J=5.1Hz), 9.32(1H, s), 10.06(1H, m). YA0366 3.38-3.60(4H, m), 3.47(3H, s), 3.88-3.95(2H, m), 397 3.90(3H, s), 4.86-4.92(1H, m), 6.96-7.01(1H, m), 7.06(1H, s), 7.12(1H, d, J=8.8Hz), 7.71-7.79(1H, m), 8.23-8.24(1H, m), 9.03(1H, d, J=5.1Hz), 9.32(1H, d, J=1.2Hz), 9.55-9.72(2H, m) (DMSO) YA0367/ (DMSO-d6): 3.30-3.75(7H, m), 3.80-4.00(5H, m), 397 YA0368 4.80-5.00(1H, m), 6.93-7.00(1H, m), 7.05(1H, s), 7.11(1H, dd, J=2.4, 11.4Hz), 7.84(1H, m), 8.23(1H, d, J=5.1Hz), 9.03(1H, d, J=5.1Hz), 9.31(1H, s), 9.60-9.80(1H, brd), 9.90-10.15(1H, brd). YA0370 3.31-3.56(3H, m), 3.45(3H, s), 3.69-3.78(1H, m), 397 3.90-3.99(2H, m), 3.94(3H, s), 4.95-5.03(1H, m), 6.96-7.02(1H, m), 7.03-7.09(2H, m), 7.49-7.56(1H, m), 8.24(1H, d, J=4.4Hz), 8.51-8.69(1H, m), 9.03(1H, d, J=5.1Hz), 9.32(1H, s), 10.55-10.67(1H, m) (DMSO) YA0378 2.77(1H, dd, J=10.5, 12.0Hz), 3.18-3.30(3H, m), 413 3.61(3H, s), 3.64-3.71(2H, m), 3.86(3H, s), 4.37(1H, dd, J=2.1, 10.1Hz), 6.89(1H, d, J=1.7Hz), 6.99(1H, dd, J=1.6, 8.2Hz), 7.32(1H, s), 7.50(1H, d, J=8.2Hz), 8.19(1H, d, J=5.2Hz), 8.86(1H, d, J=5.2Hz), 9.27(1H, s) (CDCl3) YA0399 (CDCl3): 2.76(1H, dd, J=10.2, 12.3Hz), 457 3.10-3.40(3H, m), 3.55-3.80(5H, m), 3.85(3H, s), 4.39(1H, dd, J=2.4, 10.2Hz), 6.78(1H, d, J=8.7Hz), 7.32(1H, s), 7.39(1H, dd, J=2.7, 8.7Hz), 7.72(1H, d, J=2.4Hz), 8.20(1H, dd, J=1.2, 5.1Hz), 8.87(1H, d, J=5.1Hz), 9.27(1H, d, J=1.2Hz). YA0408 (CDCl3): 1.98-2.03(4H, m), 2.84(1H, m), 448 3.17-3.32(7H, m), 3.60(3H, s), 3.59-3.71(2H, m), 3.85(3H, s), 4.28(1H, d, 8.4Hz), 6.10(1H, d, J=1.8Hz), 6.18(1H, d, J=8.3Hz), 7.29(1H, s), 7.33(1H, d, J=8.4Hz), 8.21(1H, d, J=5.2Hz), 8.85(1H, d, J=5.2Hz), 9.27(1H, s). YA0409 (CDCl3): 1.95-2.10(4H, m), 2.95-3.10(1H, m), 448 3.19-3.45(7H, m), 3.59(3H, s), 3.50-3.80(2H, m), 3.80(3H, s), 4.48(1H, dd, J=2.2, 10.2Hz), 6.49(1H, dd, J=3.0, 8.9Hz), 6.63-6.87(2H, m), 7.32(1H, s), 8.20(1H, dd, J=1.4, 5.2Hz), 8.86(2H, d, J=5.2Hz), 9.27(1H, d, J=1.1Hz). YA0414 (CDCl3): 3.14(2H, m), 3.22(1H, t, J=11.6Hz), 415 3.41(1H, t, J=11.6Hz), 3.82(2H, m), 3.83(3H, s), 3.88(3H, s), 4.58(1H, dd, J=3.1, 11.0Hz), 6.51(2H, m), 7.32(1H, s), 8.19(1H, dd, J=1.5, 5.3Hz), 8.86(1H, d, J=5.3Hz), 9.27(1H, d, J=1.5Hz). YA0423 (DMSO-d6): 3.35-3.70(4H, m), 3.48(3H, s), 455 3.78(3H, s), 3.97(2H, m), 4.70(1H, m), 7.06(1H, t, J=7.7Hz), 7.07(1H, s), 7.15(1H, d, J=7.7Hz), 7.31(1H, d, J=7.7Hz), 7.39(1H, t, J=7.7Hz), 7.61(2H, d, J=8.1Hz), 7.70(2H, d, J=8.1Hz), 8.25(1H, d, J=4.5Hz), 9.07(1H, d, J=4.5Hz), 9.33(1H, s), 9.66(1H, br s). YA0425 (DMSO-d6): 3.61(3H, m), 3.76(3H, s), 3.81(3H, s), 455 4.01(3H, m), 4.69(1H, t, J=9.9Hz), 7.05(2H, d, J=9.0Hz), 7.07(1H, s), 7.67(2H, d, J=9.0Hz), 7.76(4H, s), 8.24(1H, dd, J=1.2, 5.1Hz), 9.03(1H, d, J=5.1Hz), 9.32(1H, d, J=1.2Hz), 9.79(1H, d, J=10.2Hz), 10.07(1H, s). YA0434 (DMSO-d6): 3.30-3.70(4H, m), 3.42(3H, s), 443 3.96(2H, d, J=13.8Hz), 4.71(1H, t, J=11.3Hz), 7.06(1H, s), 7.33(2H, t, J=8.0Hz), 7.77(6H, m), 8.24(1H, d, J=5.4Hz), 9.03(1H, d, J=5.4Hz), 9.32(1H, s), 9.80(1H, d, J=8.7Hz), 10.03(1H, s). YA0442 3.43-3.59(2H, m), 3.48(3H, s), 3.63-3.75(2H, m), 399 3.97-4.01(2H, m), 4.80-4.86(1H, m), 7.06(1H, s), 7.60-7.64(2H, m), 7.86-7.88(1H, m), 7.95-8.00(2H, m), 8.05-8.07(1H, m), 8.24-8.27(2H, m), 9.02(1H, d, J=5.4Hz), 9.32(1H, s), 10.01(1H, d, J=10.2Hz), 10.30-10.41(1H, m) (DMSO-d6) YA0517 (CDCl3): 2.97(1H, dd, J=12.3, 10.5Hz), 391 3.18-3.28(5H, m), 3.58(3H, s), 3.59(1H, m), 3.77(1H, m), 4.27(1H, dd, 10.2, 2.7Hz), 4.62(2H, m), 6.89(1H, t, J=7.5Hz), 7.16(1H, m), 7.27(1H, m), 7.28(1H, s), 8.26(1H, dd, J=5.4, 1.5Hz), 8.86(1H, d, J=5.4Hz), 9.26(1H, s). YA0864 (DMSO-d6): 3.15-3.35(1H, m), 3.38-3.50(4H, m), 487 3.70-4.30(9H, m), 5.00-5.20(1H, m), 7.00-7.10(2H, m), 7.10-7.20(1H, m), 7.30-7.50(6H, m), 8.15-8.20(1H, m), 8.30-8.40(1H, brd), 9.05(1H, d, J=5.1Hz), 9.31(1H, d, J=0.9Hz). YA1074 (CDCl3): 1.80-2.40(3H, m), 3.12-3.34(4H, m), 439 3.39-4.20(7.6H, m), 4.50-5.07(0.6H, m), 5.30-5.60(0.7H, m), 5.72-6.05(0.1H, m), 6.52-6.80(2H, m), 6.82-7.22(1H, m), 7.28(1H, s), 8.18(1H, d, J=4.8Hz), 8.89(1H, d, J=5.1Hz), 9.28(1H, d, J=1.2Hz) YA1339 (CDCl3): 2.50-2.62(1H, m), 2.80-2.95(1H, m), 411 3.02-3.20(1H, m), 3.25-3.40(1H, m), 3.50-3.74(5H, m), 3.75-3.80(1H, m), 3.85(3H, s), 6.60-6.80(2H, m), 7.30(1H, s), 7.48(1H, t, J=8.4Hz), 8.19(1H, dd, J=1.2, 5.1Hz), 8.86(1H, d, J=5.1Hz), 9.27(1H, d, J=1.5Hz). YA1340/ (DMSO-d6): 2.55(3H, d, J=3.9Hz), 411 YA1341 3.40-3.80(3H, m), 3.45(3H, s), 3.80-4.15(6H, m), 4.85-5.15(1H, m), 6.90-7.05(1H, m), 7.05(1H, s), 7.13(1H, dd, J=2.4, 11.4Hz), 8.21(1H, dd, J=1.2, 5.1Hz), 9.04(1H, d, J=5.1Hz), 9.31(1H, d, J=1.2Hz), 11.50-12.20(1H, brd). YA1534 2.90-3.10(1H, m), 3.15-3.35(3H, m), 408 3.50-3.70(5H, m), 3.80-4.05(7H, m), 6.87(1H, d, J=8.1Hz), 6.90-7.10(2H, m), 7.31(1H, s), 8.16(1H, d, J=4.6Hz), 8.85(1H, d, J=5.0Hz), 9.27(1H, s) (CDCl3) YA1535 3.45(3H, s), 3.46(2H, m), 3.64(m, 2H), 3.91(2H, 383 t, J=16.1Hz), 4.68(1H, t, J=10.5Hz), 7.05(1H, s), 7.59(2H, d, J=8.4Hz), 7.79(2H, d, J=8.4Hz), 8.23(1H, dd, J=5.1, 1.2Hz), 9.02(1H, d, J=5.1Hz), 9.31(1H, d, J=1.2Hz), 10.00(1H, d, J=8.7Hz), 10.49(1H, br s) (DMSO-6) YA1536 3.45(3H, s), 3.46(2H, m), 3.64(m, 2H), 3.91(2H, 383 t, J=16.1Hz), 4.68(1H, t, J=10.5Hz), 7.05(1H, s), 7.59(2H, d, J=8.4Hz), 7.79(2H, d, J=8.4Hz), 8.23(1H, dd, J=5.1, 1.2Hz), 9.02(1H, d, J=5.1Hz), 9.31(1H, d, J=1.2Hz), 10.00(1H, d, J=8.7Hz), 10.49(1H, br s) (DMSO-6) YA1537 2.39(3H, s), 2.60(4H, t, J=4.6Hz), 3.37(4H, t, 286 J=4.8Hz), 3.53(3H, s), 7.27(1H, s), 8.18(1H, dd, J=1.2, 5.4Hz), 8.87(1H, d, J=5.1Hz), 9.28(1H, s) (CDCl3) YA1538 2.64-2.74(1H, br.s), 2.66(2H, t, J=5.3Hz), 316 2.73(4H, t, J=4.4Hz), 3.39(4H, t, J=4.0Hz), 3.54(3H, s), 3.69-3.70(2H, m), 7.26(1H, s), 8.18(1H, d, J=5.0Hz), 8.88(1H, t, J=5.0Hz), 9.28(1H, s) (CDCl3) YA1539 1.10(6H, t, J=6.6Hz), 2.71(4H, t, J=4.9Hz), 314 2.77(1H, m), 3.36(4H, t, J=4.9Hz), 3.54(3H, s), 7.27(1H, s), 8.18(1H, dd, J=1.1, 5.2Hz), 8.87(2H, d, J=5.1Hz), 9.27(1H, s) (CDCl3) YA1540 1.15(6H, d, J=6.2Hz), 1.50(1H, br.s), 2.61(2H, 300 dd, J=1.6, 12.4Hz), 3.06-3.16(2H, m), 3.49(2H, d, J=13.0Hz), 3.52(3H, s), 7.27(1H, s), 8.16(1H, dd, J=1.3, 5.0Hz), 8.88(1H, d, J=5.0Hz), 9.27(1H, d, J=1.3Hz) (CDCl3) YA1541 2.98(1H, t, J=11.5Hz), 3.20(3H, m), 3.57(3H, 417 s), 3.58(2H, m), 4.02(1H, dd, J=10.5, 2.2Hz), 7.27(1H, s), 7.29(1H, d, J=8.3Hz), 7.46(1H, d, J=8.3Hz), 7.61(1H, s), 8.13(1H, d, J=5.2Hz), 8.86(1H, d, J=5.2Hz), 9.27(1H, s) (CDCl3) YA1542 3.44(3H, s), 3.62-3.73(2H, m), 3.86-3.93(2H, m), 427 4.66(1H, m), 7.05(1H, s), 7.45(1H, dd, J=8.4, 8.4Hz), 7.67(1H, d, J=8.4Hz), 7.81(1H, d, J=8.4Hz), 8.04(1H, s), 8.25(1H, dd, J=5.4, 1.5Hz), 9.02(1H, d, J=5.4Hz), 8.18(1H, dd, J=5.4, 1.2Hz), 8.99(1H, d, J=5.1Hz), 9.32(1H, d, J=1.5Hz), 10.13(1H, m), 10.67(1H, m) (DMSO) YA1543 3.33(1H, dd, J=13.5, 8.9Hz), 3.47(3H, s), 397 3.79(1H, dd, J=13.5, 3.9Hz), 4.73(1H, d, J=17.1Hz), 4.22(1H, d, J=17.1Hz), 4.82(1H, dd, J=8.9, 3.9Hz), 6.08(1H, s), 7.31(2H, d, J=8.4Hz), 7.42(2H, d, J=8.4Hz), 8.14(1H, d, J=5.1, 1.5Hz), 8.90(1H, d, J=5.1Hz), 9.29(1H, d, J=1.5Hz) (CDCl3) YA1544 1.97(4H, m), 3.26(4H, m), 3.39(2H, m), 418 3.44(3H, s), 3.60(2H, m), 3.79(1H, d, J=13.5Hz), 3.91(1H, d, J=13.8Hz), 4.48(1H, t, J=10.1Hz), 6.66(2H, d, J=8.4Hz), 7.04(1H, s), 7.51(2H, d, J=8.4Hz), 8.21(1H, d, J=5.1Hz), 9.02(1H, d, J=5.1Hz), 9.31(1H, s), 9.70(1H, d, J=10.8Hz), 10.07(1H, br s) (DMSO-d6) YA1545 3.21(4H, m), 3.42(2H, m), 3.44(3H, s), 3.62(2H, 434 m), 3.79(4H, m), 3.90(2H, t, J=14.6Hz), 4.54(1H, t, J=10.5Hz), 7.05(1H, s), 7.13(2H, d, J=8.7Hz), 7.62(2H, d, J=8.7Hz), 8.22(1H, d, J=4.8Hz), 9.02(1H, d, J=4.8Hz), 9.31(1H, s), 9.80(1H, d, J=9.3Hz), 10.23(1H, br s) (DMSO-d6) YA1546 2.80(3H, d, J=4.5Hz), 3.26(4H, m), 3.44(3H, 447 s), 3.45(4H, m), 3.60(2H, m), 3.80(1H, d, J=3.5Hz), 3.90(3H, m), 4.54(1H, t, J=10.5Hz), 7.04(1H, s), 7.10(2H, d, J=8.7Hz), 7.62(2H, d, J=8.7Hz), 8.20(1H, dd, J=5.1, 1.2Hz), 9.02(1H, d, J=5.1Hz), 9.32(1H, d, J=1.2Hz), 9.86(1H, d, J=10.2Hz), 10.33(1H, br s), 11.15(1H, br s) (DMSO-d6) YA1547 2.28(3H, s), 3.07(4H, t, J=4.7Hz), 3.37(4H, t, 428 J=4.8Hz), 3.75(3H, s), 5.76(1H, s), 7.26-7.33(2H, m), 7.45(2H, dd, J=7.8, 7.8Hz), 7.79(2H, d, J=7.8Hz), 8.14(1H, d, J=5.4Hz), 8.87(1H, dd, J=7.8, 7.8Hz), 9.28(1H, d, J=1.2Hz) (CDCl3) YA1548 2.37(1H, m), 2.43(1H, m), 2.80(3H, d, J=5.2Hz), 461 2.81(3H, d, J=5.2Hz), 3.28(1H, q, J=8.8Hz), 3.40(2H, m), 3.44(3H, s), 3.57(5H, m), 3.79(1H, d, J=11.4Hz), 3.97(2H, m), 4.50(1H, t, J=10.0Hz), 6.69(2H, d, J=8.4Hz), 7.05(1H, s), 7.54(2H, d, J=8.4Hz), 8.20(1H, dd, J=4.8, 1.2Hz), 9.03(1H, d, J=4.8Hz), 9.32(1H, d, J=1.2Hz), 9.71(1H, br s), 10.06(1H, br s), 11.35(1H, br s) (DMSO-d6) YA1549 2.33(1H, m), 2.41(1H, m), 2.79(3H, d, J=4.8Hz), 461 2.81(3H, d, J=4.8Hz), 3.28(1H, d, J=8.4Hz), 3.39(2H, m), 3.44(3H, s), 3.57(5H, m), 3.79(1H, d, J=13.3Hz), 3.97(2H, m), 4.50(1H, t, J=11.6Hz), 6.69(2H, d, J=8.4Hz), 7.04(1H, s), 7.55(2H, d, J=8.4Hz), 8.21(2H, d, J=5.2Hz), 9.02(2H, d, J=5.2Hz), 9.32(1H, s), 9.75(1H, br s), 10.14(1H, br s), 11.45(1H, br s) (DMSO-d6) YA1550 3.47(3H, s), 3.60(2H, m), 3.76(2H, m), 3.81(3H, 455 s), 3.94(2H, m), 4.68(1H, m), 7.05(2H, d, J=8.6Hz), 7.06(1H, s), 7.67(2H, d, J=8.6Hz), 7.76(4H, s), 8.25(1H, d, J=5.0Hz), 9.03(1H, d, J=5.0Hz), 9.32(1H, s) (DMSO-d6) YA1551 1.18(1H, m), 1.40(4H, m), 1.70(1H, m), 431 1.80(4H, m), 2.55(1H, m), 3.43(2H, m), 3.45(3H, s), 3.60(2H, m), 3.91(2H, m), 4.60(1H, t, J=10.8Hz), 7.05(1H, s), 7.35(2H, d, J=8.0Hz), 7.64(2H, d, J=8.0Hz), 9.03(1H, d, J=4.8Hz), 9.31(1H, s), 9.80(1H, d, J=8.8Hz), 10.24(1H, m) (DMSO-d6) YA1552 3.02(4H, m), 3.23(4H, m), 3.49(3H, s), 424 7.08-7.67(10H, m), 8.15(1H, d, J=5.1Hz), 8.87(1H, d, J=5.1Hz), 9.27(1H, s) (CDCl3) YA1553 2.90(1H, dd, J=13.2, 9.6Hz), 3.16(2H, m), 363 3.24(1H, d, 14.4Hz), 3.31(3H, s), 3.34(1H, d, J=13.6Hz), 3.47(1H, t, J=13.2Hz), 3.80(3H, m), 6.97(1H, s), 7.38(2H, m), 7.45(3H, m), 7.64(1H, dd, J=5.2, 1.2Hz), 8.94(1H, d, J=5.2Hz), 9.28(1H, d, J=1.2Hz), 9.54(1H, br s), 9.78(1H, br s) (DMSO-d6) YA1554 2.95(1H, m), 3.29-3.05(3H, m), 3.34(3H, s), 397 3.35(1H, m), 3.44(1H, t, J=12.4Hz), 3.79(3H, m), 6.99(1H, s), 7.40(2H, d, J=8.4Hz), 7.51(2H, d, J=8.4Hz), 7.76(1H, dd, J=4.8, 1.2Hz), 8.96(1H, d, J=4.8Hz), 9.29(1H, d, J=1.2Hz), 9.38(1H, br s), 9.71(1H, br s) (DMSO-d6) YA1555 1.65(2H, br s), 1.90(4H, br s), 3.44(6H, m), 432 3.45(3H, s), 3.61(2H, m), 3.88(1H, d, J=13.6Hz), 3.94(1H, d, J=13.6Hz), 4.66(1H, t, J=8.8Hz), 7.05(1H, s), 7.82(4H, br s), 8.23(1H, dd, J=5.2, 1.2Hz), 9.02(1H, d, J=5.2Hz), 9.31(1H, d, J=1.2Hz), 9.89(1H, br s), 10.37(1H, br s) (DMSO-d6) YA1556 3.42(2H, m), 3.45(3H, s), 3.56(2H, m), 3.85(1H, 509 d, J=13.2Hz), 3.93(1H, d, J=14.0Hz), 4.55(1H, t, J=10.8Hz), 6.94(1H, br s), 7.05(1H, s), 7.15(4H, br s), 7.31(2H, br s), 7.57(2H, br s), 8.22(1H, d, J=4.8Hz), 9.03(1H, d, J=4.8Hz), 9.32(1H, s), 9.66(1H, br s), 9.90(1H, br s) (DMSO-d6) YA1557 1.40(1H, m), 1.78(8H, m), 2.18(2H, d, J=11.2Hz), 515 2.78(2H, m), 2.91(2H, m), 3.30(1H, m), 3.40(3H, m), 3.44(3H, s), 3.58(2H, m), 3.82(1H, d, J=13.3Hz), 3.93(3H, m), 4.53(1H, m), 7.05(1H, s), 7.11(2H, d, J=8.8Hz), 7.57(2H, d, J=8.8Hz), 8.21(1H, d, J=5.2Hz), 9.02(1H, d, J=5.2Hz), 9.32(1H, s), 9.73(1H, d, J=8.4Hz), 10.09(1H, br s), 10.39(1H, br s) (DMSO-d6) YA1558 2.84-2.91(1H, m), 3.01-3.05(4H, m), 3.22(3H, s), 427 3.46(3H, s), 3.68-3.72(2H, m), 4.07-4.11(1H, m), 6.95(1H, s), 7.78(2H, d, J=7.2Hz), 7.93(2H, d, J=7.2Hz), 8.31(1H, d, J=4.2Hz), 8.99(1H, d, J=4.2Hz), 9.28(1H, s) (DMSO-d6) YA1559 1.84(4H, m), 1.97(2H, m), 2.13(2H, m), 501 2.79(2H, t, J=11.6Hz), 3.04(2H, m), 3.24(1H, m), 3.40(2H, m), 3.44(3H, s), 3.59(2H, m), 3.80(1H, d, J=14.0Hz), 3.91(3H, m), 4.53(1H, t, J=11.2Hz), 7.05(1H, s), 7.13(2H, d, J=8.4Hz), 7.58(2H, d, J=8.4Hz), 8.22(1H, d, J=5.2Hz), 9.02(1H, d, J=5.2Hz), 9.31(1H, s), 9.75(1H, d, J=8.4Hz), 10.10(1H, br s), 11.04(1H, br s) (DMSO-d6) YA1560 1.71(2H, m), 2.12(2H, m), 2.74(6H, d, J=4.8Hz), 475 2.74-2.80(3H, m), 3.30-3.96(8H, m), 3.40(3H, s), 4.54(1H, m), 7.05(1H, s), 7.10(2H, d, J=9.0Hz), 7.54(2H, d, J=9.0Hz), 8.21(1H, dd, J=5.1, 1.2Hz), 9.03(1H, d, J=5.4Hz), 9.32(1H, s), 9.68(1H, m), 9.92(1H, m), 10.54(1H, m), (DMSO-d6) YA1561 1.51(2H, m), 1.84(2H, m), 3.00-3.20(3H, m), 448 3.38(3H, s), 3.38-3.91(8H, m), 4.55(1H, m), 7.05(1H, s), 7.18(2H, d, J=9.0Hz), 7.51(2H, d, J=9.0Hz), 8.21(1H, d, J=6.0Hz), 9.02(1H, d, J=5.1Hz), 9.31(1H, s), 9.54-9.62(3H, m), (DMSO-d6) YA1562 1.89-2.05(2H, m), 2.65-3.20(5H, m), 434 3.25-3.82(5H, m), 3.41(3H, s), 4.39(1H, m), 4.91(1H, m), 6.49(2H, d, J=8.4Hz), 6.96(1H, s), 7.25(2H, d, J=8.4Hz), 8.18(1H, dd, J=4.2, 0.9Hz), 8.99(1H, d, J=5.1Hz), 9.28(1H, s), (DMSO-d6) YA1563 1.06(1H, m), 1.30(2H, m), 1.43(2H, m), 460 1.60(2H, m), 1.79(3H, m), 2.97(3H, m), 3.45(3H, s), 3.60(2H, m), 3.80(3H, s), 3.90(2H, m), 4.63(1H, m), 7.05(1H, s), 7.70(4H, br s), 8.23(1H, d, J=5.2Hz), 9.03(1H, d, J=5.2Hz), 9.32(1H, s), 9.75(1H, br s) (DMSO-d6) YA1564 2.99(6H, m), 3.44(1H, m), 3.45(3H, s), 3.57(3H, 392 m), 3.82(1H, d, J=13.2Hz), 4.92(1H, d, J=14.4Hz), 4.55(1H, t, J=10.0Hz), 7.05(1H, s), 7.06(2H, br s), 7.61(2H, br s), 8.22(1H, d, J=5.2Hz), 9.03(1H, d, J=5.2Hz), 9.32(1H, s), 9.73(1H, br s), 10.11(1H, br s) (DMSO-d6) YA1565 3.20-3.22(4H, m), 3.44-3.89(15H, m), 567 4.51-4.55(1H, m), 5.11(2H, s), 7.04-7.07(3H, m), 7.35-7.39(5H, m), 7.53(2H, d, J=7.2Hz), 8.20(1H, d, J=4.2Hz), 9.01(1H, d, J=4.2Hz), 9.31(1H, s), 9.78-9.92(2H, br) (DMSO-d6) YA1566 1.33(6H, d, J=6.8Hz), 3.02-3.55(13H, m), 475 3.89-3.93(5H, m), 4.52-4.55(1H, m), 6.99-7.13(3H, m), 7.60(2H, d, J=7.2Hz), 8.21(1H, d, J=4.2Hz), 9.02(1H, d, J=4.2Hz), 9.32(1H, s), 9.67-10.15(3H, br), 10.84-10.88(1H, br) (DMSO-d6) YA1567 3.17-3.26(8H, m), 3.44-3.55(6H, m), 477 3.80-3.94(9H, m), 4.50-4.57(1H, m), 7.05-7.12(3H, m), 7.60(2H, d, J=7.2Hz), 8.21(1H, d, J=4.2Hz), 9.02(1H, d, J=4.2Hz), 9.32(1H, s), 9.77-9.80(1H, br), 10.16-10.20(1H, br), 10.49-10.52(1H, br) (DMSO-d6) YA1568 3.18-3.24(3H, m), 3.40-3.59(13H, m), 433 4.02-4.06(2H, m), 4.51-4.55(1H, m), 7.03-7.11(3H, m), 7.52(2H, d, J=7.2Hz), 8.21(1H, d, J=4.2Hz), 9.02(1H, d, J=4.2Hz), 9.18-9.22(1H, br), 9.38(1H, s), 9.72-9.78(1H, br), 10.04-10.10(1H, br) (DMSO-d6) YA1569 1.90-2.02(2H, m), 2.80-3.06(5H, m), 434 3.25-3.82(5H, m), 3.65(3H, s), 4.39(1H, m), 4.94(1H, m), 6.49(2H, d, J=8.4Hz), 6.96(1H, s), 7.25(2H, d, J=8.4Hz), 8.16(1H, dd, J=5.4, 0.9Hz), 8.99(1H, d, J=5.1Hz), 9.29(1H, s) (DMSO-d6) YA1570 1.15(6H, d, J=6.3Hz), 2.31(2H, dd, J=11.1Hz), 461 2.98-3.23(6H, m), 3.48-3.62(4H, m), 3.56(3H, s), 3.94(1H, dd, J=10.2, 2.1Hz), 6.94(2H, d, J=8.7Hz), 7.31(1H, s), 7.34(2H, d, J=8.7Hz), 8.16(1H, dd, J=5.1, 1.2Hz), 8.86(1H, d, J=5.1Hz), 9.26(1H, s) (CDCl3) YA1571 1.27(6H, d, J=6.0Hz), 2.43(2H, dd, J=11.1, 11.1Hz), 462 3.02(1H, dd, J=12.0, 10.5Hz), 3.17-3.23(3H, m), 3.45-3.61(4H, m), 3.56(3H, s), 3.81(1H, m), 3.95(1H, m), 6.92(2H, d, J=8.7Hz), 7.32(1H, s), 7.35(2H, d, J=8.7Hz), 8.17(1H, m), 8.86(1H, d, J=5.1Hz), 9.26(1H, d, J=1.2Hz) (CDCl3) YA1572 3.27-3.32(8H, m), 3.47(3H, s), 3.82-3.86(2H, m), 503 4.36-4.39(1H, m), 7.02(1H, s), 7.72(2H, d, J=7.2Hz), 7.84(2H, d, J=7.2Hz), 7.96-8.04(4H, m), 8.22(1H, d, J=4.2Hz), 9.01(1H, d, J=4.2Hz), 9.30(1H, s) (DMSO-d6) YA1573 2.93-3.10(5H, m), 3.46(3H, s), 3.69-3.71(1H, m), 450 4.01-4.04(1H, m), 6.99(1H, s), 7.63(2H, d, J=7.2Hz), 7.77(2H, d, J=7.2Hz), 7.88-7.95(4H, m), 8.18(1H, d, J=4.2Hz), 8.99(1H, d, J=4.2Hz), 9.29(1H, s) (DMSO-d6) YA1574 3.08(1H, dd, J=12.5, 10.4Hz), 3.24(3H, m), 509 3.59(3H, s), 3.66(2H, m), 4.09(1H, dd, J=10.4, 2.4Hz), 7.29(2H, d, J=8.3Hz), 7.33(1H, s), 7.54(2H, d, J=8.3Hz), 7.56(2H, d, J=8.3Hz), 7.59(2H, d, J=8.3Hz), 8.17(1H, d, J=4.9Hz), 8.86(1H, d, J=4.9Hz), 9.27(1H, s) (CDCl3) YA1575 3.08(1H, dd, J=12.4, 10.0Hz), 3.25(3H, m), 493 3.59(3H, s), 3.67(2H, m), 4.11(1H, dd, J=10.0, 2.0Hz), 7.33(1H, s), 7.57(2H, d, J=8.0Hz), 7.63(2H, d, J=8.0Hz), 7.71(4H, s), 8.16(1H, dd, J=5.2, 1.2Hz), 8.16(1H, dd, J=5.2, 1.2Hz), 8.86(1H, d, J=5.2Hz), 9.27(1H, d, J=1.2Hz) (CDCl3) YA1576 1.45(3H, t, J=7.0Hz), 3.08(1H, dd, J=12.5, 469 10.6Hz), 3.22(3H, m), 3.58(3H, s), 3.62(2H, m), 4.05(1H, m), 4.08(2H, q, J=7.0Hz), 6.98(2H, d, J=8.0Hz), 7.32(1H, s), 7.49(2H, d, J=8.0Hz), 7.52(2H, d, J=8.0Hz), 7.58(2H, d, J=8.0Hz), 8.17(1H, d, J=5.3Hz), 8.86(1H, d, J=5.3Hz), 9.27(1H, s), (CDCl3) YA1577 1.83(4H, m), 1.99(1H, m), 2.21(1H, m), 487 2.61(4H, m), 2.87(1H, m), 3.03(1H, dd, J=12.0, 10.0Hz), 3.20(4H, m), 3.33(1H, m), 3.42(1H, m), 3.49(1H, m), 3.56(3H, s), 3.61(2H, m), 3.90(1H, dd, J=10.0, 2.0Hz), 6.55(2H, d, J=8.8Hz), 7.29(2H, d, J=8.8Hz), 7.30(1H, s), 8.16(1H, d, J=5.2Hz), 8.85(1H, d, J=5.2Hz), 9.26(1H, s) (CDCl3) YA1578 3.09(1H, dd, J=12.4, 10.8Hz), 3.20(3H, m), 485 3.58(3H, s), 3.64(2H, m), 3.82(3H, s), 3.86(3H, s), 4.05(1H, dd, J=10.4, 2.8Hz), 6.58(2H, m), 7.24(2H, m), 7.32(1H, s), 7.47(2H, d, J=8.4Hz), 7.53(2H, d, J=8.4Hz), 8.17(1H, dd, J=5.2, 1.2Hz), 8.86(1H, d, J=5.2Hz), 9.27(1H, d, J=1.2Hz) (CDCl3) YA1579 3.08(1H, dd, J=12.5, 10.6Hz), 3.23(3H, m), 485 3.59(3H, s), 3.66(2H, m), 3.93(3H, s), 3.96(3H, s), 4.07(1H, dd, J=10.3, 2.2Hz), 6.95(1H, d, J=8.3Hz), 7.11(1H, d, J=2.0Hz), 7.16(1H, dd, J=8.3, 2.0Hz), 7.33(1H, s), 7.52(1H, d, J=8.1Hz), 7.59(1H, d, J=8.1Hz), 8.17(1H, dd, J=5.3, 1.2Hz), 8.85(1H, d, J=5.3Hz), 9.27(1H, d, J=1.2Hz) (CDCl3) YA1580 3.07(1H, dd, J=12.4, 10.4Hz), 3.23(3H, m), 459 3.59(3H, s), 3.65(2H, m), 4.08(1H, dd, J=10.4, 2.0Hz), 7.32(1H, s), 7.41(2H, d, J=8.4Hz), 7.52(2H, d, J=8.4Hz), 7.53(2H, d, J=8.4Hz), 7.58(2H, d, J=8.4Hz), 8.16(1H, d, J=4.8Hz), 8.86(1H, d, J=4.8Hz), 9.27(1H, s) (CDCl3) YA1581 3.09(1H, dd, J=12.2, 11.0Hz), 3.24(3H, m), 493 3.59(3H, s), 3.66(2H, m), 4.10(1H, dd, J=10.4, 2.4Hz), 7.29(2H, m), 7.33(1H, s), 7.44(2H, d, J=8.0Hz), 7.52(3H, m), 8.18(1H, dd, J=5.3, 1.0Hz), 8.87(1H, d, J=5.3Hz), 9.27(1H, d, J=1.0Hz) (CDCl3) YA1582 3.06(1H, dd, J=12.4, 10.4Hz), 3.25(3H, m), 493 3.58(3H, s), 3.65(2H, m), 4.09(1H, dd, J=10.0, 2.0Hz), 7.33(1H, s), 7.42(1H, dd, J=8.0, 2.0Hz), 7.56(5H, m), 7.68(1H, d, J=2.0Hz), 8.16(1H, dd, J=5.2, 1.2Hz), 8.85(1H, d, J=5.2Hz), 9.27(1H, d, J=1.2Hz) (CDCl3) YA1583 3.06(1H, dd, J=12.3, 10.8Hz), 3.23(3H, m), 417 3.59(3H, s), 3.65(2H, m), 4.13(1H, dd, J=10.2, 2.2Hz), 7.33(1H, s), 8.14(1H, d, J=5.3Hz), 8.15(2H, d, J=8.4Hz), 8.78(1H, s), 8.86(1H, d, J=5.3Hz), 9.27(1H, s) (CDCl3) YA1584 1.37(6H, d, J=6.0Hz), 3.07(1H, dd, J=12.6, 10.8Hz), 483 3.20-3.26(3H, m), 3.58(3H, s), 3.65-3.68(2H, m), 4.07(1H, m), 4.59(1H, m), 6.98(2H, d, J=8.7Hz), 7.48(1H, s), 7.50-7.61(6H, m), 8.17(1H, d, J=4.8Hz), 8.86(1H, d, J=5.1Hz), 9.26(1H, d, J=1.2Hz) (CDCl3) YA1585 0.99(3H, t, J=7.5Hz), 1.47-1.82(4H, m), 497 3.07(1H, dd, J=12.3, 10.5Hz), 3.22-3.27(3H, m), 3.58(3H, s), 3.62-3.65(2H, m), 4.03(2H, t, J=6.3Hz), 4.04(1H, m), 6.98(2H, d, J=8.7Hz), 7.48(1H, s), 7.50-7.59(6H, m), 8.17(1H, dd, J=5.1, 1.2Hz), 8.86(1H, d, J=5.1Hz), 9.26(1H, d, J=1.2Hz) (CDCl3) YA1586 1.28(1H, br.s), 2.51(3H, s), 3.07(1H, dd, J=10.8, 470 12.6Hz), 3.21-3.28(3H, m), 3.58(3H, s), 3.64(2H, m), 4.08(1H, dd, J=2.5, 19.5Hz), 7.34(2H, d, J=7.8Hz), 7.45-7.67(7H, m), 8.17(1H, d, J=5.4Hz), 8.86(1H, d, J=5.1Hz), 9.27(1H, d, J=1.2Hz) (CDCl3) YA1587 1.86(1H, br.s), 2.40(3H, s), 3.07(1H, dd, J=10.8, 438 12.6Hz), 3.20-3.27(2H, m), 3.58(3H, s), 3.62-3.68(3H, m), 4.06(1H, dd, J=2.5, 19.5Hz), 7.24-7.27(2H, m), 7.49-7.52(5H, m), 7.60(2H, d, J=8.2Hz), 8.17(1H, d, J=5.4Hz), 8.85(1H, d, J=5.2Hz), 9.27(1H, s) (CDCl3) YA1588 1.29(6H, s), 1.85(1H, br.s), 2.94-2.96(1H, m), 466 3.08(1H, dd, J=10.8, 12.6Hz), 3.21-3.27(3H, m), 3.59(3H, s), 3.65(2H, m), 4.07(1H, dd, J=2.5, 19.5Hz), 7.28-7.62(9H, m), 8.17(1H, dd, J=1.2, 5.7Hz), 8.86(1H, d, J=5.1Hz), 9.27(1H, d, J=1.2Hz) (CDCl3) YA1589 1.72(1H, br.s), 3.10(1H, m), 3.21-3.24(3H, m), 439 3.58(3H, s), 3.58-3.73(4H, m), 4.09(1H, dd, J=2.5, 19.5Hz), 6.75(2H, dd, J=2.1, 6.6Hz), 7.23-7.57(7H, m), 8.16(1H, d, J=5.4Hz), 8.86(1H, d, J=5.1Hz), 9.27(1H, d, J=1.2Hz) (CDCl3) YA1590 2.79(1H, dd, J=10.5, 12.6Hz), 3.20-3.40(3H, 427 m), 3.50-3.80(5H, m), 4.45(1H, dd, J=3.0, 10.2Hz), 7.10-7.20(1H, m), 7.30-7.40(2H, m), 7.58(1H, dd, J=0.9, 7.8Hz), 7.73(1H, dd, J=1.5, 7.8Hz), 8.19(1H, dd, J=0.9, 4.8Hz), 8.85(1H, d, J=5.1Hz), 9.26(1H, d, J=0.9Hz) (CDCl3) YB013 1.31-1.46(1H, m), 1.60-1.96(3H, m), 378 2.17-2.30(1H, m), 2.89-3.02(2H, m), 3.41(3H, s), 3.61(1H, d, J=12.4Hz), 3.80(1H, d, J=13.5Hz), 3.90-4.01(2H, m), 6.89-7.01(3H, m), 6.96(1H, s), 7.27-7.32(2H, m), 8.18(1H, d, J=4.4Hz), 8.96(1H, d, J=5.0Hz), 9.28(1H, s) (DMSO-d6) YB014 1.33-1.49(1H, m), 1.60-1.93(3H, m), 406 2.20-2.32(1H, m), 2.89-3.04(2H, m), 3.41(3H, s), 3.63(1H, d, J=13.3Hz), 3.82(1H, d, J=11.1Hz), 4.22-4.37(2H, m), 6.95(1H, s), 7.51-7.56(2H, m), 7.65-7.70(1H, m), 8.00-8.03(2H, m), 8.17(1H, dd, J=1.1, 5.1Hz), 8.87(1H, d, J=5.1Hz), 9.28(1H, d, J=1.0Hz) (DMSO-d6) YB048 (CDCl3):1.93-2.07(3H, m), 2.38(1H, m), 389 3.09(1H, m), 3.46(1H, m), 3.57(3H, s), 3.61-3.70(2H, m), 4.05(1H, m), 7.26-7.34(2H, m), 7.59-7.61(2H, m), 7.76(1H, m), 8.16(1H, m), 8.83(1H, m), 9.27(1H, s). YB049 (CDCl3):1.92-2.08(3H, m), 2.36(1H, m), 407 3.11(1H, m), 3.44(1H, dd, J=12.9, 10.8Hz), 3.58(3H, s), 3.61-3.70(2H, m), 4.06(1H, m), 7.11(1H, m), 7.28-7.33(2H, m), 7.70(1H, dd, J=8.7, 4.8Hz), 8.15(1H, m), 8.86(1H, d, J=5.4Hz), 9.28(1H, s). YB050 1.93-2.11(3H, m), 2.33-2.45(1H, m), 389 3.08-3.16(1H, m), 3.46(1H, dd, J=11.4, 12.9Hz), 3.59(3H, s), 3.62-3.71(2H, m), 4.06(1H, d, J=12.6Hz), 7.32-7.37(1H, m), 7.32(1H, s), 7.57-7.64(2H, m), 7.75(1H, d, J=8.1Hz), 8.16(1H, dd, J=1.2, 5.4Hz), 8.84(1H, d, J=4.8Hz), 9.28(1H, d, J=0.9Hz) (CDCl3) YB051 1.91-2.11(3H, m), 2.35-2.43(1H, m), 389 3.08-3.16(1H, m), 3.42-3.50(1H, m), 3.59(3H, s), 3.62-3.71(2H, m), 4.05(1H, d, J=11.1Hz), 7.32(1H, s), 7.33-7.37(1H, m), 7.57-7.65(2H, m), 7.75(1H, d, J=7.8Hz), 8.16(1H, d, J=5.7Hz), 8.84(1H, d, J=5.4Hz), 9.28(1H, d, J=1.2Hz) (CDCl3) YB103 1.78-1.96(4H, m), 2.73-2.90(1H, m), 366 3.02-3.09(2H, m), 3.46(3H, s), 3.84(2H, d, J=12.6Hz), 6.98(1H, s), 7.11-7.17(2H, m), 7.33-7.38(2H, m), 8.25(1H, d, J=5.1Hz), 9.01(1H, d, J=4.8Hz), 9.30(1H, s) (DMSO-d6) YB157 1.90-2.05(2H, m), 2.18-2.35(2H, m), 406 2.92-3.09(1H, m), 3.10-3.23(2H, m), 3.58(3H, s), 3.72-3.83(2H, m), 6.95-7.07(1H, m), 7.22(1H, dd, J=2.2, 9.0Hz), 7.34(1H, s), 7.46(1H, s), 7.48-7.55(1H, m), 8.20(1H, d, J=5.3Hz), 8.88(1H, d, J=5.2Hz), 9.29(1H, s) (CDCl3) YB158 1.91-2.04(2H, m), 2.23(2H, d, J=8.9Hz), 2.44(3H, 402 s), 2.97-3.11(1H, m), 3.16(2H, dd, J=11.1, 12.4Hz), 3.58(3H, s), 3.77(2H, d, J=13.0Hz), 7.12(1H, d, J=8.5Hz), 7.36-7.41(4H, m), 8.20(1H, d, J=5.3Hz), 8.87(1H, d, J=4.8Hz), 9.28(1H, s) (CDCl3) YB159 1.93-2.05(2H, m), 2.23(2H, d, J=12.6Hz), 422 3.19(3H, m), 3.58(3H, s), 3.81(2H, d, J=13.2Hz), 7.12-7.16(1H, m), 7.26(1H, s), 7.34(1H, s), 7.56(1H, dd, J=2.4, 8.7Hz), 7.77-7.76(1H, m), 8.20(1H, dd, J=1.2, 5.1Hz), 8.87(1H, d, J=5.1Hz), 9.29(1H, s) (CDCl3) YB160 2.01-2.22(5H, m), 3.20(2H, dd, J=1.4, 11.7Hz), 407 3.47(3H, s), 3.84(2H, d, J=13.2Hz), 6.99(1H, s), 7.32(1H, m), 7.72(1H, dd, J=2.1, 9.0Hz), 8.09(1H, dd, J=2.7, 9.1Hz), 8.27(1H, m), 9.01(1H, d, J=5.1Hz), 9.31(1H, d, J=1.5Hz) (DMSO-d6) YB162 2.13-2.43(4H, m), 3.10-3.38(3H, m), 3.57(3H, s), 389 3.65-3.83(2H, m), 7.30-7.40(3H, m), 7.45-7.59(1H, m), 7.62-7.80(1H, m), 8.10-8.22(1H, m), 8.88(1H, d, J=5.1Hz), 9.28(1H, s) (CDCl3) YB193 2.22-2.39(4H, m), 3.21-3.35(2H, m), 3.48(3H, s), 373 3.90(2H, d, J=13.5Hz), 7.03(1H, s), 7.38-7.43(1H, m), 7.46-7.51(2H, m), 7.59-7.66(2H, m), 8.28(1H, d, J=5.0Hz), 9.01(1H, d, J=5.0Hz), 9.30(1H, s) (DMSO-d6) YB251 2.01-2.22(5H, m), 3.20(2H, dd, J=11.4, 11.7Hz), 406 3.47(3H, s), 3.82(2H, d, J=13.2Hz), 7.32(1H, m), 6.70(1H, s), 7.72(1H, dd, J=2.1, 9.0Hz), 8.09(1H, dd, J=2.7, 9.1Hz), 8.27(1H, m), 9.01(1H, d, J=5.1Hz), 9.31(1H, d, J=1.5Hz) (DMSO-d6) YB252 1.64(2H, m), 2.23(2H, d, J=8.9Hz), 2.44(3H, s), 401 2.97-3.11(1H, m), 3.16(2H, dd, J=11.1, 11.4Hz), 3.58(3H, s), 3.77(2H, d, J=13.0Hz) 7.12(1H, d, J=8.5Hz), 7.36-7.41(4H, m), 8.20(1H, d, J=5.3Hz), 8.87(1H, d, J=4.8Hz), 9.28(1H, s) (CDCl3) YB253 1.93-2.05(2H, m), 2.23(2H, d, J=12.6Hz), 421 3.19(3H, m), 3.58(3H, s), 3.81(2H, d, J=13.2Hz), 7.12-7.16(1H, m), 7.26(1H, s) 7.34(1H, s), 7.56(1H, dd, J=2.4, 8.7Hz), 7.11-7.76(1H, m), 8.20(1H, dd, J=1.2, 5.1Hz), 8.87(1H, d, J=5.1Hz), 9.29(1H, s) (CDCl3) YB254 1.72-1.94(8H, m), 2.52(4H, m), 2.97-3.05(3H, 431 m), 3.56(3H, s), 3.61(2H, s), 3.67-3.73(2H, m), 7.21-7.34(4H, m), 8.17(1H, d, J=5.4Hz), 8.86(1H, d, J=5.1Hz), 9.27(1H, s) (CDCl3) YB255 1.78(1H, m), 1.89(3H, m), 1.96(3H, m), 444 2.13(1H, d, J=13.6Hz), 3.46(2H, m), 3.56(3H, s), 3.66(2H, t, J=6.8Hz), 3.73(2H, m), 7.30(2H, d, J=8.0Hz), 7.31(1H, s), 7.52(2H, d, J=5.2Hz), 8.15(1H, d, J=5.2Hz), 8.86(1H, d, J=5.2Hz), 9.27(1H, s) YB256 1.46-1.73(9H, m), 2.01(2H, d, J=12.1Hz), 354 2.56(4H, t, J=5.0Hz), 2.94(2H, td, J=1.3, 12.7Hz), 3.52(3H, s), 3.70(2H, d, J=13.8Hz), 7.27(1H, s), 8.18(1H, dd, J=1.3, 5.3Hz), 8.86(1H, d, J=5.3Hz), 9.27(1H, d, J=1.3Hz) (CDCl3) YB257 1.81-1.88(4H, m), 2.80(1H, m), 2.99-3.08(2H, m), 425 3.46(3H, s), 3.82-3.86(2H, m), 6.98(1H, s), 7.26-7.43(3H, m), 7.53(1H, s), 8.26(1H, d, J=4.8Hz), 9.01(1H, d, J=4.8Hz), 9.30(1H, s) (DMSO-d6) YB258 1.80-1.90(4H, m), 2.83(1H, m), 2.99-3.08(2H, m), 425 3.46(3H, s), 3.81-3.86(2H, m), 6.98(1H, s), 7.26-7.43(3H, m), 7.53(1H, s), 8.26(1H, d, J=4.8Hz), 9.01(1H, d, J=4.8Hz), 9.30(1H, s) (DMSO-d6) YB259 1.76-1.96(8H, m), 2.67(1H, m), 2.99-3.07(2H, m), 417 3.16-3.21(4H, m), 3.45(3H, s), 3.79-3.84(2H, m), 6.49(2H, d, J=8.4Hz) 6.97(1H, s), 7.09(2H, d, J=8.4Hz), 8.24(1H, d, J=5.1Hz), 9.01(1H, d, J=5.1Hz), 9.30(1H, s) (DMSO-d6) YB260 1.87-1.99(8H, m), 2.72(1H, m), 2.99-3.09(2H, m), 417 3.19-3.23(4H, m), 3.46(3H, s), 3.80-3.85(2H, m), 6.38(1H, d, J=7.8Hz) 6.44(1H, s), 6.53(1H, d, J=7.8Hz), 6.98(1H, s), 7.09(1H, dd, J=7.8, 7.8Hz), 8.25(1H, d, J=5.1Hz), 9.01(1H, d, J=5.1Hz), 9.30(1H, s) (DMSO-d6) YB261 1.48-1.58(2H, m), 2.00-2.07(2H, m), 2.71(6H, s), 406 3.07-3.14(2H, m), 3.34-3.36(1H, m), 3.48(3H, s), 3.69-3.73(2H, m), 4.87(1H, d, J=8.2Hz), 6.56-6.66(4H, m), 6.96(1H, s), 8.24(1H, d, J=4.2Hz), 9.00(1H, d, J=4.2Hz), 9.30(1H, s) (DMSO-d6) YB262 1.51-1.62(2H, m), 2.02-2.08(2H, m), 393 3.10-3.18(2H, m), 3.42(3H, s), 3.46-3.50(1H, m), 3.67(3H, s), 3.69-3.73(2H, m), 5.56(1H, d, J=8.2Hz), 6.10-6.24(3H, m), 6.94-6.99(2H, m), 8.24(1H, d, J=4.2Hz), 9.00(1H, d, J=4.2Hz), 9.29(1H, s) (DMSO-d6) YB263 1.48-1.58(2H, m), 2.01-2.08(2H, m), 393 3.08-3.17(2H, m), 3.40(3H, s), 3.41-3.43(1H, m), 3.63(3H, s), 3.69-3.73(2H, m), 5.09(1H, d, J=8.2Hz), 6.59(2H, d, J=7.2Hz), 6.72(2H, d, J=7.2Hz), 6.96(1H, s), 8.24(1H, d, J=4.2Hz), 9.01(1H, d, J=4.2Hz), 9.29(1H, s) (DMSO-d6) YB264 1.58-1.69(2H, m), 2.04-2.08(2H, m), 393 3.08-3.15(2H, m), 3.42(3H, s), 3.55-3.83(6H, m), 4.57(1H, d, J=8.2Hz), 6.53-6.90(4H, m), 7.03(1H, s), 8.25(1H, d, J=4.2Hz), 9.00(1H, d, J=4.2Hz), 9.30(1H, s) (DMSO-d6) YB265 1.66-1.87(3H, m), 1.91-1.99(1H, m), 426 2.93-3.08(3H, m), 3.43(3H, s), 3.72-3.78(2H, m), 6.97(1H, s), 7.34(2H, d, J=5.7Hz), 7.54(2H, d, J=5.4Hz), 8.18(1H, dd, J=5.4, 1.2Hz), 8.99(1H, d, J=5.1Hz), 9.29(1H, d, J=0.9Hz) (DMSO) YB266 1.71-1.91(4H, m), 2.41-2.45(2H, m), 476 2.53-2.56(4H, m), 2.93-3.00(3H, m), 3.08-3.10(4H, m), 3.43(3H, s), 3.50-3.54(2H, m), 3.67-3.71(2H, m), 4.42-4.46(1H, m), 6.90(2H, d, J=7.2Hz), 6.96(1H, s), 7.19(2H, d, J=7.2Hz), 8.17(1H, dd, J=1.2, 4.2Hz), 8.99(1H, d, J=4.2Hz), 9.29(1H, d, J=1.2Hz) (DMSO-d6) YB267 1.70-1.94(4H, m), 2.86(6H, s), 2.89-2.90(3H, m), 391 3.43(3H, s), 3.66-3.77(2H, m), 6.71(2H, d, J=7.2Hz), 6.96(1H, s), 7.15(2H, d, J=7.2Hz), 8.17(1H, d, J=4.2Hz), 8.99(1H, d, J=4.2Hz), 9.28(1H, s) (DMSO-d6) YB268 1.72-1.84(4H, m), 2.89-3.08(7H, m), 3.43(3H, s), 433 3.67-3.77(6H, m), 6.90-6.96(3H, m), 7.21(2H, d, J=7.2Hz), 8.17(1H, d, J=4.2Hz), 8.99(1H, d, J=4.2Hz), 9.29(1H, s) (DMSO-d6) YB269 1.51-1.83(10H, m), 2.87-3.00(3H, m), 431 3.07-3.10(4H, m), 3.43(3H, s), 3/68-3.77(2H, m), 6.89(2H, d, J=7.2Hz), 6.96(1H, s), 7.17(2H, d, J=7.2Hz), 8.18(1H, d, J=4.2Hz), 8.99(1H, d, J=4.2Hz), 9.29(1H, s) (DMSO-d6) YB270 1.72-1.90(4H, m), 2.21(3H, s), 2.42-2.45(4H, m), 446 2.87-2.97(3H, m), 3.08-3.10(4H, m), 3.43(3H, s), 3.67-3.77(2H, m), 6.90(2H, d, J=7.2Hz), 6.96(1H, s), 7.19(2H, d, J=7.2Hz), 8.17(1H, d, J=4.2Hz), 8.98(1H, d, J=4.2Hz), 9.29(1H, s) (DMSO-d6) YB271 1.63-1.95(6H, m), 2.04-2.08(2H, m), 474 2.61-2.65(2H, m), 2.69(6H, s), 2.86-3.00(3H, m), 3.13-3.16(1H, m), 3.43(3H, s), 3.67-3.81(4H, m) 6.92-6.96(3H, m), 7.20(2H, d, J=7.2Hz), 8.17(1H, d, J=4.2Hz), 9.00(1H, d, J=4.2Hz), 9.29(1H, s) (DMSO-d6) YB272 1.72-1.83(4H, m), 2.89-3.09(7H, m), 3.42(3H, s), 566 3.54-3.57(4H, m), 3.67-3.77(2H, m), 5.11(2H, s), 6.91-6.96(3H, m), 7.21(2H, d, J=7.2Hz), 7.26-7.44(5H, m), 8.17(1H, d, J=4.2Hz), 8.99(1H, d, J=4.2Hz), 9.29(1H, s) (DMSO-d6) YB273 1.57-1.63(2H, m), 1.82-1.89(2H, m), 370 2.51-2.98(13H, m), 3.41(3H, s), 3.76-3.80(3H, m), 6.70(1H, s), 8.22(1H, d, J=4.2Hz), 9.01(1H, d, J=4.2Hz), 9.30(1H, s) (DMSO-d6) YB274 1.52-1.63(2H, m), 1.84-1.90(2H, m), 400 2.36-2.42(11H, m), 2.86-2.94(2H, m), 3.40(3H, s), 3.49-3.53(2H, m), 3.73-3.77(2H, m), 4.40-4.43(1H, m), 6.96(1H, s), 8.22(1H, d, J=4.2Hz), 9.01(1H, d, J=4.2Hz), 9.30(1H, s) (DMSO-d6) YB275 1.72-1.92(4H, m), 2.80-3.02(11H, m), 432 3.28-3.30(1H, m), 3.43(3H, s), 6.88(2H, d, J=7.2Hz), 6.96(1H, s), 7.18(2H, d, J=7.2Hz), 8.18(1H, d, J=4.2Hz), 8.99(1H, d, J=4.2Hz), 9.29(1H, s) (DMSO-d6) YB276 1.06-1.38(5H, m), 1.61-1.92(9H, m), 445 2.77-2.91(3H, m), 3.03-3.12(1H, m), 3.42(3H, s), 3.64-3.75(2H, m), 5.27(1H, d, J=8.2Hz), 6.52(2H, d, J=7.2Hz), 6.96(1H, s), 7.02(2H, d, J=7.2Hz), 8.17(1H, d, J=4.2Hz), 8.99(1H, d, J=4.2Hz), 9.28(1H, s) (DMSO-d6) YB277 1.76-1.97(4H, m), 2.97-3.10(5H, m), 3.47(3H, s), 465 3.73-3.76(2H, m), 3.88-3.93(2H, m), 6.71(1H, dd, J=7.2, 7.3Hz), 6.96-7.34(8H, m), 8.19(1H, d, J=4.2Hz), 9.00(1H, d, J=4.2Hz), 9.29(1H, s) (DMSO-d6) YB278 1.10-1.15(1H, m), 1.32-1.47(4H, m), 459 1.64-1.82(9H, m), 2.69(3H, s), 2.82-2.97(3H, m), 3.42(3H, s), 3.54-3.75(3H, m), 6.73(2H, d, J=7.2Hz), 6.95(1H, s), 7.13(2H, d, J=7.2Hz), 8.16(1H, d, J=4.2Hz), 8.98(1H, d, J=4.2Hz), 9.28(1H, s) (DMSO-d6)

Test Example Inhibitory Activity of the Medicament of the Present Invention against P-GS1 Phosphorylation by Bovine Cerebral TPK1

A mixture containing 100 mM MES-sodium hydroxide (pH 6.5), 1 mM magnesium acetate, 0.5 mM EGTA, 5 mM β-mercaptoethanol, 0.02% Tween 20, 10% glycerol, 12 μg/ml P-GS1, 41.7 μM [γ-³²P] ATP (68 kBq/ml), bovine cerebral TPK1 and a compound shown in Table (a final mixture contained 1.7% DMSO deriving from a solution of a test compound prepared in the presence of 10% DMSO) was used as a reaction system. The phosphorylation was started by adding ATP, and the reaction was conducted at 25° C. for 2 hours, and then stopped by adding 21% perchloric acid on ice cooling. The reaction mixture was centrifuged at 12,000 rpm for 5 minutes and adsorbed on P81 paper (Whatmann), and then the paper was washed four times with 75 mM phosphoric acid, three times with water and once with acetone. The paper was dried, and the residual radioactivity was measured using a liquid scintillation counter. The results are shown in the table below. The test compound markedly inhibited the P-GS1 phosphorylation by TPK1. The results strongly suggest that the medicaments of the present invention inhibit the TPK1 activity, thereby suppress the A B neurotoxicity and the PHF formation, and that the medicaments of the present invention are effective for preventive and/or therapeutic treatment of Alzheimer disease and the above-mentioned diseases. TABLE 6 Compound No. IC₅₀ XA361 0.018 μM XB80  0.23 μM YA0864 0.216 μM YB257 0.014 μM

Formulation Example

(1) Tablets

The ingredients below were mixed by an ordinary method and compressed by using a conventional apparatus. Compound of Example 1 30 mg Crystalline cellulose 60 mg Corn starch 100 mg Lactose 200 mg Magnesium stearate 4 mg (2) Soft Capsules

The ingredients below were mixed by an ordinary method and filled in soft capsules. Compound of Example 1 30 mg Olive oil 300 mg Lecithin 20 mg

INDUSTRIAL APPLICABILITY

The compounds of the present invention have TPK1 inhibitory activity and are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases caused by abnormal advance of TPK1 such as neurodegenerative diseases (e.g. Alzheimer disease) and the above-mentioned diseases. 

1. A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof:

wherein Q represents CH or nitrogen atom; R represents a C₁-C₁₂ alkyl group which may be substituted; the ring of:

represents piperazine ring or piperidine ring; each X independently represents X¹—X²— wherein X¹ represents an oxo group; a C₁-C₈ alkyl group which may be substituted; a C₃-C₈ cycloalkyl group which may be substituted; an optionally partially hydrogenated C₆-C₁₀ aryl ring which may be substituted; an indan ring which may be substituted; an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom, and nitrogen atom, and having 5 to 10 ring-constituting atoms in total; an aralkyloxy group; a group represented by —N(Ra)(Rb) wherein Ra and Rb are the same or different and each is hydrogen, a C₁-C₄ alkyl group which may be substituted, an aralkyl group which may be substituted, a C₈-C₈ cycloalkyl group which may be substituted, an aryl group which may be substituted, C₁-C₈ alkylcarbonyl group which may be substituted, C₃-C₈ cycloalkylcarbonyl group which may be substituted, aralkycarbonyl group which may be substituted, C₆-C₁₀ arylcarbonyl group which may be substituted, C₁-C₈ alkysulfonyl group which may be substituted, C₃-C₈ cycloalkylsulfonyl group which may be substituted, aralkysulfonyl group which may be substituted, C₆-C₁₀ arylsulfonyl group which may be substituted, C₁-C₈ alkyloxycarbonyl group which may be substituted, C₃-C₈ cycloalkyloxycarbonyl group which may be substituted, aralkyoxycarbonyl group which may be substituted, C₆-C₁₀ aryloxycarbonyl group which may be substituted, aminocarbonyl, N—C₁-C₈ alkylaminocarbonyl group which may be substituted, N,N′-C₁-C₈ dialkylaminocarbonyl group which may be substituted, N—C₁-C₈ alkyl-N′-C₃-C₈ cycloalkylaminocarbonyl group which may be substituted, N—C₁-C₈ alkyl-N′-aralkylaminocarbonyl group which may be substituted, N—C₁-C₈ alkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted, C₃-C₈ cycloalkylaminocarbonyl group which may be substituted, N,N′-C₃-C₈ dicycloalkylaminoycarbonyl group which may be substituted, N—C₃-C₈ cycloalkyl-N′-aralkylaminocarbonyl group which may be substituted, N—C₃-C₈ cycloalkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted, aralkylaminocarbonyl group which may be substituted, N,N′-diaralkylaminocarbonyl group which may be substituted, N-aralkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted, C₆-C₁₀ arylaminocarbonyl group which may be substituted, N,N′-C₆-C₁₀ diarylaminocarbonyl group which may be substituted, or an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom, and nitrogen atom, and having 5 to 10 ring-constituting atoms in total; or Ra and Rb together with the adjacent nitrogen atom form a 4 to 7 membered heterocyclic ring which may further contain 1 to 4 groups selected from an oxygen atom, a sulfur atom, N-Rc (wherein Rc represents a hydrogen atom, a C₁-C₄ alkyl group which may be substituted, an aralkyl group which may be substituted, C₃-C₈ cycloalkyl group which may be substituted or an aryl group which may be substituted, C₁-C₈ alkylcarbonyl group which may be substituted, C₃-C₈ cycloalkylcarbonyl group which may be substituted, aralkycarbonyl group which may be substituted, C₆-C₁₀ arylcarbonyl group which may be substituted, C₁-C₈ alkysulfonyl group which may be substituted, C₃-C₈ cycloalkylsulfonyl group which may be substituted, aralkysulfonyl group which may be substituted, C₆-C₁₀ arylsulfonyl group which may be substituted, C₁-C₈ alkyloxycarbonyl group which may be substituted, C₃-C₈ cycloalkyloxycarbonyl group which may be substituted, aralkyoxycarbonyl group which may be substituted, C₆-C₁₀ aryloxycarbonyl group which may be substituted, aminocarbonyl, N—C₁-C₈ alkylaminocarbonyl group which may be substituted, N,N′-C₁-C₈ dialkylaminocarbonyl group which may be substituted, N—C₁-C₈ alkyl-N′-C₃-C₈ cycloalkylaminocarbonyl group which may be substituted, N—C₁-C₈ alkyl-N′-aralkylaminocarbonyl group which may be substituted, N—C₁-C₈ alkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted, C₃-C₈ cycloalkylaminocarbonyl group which may be substituted, N,N′-C₃-C₈ dicycloalkylaminoycarbonyl group which may be substituted, N—C₃-C₈ cycloalkyl-N′-aralkylaminocarbonyl group which may be substituted, N—C₃-C₈ cycloalkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted, aralkylaminocarbonyl group which may be substituted, N,N′-diaralkylaminocarbonyl group which may be substituted, N-aralkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted, C₆-C₁₀ arylaminocarbonyl group which may be substituted, N,N′-C₆-C₁₀ diarylaminocarbonyl group which may be substituted, or an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom, and nitrogen atom, and having 5 to 10 ring-constituting atoms in total), a carbonyl group, a sulfinyl group or a sulfonyl group in the ring, and said 4 to 7 membered heterocyclic ring may optionally be fused with an aryl group which may be substituted; X² represents a bond, a carbonyl group, a sulfinyl group, a sulfonyl group, an oxygen atom, a sulfur atom, a C₁-C₄ alkylene group which may be substituted or N-Rd (Rd represents a hydrogen atom, a C₁-C₄ alkyl group which may be substituted, an aralkyl group which may be substituted, C₃-C₈ cycloalkyl group which may be substituted or an aryl group which may be substituted, C₁-C₈ alkylcarbonyl group which may be substituted, C₃-C₈ cycloalkylcarbonyl group which may be substituted, aralkycarbonyl group which may be substituted, C₆-C₁₀ arylcarbonyl group which may be substituted, C₁-C₈ alkysulfonyl group which may be substituted, C₃-C₈ cycloalkylsulfonyl group which may be substituted, aralkysulfonyl group which may be substituted, C₆-C₁₀ arylsulfonyl group which may be substituted, C₁-C₈ alkyloxycarbonyl group which may be substituted, C₃-C₈ cycloalkyloxycarbonyl group which may be substituted, aralkyoxycarbonyl group which may be substituted, C₆-C₁₀ aryloxycarbonyl group which may be substituted, aminocarbonyl, N—C₁-C₈ alkylaminocarbonyl group which may be substituted, N,N′-C₁-C₈ dialkylaminocarbonyl group which may be substituted, N—C₁-C₈ alkyl-N′-C₃-C₈ cycloalkylaminocarbonyl group which may be substituted, N—C₁-C₈ alkyl-N′-aralkylaminocarbonyl group which may be substituted, N—C₁-C₈ alkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted, C₃-C₈ cycloalkylaminocarbonyl group which may be substituted, N,N′-C₃-C₈ dicycloalkylaminoycarbonyl group which may be substituted, N—C₃-C₈ cycloalkyl-N′-aralkylaminocarbonyl group which may be substituted, N—C₃-C₈ cycloalkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted, aralkylaminocarbonyl group which may be substituted, N,N′-diaralkylaminocarbonyl group which may be substituted, N-aralkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted, C₆-C₁₀ arylaminocarbonyl group which may be substituted, N,N′-C₆-C₁₀ diarylaminocarbonyl group which may be substituted, or an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom, and nitrogen atom, and having 5 to 10 ring-constituting atoms in total); m represents an integer of 1 to 3; each Y independently represents a halogen atom, a hydroxy group, a cyano group, Y¹-Y³ wherein Y¹ represents a C₁-C₈ alkyl group which may be substituted; a C₃-C₈ cycloalkyl group which may be substituted or a C₆-C₁₀ aryl ring which may be substituted; Y³ represents a carbonyl group, a sulfinyl group, a sulfonyl group, an oxygen atom, a sulfur atom, a C₁-C₄ alkylene group which may be substituted or N-Re (Re represents a hydrogen atom, a C₁-C₄ alkyl group which may be substituted, an aralkyl group which may be substituted, C₃-C₈ cycloalkyl group which may be substituted or an aryl group which may be substituted, C₁-C₈ alkylcarbonyl group which may be substituted, C₃-C₈ cycloalkylcarbonyl group which may be substituted, aralkycarbonyl group which may be substituted, C₆-C₁₀ arylcarbonyl group which may be substituted, C₁-C₈ alkysulfonyl group which may be substituted, C₃-C₈ cycloalkylsulfonyl group which may be substituted, aralkysulfonyl group which may be substituted, C₆-C₁₀ arylsulfonyl group which may be substituted, C₁-C₈ alkyloxycarbonyl group which may be substituted, C₃-C₈ cycloalkyloxycarbonyl group which may be substituted, aralkyoxycarbonyl group which may be substituted, C₆-C₁₀ aryloxycarbonyl group which may be substituted, aminocarbonyl, N—C₁-C₈ alkylaminocarbonyl group which may be substituted, N,N′-C₁-C₈ dialkylaminocarbonyl group which may be substituted, N—C₁-C₈ alkyl-N′-C₃-C₈ cycloalkylaminocarbonyl group which may be substituted, N—C₁-C₈ alkyl-N′-aralkylaminocarbonyl group which may be substituted, N—C₁-C₈ alkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted, C₃-C₈ cycloalkylaminocarbonyl group which may be substituted, N,N′-C₃-C₈ dicycloalkylaminoycarbonyl group which may be substituted, N—C₃-C₈ cycloalkyl-N′-aralkylaminocarbonyl group which may be substituted, N—C₃-C₈ cycloalkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted, aralkylaminocarbonyl group which may be substituted, N,N′-diaralkylaminocarbonyl group which may be substituted, N-aralkyl-N′-C₆-C₁₀ arylaminocarbonyl group which may be substituted, C₆-C₁₀ arylaminocarbonyl group which may be substituted, N,N′-C₆-C₁₀ diarylaminocarbonyl group which may be substituted, or an optionally substituted heterocyclic ring having 1 to 4 hetero atoms selected from the group consisting of oxygen atom, sulfur atom, and nitrogen atom, and having 5 to 10 ring-constituting atoms in total), n represents an integer of 0 to 8; when X and Y or two Y groups are attached on the same carbon atom, they may combine to each other to form a C₂-C₆ alkylene group; and when m is 1, n is 0, and X is X¹—CO—, (1) X does not bind to 3-position of unsubstituted 1-piperazinyl group or does not bind to 3-position of a 4-alkyl-1-piperazinyl group; or (2) X does not bind to 3-position or 4-position of non-substituted 1-piperidinyl group.
 2. The pyrimidone derivative or the salt thereof, or the solvate thereof or the hydrate thereof according to claim 1 having the following formula (II)

wherein Q, R, X and Y are the same as those defined in claim 1; p is 0 or 1; q is 0 or 1; r is an integer of 0 to 6; p+q is 1 or 2; and Z represents N or CZ¹ wherein Z¹ represents hydrogen atom or Y.
 3. The pyrimidone derivative or the salt thereof, or the solvate thereof or the hydrate thereof according to claim 2, wherein R is a C₁-C₃ alkyl group which may be substituted by a C₃-C₈ cycloalkyl group.
 4. The pyrimidone derivative or the salt thereof, or the solvate thereof or the hydrate thereof according to claim 3, wherein R is methyl group or ethyl group; Y is in 3-, 4- or 5-position of the piperazine ring or the piperidine ring; p+q is 1; and r is an integer of 0 to
 3. 5. The pyrimidone derivative or the salt thereof, or the solvate thereof or the hydrate thereof according to claim 4, wherein X is a C₁-C₈ alkyl group which may be substituted or a C₆-C₁₀ aryl ring which may be substituted; Y is a C₁-C₆ alkyl group which may be substituted; p is 1; q is 0; r is an integer of 0 to 3; and Z is N or CH.
 6. The pyrimidone derivative or the salt thereof, or the solvate thereof or the hydrate thereof according to claim 5, wherein X is a benzene ring which may be substituted, a benzyl group which may be substituted; Y is a methyl group which may be substituted; Z is N and r is 0 or
 1. 7. The pyrimidone derivative or the salt thereof, or the solvate thereof or the hydrate thereof according to claim 4, wherein X is a benzene ring which may be substituted, a benzyl group which may be substituted, a benzoyl group which may be substituted, or a benzisothiazol ring which may be substituted; Y is a methyl group which may be substituted; Z is N and p is
 0. 8. The pyrimidone derivative or the salt thereof, or the solvate thereof or the hydrate thereof according to claim 4, wherein X is a C₁-C₈ alkyl group substituted by a benzene ring which may be substituted or a benzene ring which may be substituted; Y is a hydroxy group, a cyano group, or Y¹—CO— wherein Y¹ is a C₁-C₈ alkyl group; Z is CH or C—Y and r is 0 or
 1. 9. The pyrimidone derivative or the salt thereof, or the solvate thereof or the hydrate thereof according to claim 8, wherein X is a benzyl group which may be substituted or a benzene ring which may be substituted; Y is a hydroxy group, a cyano group, or an acetyl group; Z is CH or C—Y and r is 0 or
 1. 10. A pyrimidone derivative which is selected from the group consisting of: 2-(3-Phenylpiperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(4-Fluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(3-Fluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(2-Fluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(4-Chlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; (S)-2-(3-(4-Chlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; (R)-2-(3-(4-Chlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(3-Chlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(2-Chlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(4-Bromophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(3-Bromophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(2-Bromophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(4-Methylphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(3-Methylphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(2-Methylphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(4-Cyanophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(3-Cyanophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(2-Cyanophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(4-Methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(3-Methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(2-Methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(2-Ethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(5-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(4-Fluoro-3-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; (S)-2-(3-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; (R)-2-(3-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(4-Chloro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(4-Fluoro-2-methylphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(2-Fluoro-6-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(5-Bromo-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(2-Bromo-4-fluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(2-Chloro-6-fluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(2,4-Difluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(2,6-Difluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(2,6-Dichlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(2,4-Dimethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(3,4-Dimethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(2,5-Dimethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(2,6-Dimethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(2,4-Difluoro-6-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; (1034) 2-(3-(5-Cyano-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(4-Cyano-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(1-Naphthyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(2-Naphthyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(2,3-Dihydrobenzofuran-7-yl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(Benzofuran-2-yl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; (S)-2-(3-(Benzofuran-2-yl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(4-(Pyrrolidin-1-yl-methyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(4-(Pyrrolidin-1-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(2-methoxy-4-(pyrrolidin-1-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(2-methoxy-5-(pyrrolidin-1-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(4-(Phenyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(4-(4-Fluorophenyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(4-(4-Methoxyphenyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(4-(2-Methoxyphenyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(4-(Morpholin-4-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(4-(4-Methylpiperazin-1-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(4-Phenylpiperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(4-Benzylpiperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(4-Benzoylpiperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(4-(1,2-Benzisothiazol-3-yl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(4-Methyl-3-phenylpiperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(4-Fluoro-2-methoxyphenyl)-4-methylpiperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; (S)-2-(3-(4-Fluoro-2-methoxyphenyl)-4-methylpiperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; (R)-2-(3-(4-Fluoro-2-methoxyphenyl)-4-methylpiperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(4-Acetyl-3-(4-fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(4-Benzyl-3-(4-fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(4-Benzyl-3-(ethoxycarbonyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(4-methyl-3-(1-naphthyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(5,5-Dimethyl-3-(2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-Phenylpiperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(4-Fluorophenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(3-Fluorophenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(2-Fluorophenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(4-Chlorophenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(4-Bromophenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(4-Methoxyphenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(3-Methoxyphenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(2-Methoxyphenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(4-((Pyrrolidin-1-yl)methyl)phenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; (S)-2-(3-(4-(Pyrrolidin-1-yl-methyl)phenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; (R)-2-(3-(4-(Pyrrolidin-1-yl-methyl)phenyl)piperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-Hydroxy-3-phenylpiperidin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-Phenylpiperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(4-Fluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(3-Fluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(2-Fluorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(4-Chlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(3-Chlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(2-Chlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(4-Bromophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(3-Bromophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(2-Bromophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(4-Cyanophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(3-Cyanophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(2-Cyanophenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(4-Methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(3-Methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(2-Methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(2-Ethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(6-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(5-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; (S)-2-(3-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; (R)-2-(3-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(4-Chloro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(5-Bromo-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(2,6-Dichlorophenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(2,4-Dimethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyridyl)-3H-pyrimidin-4-one; 2-(3-(3,4-Dimethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(2,5-Dimethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(2,6-Dimethoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(2,4-Difluoro-6-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(1-Naphthyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(2-Naphthyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(2,3-Dihydrobenzofuran-7-yl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(Benzofuran-2-yl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(4-(Pyrrolidin-1-yl-methyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(4-(Pyrrolidin-1-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(2-methoxy-4-(pyrrolidin-1-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(2-methoxy-5-(pyrrolidin-1-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(4-(Phenyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(4-(4-Fluorophenyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(4-(4-Methoxyphenyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(4-(2-Methoxyphenyl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(4-(Morpholin-4-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(4-(4-Methylpiperazin-1-yl)phenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(4-Fluoro-2-methoxyphenyl)-4-methylpiperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; (S)-2-(3-(4-Fluoro-2-methoxyphenyl)-4-methylpiperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; (R)-2-(3-(4-Fluoro-2-methoxyphenyl)-4-methylpiperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(4-Acetyl-3-(4-fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(4-Benzyl-3-(4-fluoro-2-methoxyphenyl)piperazin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(4-(4-Fluorophenyl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(4-Cyano-4-phenylpiperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(4-(6-Fluorobenofuran-3-yl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(Benzoisoxazol-3-yl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; (S)-2-(3-(Benzoisoxazol-3-yl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; (R)-2-(3-(Benzoisoxazol-3-yl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(3-(6-Fluorobenzoisoxazol-3-yl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(4-(6-Fluorobenzoisoxazol-3-yl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; 2-(4-(5-Methylbenzofuran-3-yl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one; and 2-(4-(6-Fluorobenzothiophene-3-yl)piperidin-1-yl)-3-methyl-6-(4-pyrimidyl)-3H-pyrimidin-4-one or a salt thereof, or a solvate thereof or a hydrate thereof.
 11. A medicament comprising as an active ingredient a substance selected from the group consisting of the pyrimidone derivative represented by formula (I) and a salt thereof, and a solvate thereof and a hydrate thereof according to claim
 1. 12. A tau protein kinase 1 inhibitor selected from the group consisting of the pyrimidone derivative represented by formula (I) and a salt thereof, and a solvate thereof and a hydrate thereof according to claim
 1. 13. The medicament according to claim 11 which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity.
 14. The medicament according to claim 11 which is used for preventive and/or therapeutic treatment of a neurodegenerative disease.
 15. The medicament according to claim 14, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer disease, ischemic cerebrovascular accidents, Down syndrome, cerebral bleeding due to cerebral amyloid angiopathy, progressive supranuclear palsy, subacute sclerosing panencephalitic parkinsonism, postencephalitic parkinsonism, pugilistic encephalitis, Guam parkinsonism-dementia complex, Lewy body disease, Pick's disease, corticobasal degeneration, frontotemporal dementia, vascular dementia, traumatic injuries, brain and spinal cord trauma, peripheral neuropathies, retinopathies, and glaucoma.
 16. The medicament according to claim 11, wherein the disease is selected from the group consisting of non-insulin dependent diabetes, obesity, manic depressive illness, schizophrenia, alopecia, breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia, and a virus-induced tumor. 